

PR	18-AUG-1998;	98US-0097022P.
PR	26-AUG-1998;	98US-0097952P.
PR	26-AUG-1998;	98US-0097954P.
PR	26-AUG-1998;	98US-0097955P.
PR	26-AUG-1998;	98US-0097971P.
PR	26-AUG-1998;	98US-0097974P.
PR	26-AUG-1998;	98US-0098014P.
PR	01-SEP-1998;	98US-0098716P.
PR	01-SEP-1998;	98US-0098723P.
PR	02-SEP-1998;	98US-0098803P.
PR	02-SEP-1998;	98US-0098821P.
PR	02-SEP-1998;	98US-0098843P.
PR	09-SEP-1998;	98US-0099602P.
PR	10-SEP-1998;	98US-0099741P.
PR	10-SEP-1998;	98US-0099754P.
PR	10-SEP-1998;	98US-0099763P.
PR	10-SEP-1998;	98US-0099812P.
PR	15-SEP-1998;	98US-0100388P.
PR	16-SEP-1998;	98US-0100662P.
PR	16-SEP-1998;	98US-0100664P.
PR	16-SEP-1998;	98US-0101751P.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98US-0100683P.
PR	17-SEP-1998;	98US-0100684P.
PR	17-SEP-1998;	98US-0100919P.
PR	17-SEP-1998;	98US-0100930P.
PR	18-SEP-1998;	98US-0100849P.
PR	18-SEP-1998;	98US-0101014P.
PR	18-SEP-1998;	98US-0101068P.
PR	23-SEP-1998;	98US-0101471P.
PR	23-SEP-1998;	98US-0101472P.
PR	23-SEP-1998;	98US-0101475P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101738P.
PR	24-SEP-1998;	98US-0101739P.
PR	24-SEP-1998;	98US-0101743P.
PR	24-SEP-1998;	98US-0101922P.
PR	25-SEP-1998;	98US-0101786P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
PR	02-OCT-1998;	98US-0102958P.
PR	06-OCT-1998;	98US-0103258P.
PR	06-OCT-1998;	98US-0103449P.

Query Match	3.0%;	Score 66.6;	DB 9;	Length 2846;
Best Local Similarity	71.3%;	Pred. No. 0.00023;		
Matches 87;	Conservative 0;	Mismatches 35;	Indels 0;	Gaps 0;

  

Qy	2121	CC	TTTGCTTTACCACTCTTTCC	TTTTATCTTTATTAATAAAAAATGTTGGTCTCCACCACTG	2180
Db	2653	CC	TTTTCCTTCCCATCTCTTG	TACACATTTTATAAAATAAGGTTGGCTTCTGAACTA	2712
Qy	2181	NC	TCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	AAAAAAAAAAAAAAAAAAAA	2240
Db	2713	CA	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	AAAAAAAAAAAAAAAAAAAA	2772
Qy	2241	AA	2242		
Db	2773	AA	2774		

RESULT 698  
ACD16800  
ID ACD16800 standard; cDNA; 2846 BP.  
XX  
AC ACD16800;

XX	20-AUG-2003	(first entry)
DT		
XX		
DE		cDNA encoding human PRO polypeptide #85.
XX		
KW		Human; PRO polypeptide; secreted protein; transmembrane protein;
KW		chromosome mapping; gene mapping; molecular weight marker;
KW		protein electrophoresis; affinity purification; gene therapy; gene; ss.
XX		
OS		Homo sapiens.
XX		
PN		US2003036151-A1.
XX		
PD		20-FEB-2003.
XX		
PF		02-JUL-2002; 2002US-00187751.
XX		
PR	18-SEP-1997;	97US-0059263P.
PR	18-SEP-1997;	97US-0059266P.
PR	17-OCT-1997;	97US-0062250P.
PR	21-OCT-1997;	97US-0063486P.
PR	24-OCT-1997;	97US-0063120P.
PR	24-OCT-1997;	97US-0063121P.
PR	28-OCT-1997;	97US-0063540P.
PR	28-OCT-1997;	97US-0063541P.
PR	28-OCT-1997;	97US-0063544P.
PR	28-OCT-1997;	97US-0063564P.
PR	29-OCT-1997;	97US-0063734P.
PR	31-OCT-1997;	97US-0063870P.
PR	31-OCT-1997;	97US-0064103P.
PR	13-NOV-1997;	97US-0065311P.
PR	21-NOV-1997;	97US-0066120P.
PR	24-NOV-1997;	97US-0066466P.
PR	24-NOV-1997;	97US-0066772P.
PR	11-DEC-1997;	97US-0069335P.
PR	12-DEC-1997;	97US-0069425P.
PR	17-DEC-1997;	97US-0069870P.
PR	18-DEC-1997;	97US-0068017P.
PR	10-MAR-1998;	98US-0077450P.
PR	11-MAR-1998;	98US-0077632P.
PR	11-MAR-1998;	98US-0077649P.
PR	20-MAR-1998;	98US-0078886P.
PR	20-MAR-1998;	98US-0078939P.
PR	27-MAR-1998;	98US-0079664P.
PR	27-MAR-1998;	98US-0079786P.
PR	31-MAR-1998;	98US-0080107P.
PR	31-MAR-1998;	98US-0080194P.
PR	01-APR-1998;	98US-0080327P.
PR	01-APR-1998;	98US-0080333P.
PR	08-APR-1998;	98US-0081049P.
PR	08-APR-1998;	98US-0081070P.
PR	09-APR-1998;	98US-0081195P.
PR	15-APR-1998;	98US-0081838P.
PR	21-APR-1998;	98US-0082568P.
PR	21-APR-1998;	98US-0082569P.
PR	22-APR-1998;	98US-0082704P.
PR	22-APR-1998;	98US-0082797P.
PR	28-APR-1998;	98US-0083322P.
PR	29-APR-1998;	98US-0083495P.
PR	29-APR-1998;	98US-0083496P.
PR	29-APR-1998;	98US-0083499P.
PR	29-APR-1998;	98US-0083559P.
PR	05-MAY-1998;	98US-0084366P.
PR	06-MAY-1998;	98US-0084414P.
PR	07-MAY-1998;	98US-0084639P.
PR	07-MAY-1998;	98US-0084640P.
PR	07-MAY-1998;	98US-0084643P.
PR	15-MAY-1998;	98US-0085579P.
PR	15-MAY-1998;	98US-0085580P.
PR	15-MAY-1998;	98US-0085582P.
PR	15-MAY-1998;	98US-0085700P.
PR	18-MAY-1998;	98US-0086023P.
PR	22-MAY-1998;	98US-0086392P.





AC	ACH65430;		PR	19-JUN-1998;	98US-0089948P.
XX			PR	19-JUN-1998;	98US-0089952P.
DT	14-OCT-2003 (first entry)		PR	22-JUN-1998;	98US-0090246P.
XX			PR	22-JUN-1998;	98US-0090252P.
DE	Human cDNA encoding secreted/transmembrane protein PRO1344.		PR	22-JUN-1998;	98US-0090254P.
XX			PR	23-JUN-1998;	98US-0090349P.
KW	Human; ss; gene; secreted protein; transmembrane protein; PRO;		PR	23-JUN-1998;	98US-0090355P.
KW	adrenal cortical capillary endothelial cell; angiogenesis; wound healing;		PR	24-JUN-1998;	98US-0090429P.
KW	diabetes; obesity; hyper-insulinaemia; hypo-insulinaemia;		PR	24-JUN-1998;	98US-0090431P.
KW	chondrocyte redifferentiation; bone disorder; cartilage disorder;		PR	24-JUN-1998;	98US-0090435P.
KW	sports injury; arthritis; kidney mesangial cell proliferation;		PR	24-JUN-1998;	98US-0090444P.
KW	kidney disorder; Berger disease; neuropathy; coeliac disease;		PR	24-JUN-1998;	98US-0090445P.
KW	dermatitis herpetiformis; Crohn's disease; tumour; cancer.		PR	24-JUN-1998;	98US-0090472P.
XX			PR	24-JUN-1998;	98US-0090535P.
OS	Homo sapiens.		PR	24-JUN-1998;	98US-0090540P.
XX			PR	24-JUN-1998;	98US-0090542P.
PN	US2003044806-A1.		PR	24-JUN-1998;	98US-0090557P.
XX			PR	25-JUN-1998;	98US-0090676P.
PD	06-MAR-2003.		PR	25-JUN-1998;	98US-0090678P.
XX			PR	25-JUN-1998;	98US-0090690P.
PF	15-NOV-2001; 2001US-00998156.		PR	25-JUN-1998;	98US-0090694P.
XX			PR	25-JUN-1998;	98US-0090695P.
PR	16-JUN-1997; 97US-0049787P.		PR	25-JUN-1998;	98US-0090696P.
PR	17-OCT-1997; 97US-0062250P.		PR	26-JUN-1998;	98US-0090862P.
PR	05-NOV-1997; 97WO-US020069.		PR	26-JUN-1998;	98US-0090863P.
PR	12-NOV-1997; 97US-0065186P.		PR	01-JUL-1998;	98US-0091360P.
PR	13-NOV-1997; 97US-0065311P.		PR	01-JUL-1998;	98US-0091544P.
PR	24-NOV-1997; 97US-0066770P.		PR	02-JUL-1998;	98US-0091519P.
PR	25-FEB-1998; 98US-0075945P.		PR	02-JUL-1998;	98US-0091626P.
PR	20-MAR-1998; 98US-0078910P.		PR	02-JUL-1998;	98US-0091628P.
PR	07-MAY-1998; 98US-0083322P.		PR	02-JUL-1998;	98US-0091633P.
PR	28-MAY-1998; 98US-0087106P.		PR	02-JUL-1998;	98US-0091646P.
PR	02-JUN-1998; 98US-0087607P.		PR	02-JUL-1998;	98US-0091673P.
PR	02-JUN-1998; 98US-0087609P.		PR	07-JUL-1998;	98US-0091978P.
PR	02-JUN-1998; 98US-0087759P.		PR	07-JUL-1998;	98US-0091982P.
PR	03-JUN-1998; 98US-0087827P.		PR	09-JUL-1998;	98US-0092182P.
PR	04-JUN-1998; 98US-0088021P.		PR	10-JUL-1998;	98US-0092472P.
PR	04-JUN-1998; 98US-0088025P.		PR	20-JUL-1998;	98US-0093339P.
PR	04-JUN-1998; 98US-0088026P.		PR	30-JUL-1998;	98US-0094651P.
PR	04-JUN-1998; 98US-0088028P.		PR	04-AUG-1998;	98US-0095282P.
PR	04-JUN-1998; 98US-0088029P.		PR	04-AUG-1998;	98US-0095285P.
PR	04-JUN-1998; 98US-0088030P.		PR	04-AUG-1998;	98US-0095301P.
PR	04-JUN-1998; 98US-0088033P.		PR	04-AUG-1998;	98US-0095302P.
PR	04-JUN-1998; 98US-0088326P.		PR	04-AUG-1998;	98US-0095318P.
PR	05-JUN-1998; 98US-0088167P.		PR	04-AUG-1998;	98US-0095321P.
PR	05-JUN-1998; 98US-0088202P.		PR	04-AUG-1998;	98US-0095325P.
PR	05-JUN-1998; 98US-0088212P.		PR	10-AUG-1998;	98US-0095916P.
PR	05-JUN-1998; 98US-0088217P.		PR	10-AUG-1998;	98US-0095929P.
PR	09-JUN-1998; 98US-0088655P.		PR	10-AUG-1998;	98US-0096012P.
PR	10-JUN-1998; 98US-0088734P.		PR	11-AUG-1998;	98US-0096146P.
PR	10-JUN-1998; 98US-0088738P.		PR	12-AUG-1998;	98US-0096329P.
PR	10-JUN-1998; 98US-0088742P.		PR	13-AUG-1998;	98US-0096413P.
PR	10-JUN-1998; 98US-0088810P.		PR	17-AUG-1998;	98US-0096757P.
PR	10-JUN-1998; 98US-0088824P.		PR	17-AUG-1998;	98US-0096766P.
PR	10-JUN-1998; 98US-0088826P.		PR	17-AUG-1998;	98US-0096768P.
PR	11-JUN-1998; 98US-0088858P.		PR	17-AUG-1998;	98US-0096773P.
PR	11-JUN-1998; 98US-0088861P.		PR	17-AUG-1998;	98US-0096791P.
PR	11-JUN-1998; 98US-0088876P.		PR	17-AUG-1998;	98US-0096867P.
PR	12-JUN-1998; 98US-0089105P.		PR	17-AUG-1998;	98US-0096891P.
PR	16-JUN-1998; 98US-0089440P.		PR	17-AUG-1998;	98US-0096894P.
PR	16-JUN-1998; 98US-0089512P.		PR	17-AUG-1998;	98US-0096895P.
PR	16-JUN-1998; 98US-0089514P.		PR	17-AUG-1998;	98US-0096897P.
PR	17-JUN-1998; 98US-0089532P.		PR	17-AUG-1998;	98US-0096899P.
PR	17-JUN-1998; 98US-0089538P.		PR	18-AUG-1998;	98US-0096949P.
PR	17-JUN-1998; 98US-0089598P.		PR	18-AUG-1998;	98US-0096950P.
PR	17-JUN-1998; 98US-0089599P.		PR	18-AUG-1998;	98US-0096959P.
PR	17-JUN-1998; 98US-0089600P.		PR	18-AUG-1998;	98US-0096960P.
PR	17-JUN-1998; 98US-0089653P.		PR	18-AUG-1998;	98US-0097022P.
PR	18-JUN-1998; 98US-0089801P.		PR	19-AUG-1998;	98US-0097141P.
PR	18-JUN-1998; 98US-0089907P.		PR	20-AUG-1998;	98US-0097218P.
PR	18-JUN-1998; 98US-0089908P.		PR	24-AUG-1998;	98US-0097661P.
PR	19-JUN-1998; 98US-0089947P.		PR	26-AUG-1998;	98US-0097952P.
PR			PR	26-AUG-1998;	98US-0097954P.

PR	26-AUG-1998;	98US-0097955P.
PR	26-AUG-1998;	98US-0097971P.
PR	26-AUG-1998;	98US-0097974P.
PR	26-AUG-1998;	98US-0097978P.
PR	26-AUG-1998;	98US-0097979P.
PR	26-AUG-1998;	98US-0097986P.
PR	26-AUG-1998;	98US-0098014P.
PR	31-AUG-1998;	98US-0098525P.
PR	16-SEP-1998;	98US-0100634P.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98US-0100858P.
PR	17-SEP-1998;	98WO-US019437.
PR	07-OCT-1998;	98WO-US021141.
PR	01-DEC-1998;	98WO-US025108.
PR	22-DEC-1998;	98US-0113296P.
PR	05-JAN-1999;	99WO-US000106.
PR	08-MAR-1999;	99WO-US005028.
PR	12-MAR-1999;	99US-0123957P.
PR	02-JUN-1999;	99WO-US012252.
PR	23-JUN-1999;	99US-0141037P.
PR	07-JUL-1999;	99US-0143048P.
PR	20-JUL-1999;	99US-0144758P.
PR	26-JUL-1999;	99US-0145698P.
PR	28-JUL-1999;	99US-0146222P.
PR	17-AUG-1999;	99US-0149396P.
PR	15-SEP-1999;	99WO-US021090.
PR	15-SEP-1999;	99WO-US021547.
PR	08-OCT-1999;	99US-0158663P.
PR	30-NOV-1999;	99WO-US028313.
PR	01-DEC-1999;	99WO-US028301.
PR	01-DEC-1999;	99WO-US028634.
PR	16-DEC-1999;	99WO-US030095.
PR	20-DEC-1999;	99WO-US030911.
PR	05-JAN-2000;	2000WO-US000219.
PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US003565.
PR	18-FEB-2000;	2000WO-US004341.
PR	22-FEB-2000;	2000WO-US004414.
PR	24-FEB-2000;	2000WO-US005004.
PR	02-MAR-2000;	2000WO-US005841.
PR	10-MAR-2000;	2000WO-US006319.
PR	15-MAR-2000;	2000WO-US006884.
PR	20-MAR-2000;	2000WO-US007377.
PR	30-MAR-2000;	2000WO-US008439.
PR	15-MAY-2000;	2000WO-US013358.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	23-JUN-2000;	2000US-021637P.
PR	28-JUL-2000;	2000WO-US020710.

	Query Match	3.0%;	Score 66.6;	DB 9;	Length 2846;
	Best Local Similarity	71.3%;	Pred. No. 0.00023;		
	Matches 87;	Conservative 0;	Mismatches 35;	Indels 0;	Gaps 0;
QY	2121	CCTTTGCTTTACCACTCTTTCCCTTTTATCTTTATTAATAAAAAATGTTGGTCTCCACCACTG	2180		
Db	2653	CCTTTTCCTTCCCCATCTCTGTGACACATTTTATAAAAAATAAGGTTGGCTTCTGAACATA	2712		
QY	2181	NCTCCCAA	2240		
Db	2713	CAA	2772		
QY	2241	AA	2242		
Db	2773	AA	2774		

RESULT 700  
ACC99097  
ID ACC99097 standard; cDNA; 2846 BP.

XX	AC	ACC99097;	
XX	DT	19-SEP-2003	(first entry)
XX	DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.	
XX	KW	Human; PRO; secreted protein; transmembrane protein; extracellular domain; tumour necrosis factor-alpha; TNF-alpha; chondrocyte; proliferation; differentiation; cartilage disorder; bone disorder; arthritis; sports injury; cancer; tumour; diagnosis; adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix; liver; drug screening; transgenic animal; genetic analysis; antiarthritic; vulnery; gene therapy; gene; ss.	
XX	OS	Homo sapiens.	
XX	PN	US2003040067-A1.	
XX	PD	27-FEB-2003.	
XX	PF	27-JUN-2002; 2002US-00184618.	
XX	PR	18-SEP-1997; 97US-0059263P.	
PR	PR	18-SEP-1997; 97US-0059266P.	
PR	PR	17-OCT-1997; 97US-0062250P.	
PR	PR	21-OCT-1997; 97US-0063486P.	
PR	PR	24-OCT-1997; 97US-0063120P.	
PR	PR	24-OCT-1997; 97US-0063121P.	
PR	PR	28-OCT-1997; 97US-0063540P.	
PR	PR	28-OCT-1997; 97US-0063541P.	
PR	PR	28-OCT-1997; 97US-0063544P.	
PR	PR	28-OCT-1997; 97US-0063564P.	
PR	PR	29-OCT-1997; 97US-0063734P.	
PR	PR	31-OCT-1997; 97US-0063870P.	
PR	PR	31-OCT-1997; 97US-0064103P.	
PR	PR	13-NOV-1997; 97US-0065311P.	
PR	PR	21-NOV-1997; 97US-0066120P.	
PR	PR	24-NOV-1997; 97US-0066466P.	
PR	PR	24-NOV-1997; 97US-0066772P.	
PR	PR	11-DEC-1997; 97US-0069335P.	
PR	PR	12-DEC-1997; 97US-0069425P.	
PR	PR	17-DEC-1997; 97US-0069870P.	
PR	PR	18-DEC-1997; 97US-0068017P.	
PR	PR	10-MAR-1998; 98US-0077450P.	
PR	PR	11-MAR-1998; 98US-0077632P.	
PR	PR	11-MAR-1998; 98US-0077649P.	
PR	PR	20-MAR-1998; 98US-0078886P.	
PR	PR	20-MAR-1998; 98US-0078939P.	
PR	PR	27-MAR-1998; 98US-0079664P.	
PR	PR	27-MAR-1998; 98US-0079786P.	
PR	PR	31-MAR-1998; 98US-0080107P.	
PR	PR	31-MAR-1998; 98US-0080194P.	
PR	PR	01-APR-1998; 98US-0080327P.	
PR	PR	01-APR-1998; 98US-0080333P.	
PR	PR	08-APR-1998; 98US-0081049P.	
PR	PR	08-APR-1998; 98US-0081070P.	
PR	PR	09-APR-1998; 98US-0081195P.	
PR	PR	15-APR-1998; 98US-0081838P.	
PR	PR	21-APR-1998; 98US-0082568P.	
PR	PR	21-APR-1998; 98US-0082569P.	
PR	PR	22-APR-1998; 98US-0082704P.	
PR	PR	22-APR-1998; 98US-0082797P.	
PR	PR	28-APR-1998; 98US-0083322P.	
PR	PR	29-APR-1998; 98US-0083495P.	
PR	PR	29-APR-1998; 98US-0083496P.	
PR	PR	29-APR-1998; 98US-0083499P.	
PR	PR	29-APR-1998; 98US-0083559P.	
PR	PR	05-MAY-1998; 98US-0084366P.	
PR	PR	06-MAY-1998; 98US-0084414P.	
PR	PR	07-MAY-1998; 98US-0084639P.	
PR	PR	07-MAY-1998; 98US-0084640P.	
PR	PR	07-MAY-1998; 98US-0084643P.	



ID ACF00491 standard; cDNA; 2846 BP.  
XX AC ACF00491;  
XX DT 19-SEP-2003 (first entry)  
XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.  
XX KW Human; PRO; secreted protein; transmembrane protein;  
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;  
KW chondrocyte; proliferation; differentiation; cartilage disorder;  
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;  
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;  
KW liver; drug screening; transgenic animal; genetic analysis;  
KW antiarthritic; vulnery; gene therapy; gene; ss.  
XX OS Homo sapiens.  
XX PN US2003054456-A1.  
XX PD 20-MAR-2003.  
XX PF 27-JUN-2002; 2002US-00184638.  
XX PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.

PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 26-JUN-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 01-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 04-JUL-1998; 98US-0094006P.  
PR 24-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.





Db 2653 CCTTTCTCTCCCATCTCTTGTCACATTTTAATAAAATAAGGTTGGCTTCTGAACTA 2712  
Qy 2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240  
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

Qy 2241 AA 2242  
Db 2773 AA 2774

RESULT 703  
ID ACF14567 standard; cDNA; 2846 BP.  
XX ACF14567;  
XX 02-OCT-2003 (first entry)  
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX Human; PRO; secreted protein; transmembrane protein;  
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;  
KW chondrocyte; proliferation; differentiation; cartilage disorder;  
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;  
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;  
KW liver; drug screening; transgenic animal; genetic analysis;  
KW antiarthritic; vulnerary; gene therapy; gene; ss.

XX Homo sapiens.  
XX US2003054457-A1.  
XX 20-MAR-2003.

XX 01-JUL-2002; 2002US-00187752.  
XX 05-APR-1999; 99US-0127706P.  
XX 01-MAR-2000; 2000WO-US005601.  
XX 28-FEB-2001; 2001WO-US006520.  
XX 15-JAN-2002; 2002US-00052586.

XX (GETH ) GENENTECH INC.  
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;  
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-540605/51.  
XX P-PSDB; ABR93774.

XX New secreted and transmembrane polypeptides and nucleic acids encoding  
XX the polypeptides, useful in gene therapy, in identifying chromosomes, as  
XX chromosome markers, and in generating probes.  
XX Claim 2; Fig 169; 700pp; English.

XX The invention relates to human PRO secreted/transmembrane polypeptides  
XX (ABR93690-93994) and nucleic acids encoding them (ACF1483-ACF14787). The  
XX invention also relates to sequences at least 80% identical to the PRO  
XX nucleic acid and polypeptide sequences of the invention, recombinant  
XX vectors and host cells comprising a PRO nucleic acid, a method for the  
XX recombinant production of a PRO polypeptide, antibodies against a PRO  
XX polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic  
XX acids encoding PRO polypeptides of the invention were initially  
XX identified via homology screening using consensus sequences based on the  
XX extracellular domain sequences from known secreted proteins. Human cDNA  
XX libraries containing sequences of interest were identified using  
XX oligonucleotides based on the consensus sequences, and cDNA clones were  
XX isolated and characterised. The PRO polypeptides are useful for  
XX stimulating release of tumour necrosis factor-alpha (TNF-alpha) from  
XX human blood and may thus be used in the treatment of conditions in which  
XX enhanced TNF-alpha release would be beneficial. They are also useful for  
XX stimulating the proliferation or differentiation of chondrocytes and as

CC such may be used in the treatment of various bone and/or cartilage  
CC disorders such as arthritis and sports injuries. The PRO polypeptides may  
CC be used in a method for detecting the presence of a tumour (e.g., an  
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate  
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This  
CC method involves comparing the level of expression of the PRO polypeptide  
CC in test and control samples, where a higher level of expression of PRO  
CC polypeptide in the test sample as compared to the control sample is  
CC indicative of the presence of a tumour. The PRO polypeptides are  
CC additionally useful for in drug screening to identify agonists and  
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as  
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and  
CC gene mapping, in the generation of antisense RNA and DNA and in gene  
CC therapy. The nucleic acids can also be used for mapping genes encoding  
CC PRO polypeptides, for genetic analysis of individuals with genetic  
CC disorders, and for generating either transgenic animals or knock-out  
CC animals which are useful in the development and screening of  
CC therapeutically useful compounds. Sequences ACF1483-ACF14787 represent  
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the  
CC invention. Note: The sequence data for this patent is also available in  
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACCTCTTCTCTTATCTTATTAATAAATGTTGGTCTCCACCACTG 2180  
Db 2653 CCTTTCTCTCTCCCATCTCTTGTCACATTTTAATAAATAGGTTGGTCTGAACTA 2712  
Qy 2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240  
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772  
Qy 2241 AA 2242  
Db 2773 AA 2774

RESULT 704  
ACF22342  
ID ACF22342 standard; cDNA; 2846 BP.  
XX ACF22342;  
XX 19-SEP-2003 (first entry)  
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX Human; PRO; secreted protein; transmembrane protein;  
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;  
KW chondrocyte; proliferation; differentiation; cartilage disorder;  
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;  
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;  
KW liver; drug screening; transgenic animal; genetic analysis;  
KW antiarthritic; vulnerary; gene therapy; gene; ss.

XX Homo sapiens.  
XX OS  
XX US2003059883-A1.  
XX 27-MAR-2003.

XX 19-JUL-2002; 2002US-00199308.  
XX 29-SEP-1998; 98US-0102331P.  
XX 01-SEP-1999; 99WO-US020111.  
XX 18-OCT-1999; 99US-00403297.  
XX 28-FEB-2001; 2001WO-US006520.  
XX 15-JAN-2002; 2002US-00052586.

PA (GETH ) GENENTECH INC.  
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;  
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-555482/52.  
DR P-PSDB; ABM01817.  
XX  
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
PT in gene therapy, or for preparing a medicament for treating a condition  
PT that is responsive to the PRO polypeptide or anti-PRO antibody.  
XX  
PS Claim 2; Fig 169; 700pp; English.  
XX  
XX The invention relates to human PRO secreted/transmembrane polypeptides  
CC (ABM01733-ABM02037) and nucleic acids encoding them (ACF22258-ACF22562).  
CC The invention also relates to sequences at least 80% identical to the PRO  
CC nucleic acid and polypeptide sequences of the invention, recombinant  
CC vectors and host cells comprising a PRO nucleic acid, a method for the  
CC recombinant production of a PRO polypeptide, antibodies against a PRO  
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic  
CC acids encoding PRO polypeptides of the invention were initially  
CC identified via homology screening using consensus sequences based on the  
CC extracellular domain sequences from known secreted proteins. Human cDNA  
CC libraries containing sequences of interest were identified using  
CC oligonucleotides based on the consensus sequences, and cDNA clones were  
CC isolated and characterised. The PRO polypeptides are useful for  
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from  
CC human blood and may thus be used in the treatment of conditions in which  
CC enhanced TNF-alpha release would be beneficial. They are also useful for  
CC stimulating the proliferation or differentiation of chondrocytes and as  
CC such may be used in the treatment of various bone and/or cartilage  
CC disorders such as arthritis and sports injuries. The PRO polypeptides may  
CC be used in a method for detecting the presence of a tumour (e.g., an  
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate  
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This  
CC method involves comparing the level of expression of the PRO polypeptide  
CC in test and control samples, where a higher level of expression of PRO  
CC polypeptide in the test sample as compared to the control sample is  
CC indicative of the presence of a tumour. The PRO polypeptides are  
CC additionally useful for in drug screening to identify agonists and  
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as  
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and  
CC gene mapping, in the generation of antisense RNA and DNA and in gene  
CC therapy. The nucleic acids can also be used for mapping genes encoding  
CC PRO polypeptides, for genetic analysis of individuals with genetic  
CC disorders, and for generating either transgenic animals or knock-out  
CC animals which are useful in the development and screening of  
CC therapeutically useful compounds. Sequences ACF22258-ACF22562 represent  
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the  
CC invention. Note: The sequence data for this patent is also available in  
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html  
XX  
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACCTCTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACGTG 2180  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 2653 CCTTTTCCTTCCCCATCTCTGTACACATTTTAAATAAAATAAGGTTGGCTTCTGAACATA 2712  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
QY 2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2240  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 2713 CAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2772  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
QY 2241 AA 2242  
||  
Db 2773 AA 2774

RESULT 705

ACF78919  
ID ACF78919 standard; cDNA; 2846 BP.  
XX  
AC ACF78919;  
XX  
DT 06-NOV-2003 (first entry)  
XX  
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.  
XX  
KW Human; PRO; secreted protein; transmembrane protein;  
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;  
KW chondrocyte; proliferation; differentiation; cartilage disorder;  
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;  
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;  
KW liver; drug screening; transgenic animal; genetic analysis;  
KW antiarthritic; vulnery; gene therapy; gene; ss.  
OS Homo sapiens.  
XX  
XX US2003049764-A1.  
PN  
XX 13-MAR-2003.  
PD  
XX 18-JUL-2002; 2002US-00199665.  
PF  
XX 31-MAR-1998; 98US-0080194P.  
PR 08-MAR-1999; 99WO-US005028.  
PR 25-AUG-1999; 99US-00380138.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 15-JAN-2002; 2002US-00052586.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;  
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR WPI; 2003-585113/55.  
DR P-PSDB; ABM78240.  
XX  
PT New PRO polypeptides and nucleic acids encoding the polypeptides, useful  
PT in gene therapy, chromosome identification, tissue typing, or as  
PT hybridization probes in chromosome and gene mapping.  
XX  
PS Claim 2; Fig 169; 700pp; English.  
XX  
CC The invention relates to human PRO secreted/transmembrane polypeptides  
CC and nucleic acids encoding them, the invention also provides recombinant  
CC vectors and host cells comprising a PRO nucleic acid, a method for the  
CC recombinant production of a PRO polypeptide, antibodies against a PRO  
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic  
CC acids encoding PRO polypeptides of the invention were initially  
CC identified via homology screening using consensus sequences based on the  
CC extracellular domain sequences from known secreted proteins. Human cDNA  
CC libraries containing sequences of interest were identified using  
CC oligonucleotides based on the consensus sequences, and cDNA clones were  
CC isolated and characterised. The PRO polypeptides are useful for  
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from  
CC human blood and may thus be used in the treatment of conditions in which  
CC enhanced TNF-alpha release would be beneficial. They are also useful for  
CC stimulating the proliferation or differentiation of chondrocytes and as  
CC such may be used in the treatment of various bone and/or cartilage  
CC disorders such as arthritis and sports injuries. The PRO polypeptides may  
CC be used in a method for detecting the presence of a tumour (e.g., an  
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate  
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This  
CC method involves comparing the level of expression of the PRO polypeptide  
CC in test and control samples, where a higher level of expression of PRO  
CC polypeptide in the test sample as compared to the control sample is  
CC indicative of the presence of a tumour. The PRO polypeptides are  
CC additionally useful for in drug screening to identify agonists and  
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as  
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and  
CC gene mapping, in the generation of antisense RNA and DNA and in gene



```
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. The present sequence appears in the
CC exemplification of the specification. Note: The sequence data for this
CC patent is also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTGTTTACCACCTCTTTCCCTTTTATCTTATTATAATAAATGTTGGTCTCCACCCTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTTCTTCCCATCTCTTGTACACATTTTAATAAATAAGGCTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
Db ||
2773 AA 2774

RESULT 706
ACF11640
ID ACF11640 standard; cDNA; 2846 BP.
XX
AC ACF11640;
XX
DT 09-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulneryary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003073177-A1.
XX
PD 17-APR-2003.
XX
PF 12-JUL-2002; 2002US-00194365.
XX
PR 26-JUN-1998; 98US-00105413.
PR 16-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 06-NOV-1998; 98US-00187368.
PR 01-DEC-1998; 98WO-US025108.
PR 07-DEC-1998; 98US-00202054.
PR 03-MAR-1999; 99US-00254311.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021090.
PR 18-OCT-1999; 99US-00403297.
```

```
PR 12-NOV-1999; 99US-00423844.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028551.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00866028.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 30-JUL-2001; 2001US-00918585.
PR 06-AUG-2001; 2001US-00924419.
PR 13-AUG-2001; 2001US-00929404.
PR 16-AUG-2001; 2001US-00931836.
PR 28-AUG-2001; 2001US-00941992.
PR 29-AUG-2001; 2001WO-US027099.
PR 04-SEP-2001; 2001US-00946374.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-585300/55.
DR P-PSDB; ABR90029.
XX
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for the manufacture of a medicament for diagnosing or treating tumor or
PT for measuring or detecting expression of an associated gene.
XX
PS Claim 2; Fig 169; 701pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABR89945-ABR90249) and nucleic acids encoding them (ACF11556-ACF11860).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, a method for the
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
```















XX US2003068683-A1.  
PN 10-APR-2003.  
XX  
PD  
XX  
XX  
PF 27-JUN-2002; 2002US-00184633.  
XX  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.

PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.

PR	02-SEP-1998;	98US-0098821P.	
PR	02-SEP-1998;	98US-0098843P.	
PR	09-SEP-1998;	98US-0099602P.	
PR	10-SEP-1998;	98US-0099741P.	
PR	10-SEP-1998;	98US-0099754P.	
PR	10-SEP-1998;	98US-0099763P.	
PR	10-SEP-1998;	98US-0099812P.	
PR	15-SEP-1998;	98US-0100388P.	
PR	16-SEP-1998;	98US-0100662P.	
PR	16-SEP-1998;	98US-0100664P.	
PR	16-SEP-1998;	98US-0101751P.	
PR	16-SEP-1998;	98WO-US019330.	
PR	17-SEP-1998;	98US-0100683P.	
PR	17-SEP-1998;	98US-0100684P.	
PR	17-SEP-1998;	98US-0100919P.	
PR	17-SEP-1998;	98US-0100930P.	
PR	18-SEP-1998;	98US-0100849P.	
PR	18-SEP-1998;	98US-0101014P.	
PR	18-SEP-1998;	98US-0101068P.	
PR	23-SEP-1998;	98US-0101471P.	
PR	23-SEP-1998;	98US-0101472P.	
PR	23-SEP-1998;	98US-0101475P.	
PR	23-SEP-1998;	98US-0101477P.	
PR	24-SEP-1998;	98US-0101738P.	
PR	24-SEP-1998;	98US-0101739P.	
PR	24-SEP-1998;	98US-0101743P.	
PR	24-SEP-1998;	98US-0101922P.	
PR	25-SEP-1998;	98US-0101786P.	
PR	29-SEP-1998;	98US-0102207P.	
PR	29-SEP-1998;	98US-0102240P.	
PR	29-SEP-1998;	98US-0102330P.	
PR	29-SEP-1998;	98US-0102331P.	
PR	30-SEP-1998;	98US-0102487P.	
PR	30-SEP-1998;	98US-0102570P.	
PR	30-SEP-1998;	98US-0102571P.	
PR	01-OCT-1998;	98US-0102684P.	
PR	01-OCT-1998;	98US-0102687P.	
<div>Query Match 3.0%; Score 66.6; DB 9; Length 2846; Best Local Similarity 71.3%; Pred. No. 0.00023; Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;</div>			
QY	2121	CCTTGGCTTTACCACTCTTTCCTTTTATCTTTATTAATAAAAAATGTTGGTCTCCACCAC	2180
Db	2653	CCTTTCTCTCCCATCTCTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAAC	2712
QY	2181	NTCTCCAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA	2240
Db	2713	CAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA	2772
QY	2241	AA 2242	
Db	2773	AA 2774	
RESULT 712			
ACF28540			
ID	ACF28540 standard; cDNA; 2846 BP.		
XX	ACF28540;		
AC	ACF28540;		
XX	20-SEP-2003 (first entry)		
DT	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.		
DE	Human; PRO; secreted protein; transmembrane protein;		
XX	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;		
KW	chondrocyte; proliferation; differentiation; cartilage disorder;		
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;		
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;		
KW	liver; drug screening; transgenic animal; genetic analysis;		
KW	antiarthritic; vulnery; gene therapy; gene; ss.		
XX			

OS	Homo sapiens.																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																														
----	---------------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Db	2653	CCTTTCTCCCATCTCTTGTGACACATTTTAATAAATAAGGGTTGGCTTCTGAACTA	2712	22-APR-1998;	98US-0082797P;
				PR	98US-00833222P;
Qy	2181	NCTCCCAA	2240	28-APR-1998;	98US-0083495P;
				PR	98US-0083496P;
Db	2713	CAA	2772	29-APR-1998;	98US-0083499P;
				PR	98US-0083559P;
Qy	2241	AA 2242		PR	98US-0084366P;
				PR	98US-0084414P;
Db	2773	AA 2774		PR	98US-0084639P;
				PR	98US-0084640P;
RESULT 713				PR	98US-0084643P;
ACD88616				PR	98US-0085579P;
ID	ACD88616	standard; cDNA; 2846 BP.		PR	98US-0085580P;
XX	XX			PR	98US-0085582P;
AC	AC			PR	98US-0085700P;
XX	XX			PR	98US-0086023P;
DT	DT			PR	98US-0086392P;
XX	XX			PR	98US-0086486P;
DE	DE			PR	98US-0087098P;
XX	XX			PR	98US-0087208P;
DE	DE	Human secreted/transmembrane protein (PRO) cDNA #85.		PR	98US-0087609P;
XX	XX			PR	98US-0087759P;
KW	KW	Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;		PR	98US-0087827P;
KW	KW	tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;		PR	98US-0088025P;
KW	KW	tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;		PR	98US-0088028P;
KW	KW	prostate tumour; rectal tumour; cervical tumour; liver tumour.		PR	98US-0088029P;
OS	OS	Homo sapiens.		PR	98US-0088033P;
XX	XX			PR	98US-0088326P;
PN	PN	US2003068681-A1.		PR	98US-0088167P;
XX	XX			PR	98US-0088202P;
PD	PD	10-APR-2003.		PR	98US-0088212P;
XX	XX			PR	98US-0088217P;
PF	PF	21-JUN-2002; 2002US-00176923.		PR	98US-0088655P;
XX	XX			PR	98US-0088722P;
PR	PR	18-SEP-1997; 97US-0059263P.		PR	98US-0088738P;
PR	PR	18-SEP-1997; 97US-0059266P.		PR	98US-0088740P;
PR	PR	17-OCT-1997; 97US-0062250P.		PR	98US-0088811P;
PR	PR	21-OCT-1997; 97US-0063486P.		PR	98US-0088824P;
PR	PR	24-OCT-1997; 97US-0063120P.		PR	98US-0088825P;
PR	PR	24-OCT-1997; 97US-0063121P.		PR	98US-0088826P;
PR	PR	28-OCT-1997; 97US-0063540P.		PR	98US-0088861P;
PR	PR	28-OCT-1997; 97US-0063541P.		PR	98US-0088863P;
PR	PR	28-OCT-1997; 97US-0063544P.		PR	98US-0088876P;
PR	PR	28-OCT-1997; 97US-0063564P.		PR	98US-0089090P;
PR	PR	29-OCT-1997; 97US-0063734P.		PR	98US-0089105P;
PR	PR	31-OCT-1997; 97US-0063870P.		PR	98US-0089512P;
PR	PR	31-OCT-1997; 97US-0064103P.		PR	98US-0089514P;
PR	PR	13-NOV-1997; 97US-0065311P.		PR	98US-0089538P;
PR	PR	21-NOV-1997; 97US-0066120P.		PR	98US-0089598P;
PR	PR	24-NOV-1997; 97US-0066466P.		PR	98US-0089653P;
PR	PR	24-NOV-1997; 97US-0066772P.		PR	98US-0089908P;
PR	PR	11-DEC-1997; 97US-0069335P.		PR	98US-0089952P;
PR	PR	12-DEC-1997; 97US-0069425P.		PR	98US-0090246P;
PR	PR	17-DEC-1997; 97US-0069870P.		PR	98US-0090254P;
PR	PR	18-DEC-1997; 97US-0068017P.		PR	98US-0090429P;
PR	PR	10-MAR-1998; 98US-0077450P.		PR	98US-0090435P;
PR	PR	11-MAR-1998; 98US-0077632P.		PR	98US-0090444P;
PR	PR	11-MAR-1998; 98US-0077649P.		PR	98US-0090461P;
PR	PR	20-MAR-1998; 98US-0078886P.		PR	98US-0090535P;
PR	PR	20-MAR-1998; 98US-0078939P.		PR	98US-0090540P;
PR	PR	27-MAR-1998; 98US-0079664P.		PR	98US-0090676P;
PR	PR	27-MAR-1998; 98US-0079786P.		PR	98US-0090678P;
PR	PR	31-MAR-1998; 98US-0080107P.		PR	98US-0090688P;
PR	PR	31-MAR-1			



PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 16-SEP-1998; 98US-0100662P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.  
PR 17-SEP-1998; 98US-0100919P.  
PR 17-SEP-1998; 98US-0100930P.  
PR 18-SEP-1998; 98US-0100849P.  
PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.  
PR 23-SEP-1998; 98US-0101471P.  
PR 23-SEP-1998; 98US-0101472P.  
PR 23-SEP-1998; 98US-0101475P.  
PR 23-SEP-1998; 98US-0101477P.  
PR 24-SEP-1998; 98US-0101738P.  
PR 24-SEP-1998; 98US-0101739P.  
PR 24-SEP-1998; 98US-0101743P.  
PR 24-SEP-1998; 98US-0101922P.  
PR 25-SEP-1998; 98US-0101786P.  
PR 29-SEP-1998; 98US-0102207P.  
PR 29-SEP-1998; 98US-0102240P.  
PR 29-SEP-1998; 98US-0102330P.  
PR 29-SEP-1998; 98US-0102331P.  
PR 30-SEP-1998; 98US-0102487P.  
PR 30-SEP-1998; 98US-0102570P.  
PR 30-SEP-1998; 98US-0102571P.  
PR 01-OCT-1998; 98US-0102684P.  
PR 01-OCT-1998; 98US-0102687P.  
PR 02-OCT-1998; 98US-0102965P.  
PR 06-OCT-1998; 98US-0103258P.  
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;  
QY 2121 CCTTTGCTTTACCACCTTTCTCTTTTATCTTTAATAAATAAGTTGGTCTCCACCACTG 2180

Db 2653 CCTTTTCTTCCCATCTCTTGTACACATTTTATAAATAAGGTTGGCTTCTGAACTA 2712  
QY 2181 NCTCCCAA 2240  
Db 2713 CAAA 2772  
QY 2241 AA 2242  
Db 2773 AA 2774  
RESULT 714  
ACF75235  
ID ACF75235 standard; cDNA; 2846 BP.  
XX  
AC ACF75235;  
XX 06-NOV-2003 (first entry)  
DT Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.  
DE Human; PRO; secreted protein; transmembrane protein;  
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;  
KW chondrocyte; proliferation; differentiation; cartilage disorder;  
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;  
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;  
KW liver; drug screening; transgenic animal; genetic analysis;  
KW antiarthritic; vulnerary; gene therapy; gene; ss.  
XX Homo sapiens.  
OS  
XX US2003096351-A1.  
PN  
XX PD 22-MAY-2003.  
XX  
XX PF 18-JUN-2002; 2002US-00174575.  
XX  
XX PR 27-MAR-1998; 98US-0079786P.  
PR 08-MAR-1999; 99WO-US005028.  
PR 25-AUG-1999; 99US-00380138.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 15-JAN-2002; 2002US-00052586.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;  
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-658244/62.  
DR P-PSDB; ABM74581.  
XX  
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful  
PT for the manufacture of a medicament for diagnosing or treating tumor or  
PT for tissue typing.  
XX  
PS Claim 2; Fig 169; 709pp; English.  
XX  
CC The invention relates to human PRO secreted/transmembrane polypeptides  
CC (ABM74497-ABM74801) and nucleic acids encoding them (ACF75151-ACF75455).  
CC The invention also relates to sequences at least 80% identical to the PRO  
CC nucleic acid and polypeptide sequences of the invention, recombinant  
CC vectors and host cells comprising a PRO nucleic acid, a method for the  
CC recombinant production of a PRO polypeptide, antibodies against a PRO  
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic  
CC acids encoding PRO polypeptides of the invention were initially  
CC identified via homology screening using consensus sequences based on the  
CC extracellular domain sequences from known secreted proteins. Human cDNA  
CC libraries containing sequences of interest were identified using  
CC oligonucleotides based on the consensus sequences, and cDNA clones were  
CC isolated and characterised. The PRO polypeptides are useful for  
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from  
CC human blood and may thus be used in the treatment of conditions in which











PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.

PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 11-AUG-1998; 98US-0096012P.  
PR 12-AUG-1998; 98US-0096146P.  
PR 13-AUG-1998; 98US-0096329P.  
PR 13-AUG-1998; 98US-0096413P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 31-AUG-1998; 98US-0098525P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 12-MAR-1999; 99US-0123957P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 17-AUG-1999; 99US-0149396P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 08-OCT-1999; 99US-0158663P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.

```
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTTACCACTCTTTCCTTTTATCTTATTAATAATAAATGTTGGTCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAATAAAGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 719
ACC93841
ID ACC93841 standard; cDNA; 2846 BP.
XX
AC ACC93841;
XX
DT 22-AUG-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003036122-A1.
XX
PD 20-FEB-2003.
XX
PF 25-JUN-2002; 2002US-00180548.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
```





PR	25-AUG-1999;	99US-00380142;
PR	01-SEP-1999;	99WO-US020111;
PR	15-SEP-1999;	99WO-US021090;
PR	18-OCT-1999;	99US-00403297;
PR	12-NOV-1999;	99US-00423844;
PR	01-DEC-1999;	99WO-US028301;
PR	02-DEC-1999;	99WO-US028551;
PR	30-DEC-1999;	99WO-US031274;
PR	05-JAN-2000;	2000WO-US000219;
PR	18-FEB-2000;	2000WO-US004341;
PR	18-FEB-2000;	2000WO-US004342;
PR	22-FEB-2000;	2000WO-US004414;
PR	24-FEB-2000;	2000WO-US005004;
PR	01-MAR-2000;	2000WO-US005601;
PR	02-MAR-2000;	2000WO-US005841;
PR	15-MAR-2000;	2000WO-US006884;
PR	30-MAR-2000;	2000WO-US008439;
PR	17-MAY-2000;	2000WO-US013705;
PR	22-MAY-2000;	2000WO-US014042;
PR	30-MAY-2000;	2000WO-US014941;
PR	02-JUN-2000;	2000WO-US015264;
PR	28-JUL-2000;	2000WO-US020710;
PR	22-AUG-2000;	2000US-00644848;
PR	24-AUG-2000;	2000WO-US023328;
PR	18-SEP-2000;	2000US-00664610;
PR	18-SEP-2000;	2000US-00665350;
PR	08-NOV-2000;	2000US-00709238;
PR	08-NOV-2000;	2000WO-US030952;
PR	01-DEC-2000;	2000WO-US032678;
PR	20-DEC-2000;	2000US-00747259;
PR	20-DEC-2000;	2000WO-US034956;
PR	28-FEB-2001;	2001WO-US006520;
PR	22-MAR-2001;	2001US-00816744;
PR	10-MAY-2001;	2001US-00854208;
PR	10-MAY-2001;	2001US-00854280;
PR	25-MAY-2001;	2001US-00866028;
PR	01-JUN-2001;	2001WO-US017800;
PR	20-JUN-2001;	2001WO-US019692;
PR	29-JUN-2001;	2001WO-US021066;
PR	09-JUL-2001;	2001WO-US021735;
PR	18-JUL-2001;	2001US-00908827;
PR	30-JUL-2001;	2001US-00918585;
PR	06-AUG-2001;	2001US-00924419;
PR	13-AUG-2001;	2001US-00929404;
PR	16-AUG-2001;	2001US-00931836;
PR	28-AUG-2001;	2001US-00941992;
PR	29-AUG-2001;	2001WO-US027099;
PR	04-SEP-2001;	2001US-00946374;
PR	15-JAN-2002;	2002US-00052586;

sequences. The nucleotide sequences are useful as probes, in chromosome and gene mapping, in generating antisense RNA and DNA, in preparing PRO polypeptides by recombinant techniques and in gene therapy (e.g. for replacement of defective gene). The PRO polypeptides are useful as molecular weight markers for protein electrophoresis purposes, for chromosome identification, as chromosome markers, as therapeutic agents, for stimulating the release of TNF-alpha from human blood, for stimulating the proliferation or differentiation of chondrocytes and detecting the presence, prevention and/or treatment of a tumour, such as adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour. The PRO polypeptides and nucleic acids may also be used diagnostically for tissue typing. The sequence presented is a cDNA encoding one of the PRO polypeptides of the invention. Note: The sequence data for this patent can also be obtained in electronic format directly from USPTO at [segdata.uspto.gov/sequence.html](http://segdata.uspto.gov/sequence.html)

PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-007886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.

PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 16-SEP-1998; 98US-0100662P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.  
PR 17-SEP-1998; 98US-0100919P.  
PR 17-SEP-1998; 98US-0100930P.  
PR 18-SEP-1998; 98US-0100849P.  
PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.

PR	23-SEP-1998;	98US-0101471P.	
PR	23-SEP-1998;	98US-0101472P.	
PR	23-SEP-1998;	98US-0101475P.	
PR	23-SEP-1998;	98US-0101477P.	
PR	24-SEP-1998;	98US-0101738P.	
PR	24-SEP-1998;	98US-0101739P.	
PR	24-SEP-1998;	98US-0101743P.	
PR	24-SEP-1998;	98US-0101922P.	
PR	25-SEP-1998;	98US-0101786P.	
PR	29-SEP-1998;	98US-0102207P.	
PR	29-SEP-1998;	98US-0102240P.	
PR	29-SEP-1998;	98US-0102331P.	
PR	29-SEP-1998;	98US-0102487P.	
PR	30-SEP-1998;	98US-0102570P.	
PR	30-SEP-1998;	98US-0102571P.	
PR	01-OCT-1998;	98US-0102684P.	
PR	01-OCT-1998;	98US-0102687P.	
Query Match 3.0%; Score 66.6; DB 9; Length 2846;			
Best Local Similarity 71.3%; Pred. No. 0.00023;			
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;			
Qy	2121	CCTTGCTTTACCACTCTTCCCTTTTATCTTATTATAATAAATGTTGGTCTCCACCACTG	2180
Db	2653	CCTTTCCTTCCCATCTCTGTACACATTTTAATAAATAAGGTTGGCTTCTGAACTA	2712
Qy	2181	NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	2240
Db	2713	CAA	2772
Qy	2241	AA 2242	
Db	2773	AA 2774	
RESULT 722			
ID	ACD20639	standard; cDNA; 2846 BP.	
XX	AC	ACD20639;	
XX	DT	28-AUG-2003 (first entry)	
XX	DE	Human secreted/transmembrane protein (PRO) cDNA #85.	
XX	KW	Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;	
XX	KW	tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;	
XX	KW	tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;	
XX	KW	prostate tumour; rectal tumour; cervical tumour; liver tumour.	
OS	XX	Homo sapiens.	
XX	PN	US2003044919-A1.	
XX	PD	06-MAR-2003.	
XX	PF	21-JUN-2002; 2002US-00176982.	
XX	PR	18-SEP-1997; 97US-0059263P.	
PR	PR	18-SEP-1997; 97US-0059266P.	
PR	PR	17-OCT-1997; 97US-0062250P.	
PR	PR	21-OCT-1997; 97US-0063486P.	
PR	PR	24-OCT-1997; 97US-0063120P.	
PR	PR	24-OCT-1997; 97US-0063121P.	
PR	PR	28-OCT-1997; 97US-0063540P.	
PR	PR	28-OCT-1997; 97US-0063541P.	
PR	PR	28-OCT-1997; 97US-0063544P.	
PR	PR	28-OCT-1997; 97US-0063564P.	
PR	PR	29-OCT-1997; 97US-0063734P.	
PR	PR	31-OCT-1997; 97US-0063870P.	
PR	PR	31-OCT-1997; 97US-0064103P.	
PR	PR	13-NOV-1997; 97US-0065311P.	

PR	21-NOV-1997;	97US-0066120P.
PR	24-NOV-1997;	97US-0066466P.
PR	24-NOV-1997;	97US-0066772P.
PR	11-DEC-1997;	97US-0069335P.
PR	12-DEC-1997;	97US-0069425P.
PR	17-DEC-1997;	97US-0069870P.
PR	18-DEC-1997;	97US-0068017P.
PR	10-MAR-1998;	98US-0077450P.
PR	11-MAR-1998;	98US-0077632P.
PR	11-MAR-1998;	98US-0077649P.
PR	20-MAR-1998;	98US-0078886P.
PR	20-MAR-1998;	98US-0078939P.
PR	27-MAR-1998;	98US-0079664P.
PR	27-MAR-1998;	98US-0079786P.
PR	31-MAR-1998;	98US-0080107P.
PR	31-MAR-1998;	98US-0080194P.
PR	01-APR-1998;	98US-0080327P.
PR	01-APR-1998;	98US-0080333P.
PR	08-APR-1998;	98US-0081049P.
PR	08-APR-1998;	98US-0081070P.
PR	09-APR-1998;	98US-0081195P.
PR	15-APR-1998;	98US-0081838P.
PR	21-APR-1998;	98US-0082568P.
PR	21-APR-1998;	98US-0082569P.
PR	22-APR-1998;	98US-0082704P.
PR	22-APR-1998;	98US-0082797P.
PR	28-APR-1998;	98US-0083322P.
PR	29-APR-1998;	98US-0083495P.
PR	29-APR-1998;	98US-0083496P.
PR	29-APR-1998;	98US-0083499P.
PR	29-APR-1998;	98US-0083559P.
PR	05-MAY-1998;	98US-0084366P.
PR	06-MAY-1998;	98US-0084414P.
PR	07-MAY-1998;	98US-0084639P.
PR	07-MAY-1998;	98US-0084640P.
PR	15-MAY-1998;	98US-0084643P.
PR	15-MAY-1998;	98US-0085579P.
PR	15-MAY-1998;	98US-0085580P.
PR	15-MAY-1998;	98US-0085582P.
PR	15-MAY-1998;	98US-0085700P.
PR	18-MAY-1998;	98US-0086023P.
PR	22-MAY-1998;	98US-0086392P.
PR	22-MAY-1998;	98US-0086486P.
PR	28-MAY-1998;	98US-0087098P.
PR	28-MAY-1998;	98US-0087208P.
PR	02-JUN-1998;	98US-0087609P.
PR	02-JUN-1998;	98US-0087759P.
PR	03-JUN-1998;	98US-0087827P.
PR	04-JUN-1998;	98US-0088025P.
PR	04-JUN-1998;	98US-0088028P.
PR	04-JUN-1998;	98US-0088029P.
PR	04-JUN-1998;	98US-0088033P.
PR	04-JUN-1998;	98US-0088326P.
PR	05-JUN-1998;	98US-0088167P.
PR	05-JUN-1998;	98US-0088202P.
PR	05-JUN-1998;	98US-0088212P.
PR	05-JUN-1998;	98US-0088217P.
PR	09-JUN-1998;	98US-0088555P.
PR	10-JUN-1998;	98US-0088722P.
PR	10-JUN-1998;	98US-0088738P.
PR	10-JUN-1998;	98US-0088740P.
PR	10-JUN-1998;	98US-0088811P.
PR	10-JUN-1998;	98US-0088824P.
PR	10-JUN-1998;	98US-0088825P.
PR	10-JUN-1998;	98US-0088826P.
PR	11-JUN-1998;	98US-0088861P.
PR	11-JUN-1998;	98US-0088863P.
PR	11-JUN-1998;	98US-0088876P.
PR	12-JUN-1998;	98US-0089090P.
PR	12-JUN-1998;	98US-0089105P.
PR	16-JUN-1998;	98US-0089512P.
PR	16-JUN-1998;	98US-0089514P.
PR	17-JUN-1998;	98US-0089538P.



PR	17-JUN-1998;	98US-0089598P.
PR	17-JUN-1998;	98US-0089653P.
PR	18-JUN-1998;	98US-0089908P.
PR	19-JUN-1998;	98US-0089952P.
PR	22-JUN-1998;	98US-0090246P.
PR	22-JUN-1998;	98US-0090252P.
PR	22-JUN-1998;	98US-0090254P.
PR	24-JUN-1998;	98US-0090429P.
PR	24-JUN-1998;	98US-0090435P.
PR	24-JUN-1998;	98US-0090444P.
PR	24-JUN-1998;	98US-0090461P.
PR	24-JUN-1998;	98US-0090535P.
PR	24-JUN-1998;	98US-0090540P.
PR	25-JUN-1998;	98US-0090676P.
PR	25-JUN-1998;	98US-0090678P.
PR	25-JUN-1998;	98US-0090688P.
PR	25-JUN-1998;	98US-0090690P.
PR	25-JUN-1998;	98US-0090694P.
PR	25-JUN-1998;	98US-0090695P.
PR	25-JUN-1998;	98US-0090696P.
PR	26-JUN-1998;	98US-00105413.
PR	26-JUN-1998;	98US-0090862P.
PR	26-JUN-1998;	98US-0090863P.
PR	26-JUN-1998;	98US-0091010P.
PR	01-JUL-1998;	98US-0091359P.
PR	01-JUL-1998;	98US-0091544P.
PR	02-JUL-1998;	98US-0091478P.
PR	02-JUL-1998;	98US-0091486P.
PR	02-JUL-1998;	98US-0091626P.
PR	02-JUL-1998;	98US-0091628P.
PR	02-JUL-1998;	98US-0091632P.
PR	24-JUL-1998;	98US-0094006P.
PR	04-AUG-1998;	98US-0095282P.
PR	10-AUG-1998;	98US-0095998P.
PR	10-AUG-1998;	98US-0096012P.
PR	17-AUG-1998;	98US-0096757P.
PR	17-AUG-1998;	98US-0096766P.
PR	17-AUG-1998;	98US-0096867P.
PR	17-AUG-1998;	98US-0096891P.
PR	17-AUG-1998;	98US-0096897P.
PR	18-AUG-1998;	98US-0096949P.
PR	18-AUG-1998;	98US-0096959P.
PR	18-AUG-1998;	98US-0097022P.
PR	26-AUG-1998;	98US-0097952P.
PR	26-AUG-1998;	98US-0097954P.
PR	26-AUG-1998;	98US-0097955P.
PR	26-AUG-1998;	98US-0097971P.
PR	26-AUG-1998;	98US-0097974P.
PR	26-AUG-1998;	98US-0098014P.
PR	01-SEP-1998;	98US-0098716P.
PR	01-SEP-1998;	98US-0098723P.
PR	02-SEP-1998;	98US-0098803P.
PR	02-SEP-1998;	98US-0098821P.
PR	02-SEP-1998;	98US-0098843P.
PR	09-SEP-1998;	98US-0099602P.
PR	10-SEP-1998;	98US-0099741P.
PR	10-SEP-1998;	98US-0099754P.
PR	10-SEP-1998;	98US-0099763P.
PR	10-SEP-1998;	98US-0099812P.
PR	15-SEP-1998;	98US-0100388P.
PR	16-SEP-1998;	98US-0100662P.
PR	16-SEP-1998;	98US-0100664P.
PR	16-SEP-1998;	98US-0101751P.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98US-0100683P.
PR	17-SEP-1998;	98US-0100684P.
PR	17-SEP-1998;	98US-0100919P.
PR	17-SEP-1998;	98US-0100930P.
PR	18-SEP-1998;	98US-0100849P.
PR	18-SEP-1998;	98US-0101014P.
PR	18-SEP-1998;	98US-0101068P.
PR	23-SEP-1998;	98US-0101471P.
PR	23-SEP-1998;	98US-0101472P.
PR	23-SEP-1998;	98US-0101475P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101738P.
PR	24-SEP-1998;	98US-0101739P.
PR	24-SEP-1998;	98US-0101743P.
PR	24-SEP-1998;	98US-0101922P.
PR	25-SEP-1998;	98US-0101786P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
PR	02-OCT-1998;	98US-0102965P.
PR	06-OCT-1998;	98US-0103258P.
PR	06-OCT-1998;	98US-0103449P.
Query Match 3.0%; Score 66.6; DB 9; Length 2846;		
Best Local Similarity 71.3%; Pred. No. 0.00023;		
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;		
QY	2121 CCTTGCCTTTACCACTCTTTCCTTTTATCTTATTATAATAAATGTTGGTCTCCACCAC	2180
Db		
QY	2181 NCTCCAAAAA	2240
Db		
QY	2241 AA 2242	
Db		
QY	2773 AA 2774	
RESULT 723		
ACD22788		
ID	ACD22788 standard; cDNA; 2846 BP.	
XX	ACD22788;	
XX	ACD22788;	
DT	25-AUG-2003 (first entry)	
DE	Human secreted/transmembrane protein (PRO) cDNA #85.	
XX	Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;	
KW	tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;	
KW	tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;	
KW	prostate tumour; rectal tumour; cervical tumour; liver tumour.	
XX	Homo sapiens.	
PN	US2003040077-A1.	
PD	27-FEB-2003.	
XX	16-JUL-2002; 2002US-00196745.	
PR	18-SEP-1997;	97US-0059263P.
PR	18-SEP-1997;	97US-0059266P.
PR	17-OCT-1997;	97US-0062250P.
PR	21-OCT-1997;	97US-0063486P.
PR	24-OCT-1997;	97US-0063120P.
PR	24-OCT-1997;	97US-0063121P.
PR	28-OCT-1997;	97US-0063540P.
PR	28-OCT-1997;	97US-0063541P.
PR	28-OCT-1997;	97US-0063544P.
PR	28-OCT-1997;	97US-0063564P.
PR	29-OCT-1997;	97US-0063734P.
PR	31-OCT-1997;	97US-0063870P.
PR	31-OCT-1997;	97US-0064103P.

PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.

PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 16-SEP-1998; 98US-0100662P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.  
PR 17-SEP-1998; 98US-0100919P.  
PR 17-SEP-1998; 98US-0100930P.  
PR 18-SEP-1998; 98US-0100849P.  
PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.  
PR 23-SEP-1998; 98US-0101471P.







PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.

PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 13-AUG-1998; 98US-0096413P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 31-AUG-1998; 98US-0098525P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 12-MAR-1999; 99US-0123957P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 17-AUG-1999; 99US-0149396P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 08-OCT-1999; 99US-0158663P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.







PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;  
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-555155/52.  
DR P-PSDB; ABR85454.  
XX  
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful  
PT for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation,  
PT particularly for treating tumors in a mammal.  
XX  
PS Claim 2; Fig 169; 700pp; English.

XX The invention relates to human PRO secreted/transmembrane polypeptides  
XX (ABR85370-ABR85674) and nucleic acids encoding them (ACF06951-ACF07255).  
CC The invention also relates to sequences at least 80% identical to the PRO  
CC nucleic acid and polypeptide sequences of the invention, recombinant  
CC vectors and host cells comprising a PRO nucleic acid, a method for the  
CC recombinant production of a PRO polypeptide, antibodies against a PRO  
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic  
CC acids encoding PRO polypeptides of the invention were initially  
CC identified via homology screening using consensus sequences based on the  
CC extracellular domain sequences from known secreted proteins. Human cDNA  
CC libraries containing sequences of interest were identified using  
CC oligonucleotides based on the consensus sequences, and cDNA clones were  
CC isolated and characterised. The PRO polypeptides are useful for  
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from  
CC human blood and may thus be used in the treatment of conditions in which  
CC enhanced TNF-alpha release would be beneficial. They are also useful for  
CC stimulating the proliferation or differentiation of chondrocytes and as  
CC such may be used in the treatment of various bone and/or cartilage  
CC disorders such as arthritis and sports injuries. The PRO polypeptides may  
CC be used in a method for detecting the presence of a tumour (e.g., an  
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate  
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This  
CC method involves comparing the level of expression of the PRO polypeptide  
CC in test and control samples, where a higher level of expression of PRO  
CC polypeptide in the test sample as compared to the control sample is  
CC indicative of the presence of a tumour. The PRO polypeptides are  
CC additionally useful for in drug screening to identify agonists and  
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as  
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and  
CC gene mapping, in the generation of antisense RNA and DNA and in gene  
CC therapy. The nucleic acids can also be used for mapping genes encoding  
CC PRO polypeptides, for genetic analysis of individuals with genetic  
CC disorders, and for generating either transgenic animals or knock-out  
CC animals which are useful in the development and screening of  
CC therapeutically useful compounds. Sequences ACF06951-ACF07255 represent  
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the  
CC invention. Note: The sequence data for this patent is also available in  
CC electronic format from USPRO at seqdata.uspto.gov/sequence.html

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match	3.0%;	Score 66.6;	DB 9;	Length 2846;
Best Local Similarity	71.3%;	Pred. No. 0.00023;		
Matches	87;	Conservative	0;	Mismatches 35; Indels 0; Gaps 0;

  

QY	2121	CCTTTGCTTTACCACTCTTCTTTTATCTTATTATAAATAATGTTGGTCTCCACCAC	2180
Db	2653	CCTTTCTCTCCCATCTCTGTACACATTTTATAAATAAGGTTGGCTTCTGAACTA	2712
QY	2181	NTCCCAA	2240
Db	2713	CAA	2772
QY	2241	AA 2242	
Db	2773	AA 2774	

RESULT 728  
ACF77691  
ID ACF77691 standard; cDNA; 2846 BP.

XX AC ACF77691;  
XX DT 06-NOV-2003 (first entry)  
XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.  
XX KW Human; PRO; secreted protein; transmembrane protein;  
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;  
KW chondrocyte; proliferation; differentiation; cartilage disorder;  
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;  
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;  
KW liver; drug screening; transgenic animal; genetic analysis;  
KW antiarthritic; vulnery; gene therapy; gene; ss.  
XX Homo sapiens.  
OS US2003054464-A1.  
XX PN 20-MAR-2003.  
XX PD 17-JUL-2002; 2002US-00197707.  
XX PF 04-JUN-1998; 98US-0088025P.  
XX PR 02-JUN-1999; 99WO-US012252.  
XX PR 25-AUG-1999; 99US-00380137.  
XX PR 28-FEB-2001; 2001WO-US006520.  
XX PR 15-JAN-2002; 2002US-00052586.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;  
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-585165/55.  
DR P-PSDB; ABM77020.  
XX  
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic  
PT acids, useful for diagnosing, preventing and/or treating tumors, such as  
PT adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.  
XX Claim 2; Fig 169; 700pp; English.  
XX The invention relates to human PRO secreted/transmembrane polypeptides  
CC and nucleic acids encoding them, the invention also provides recombinant  
CC vectors and host cells comprising a PRO nucleic acid, a method for the  
CC recombinant production of a PRO polypeptide, antibodies against a PRO  
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic  
CC acids encoding PRO polypeptides of the invention were initially  
CC identified via homology screening using consensus sequences based on the  
CC extracellular domain sequences from known secreted proteins. Human cDNA  
CC libraries containing sequences of interest were identified using  
CC oligonucleotides based on the consensus sequences, and cDNA clones were  
CC isolated and characterised. The PRO polypeptides are useful for  
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from  
CC human blood and may thus be used in the treatment of conditions in which  
CC enhanced TNF-alpha release would be beneficial. They are also useful for  
CC stimulating the proliferation or differentiation of chondrocytes and as  
CC such may be used in the treatment of various bone and/or cartilage  
CC disorders such as arthritis and sports injuries. The PRO polypeptides may  
CC be used in a method for detecting the presence of a tumour (e.g., an  
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate  
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This  
CC method involves comparing the level of expression of the PRO polypeptide  
CC in test and control samples, where a higher level of expression of PRO  
CC polypeptide in the test sample as compared to the control sample is  
CC indicative of the presence of a tumour. The PRO polypeptides are  
CC additionally useful for in drug screening to identify agonists and  
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as  
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and  
CC gene mapping, in the generation of antisense RNA and DNA and in gene  
CC therapy. The nucleic acids can also be used for mapping genes encoding  
CC PRO polypeptides, for genetic analysis of individuals with genetic











bone disorder; arthritis; sports injury; cancer; tumour; diagnosis; adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix; liver; drug screening; transgenic animal; genetic analysis; antiarthritic; vulnery; gene therapy; gene; ss.

Homo sapiens.

US2003068744-A1.

10-APR-2003.

23-JUL-2002; 2002US-00202474.

17-NOV-1998; 98US-0108779P.  
01-SEP-1999; 99WO-US020111.  
18-OCT-1999; 99US-00403297.  
28-FEB-2001; 2001WO-US006520.  
15-JAN-2002; 2002US-00052586.

(GETH ) GENENTECH INC.

Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL; Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-615895/58.  
P-PSDB; ABM21455.

New isolated nucleic acid encoding a secreted and transmembrane PRO polypeptide e.g. PRO1079 or PRO827, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy.

Claim 2; Fig 169; 706pp; English.

The invention relates to human PRO secreted/transmembrane polypeptides (ABM21371-ABM21675) and nucleic acids encoding them (ACF45373-ACF45677). The invention also relates to sequences at least 80% identical to the PRO nucleic acid and polypeptide sequences of the invention, recombinant vectors and host cells comprising a PRO nucleic acid, a method for the recombinant production of a PRO polypeptide, antibodies against a PRO polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic acids encoding PRO polypeptides of the invention were initially identified via homology screening using consensus sequences based on the extracellular domain sequences from known secreted proteins. Human CDNA libraries containing sequences of interest were identified using oligonucleotides based on the consensus sequences, and cDNA clones were isolated and characterised. The PRO polypeptides are useful for stimulating release of tumour necrosis factor-alpha (TNF-alpha) from human blood and may thus be used in the treatment of conditions in which enhanced TNF-alpha release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as arthritis and sports injuries. The PRO polypeptides may be used in a method for detecting the presence of a tumour (e.g., an adrenal tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This method involves comparing the level of expression of the PRO polypeptide in test and control samples, where a higher level of expression of PRO polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumour. The PRO polypeptides are additionally useful for in drug screening to identify agonists and antagonists of PRO polypeptides. PRO nucleic acids are useful as hybridisation probes (for isolation of cDNA molecules), in chromosome and gene mapping, in the generation of antisense RNA and DNA and in gene therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. Sequences ACF45373-ACF45677 represent cDNAs encoding the human PRO secreted/transmembrane polypeptides of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html)

```

SQ      Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

      Query Match          3.0%; Score 66.6; DB 9; Length 2846;
      Best Local Similarity 71.3%; Pred. No. 0.00023;
      Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY      2121 CCTTTGCTTTACCACTCTTTCCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACCTG 2180
      ||||| | ||||| ||||| | ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB      2653 CCTTTTCTTCCCATCTCTTGTCACACATTTTAATAAATAAGGGTTGGCTTCTGAACTA 2712

QY      2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB      2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY      2241 AA 2242
      ||
DB      2773 AA 2774

RESULT 734
ACF38476
ID      ACF38476 standard; cDNA; 2846 BP.
XX
AC      ACF38476;
XX
DT      08-OCT-2003 (first entry)
XX
DE      Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW      Human; PRO; secreted protein; transmembrane protein;
KW      extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW      chondrocyte; proliferation; differentiation; cartilage disorder;
KW      bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW      adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW      liver; drug screening; transgenic animal; genetic analysis;
KW      antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS      Homo sapiens.
XX
PN      US2003068766-A1.
XX
PD      10-APR-2003.
XX
PF      29-JUL-2002; 2002US-00207917.
XX
PR      25-APR-2000; 2000US-0199550P.
PR      28-FEB-2001; 2001WO-US006520.
PR      15-JAN-2002; 2002US-00052586.
XX
PA      (GETH ) GENENTECH INC.
XX
PI      Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI      Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR      WPI; 2003-615907/58.
DR      P-PSDB; ABM14986.
XX
PT      New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT      acids, useful in gene therapy, chromosome identification, tissue typing,
PT      or as hybridization probes in chromosome and gene mapping.
XX
PS      Claim 2; Fig 169; 699pp; English.
XX
CC      The invention relates to human PRO secreted/transmembrane polypeptides
CC      (ABM15207-ABM15511) and nucleic acids encoding them (ACF38699-ACF39603).
CC      The invention also relates to sequences at least 80% identical to the PRO
CC      nucleic acid and polypeptide sequences of the invention, recombinant
CC      vectors and host cells comprising a PRO nucleic acid, a method for the
CC      recombinant production of a PRO polypeptide, antibodies against a PRO
CC      polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC      acids encoding PRO polypeptides of the invention were initially
CC      identified via homology screening using consensus sequences based on the
CC      extracellular domain sequences from known secreted proteins Human cDNA

```





```
XX Homo sapiens.
OS US2003068715-A1.
XX
PN
XX
XX
XX 10-APR-2003.
XX
XX 17-JUL-2002; 2002US-00197703.
XX
XX 04-JUN-1998; 98US-0088326P.
XX 02-JUN-1999; 99WO-US012252.
XX 25-AUG-1999; 99US-00380137.
XX 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-625467/59.
XX P-PSDB; ABO36791.
XX
XX New PRO nucleic acid, useful for the manufacture of a medicament for
XX diagnosing or treating tumor or for tissue typing.
XX
XX Claim 2; Fig 169; 700pp; English.
XX
XX The invention discloses human nucleic acids encoding secreted and
XX transmembrane (PRO) polypeptides, with or without their associated signal
XX peptide. Also disclosed is an antibody that specifically binds to the PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor alpha (TNF-alpha) from human blood by contacting the blood with a
XX PRO polypeptide, a method for stimulating the proliferation or
XX differentiation of chondrocyte cells by contacting the cells with a PRO
XX polypeptide, a method for detecting the presence of a tumour in a mammal
XX and an oligonucleotide probe derived from any of the PRO nucleotide
XX sequences. The nucleotide sequences are useful as probes, in chromosome
XX and gene mapping, in generating antisense RNA and DNA, in preparing PRO
XX polypeptides by recombinant techniques and in gene therapy (e.g. for
XX replacement of defective gene). The PRO polypeptides are useful as
XX molecular weight markers for protein electrophoresis purposes, for
XX chromosome identification, as chromosome markers, as therapeutic agents,
XX for stimulating the release of TNF-alpha from human blood, for
XX stimulating the proliferation or differentiation of chondrocytes and
XX detecting the presence, prevention and/or treatment of a tumour, such as
XX adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
XX The PRO polypeptides and nucleic acids may also be used diagnostically
XX for tissue typing. The sequence presented is a cDNA encoding one of the
XX PRO polypeptides of the invention. Note: The sequence data for this
XX patent can also be obtained in electronic format directly from USPTO at
XX seqdata.uspto.gov/sequence.html
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
XX
XX Query Match 3.0%; Score 66.6; DB 9; Length 2846;
XX Best Local Similarity 71.3%; Pred. No. 0.00023;
XX Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
XX
XX QY 2121 CCTTGTCTTACCACTCTTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX Db 2653 CCTTTTCTTCCCATCTCTTGTACACATTTTAATAAAATAGGGTTGGCTTCTGAACATA 2712
XX
XX QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
XX
XX QY 2241 AA 2242
XX ||
XX Db 2773 AA 2774
```

RESULT 737

```
ACD85853
ID ACD85853 standard; cDNA; 2846 BP.
XX
XX ACD85853;
AC
XX
XX 05-OCT-2003 (first entry)
DT
XX
XX Human secreted/transmembrane protein (PRO) cDNA #85.
DE
XX
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
XX tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
XX prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
XX Homo sapiens.
OS
XX
XX US2003068726-A1.
PN
XX
XX 10-APR-2003.
PD
XX
XX 19-JUL-2002; 2002US-00199316.
XX
XX 26-JUN-1998; 98US-00105413.
XX 16-SEP-1998; 98WO-US019330.
XX 07-OCT-1998; 98US-00168978.
XX 07-OCT-1998; 98WO-US021141.
XX 06-NOV-1998; 98US-00187368.
XX 01-DEC-1998; 98WO-US025108.
XX 07-DEC-1998; 98US-00202054.
XX 03-MAR-1999; 99US-00254311.
XX 08-MAR-1999; 99WO-US005028.
XX 14-MAY-1999; 99US-00311832.
XX 14-MAY-1999; 99WO-US010733.
XX 02-JUN-1999; 99WO-US012252.
XX 25-AUG-1999; 99US-00380137.
XX 25-AUG-1999; 99US-00380138.
XX 25-AUG-1999; 99US-00380139.
XX 25-AUG-1999; 99US-00380142.
XX 01-SEP-1999; 99WO-US020111.
XX 18-OCT-1999; 99US-00403297.
XX 12-NOV-1999; 99US-00423844.
XX 01-DEC-1999; 99WO-US028301.
XX 02-DEC-1999; 99WO-US028551.
XX 30-DEC-1999; 99WO-US031274.
XX 05-JAN-2000; 2000WO-US000219.
XX 18-FEB-2000; 2000WO-US004341.
XX 18-FEB-2000; 2000WO-US004342.
XX 22-FEB-2000; 2000WO-US004414.
XX 24-FEB-2000; 2000WO-US005004.
XX 01-MAR-2000; 2000WO-US005601.
XX 02-MAR-2000; 2000WO-US005841.
XX 15-MAR-2000; 2000WO-US006884.
XX 30-MAR-2000; 2000WO-US008439.
XX 17-MAY-2000; 2000WO-US013705.
XX 22-MAY-2000; 2000WO-US014042.
XX 30-MAY-2000; 2000WO-US014941.
XX 02-JUN-2000; 2000WO-US015264.
XX 28-JUL-2000; 2000WO-US020710.
XX 22-AUG-2000; 2000US-00644848.
XX 24-AUG-2000; 2000WO-US023328.
XX 18-SEP-2000; 2000US-00664610.
XX 18-SEP-2000; 2000US-00665350.
XX 08-NOV-2000; 2000US-00709238.
XX 08-NOV-2000; 2000WO-US030952.
XX 01-DEC-2000; 2000WO-US032678.
XX 20-DEC-2000; 2000US-00747259.
XX 20-DEC-2000; 2000WO-US034956.
XX 28-FEB-2001; 2001WO-US006520.
XX 22-MAR-2001; 2001US-00816744.
XX 10-MAY-2001; 2001US-00854208.
XX 25-MAY-2001; 2001US-00866028.
```

```
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 30-JUL-2001; 2001US-00918585.
PR 06-AUG-2001; 2001US-00924419.
PR 13-AUG-2001; 2001US-00929404.
PR 16-AUG-2001; 2001US-00931836.
PR 28-AUG-2001; 2001US-00941992.
PR 29-AUG-2001; 2001WO-US027099.
PR 04-SEP-2001; 2001US-00946374.
PR 15-JAN-2002; 2002US-00052586.
XX
XX (GETH ) GENENTECH INC.
PA
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-625469/59.
DR P-PSDB; ABO37401.
DR
XX
XX New isolated and secreted PRO nucleic acids, useful for the manufacture
PT of a medicament for diagnosing or treating tumors or for tissue typing.
PT
XX
XX Claim 2; Fig 169; 701pp; English.
PS
XX The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC PRO polypeptide, a method for stimulating the proliferation or
CC differentiation of chondrocyte cells by contacting the cells with a PRO
CC polypeptide, a method for detecting the presence of a tumour in a mammal
CC and an oligonucleotide probe derived from any of the PRO nucleotide
CC sequences. The nucleotide sequences are useful as probes, in chromosome
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC polypeptides by recombinant techniques and in gene therapy (e.g. for
CC replacement of defective gene). The PRO polypeptides are useful as
CC molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention and/or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGGCTTTACCACTCTTTCCCTTTTATCTTATTATAAAATGTGGTCTCCACCACTG 2180
Db ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
2653 CCTTTTCCTCCCATCTCTGTGACATTTTAATAAAATAAGGTTGGCTTCTGAACATA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db ||
2773 AA 2774
RESULT 738
```

```
ACF75849
ID ACF75849 standard; cDNA; 2846 BP.
XX
AC ACF75849;
XX
DT 06-NOV-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
DE
XX Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulneryary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003104544-A1.
XX
PD 05-JUN-2003.
XX
PF 09-JUL-2002; 2002US-00192007.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
XX (GETH ) GENENTECH INC.
PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-658682/62.
DR P-PSDB; ABM75191.
XX
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful in
PT molecular biology, chromosome and gene mapping, in generating antisense
PT RNA and DNA, and in gene therapy.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM75107-ABM75411) and nucleic acids encoding them (ACF75765-ACF76069).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
```



CC	therapy. The nucleic acids can also be used for mapping genes encoding
CC	PRO polypeptides, for genetic analysis of individuals with genetic
CC	disorders, and for generating either transgenic animals or knock-out
CC	animals which are useful in the development and screening of
CC	therapeutically useful compounds. Sequences ACF76070-ACF76071 represent
CC	cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC	invention. Note: The sequence data for this patent is also available in
CC	electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX	
SQ	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match	3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity	71.3%; Pred. No. 0.00023;
Matches	87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
OY	2121 CCTTTGGCTTACCACACTCTTTTCCTTTATCCTTAATAAAAGTGTTGGTCTCACCACTG 2180 
Dd	2653 CCTTTTCCTCCCACACTCTCTGTGACACATTTTAATAAATAAGGGTTGGCTTCTGAACA 2712 
OY	2181 NCTCCCCAA 2240 
Dd	2713 CAAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772 
OY	2241 AA 2242 
Dd	2773 AA 2774

The invention relates to human PRO secreted/transmembrane polypeptides (ABM33387-ABM33691) and nucleic acids encoding them (ACF60665-ACF60969). The invention also relates to sequences at least 80% identical to the PRO nucleic acid and polypeptide sequences of the invention, recombinant vectors and host cells comprising a PRO nucleic acid, antibodies against a PRO recombinant production of a PRO polypeptide, antibodies against a PRO polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic acids encoding PRO polypeptides of the invention were initially identified via homology screening using consensus sequences based on the extracellular domain sequences from known secreted proteins. Human cDNA libraries containing sequences of interest were identified using oligonucleotides based on the consensus sequences, and cDNA clones were isolated and characterised. The PRO polypeptides are useful for stimulating release of tumour necrosis factor-alpha (TNF-alpha) from human blood and may thus be used in the treatment of conditions in which enhanced TNF-alpha release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as arthritis and sports injuries. The PRO polypeptides may be used in a method for detecting the presence of a tumour (e.g., an adrenal tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This method involves comparing the level of expression of the PRO polypeptide in test and control samples, where a higher level of expression of PRO polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumour. The PRO polypeptides are additionally useful for in drug screening to identify agonists and antagonists of PRO polypeptides. PRO nucleic acids are useful as hybridisation probes (for isolation of cDNA molecules), in chromosome and gene mapping, in the generation of antisense RNA and DNA and in gene therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. Sequences ACF60665-ACF60969 represent cDNAs encoding the human PRO secreted/transmembrane polypeptides of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html)















PN US2003068762-A1.  
XX 10-APR-2003.  
XX 26-JUL-2002; 2002US-00206925.  
PF 05-JUN-2000; 2000US-0209832P.  
XX 28-FEB-2001; 2001WO-US006520.  
PR 15-JAN-2002; 2002US-00052586.  
XX (GETH ) GENENTECH INC.  
PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;  
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;  
PI WPI; 2003-615904/58.  
XX P-PSDB; ABM31215.  
DR New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1079 or  
XX PRO827, useful in molecular biology, chromosome and gene mapping, in  
PT generating antisense RNA and DNA, and in gene therapy.  
PT Claim 2; Fig 169; 700pp; English.  
XX The invention relates to human PRO secreted/transmembrane polypeptides  
CC (ABM31131-ABM31435) and nucleic acids encoding them (ACF55197-ACF55501).  
CC The invention also relates to sequences at least 80% identical to the PRO  
CC nucleic acid and polypeptide sequences of the invention, recombinant  
CC vectors and host cells comprising a PRO nucleic acid, a method for the  
CC recombinant production of a PRO polypeptide, antibodies against a PRO  
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic  
CC acids encoding PRO polypeptides of the invention were initially  
CC identified via homology screening using consensus sequences based on the  
CC extracellular domain sequences from known secreted proteins. Human cDNA  
CC libraries containing sequences of interest were identified using  
CC oligonucleotides based on the consensus sequences, and cDNA clones were  
CC isolated and characterised. The PRO polypeptides are useful for  
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from  
CC human blood and may thus be used in the treatment of conditions in which  
CC enhanced TNF-alpha release would be beneficial. They are also useful for  
CC stimulating the proliferation or differentiation of chondrocytes and as  
CC such may be used in the treatment of various bone and/or cartilage  
CC disorders such as arthritis and sports injuries. The PRO polypeptides may  
CC be used in a method for detecting the presence of a tumour (e.g., an  
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate  
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This  
CC method involves comparing the level of expression of the PRO polypeptide  
CC in test and control samples, where a higher level of expression of PRO  
CC polypeptide in the test sample as compared to the control sample is  
CC indicative of the presence of a tumour. The PRO polypeptides are  
CC additionally useful for in drug screening to identify agonists and  
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as  
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and  
CC gene mapping, in the generation of antisense RNA and DNA and in gene  
CC therapy. The nucleic acids can also be used for mapping genes encoding  
CC PRO polypeptides, for genetic analysis of individuals with genetic  
CC disorders, and for generating either transgenic animals or knock-out  
CC animals which are useful in the development and screening of  
CC therapeutically useful compounds. Sequences ACF55197-ACF55501 represent  
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the  
CC invention. Note: The sequence data for this patent is also available in  
CC electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html)  
XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;  
Query Match 3.0%; Score 66.6; DB 10; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;  
QY 2121 CCTTGTCTTACCACCTCTTCTCTTTATCTTATTAATAAATAATGTTGGTCTCCACCACTG 2180  
DB 2653 CCTTTCTCTCCCATCTCTTGTACACATTTTATAAATAAGGTTGGCTTGAACATA 2712

QY 2181 NCTCCCAA 2240  
Db |||||  
2713 CAAA 2772  
QY 2241 AA 2242  
Db ||  
2773 AA 2774  
RESULT 746  
ADB85912  
ID ADB85912 standard; cDNA; 2846 BP.  
XX  
AC ADB85912;  
XX  
DT 04-DEC-2003 (first entry)  
XX Human secreted/transmembrane protein (PRO) cDNA #85.  
DE Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;  
XX tumour necrosis factor alpha; chondrocyte cell; gene therapy;  
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;  
KW prostate tumour; rectal tumour; cervical tumour; liver tumour; tumour.  
XX  
OS Homo sapiens.  
XX US2003054472-A1.  
XX 20-MAR-2003.  
XX 22-JUL-2002; 2002US-00201528.  
PR 18-AUG-1998; 98US-0097022P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 25-AUG-1999; 99US-00380137.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 15-JAN-2002; 2002US-00052586.  
XX (GETH ) GENENTECH INC.  
PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;  
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;  
PI WPI; 2003-743748/70.  
XX P-PSDB; ADB85913.  
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
PT in gene therapy, or for preparing a medicament for treating a condition  
PT that is responsive to the PRO polypeptide or anti-PRO antibody.  
XX  
PS Claim 2; Fig 169; 699pp; English.  
XX The invention discloses human nucleic acids encoding secreted and  
CC transmembrane (PRO) polypeptides, with or without their associated signal  
CC peptide. Also disclosed is an antibody that specifically binds to the PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a  
CC PRO polypeptide, a method for stimulating the proliferation or  
CC differentiation of chondrocyte cells by contacting the cells with a PRO  
CC polypeptide, a method for detecting the presence of a tumour in a mammal  
CC and an oligonucleotide probe derived from any of the PRO nucleotide  
CC sequences. The nucleotide sequences are useful as probes, in chromosome  
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO  
CC polypeptides by recombinant techniques and in gene therapy (e.g. for  
CC replacement of defective gene). The PRO polypeptides are useful as  
CC molecular weight markers for protein electrophoresis purposes, for  
CC chromosome identification, as chromosome markers, as therapeutic agents,  
CC for stimulating the release of TNF-alpha from human blood, for  
CC stimulating the proliferation or differentiation of chondrocytes and  
CC detecting the presence, prevention and/or treatment of a tumour, such as  
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.  
CC The PRO polypeptides and nucleic acids may also be used diagnostically  
CC for tissue typing. The sequence presented is a cDNA encoding one the PRO









QY	2181	NCTCCAAAAA	2240
Db	2713	CAAAAAA	2772
QY	2241	AA 2242	
Db	2773	AA 2774	
RESULT 750			
ADB68096			
ID	ADB68096 standard; cDNA; 2846 BP.		
XX			
AC	ADB68096;		
XX			
DT	04-DEC-2003 (first entry)		
XX			
DE	Human PRO1344 cDNA.		
XX			
KW	PRO; cytostatic; cancer; diabetes; hyperinsulinaemia; hypoinsulinaemia;		
KW	sports-related joint problem; articular cartilage defect; osteoarthritis;		
KW	rheumatoid arthritis; tissue typing; gene therapy; transgenic; human; ss;		
KW	gene.		
XX			
OS	Homo sapiens.		
XX			
PN	US2003060600-A1.		
XX			
PD	27-MAR-2003.		
XX			
PF	02-MAY-2002; 2002US-00063532.		
XX			
PR	30-DEC-1998; 98KR-00062142.		
PR	08-MAR-1999; 99WO-US005028.		
PR	14-MAY-1999; 99US-00311832.		
PR	14-MAY-1999; 99WO-US010733.		
PR	25-AUG-1999; 99US-00380137.		
PR	25-AUG-1999; 99US-00380138.		
PR	25-AUG-1999; 99US-00380139.		
PR	25-AUG-1999; 99US-00380142.		
PR	15-SEP-1999; 99US-00397342.		
PR	18-OCT-1999; 99US-00403297.		
PR	12-NOV-1999; 99US-00423844.		
PR	30-DEC-1999; 99WO-US031274.		
PR	18-FEB-2000; 2000WO-US004341.		
PR	01-MAR-2000; 2000WO-US005601.		
PR	02-MAR-2000; 2000WO-US005841.		
PR	21-MAR-2000; 2000WO-US007532.		
PR	22-MAY-2000; 2000WO-US014042.		
PR	02-JUN-2000; 2000WO-US015264.		
PR	22-AUG-2000; 2000US-00644848.		
PR	24-AUG-2000; 2000WO-US023328.		
PR	18-SEP-2000; 2000US-00664610.		
PR	18-SEP-2000; 2000US-00665350.		
PR	08-NOV-2000; 2000US-00709238.		
PR	10-NOV-2000; 2000WO-US030873.		
PR	01-DEC-2000; 2000WO-US032678.		
PR	20-DEC-2000; 2000US-00747259.		
PR	20-DEC-2000; 2000WO-US034956.		
PR	28-FEB-2001; 2001WO-US006520.		
PR	22-MAR-2001; 2001US-00816744.		
PR	10-MAY-2001; 2001US-00854208.		
PR	10-MAY-2001; 2001US-00854280.		
PR	30-MAY-2001; 2001US-00870574.		
PR	01-JUN-2001; 2001WO-US017800.		
PR	05-JUN-2001; 2001US-00874503.		
PR	29-JUN-2001; 2001US-00869599.		
PR	18-JUL-2001; 2001US-00908827.		
PR	06-DEC-2001; 2001US-00006867.		
XX			
PA	(GETH ) GENENTECH INC.		
XX			
PI	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;		
PI			
PI	Eaton DL, Filvaroli E, Gerritsen ME, Goddard A, Godowski PJ;		
PI	Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;		
XX			
DR	WPI; 2003-540697/51.		
DR	N-PSDB; ADB68097.		
XX			
PT	New PRO polypeptide, useful for preparing a composition for diagnosing or		
PT	treating cancer or for tissue typing.		
XX			
PS	Example 4; Fig 37; 235pp; English.		
XX			
CC	The invention relates to a novel isolated PRO polypeptide. The		
CC	polypeptide of the invention demonstrates cytostatic activity and may be		
CC	useful during the preparation of a composition for diagnosing or treating		
CC	cancer, diabetes, hyperinsulinaemia, hypoinsulinaemia and sports-related		
CC	joint problems, including articular cartilage defects, osteoarthritis and		
CC	rheumatoid arthritis. Furthermore, the polypeptides may be utilised		
CC	during tissue typing, gene therapy and the production of transgenic		
CC	animals. The current sequence is that of the human PRO cDNA of the		
CC	invention.		
XX			
SQ	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;		
Query Match 3.0%; Score 66.6; DB 10; Length 2846;			
Best Local Similarity 71.3%; Pred. No. 0.00023;			
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;			
QY	2121	CCTTTGCTTTACCACTCTTCTCTTTTATCTTATTAATAAATAATGTTGGTCTCCACCTG	2180
Db	2653	CCTTTTCCTTCCCATCTCTTGACACATTTTATAAATAAAGGTTGGCTTCTGAACATA	2712
QY	2181	NCTCCAAAAA	2240
Db	2713	CAAAAAA	2772
QY	2241	AA 2242	
Db	2773	AA 2774	
RESULT 751			
ACF55588			
ID	ACF55588 standard; cDNA; 2846 BP.		
XX			
AC	ACF55588;		
XX			
DT	04-DEC-2003 (first entry)		
XX			
DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.		
XX			
KW	Human; PRO; secreted protein; transmembrane protein;		
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;		
KW	chondrocyte; proliferation; differentiation; cartilage disorder;		
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;		
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;		
KW	liver; drug screening; transgenic animal; genetic analysis;		
KW	antiarthritic; vulnery; gene therapy; gene; ss.		
XX			
OS	Homo sapiens.		
XX			
PN	US2003068761-A1.		
XX			
PD	10-APR-2003.		
XX			
PF	26-JUL-2002; 2002US-00206923.		
XX			
PR	05-JUN-2000; 2000US-0209832P.		
PR	28-FEB-2001; 2001WO-US006520.		
PR	15-JAN-2002; 2002US-00052586.		
XX			
PA	(GETH ) GENENTECH INC.		
XX			







PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.

PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 31-AUG-1998; 98US-0098525P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 12-MAR-1999; 99US-0123957P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 17-AUG-1999; 99US-0149396P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 08-OCT-1999; 99US-0158663P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.

```
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

Query Match      3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAATAATGTTGGTCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCCTTCCCATCTCTTGTGACACATTTTAATAATAAAGGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 755
ID ADC55074 standard; cDNA; 2846 BP.
XX
AC ADC55074;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide #65.
XX
KW Human; PRO; gene; ss; pancreatic beta-cell precursor cell;
KW pancreatic beta-cell; insulin deficiency; diabetes mellitus;
KW haemoglobin-associated disorder; thalassaemia; endothelial cell growth;
KW cancer; cystic renal dysplasia; polycystic kidney disease; renal tumour;
KW antidiabetic; antianaemic; cytostatic; cardiant; vulnerary;
KW antiinflammatory; anorectic.
XX
OS Homo sapiens.
XX
PN US2003045463-A1.
XX
PD 06-MAR-2003.
XX
PF 16-NOV-2001; 2001US-00990437.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR
```

```
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
```





PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.

PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 12-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 31-AUG-1998; 98US-0098525P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 12-MAR-1999; 99US-0123957P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 17-AUG-1999; 99US-0149396P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 08-OCT-1999; 99US-0158663P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.

```
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.

Query Match      3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCCTTCCCATCTCTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAAC 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 757
ADC06993
ID ADC06993 standard; cDNA; 2846 BP.
XX
AC ADC06993;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human PRO1344 cDNA.
XX
KW PRO; cytostatic; cancer; diabetes; hyperinsulinaemia; hypoinsulinaemia;
KW sports-related joint problem; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; tissue typing; gene therapy; transgenic; human; ss;
KW gene.
XX
OS Homo sapiens.
XX
US2003060602-A1.
PN
XX
PD 27-MAR-2003.
XX
PF 02-MAY-2002; 2002US-00063563.
XX
PR 30-DEC-1998; 98XR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
```

```
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
    (GETH ) GENENTECH INC.
XX
PA ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-596569/56.
DR N-PSDB; ADC06994.
XX
PT New PRO polypeptide, useful for preparing a composition for diagnosing or
    treating cancer or for tissue typing.
XX
PS Example 4; Fig 37; 234pp; English.
XX
CC The invention relates to a novel isolated PRO polypeptide. The
CC polypeptide of the invention demonstrates cytostatic activity and may be
CC useful during the preparation of a composition for diagnosing or treating
CC cancer, diabetes, hyperinsulinaemia, hypoinsulinaemia and sports-related
CC joint problems, including articular cartilage defects, osteoarthritis and
CC rheumatoid arthritis. Furthermore, the polypeptides may be utilised
CC during tissue typing, gene therapy and the production of transgenic
CC animals. The current sequence is that of the human PRO cDNA of the
CC invention.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match      3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCCTTCCCATCTCTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAAC 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 758
ADC56363
ID ADC56363 standard; cDNA; 2846 BP.
XX
AC ADC56363;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide #65.
XX
KW Human; PRO; gene; ss; pancreatic beta-cell precursor cell;
KW pancreatic beta-cell; insulin deficiency; diabetes mellitus;
KW haemoglobin-associated disorder; thalassaemia; endothelial cell growth;
KW cancer; cystic renal dysplasia; polycystic kidney disease; renal tumour;
KW antidiabetic; antianaemic; cytostatic; cardiant; vulnery;
KW antiinflammatory; anorectic.
XX
OS Homo sapiens.
XX
```

PN US2003064375-A1.  
XX  
PD 03-APR-2003.  
XX  
PF 15-NOV-2001; 2001US-00997857.  
XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.

PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 31-AUG-1998; 98US-0098525P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 05-JAN-1999; 99WO-US000106.



PR 08-MAR-1999; 99WO-US005028.  
PR 12-MAR-1999; 99US-0123957P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 17-AUG-1999; 99US-0149396P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 08-OCT-1999; 99US-0158663P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 23-JUN-2000; 2000US-0213637P.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.

Query Match 3.0%; Score 66.6; DB 10; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTCTCTTTATCTTATTATAAAAAATGTTGGTCTCCACCACTG 2180  
DB 2653 CCTTTCTCTCCCATCTCTGTACACATTTTATAAAAAATAAGGTTGGCTTCTGAACTA 2712  
QY 2181 NCTCCCAAAAAA AA 2240  
DB 2713 CAAAAA AA 2772  
QY 2241 AA 2242  
DB 2773 AA 2774

RESULT 759  
ADC17172  
ID ADC17172 standard; cDNA; 2846 BP.  
XX ADC17172;  
AC ADC17172;  
XX  
DT 18-DEC-2003 (first entry)  
XX cDNA sequence encoding a PRO polypeptide (seqID 37).  
DE PRO; gene; ss; cytostatic; gene therapy; cancer; recombinant DNA library.  
XX Mammalia.  
XX OS  
XX US2003065143-A1.  
PN 03-APR-2003.  
XX

PF 02-MAY-2002; 2002US-00063555.  
XX  
PR 30-DEC-1998; 98KR-00062142.  
PR 08-MAR-1999; 99WO-US005028.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380139.  
PR 25-AUG-1999; 99US-00380142.  
PR 15-SEP-1999; 99US-00397342.  
PR 18-OCT-1999; 99US-00403297.  
PR 12-NOV-1999; 99US-00423844.  
PR 30-DEC-1999; 99WO-US031274.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 22-AUG-2000; 2000US-00644848.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00664610.  
PR 18-SEP-2000; 2000US-00665350.  
PR 08-NOV-2000; 2000US-00709238.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001US-00816744.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 30-MAY-2001; 2001US-00870574.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 29-JUN-2001; 2001US-00869599.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-DEC-2001; 2001US-00006867.  
XX (GETH ) GENENTECH INC.  
PA  
XX  
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;  
XX WPI; 2003-596635/56.  
DR P-PSDB; ADC17173.  
XX  
PT New secreted and transmembrane PRO polypeptides, useful for preparing a  
XX composition for diagnosing or treating cancer or for tissue typing.  
PS Disclosure; Fig 37; 236pp; English.  
XX  
CC This invention relates to novel isolated, secreted and transmembrane PRO  
CC polypeptides. Specifically, it refers to native receptor and membrane  
CC bound proteins, which were identified from the screening of mammalian  
CC recombinant DNA libraries. The PRO proteins described in the present  
CC invention have been shown to have important and varied industrial  
CC applications as biosensors, diagnostics and bioreactors, as well as for  
CC tissue typing. Furthermore, they have cytostatic activity and via gene  
CC therapy routes can be useful for the preparation of compositions for the  
CC diagnosis or treatment of cancer. This polynucleotide sequence is a cDNA  
CC sequence encoding a PRO polypeptide of the invention.  
XX  
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;  
QY 2121 CCTTTGCTTTACCACTCTTCTCTTTATCTTATTATAAAAAATGTTGGTCTCCACCACTG 2180  
DB 2653 CCTTTCTCTCCCATCTCTGTACACATTTTATAAAAAATAAGGTTGGCTTCTGAACTA 2712

Qy 2181 NCTCCAA 2240  
Db 2713 CAAA 2772  
Qy 2241 AA 2242  
Db 2773 AA 2774

RESULT 760  
ADC07418  
ID ADC07418 standard; cDNA; 2846 BP.  
XX  
AC ADC07418;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE Human cDNA encoding secreted/transmembrane protein PRO1344..  
XX  
KW PRO; secreted protein; transmembrane protein;  
KW hypertrophy of neonatal heart; angiogenesis;  
KW vascular endothelial growth factor; VEGF-stimulated proliferation;  
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;  
KW c-fos induction; adipocyte cell; chondrocyte differentiation;  
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;  
KW cancer; human; ss; gene; colon cancer; lung cancer; breast cancer;  
KW rod photoreceptor cell.  
XX  
OS Homo sapiens.  
XX  
PN US2003068647-A1.  
XX  
PD 10-APR-2003.  
XX  
PF 15-NOV-2001; 2001US-00997542.  
XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.

PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.





PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.

PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 31-AUG-1998; 98US-0098525P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 12-MAR-1999; 99US-0123957P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 17-AUG-1999; 99US-0149396P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 08-OCT-1999; 99US-0158663P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 23-JUN-2000; 2000US-0213637P.

Query Match 3.0%; Score 66.6; DB 10; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;  
QY 2121 CCTTTGCTTTACCACCTCTTTCCCTTTATCTTATTATAAAAAATGTTGGTCTCCACCACGTG 2180

Db 2653 CCTTTCTCCCATCTCTGTACACATTTTAAATAAATAAGGTTGGCTTCTGAACTA 2712  
QY 2181 NCTCCAAAAA 2240  
Db 2713 CAAAAA 2772  
QY 2241 AA 2242  
Db 2773 AA 2774

RESULT 762  
ADC14870  
ID ADC14870 standard; cDNA; 2846 BP.  
XX  
AC ADC14870;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX  
KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;  
KW affinity purification; secreted and transmembrane protein.  
XX  
OS Homo sapiens.  
XX  
PN US2003073208-A1.  
XX  
PD 17-APR-2003.  
XX  
PF 02-MAY-2002; 2002US-00063538.  
XX  
PR 30-DEC-1998; 98KR-00062142.  
PR 08-MAR-1999; 99WO-US005028.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380139.  
PR 25-AUG-1999; 99US-00380142.  
PR 15-SEP-1999; 99US-00397342.  
PR 18-OCT-1999; 99US-00403297.  
PR 12-NOV-1999; 99US-00423844.  
PR 30-DEC-1999; 99WO-US031274.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 22-AUG-2000; 2000US-00644848.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00664610.  
PR 18-SEP-2000; 2000US-00665350.  
PR 08-NOV-2000; 2000US-00709238.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001US-00816744.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 30-MAY-2001; 2001US-00870574.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 29-JUN-2001; 2001US-00869599.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-DEC-2001; 2001US-00006867.  
(GETH ) GENENTECH INC.  
XX  
PA  
XX

PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;  
XX  
DR WPI; 2003-743815/70.  
XX P-PSDB; ADC14871.  
PT Novel isolated secreted and transmembrane PRO1277 polypeptide useful in  
PT the preparation of a medicament for treating a condition responsive to  
PT PRO polypeptides, as a therapeutic agent e.g. a vaccine, and as a  
PT molecular weight marker.  
XX  
PS Disclosure; SEQ ID NO 37; 237pp; English.  
XX  
CC The invention describes an antibody that specifically binds to a PRO  
CC polypeptide having a fully defined amino acid sequence given in the  
CC specification. The antibody is useful in identifying PRO polypeptides  
CC useful for various industrial applications, including pharmaceuticals,  
CC diagnostics, biosensors and bioreactors. The antibody is also used for  
CC affinity purification of PRO polypeptides from recombinant cell culture  
CC or natural sources. The antibody, PRO polypeptide, or its agonists or  
CC antagonists, may be used for preparing a medicament for diagnosing or  
CC treating a condition responsive to the antibody, PRO polypeptide, or its  
CC agonists or antagonists. This sequence encodes a novel human secreted and  
CC transmembrane PRO polypeptide.  
XX  
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;  
QY 2121 CCTTTGCTTTACCACTCTCTTTCTTTTATCTTATTAATAAATAAGGTTGGCTTCTGAACTA 2180  
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAATAAGGTTGGCTTCTGAACTA 2712  
QY 2181 NCTCCAAAAA 2240  
Db 2713 CAAAAA 2772  
QY 2241 AA 2242  
Db 2773 AA 2774

RESULT 763  
ADC52365  
ID ADC52365 standard; cDNA; 2846 BP.  
XX  
AC ADC52365;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX  
KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;  
KW affinity purification; secreted and transmembrane protein.  
XX  
OS Homo sapiens.  
XX  
PN US2003138882-A1.  
XX  
PD 24-JUL-2003.  
XX  
PF 08-MAY-2002; 2002US-00063735.  
XX  
PR 30-DEC-1998; 98KR-00062142.  
PR 08-MAR-1999; 99WO-US005028.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380139.  
PR 25-AUG-1999; 99US-00380142.







RESULT 765  
ADD08062  
ID ADD08062 standard; cDNA; 2846 BP.  
XX  
AC ADD08062;  
XX  
DT 01-JAN-2004 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX  
KW Human; secreted protein; transmembrane protein; PRO;  
KW neonatal heart hypertrophy; angiogenesis;  
KW vascular endothelial growth factor; VEGF-stimulated proliferation;  
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;  
KW rod photoreceptor cell; c-fos induction; adipocyte;  
KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;  
KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;  
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;  
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;  
KW polycystic kidney disease; renal tumour; neurodegenerative disorder;  
KW Parkinson's disease; Alzheimer's disease; gene therapy;  
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;  
KW antidiabetic; antianaemic; cytostatic; nootropic; neuroprotective;  
KW antiparkinsonian; gene; ss.  
XX  
OS Homo sapiens.  
XX  
PN US2003068623-A1.  
XX  
PD 10-APR-2003.  
XX  
PF 14-NOV-2001; 2001US-00993469.  
XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-009045P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.





PR	17-JUN-1998;	98US-0089600P.	PR	18-AUG-1998;	98US-0097022P.
PR	17-JUN-1998;	98US-0089653P.	PR	19-AUG-1998;	98US-0097141P.
PR	18-JUN-1998;	98US-0089801P.	PR	20-AUG-1998;	98US-0097218P.
PR	18-JUN-1998;	98US-0089907P.	PR	24-AUG-1998;	98US-0097661P.
PR	18-JUN-1998;	98US-0089908P.	PR	26-AUG-1998;	98US-0097952P.
PR	19-JUN-1998;	98US-0089947P.	PR	26-AUG-1998;	98US-0097954P.
PR	19-JUN-1998;	98US-0089948P.	PR	26-AUG-1998;	98US-0097955P.
PR	19-JUN-1998;	98US-0089952P.	PR	26-AUG-1998;	98US-0097971P.
PR	22-JUN-1998;	98US-0090246P.	PR	26-AUG-1998;	98US-0097974P.
PR	22-JUN-1998;	98US-0090252P.	PR	26-AUG-1998;	98US-0097978P.
PR	22-JUN-1998;	98US-0090254P.	PR	26-AUG-1998;	98US-0097979P.
PR	23-JUN-1998;	98US-0090349P.	PR	26-AUG-1998;	98US-0097986P.
PR	23-JUN-1998;	98US-0090355P.	PR	31-AUG-1998;	98US-0098014P.
PR	24-JUN-1998;	98US-0090429P.	PR	31-AUG-1998;	98US-0098525P.
PR	24-JUN-1998;	98US-0090431P.	PR	16-SEP-1998;	98US-0100634P.
PR	24-JUN-1998;	98US-0090444P.	PR	16-SEP-1998;	98WO-US019330.
PR	24-JUN-1998;	98US-0090445P.	PR	17-SEP-1998;	98US-0100858P.
PR	24-JUN-1998;	98US-0090472P.	PR	17-SEP-1998;	98WO-US019437.
PR	24-JUN-1998;	98US-0090535P.	PR	07-OCT-1998;	98WO-US021141.
PR	24-JUN-1998;	98US-0090540P.	PR	01-DEC-1998;	98WO-US025108.
PR	24-JUN-1998;	98US-0090542P.	PR	22-DEC-1998;	98US-0113296P.
PR	24-JUN-1998;	98US-0090557P.	PR	05-JAN-1999;	99WO-US000106.
PR	24-JUN-1998;	98US-0090676P.	PR	08-MAR-1999;	99WO-US005028.
PR	25-JUN-1998;	98US-0090678P.	PR	12-MAR-1999;	99US-0123957P.
PR	25-JUN-1998;	98US-0090690P.	PR	02-JUN-1999;	99WO-US012252.
PR	25-JUN-1998;	98US-0090694P.	PR	23-JUN-1999;	99US-0141037P.
PR	25-JUN-1998;	98US-0090695P.	PR	07-JUL-1999;	99US-0143048P.
PR	25-JUN-1998;	98US-0090696P.	PR	20-JUL-1999;	99US-0144758P.
PR	26-JUN-1998;	98US-0090862P.	PR	26-JUL-1999;	99US-0145698P.
PR	26-JUN-1998;	98US-0090863P.	PR	28-JUL-1999;	99US-0146222P.
PR	01-JUL-1998;	98US-0091360P.	PR	17-AUG-1999;	99US-0149396P.
PR	01-JUL-1998;	98US-0091544P.	PR	15-SEP-1999;	99WO-US021090.
PR	02-JUL-1998;	98US-0091478P.	PR	15-SEP-1999;	99WO-US021547.
PR	02-JUL-1998;	98US-0091519P.	PR	08-OCT-1999;	99US-0158663P.
PR	02-JUL-1998;	98US-0091626P.	PR	30-NOV-1999;	99WO-US028313.
PR	02-JUL-1998;	98US-0091628P.	PR	01-DEC-1999;	99WO-US028301.
PR	02-JUL-1998;	98US-0091633P.	PR	01-DEC-1999;	99WO-US028634.
PR	02-JUL-1998;	98US-0091646P.	PR	16-DEC-1999;	99WO-US030095.
PR	02-JUL-1998;	98US-0091673P.	PR	20-DEC-1999;	99WO-US030911.
PR	02-JUL-1998;	98US-0091673P.	PR	05-JAN-2000;	2000WO-US000219.
PR	07-JUL-1998;	98US-0091978P.	PR	06-JAN-2000;	2000WO-US000376.
PR	07-JUL-1998;	98US-0091982P.	PR	11-FEB-2000;	2000WO-US003565.
PR	09-JUL-1998;	98US-0092182P.	PR	18-FEB-2000;	2000WO-US004341.
PR	10-JUL-1998;	98US-0092472P.	PR	22-FEB-2000;	2000WO-US004914.
PR	20-JUL-1998;	98US-0093339P.	PR	24-FEB-2000;	2000WO-US005004.
PR	30-JUL-1998;	98US-0094651P.	PR	02-MAR-2000;	2000WO-US005841.
PR	04-AUG-1998;	98US-0095282P.	PR	10-MAR-2000;	2000WO-US006319.
PR	04-AUG-1998;	98US-0095285P.	PR	15-MAR-2000;	2000WO-US006884.
PR	04-AUG-1998;	98US-0095301P.	PR	20-MAR-2000;	2000WO-US007377.
PR	04-AUG-1998;	98US-0095302P.	PR	30-MAR-2000;	2000WO-US008439.
PR	04-AUG-1998;	98US-0095318P.	PR	15-MAY-2000;	2000WO-US013358.
PR	04-AUG-1998;	98US-0095321P.	PR	17-MAY-2000;	2000WO-US013705.
PR	04-AUG-1998;	98US-0095325P.	PR	22-MAY-2000;	2000WO-US014042.
PR	10-AUG-1998;	98US-0095916P.	PR	30-MAY-2000;	2000WO-US014941.
PR	10-AUG-1998;	98US-0095929P.	PR	02-JUN-2000;	2000WO-US015264.
PR	10-AUG-1998;	98US-0096012P.	PR	23-JUN-2000;	2000US-0213637P.
PR	11-AUG-1998;	98US-0096143P.	PR	28-JUL-2000;	2000WO-US020710.
PR	11-AUG-1998;	98US-0096146P.	PR	11-AUG-2000;	2000WO-US022031.
PR	12-AUG-1998;	98US-0096329P.			
PR	17-AUG-1998;	98US-0096757P.			
PR	17-AUG-1998;	98US-0096766P.			
PR	17-AUG-1998;	98US-0096768P.			
PR	17-AUG-1998;	98US-0096773P.			
PR	17-AUG-1998;	98US-0096791P.			
PR	17-AUG-1998;	98US-0096867P.			
PR	17-AUG-1998;	98US-0096891P.			
PR	17-AUG-1998;	98US-0096894P.			
PR	17-AUG-1998;	98US-0096895P.			
PR	17-AUG-1998;	98US-0096897P.			
PR	18-AUG-1998;	98US-0096949P.			
PR	18-AUG-1998;	98US-0096950P.			
PR	18-AUG-1998;	98US-0096959P.			
PR	18-AUG-1998;	98US-0096960P.			

Query Match

Best Local Similarity

Mismatches

Conservative

Score 66.6;

DB 10;

Length 2846;

71.3%;

Pred. No. 0.00023;

0;

0;

35;

Indels

0;

Gaps

0;

Qy	2121	CCTTTGCTTTACCACTCTTTCCCTTTATCTTATTATAATAAATGTTGGTCTCCACCAC	CTG	2180
Db	2653	CCTTTTCCTTCCCCATCTCTGTACACATTTTAATAAAATAAGGTTGGCTTCTGA	ACTA	2712
Qy	2181	NCTCCCAA	AAAAA	2240
Db	2713	CAA	AAAAA	2772
Qy	2241	AA	2242	

Db 2773 AA 2774

RESULT 767

ADD07529

ID ADD07529 standard; cDNA; 2846 BP.

XX

AC ADD07529;

XX

XX

DT 01-JAN-2004 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO1344 cDNA.

XX

KW Human; secreted protein; transmembrane protein; PRO;

KW neonatal heart hypertrophy; angiogenesis;

KW vascular endothelial growth factor; VEGF-stimulated proliferation;

KW endothelial cell; T-lymphocyte proliferation; retinal neuron;

KW rod photoreceptor cell; c-fos induction; adipocyte;

KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;

KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;

KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;

KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;

KW polycystic kidney disease; renal tumour; neurodegenerative disorder;

KW Parkinson's disease; Alzheimer's disease; gene therapy;

KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;

KW antidiabetic; antianaemic; cytostatic; nootropic; neuroprotective;

KW antiparkinsonian; gene; ss.

XX

OS Homo sapiens.

XX

PN US2002193299-A1.

XX

PD 19-DEC-2002.

XX

PF 19-NOV-2001; 2001US-00989735.

XX

PR 16-JUN-1997; 97US-0049787P.

PR 17-OCT-1997; 97US-0062250P.

PR 05-NOV-1997; 97WO-US020069.

PR 12-NOV-1997; 97US-0065186P.

PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0066770P.

PR 25-FEB-1998; 98US-0075945P.

PR 20-MAR-1998; 98US-0078910P.

PR 28-APR-1998; 98US-0083322P.

PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.

PR 02-JUN-1998; 98US-0087607P.

PR 02-JUN-1998; 98US-0087609P.

PR 02-JUN-1998; 98US-0087759P.

PR 03-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088021P.

PR 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088026P.

PR 04-JUN-1998; 98US-0088028P.

PR 04-JUN-1998; 98US-0088029P.

PR 04-JUN-1998; 98US-0088030P.

PR 04-JUN-1998; 98US-0088033P.

PR 04-JUN-1998; 98US-0088326P.

PR 05-JUN-1998; 98US-0088167P.

PR 05-JUN-1998; 98US-0088202P.

PR 05-JUN-1998; 98US-0088212P.

PR 05-JUN-1998; 98US-0088217P.

PR 09-JUN-1998; 98US-0088655P.

PR 10-JUN-1998; 98US-0088734P.

PR 10-JUN-1998; 98US-0088738P.

PR 10-JUN-1998; 98US-0088742P.

PR 10-JUN-1998; 98US-0088810P.

PR 10-JUN-1998; 98US-0088824P.

PR 10-JUN-1998; 98US-0088826P.

PR 11-JUN-1998; 98US-0088858P.

PR 11-JUN-1998; 98US-0088861P.

PR 11-JUN-1998; 98US-0088876P.

PR 12-JUN-1998; 98US-0089105P.

PR 16-JUN-1998; 98US-0089440P.

PR 16-JUN-1998; 98US-0089512P.

PR 16-JUN-1998; 98US-0089514P.

PR 17-JUN-1998; 98US-0089532P.

PR 17-JUN-1998; 98US-0089538P.

PR 17-JUN-1998; 98US-0089598P.

PR 17-JUN-1998; 98US-0089599P.

PR 17-JUN-1998; 98US-0089600P.

PR 17-JUN-1998; 98US-0089653P.

PR 18-JUN-1998; 98US-0089801P.

PR 18-JUN-1998; 98US-0089907P.

PR 18-JUN-1998; 98US-0089908P.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 02-JUN-1999; 99WO-US012252.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000376.

PR 11-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.

PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.

PR 24-FEB-2000; 2000WO-US005004.

PR 02-MAR-2000; 2000WO-US005841.

PR 10-MAR-2000; 2000WO-US006319.

PR 15-MAR-2000; 2000WO-US006884.

PR 20-MAR-2000; 2000WO-US007377.

PR 30-MAR-2000; 2000WO-US008439.

PR 15-MAY-2000; 2000WO-US013358.

PR 17-MAY-2000; 2000WO-US013705.

PR 22-MAY-2000; 2000WO-US014042.

PR 30-MAY-2000; 2000WO-US014941.

PR 02-JUN-2000; 2000WO-US015264.

PR 28-JUL-2000; 2000WO-US020710.

PR 11-AUG-2000; 2000WO-US022031.

PR 23-AUG-2000; 2000WO-US023522.

PR 24-AUG-2000; 2000WO-US023328.

PR 08-NOV-2000; 2000WO-US030952.

PR 01-DEC-2000; 2000WO-US032678.

PR 28-FEB-2001; 2001WO-US006520.

PR 01-JUN-2001; 2001WO-US017800.

PR 20-JUN-2001; 2001WO-US019692.

PR 29-JUN-2001; 2001WO-US021066.

PR 09-JUL-2001; 2001WO-US021735.

PR 28-AUG-2001; 2001US-00941992.

XX

PA (GETH ) GENENTECH INC.

XX

PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;

PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;

PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;

PI Zhang Z;

XX

DR WPI; 2003-657230/62.

DR P-PSDB; ADD07530.

XX

PT Isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346 and

PT PRO1375, which stimulate proliferation of stimulated T-lymphocytes and

PT are thus therapeutically useful e.g. for enhancing immune response.

XX

PS Claim 2; SEQ ID NO 230; 659pp; English.

XX The invention relates to human secreted and transmembrane PRO

CC polypeptides and the polynucleotides encoding them. The PRO polypeptides

CC or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors

CC or bioreactors. They are useful for stimulating hypertrophy of neonatal

CC heart, promoting angiogenesis, inhibiting vascular endothelial growth

CC factor (VEGF)-stimulated proliferation of endothelial cells, modulating

CC the proliferation of stimulated T-lymphocytes, enhancing the survival or

CC proliferation of retinal neurons or rod photoreceptor cells, inducing c-

CC fos in endothelial cells, modulating glucose or FFA uptake by adipocytes,

CC inducing proliferation and/or re-differentiation of chondrocytes, or

CC inducing pancreatic beta-cell precursor differentiation into mature

CC pancreatic beta-cells. They may therefore be useful in the treatment of

CC various insulin deficient states in mammals, including diabetes mellitus,

CC and in treating undesired endothelial cell growth, e.g., inhibiting

CC tumour growth. The sequences are also useful for treating mammalian

CC haemoglobin-associated disorders (e.g., various thalassaemias), cystic

CC renal dysplasia, polycystic kidney disease, renal tumours, and other

CC cancers such as those of the colon, lung and breast. PRO polypeptides or

CC antibodies to PRO polypeptides may be used to detect a PRO polypeptide in

CC a sample; to link a bioactive molecule to a cell; to modulate a

CC biological activity of a cell; as molecular weight markers for protein

CC electrophoresis purposes; for tissue typing; to prepare a medicament for

CC treating a condition responsive to the polypeptide or antibody, such as

CC neurodegenerative disorders (e.g., Parkinson's disease or Alzheimer's

CC disease); and in various diagnostic assays. The PRO polynucleotides can

CC be used as hybridisation probes, in chromosome and gene mapping, in

CC generating antisense RNA and DNA, and in gene therapy. The polynucleotide

CC may also be used in preparing PRO polypeptides by recombinant techniques,

CC and in generating either transgenic animals or knock-out animals which,

CC in turn, are useful in the development and screening of therapeutically

CC useful reagents. This sequence represents a human PRO polynucleotide of

CC the invention. Note: The sequence data for this patent is also available

CC in electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTATAAAATGTTGGTCTCCACCACTG 2180

||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Db 2653 CCTTTTCCTTCCCCATCTCTTGACACATTTTATAAAATAGGTTGGCTTCTGAACATA 2712

||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 2181 NCTCCCAA 2240

||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Db 2713 CAAA 2772

QY 2241 AA 2242

||

Db 2773 AA 2774

RESULT 768

ADC82420

ID ADC82420 standard; cDNA; 2846 BP.

XX AC ADC82420;

XX 01-JAN-2004 (first entry)

XX Human PRO polynucleotide #65.

XX Human; PRO; gene; ss; pancreatic beta-cell precursor cell;

KW pancreatic beta-cell; insulin deficiency; diabetes mellitus;

KW haemoglobin-associated disorder; thalassaemia; endothelial cell growth;

KW cancer; cystic renal dysplasia; polycystic kidney disease; renal tumour;

KW antidiabetic; antianaemic; cytostatic; cardiant; vulneryary;

XX antiinflammatory; anorectic.

OS Homo sapiens.

XX US2003059833-A1.

PN 27-MAR-2003.

XX 15-NOV-2001; 2001US-00997440.

XX 16-JUN-1997; 97US-0049787P.

PR 17-OCT-1997; 97US-0062250P.

PR 05-NOV-1997; 97WO-US020069.

PR 12-NOV-1997; 97US-0065186P.

PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0066770P.

PR 25-FEB-1998; 98US-0075945P.

PR 20-MAR-1998; 98US-0078910P.

PR 28-APR-1998; 98US-0083322P.

PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.

PR 02-JUN-1998; 98US-0087607P.

PR 02-JUN-1998; 98US-0087609P.

PR 02-JUN-1998; 98US-0087759P.

PR 03-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088021P.

PR 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088026P.

PR 04-JUN-1998; 98US-0088028P.

PR 04-JUN-1998; 98US-0088029P.

PR 04-JUN-1998; 98US-0088030P.

PR 04-JUN-1998; 98US-0088033P.

PR 04-JUN-1998; 98US-0088326P.

PR 05-JUN-1998; 98US-0088167P.

PR 05-JUN-1998; 98US-0088202P.

PR 05-JUN-1998; 98US-0088212P.

PR 05-JUN-1998; 98US-0088217P.

PR 09-JUN-1998; 98US-0088655P.

PR 10-JUN-1998; 98US-0088734P.

PR 10-JUN-1998; 98US-0088738P.

PR 10-JUN-1998; 98US-0088742P.

PR 10-JUN-1998; 98US-0088810P.

PR 10-JUN-1998; 98US-0088824P.

PR 10-JUN-1998; 98US-0088826P.

PR 11-JUN-1998; 98US-0088858P.

PR 11-JUN-1998; 98US-0088861P.

PR 11-JUN-1998; 98US-0088876P.

PR 12-JUN-1998; 98US-0089105P.

PR 16-JUN-1998; 98US-0089440P.

PR 16-JUN-1998; 98US-0089512P.

PR 16-JUN-1998; 98US-0089514P.

PR 17-JUN-1998; 98US-0089532P.

PR 17-JUN-1998; 98US-0089538P.

PR 17-JUN-1998; 98US-0089598P.

PR 17-JUN-1998; 98US-0089599P.

PR 17-JUN-1998; 98US-0089600P.

PR 17-JUN-1998; 98US-0089653P.

PR 18-JUN-1998; 98US-0089801P.

PR 18-JUN-1998; 98US-0089907P.

PR 18-JUN-1998; 98US-0089908P.

PR 19-JUN-1998; 98US-0089947P.

PR 19-JUN-1998; 98US-0089948P.

PR 19-JUN-1998; 98US-0089952P.

PR 22-JUN-1998; 98US-0090246P.

PR 22-JUN-1998; 98US-0090252P.

PR 22-JUN-1998; 98US-0090254P.

PR 23-JUN-1998; 98US-0090349P.

PR 23-JUN-1998; 98US-0090355P.

PR 23-JUN-1998; 98US-0090429P.

PR 24-JUN-1998; 98US-0090431P.

PR 24-JUN-1998; 98US-0090435P.

PR 24-JUN-1998; 98US-0090444P.

PR 24-JUN-1998; 98US-0090445P.

PR 24-JUN-1998; 98US-0090472P.

PR 24-JUN-1998; 98US-0090535P.

PR 24-JUN-1998; 98US-0090540P.











AC ADD06849;  
XX  
DT 01-JAN-2004 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX  
KW Human; secreted protein; transmembrane protein; PRO;  
KW neonatal heart hypertrophy; angiogenesis;  
KW vascular endothelial growth factor; VEGF-stimulated proliferation;  
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;  
KW rod photoreceptor cell; c-fos induction; adipocyte;  
KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;  
KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;  
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;  
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;  
KW polycystic kidney disease; renal tumour; neurodegenerative disorder;  
KW Parkinson's disease; Alzheimer's disease; gene therapy;  
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;  
KW antidiabetic; antianaemic; cytostatic; neuroprotective;  
KW antiparkinsonian; gene; ss.  
XX  
OS Homo sapiens.  
XX  
PN US2002193300-A1.  
XX  
PD 19-DEC-2002.  
XX  
PF 14-NOV-2001; 2001US-00990444.  
XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.

PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 02-JUN-1999; 99WO-US012252.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 28-AUG-2001; 2001US-00941992.  
XX  
PA (GETH ) GENENTECH INC.

Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;  
Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;  
Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;  
Zhang Z;

WPI; 2003-657231/62.  
P-PSDB; ADD06850.

Novel isolated PRO polypeptides e.g., PRO826, PRO1184, PRO1346  
and PRO1375, which stimulate proliferation of stimulated T-lymphocytes  
and are thus therapeutically useful for enhancing immune response.

Claim 2; SEQ ID NO 230; 653pp; English.

The invention relates to human secreted and transmembrane PRO  
polypeptides and the polynucleotides encoding them. The PRO polypeptides  
or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors  
or bioreactors. They are useful for stimulating hypertrophy of neonatal  
heart, promoting angiogenesis, inhibiting vascular endothelial growth  
factor (VEGF)-stimulated proliferation of endothelial cells, modulating







PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.

PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 31-AUG-1998; 98US-0098525P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 12-MAR-1999; 99US-0123957P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 20-JUL-1999; 99US-0144758P.

PR	26-JUL-1999;	99US-0145698P.	PR	24-AUG-2000;	2000WO-US023328.
PR	28-JUL-1999;	99US-0146222P.	PR	06-DEC-2001;	2001US-00006867.
PR	17-AUG-1999;	99US-0149396P.	XX		
PR	15-SEP-1999;	99WO-US021090.	PA	(GETH )	GENENTECH INC.
PR	15-SEP-1999;	99WO-US021547.	XX		
PR	08-OCT-1999;	99US-0158663P.	PI	Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;	
PR	30-NOV-1999;	99WO-US028313.	PI	Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;	
PR	01-DEC-1999;	99WO-US028301.	XX		
PR	01-DEC-1999;	99WO-US028634.	DR	WPI; 2003-829362/77.	
PR	16-DEC-1999;	99WO-US030095.	DR	P-PSDB; ADD36042.	
PR	20-DEC-1999;	99WO-US030911.	XX		
PR	05-JAN-2000;	2000WO-US000219.	PT	New antibody that binds to a secreted and transmembrane polypeptide (PRO)	
PR	06-JAN-2000;	2000WO-US000376.	PT	useful in diagnostic assays for PRO and as a PRO agonist or antagonist.	
PR	11-FEB-2000;	2000WO-US003565.	XX		
PR	18-FEB-2000;	2000WO-US004341.	PS	Disclosure; Fig 37; 408pp; English.	
PR	22-FEB-2000;	2000WO-US004414.	XX		
PR	24-FEB-2000;	2000WO-US004914.	CC	The invention describes an antibody that specifically binds to a PRO	
PR	24-FEB-2000;	2000WO-US005004.	CC	polypeptide having a fully defined amino acid sequence given in the	
PR	02-MAR-2000;	2000WO-US005841.	CC	specification. The antibody is useful in identifying PRO polypeptides	
PR	10-MAR-2000;	2000WO-US006319.	CC	useful for various industrial applications, including pharmaceuticals,	
PR	15-MAR-2000;	2000WO-US006884.	CC	diagnostics, biosensors and bioreactors. The antibody is also used for	
PR	20-MAR-2000;	2000WO-US007377.	CC	affinity purification of PRO polypeptides from recombinant cell culture	
PR	30-MAR-2000;	2000WO-US008439.	CC	or natural sources. The antibody, PRO polypeptide, or its agonists or	
PR	15-MAY-2000;	2000WO-US013358.	CC	antagonists, may be used for preparing a medicament for diagnosing or	
PR	17-MAY-2000;	2000WO-US013705.	CC	treating a condition responsive to the antibody, PRO polypeptide, or its	
PR	22-MAY-2000;	2000WO-US014042.	CC	agonists or antagonists. This sequence encodes a novel human secreted and	
PR	30-MAY-2000;	2000WO-US014941.	CC	transmembrane PRO polypeptide.	
PR	02-JUN-2000;	2000WO-US015264.	XX		
PR	23-JUN-2000;	2000US-0213637P.	SQ	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;	
PR	28-JUL-2000;	2000WO-US020710.			
PR	11-AUG-2000;	2000WO-US022031.			
Query Match 3.0%; Score 66.6; DB 10; Length 2846;			Query Match 3.0%; Score 66.6; DB 10; Length 2846;		
Best Local Similarity 71.3%; Pred. No. 0.00023;			Best Local Similarity 71.3%; Pred. No. 0.00023;		
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;			Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;		
QY	2121	CCTTTGCTTTACCACTCTTCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACTG 2180	QY	2121	CCTTTGCTTTACCACTCTTCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACTG 2180
Db	2653	CTTTTCCTTCCCACTCTCTGTACACATTTTAATAAAATAAGGGTTGGCTTCTGAACTA 2712	Db	2653	CTTTTCCTTCCCACTCTCTGTACACATTTTAATAAAATAAGGGTTGGCTTCTGAACTA 2712
QY	2181	NCTCCCAAA 2240	QY	2181	NCTCCCAAA 2240
Db	2713	CAAA 2772	Db	2713	CAAA 2772
QY	2241	AA 2242	QY	2241	AA 2242
Db	2773	AA 2774	Db	2773	AA 2774
RESULT 774			RESULT 775		
ADD36041			ADD56161		
ID	ADD36041 standard; cDNA; 2846 BP.		ID	ADD56161 standard; cDNA; 2846 BP.	
XX			XX		
AC	ADD36041;		AC	ADD56161;	
XX			XX		
DT	15-JAN-2004 (first entry)		DT	15-JAN-2004 (first entry)	
XX			XX		
DE	Novel human secreted and transmembrane protein PRO1344 cDNA.		DE	Human PRO polynucleotide #65.	
XX			XX		
SS	ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;		XX	Human; PRO; gene; ss; pancreatic beta-cell precursor cell;	
KW	affinity purification; secreted and transmembrane protein.		KW	pancreatic beta-cell; insulin deficiency; diabetes mellitus;	
XX			KW	haemoglobin-associated disorder; thalassaemia; endothelial cell growth;	
OS	Homo sapiens.		KW	cancer; cystic renal dysplasia; polycystic kidney disease; renal tumour;	
XX			KW	antidiabetic; antianaemic; cytostatic; cardiant; vulnerary;	
PN	US2003105298-A1.		KW	antiinflammatory; anorectic.	
XX			XX		
PD	05-JUN-2003.		OS	Homo sapiens.	
XX			XX		
PF	03-MAY-2002; 2002US-00063580.		PN	US2003077594-A1.	
XX			XX		
PR	16-JUN-1998; 98US-0089514P.		PD	24-APR-2003.	
PR	02-JUN-1999; 99WO-US012252.		XX		
PR	25-AUG-1999; 99US-00380137.		PF	14-NOV-2001; 2001US-00993583.	
			XX		
			PR	16-JUN-1997; 97US-0049787P.	

PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.

PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 31-AUG-1998; 98US-0098525P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 12-MAR-1999; 99US-0123957P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.











Oy 2241 AA 2242  
Db 2773 AA 2774

RESULT 778  
ADE26220  
ID ADE26220 standard; cDNA; 2846 BP.  
XX  
AC ADE26220;  
XX  
DT 29-JAN-2004 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX  
KW human; secreted and transmembrane protein; PRO; nootropic;  
KW neuroprotective; antiparkinsonian; cytostatic; gene therapy;  
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;  
KW neurodegenerative disorder; Parkinson's disease; Alzheimer's disease;  
KW gene; ss.  
XX  
OS Homo sapiens.  
XX  
PN US2003087305-A1.  
XX  
PD 08-MAY-2003.  
XX  
PF 15-NOV-2001; 2001US-00997384.  
XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.

PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.







XX PS Disclosure; Fig 37; 387pp; English.

XX CC The invention describes an antibody that specifically binds to a PRO

CC polypeptide having a fully defined amino acid sequence given in the

CC specification. The antibody is useful in identifying PRO polypeptides

CC useful for various industrial applications, including pharmaceuticals,

CC diagnostics, biosensors and bioreactors. The antibody is also used for

CC affinity purification of PRO polypeptides from recombinant cell culture

CC or natural sources. The antibody, PRO polypeptide, or its agonists or

CC antagonists, may be used for preparing a medicament for diagnosing or

CC treating a condition responsive to the antibody, PRO polypeptide, or its

CC agonists or antagonists. This sequence encodes a novel human secreted and

CC transmembrane PRO polypeptide.

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACCTCTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACCTG 2180

Db 2653 CCTTTCCCTCCCATCTCTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAACCTA 2712

QY 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 781

ADG08595

ID ADG08595 standard; cDNA; 2846 BP.

XX AC ADG08595;

XX DT 26-FEB-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.

XX KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;

XX KW affinity purification; secreted and transmembrane protein.

XX OS Homo sapiens.

XX PN US2003180793-A1.

XX PD 25-SEP-2003.

XX PF 02-MAY-2002; 2002US-00063546.

XX PR 30-DEC-1998; 98KR-00062142.

PR 08-MAR-1999; 99WO-US005028.

PR 14-MAY-1999; 99US-00311832.

PR 14-MAY-1999; 99WO-US010733.

PR 25-AUG-1999; 99US-00380137.

PR 25-AUG-1999; 99US-00380138.

PR 25-AUG-1999; 99US-00380139.

PR 25-AUG-1999; 99US-00380142.

PR 15-SEP-1999; 99US-00397342.

PR 18-OCT-1999; 99US-00403297.

PR 12-NOV-1999; 99US-00423844.

PR 30-DEC-1999; 99WO-US031274.

PR 18-FEB-2000; 2000WO-US004341.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005841.

PR 21-MAR-2000; 2000WO-US007532.

PR 22-MAY-2000; 2000WO-US014042.

PR 02-JUN-2000; 2000WO-US015264.

PR 22-AUG-2000; 2000US-00644848.

PR 24-AUG-2000; 2000WO-US023328.

PR 18-SEP-2000; 2000US-00664610.

PR 18-SEP-2000; 2000US-00665350.

PR 08-NOV-2000; 2000US-00709238.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001WO-US006520.

PR 22-MAR-2001; 2001US-00816744.

PR 10-MAY-2001; 2001US-00854208.

PR 10-MAY-2001; 2001US-00854280.

PR 30-MAY-2001; 2001US-00870574.

PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.

PR 29-JUN-2001; 2001US-00869599.

PR 18-JUL-2001; 2001US-00908827.

PR 06-DEC-2001; 2001US-00006867.

XX (GETH ) GENENTECH INC.

PA Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX WPI; 2003-787560/74.

DR P-PSDB; ADG08596.

XX Novel antibody that binds to a PRO polypeptide, useful for treating

PT cancer and in diagnostic assays, for e.g. detecting PRO expression in

PT specific cells, tissues, or serum.

XX Disclosure; SEQ ID NO 37; 562pp; English.

XX The invention describes an antibody that specifically binds to a PRO

CC polypeptide having a fully defined amino acid sequence given in the

CC specification. The antibody is useful in identifying PRO polypeptides

CC useful for various industrial applications, including pharmaceuticals,

CC diagnostics, biosensors and bioreactors. The antibody is also used for

CC affinity purification of PRO polypeptides from recombinant cell culture

CC or natural sources. The antibody, PRO polypeptide, or its agonists or

CC antagonists, may be used for preparing a medicament for diagnosing or

CC treating a condition responsive to the antibody, PRO polypeptide, or its

CC agonists or antagonists. This sequence encodes a novel human secreted and

CC transmembrane PRO polypeptide.

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACCTCTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACCTG 2180

Db 2653 CCTTTCCCTCCCATCTCTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAACCTA 2712

QY 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 782

ADG02637

ID ADG02637 standard; cDNA; 2846 BP.

XX AC ADG02637;

XX DT 26-FEB-2004 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX  
KW ss; gene; cytostatic; gene therapy; chondrocyte stimulator;  
KW secreted and transmembrane protein; PRO; chromosome mapping;  
KW gene mapping; tumour.  
XX  
OS Homo sapiens.  
XX  
PN US2003207397-A1.  
XX  
PD 06-NOV-2003.  
XX  
PF 15-JUL-2002; 2002US-00195900.  
XX  
PR 14-MAR-2000; 2000US-0189320P.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 15-JAN-2002; 2002US-00052586.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;  
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR WPI; 2003-864790/80.  
DR P-PSDB; ADG02638.  
XX  
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful  
PT for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation,  
PT particularly for treating e.g. lung or breast tumors, or arthritis in a  
PT mammal.  
XX  
PS Claim 2; Fig 169; 700pp; English.  
XX  
CC The invention describes 305 nucleic acids encoding PRO polypeptides  
CC (secreted and transmembrane). The polynucleotide is useful in molecular  
CC biology, including uses as hybridisation probes, in chromosome and gene  
CC mapping, in generating antisense RNA and DNA, and in gene therapy. The  
CC polynucleotide may also be used in preparing PRO polypeptides by  
CC recombinant techniques, and in generating either transgenic animals or  
CC knock-out animals which, in turn, are useful in the development and  
CC screening of therapeutically useful reagents. The PRO polypeptide or the  
CC antibody is used in preparing a medicament for treating a condition  
CC responsive to the polypeptide or antibody, such as tumours, and in  
CC various diagnostic assays. This sequence encodes a novel human secreted  
CC and transmembrane PRO polypeptide.  
XX  
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;  
  
Query Match 3.0%; Score 66.6; DB 10; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;  
  
QY 2121 CCTTGTCTTACCACCTCTTTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAAATAAGGGTTGGCTTCTGAACATA 2712  
  
QY 2181 NCTCCCAAA 2240  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 2713 CAA 2772  
  
QY 2241 AA 2242  
||  
Db 2773 AA 2774

RESULT 783  
ADG01344  
ID ADG01344 standard; cDNA; 2846 BP.  
XX  
AC ADG01344;  
XX  
DT 26-FEB-2004 (first entry)  
XX

DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX  
KW Human; ss; gene; cytostatic; gene therapy; chondrocyte stimulator;  
KW secreted and transmembrane protein; PRO; chromosome mapping;  
KW gene mapping; tumour.  
XX  
OS Homo sapiens.  
XX  
PN US2003207399-A1.  
XX  
PD 06-NOV-2003.  
XX  
PF 24-JUL-2002; 2002US-00205506.  
XX  
PR 28-OCT-1998; 98US-0106033P.  
PR 01-SEP-1999; 99WO-US020111.  
PR 18-OCT-1999; 99US-00403297.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 15-JAN-2002; 2002US-00052586.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;  
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR WPI; 2003-864792/80.  
DR P-PSDB; ADG01345.  
XX  
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful  
PT for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation,  
PT particularly for treating e.g. lung or breast tumors, or arthritis in a  
PT mammal.  
XX  
PS Claim 2; SEQ ID NO 169; 700pp; English.  
XX  
CC The invention describes 305 nucleic acids encoding PRO polypeptides  
CC (secreted and transmembrane). The polynucleotide is useful in molecular  
CC biology, including uses as hybridisation probes, in chromosome and gene  
CC mapping, in generating antisense RNA and DNA, and in gene therapy. The  
CC polynucleotide may also be used in preparing PRO polypeptides by  
CC recombinant techniques, and in generating either transgenic animals or  
CC knock-out animals which, in turn, are useful in the development and  
CC screening of therapeutically useful reagents. The PRO polypeptide or the  
CC antibody is used in preparing a medicament for treating a condition  
CC responsive to the polypeptide or antibody, such as tumours, and in  
CC various diagnostic assays. This sequence encodes a novel human secreted  
CC and transmembrane PRO polypeptide.  
XX  
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;  
  
Query Match 3.0%; Score 66.6; DB 10; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;  
  
QY 2121 CCTTGTCTTACCACCTCTTTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAAATAAGGGTTGGCTTCTGAACATA 2712  
  
QY 2181 NCTCCCAAA 2240  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 2713 CAA 2772  
  
QY 2241 AA 2242  
||  
Db 2773 AA 2774

RESULT 784  
ADF95519  
ID ADF95519 standard; cDNA; 2846 BP.  
XX  
AC ADF95519;  
XX





```
CC diagnostics, biosensors and bioreactors. The antibody is also used for
CC affinity purification of PRO polypeptides from recombinant cell culture
CC or natural sources. The antibody, PRO polypeptide, or its agonists or
CC antagonists, may be used for preparing a medicament for diagnosing or
CC treating a condition responsive to the antibody, PRO polypeptide, or its
CC agonists or antagonists. This sequence encodes a novel human secreted and
CC transmembrane PRO polypeptide.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTCTCTTTTATCTTATTATAAAATGTTGTTCTCCACCACTG 2180
      ||||| |||| |||| |||| |||| |||| |||| |||| |||| |||| |||| ||||
Db 2653 CCTTTCTCTCCCATCTCTTGTTACACATTTTATAAAATAAGGGTTGGCTTCTGAAC 2712
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2241 AA 2242
      ||
Db 2773 AA 2774

RESULT 786
ADG12334
ID ADG12334 standard; cDNA; 2846 BP.
XX
AC ADG12334;
XX
DT 26-FEB-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW Human; ss; gene; cytostatic; gene therapy; chondrocyte stimulator;
KW secreted and transmembrane protein; PRO; chromosome mapping;
KW gene mapping; tumour.
XX
OS Homo sapiens.
XX
PN US2003207392-A1.
XX
PD 06-NOV-2003.
XX
PF 24-JUN-2002; 2002US-00179509.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
```



```
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854208.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH ) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-830993/77.
DR P-PSDB; ADH24070.
XX
PT New isolated PRO polypeptide, useful for treating various bone and/or
PT cartilage disorders, for example, sports injuries and arthritis.
XX
PS Disclosure; SEQ ID NO 37; 397pp; English.
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide comprising the 642 amino acid sequence (S1) defined in the
CC specification. The PRO polypeptides are useful for treating various bone
CC and/or cartilage disorders, for example, sports injuries and arthritis.
CC They are also useful in the therapeutic treatment of disorders where
CC either the stimulation or inhibition of glucose uptake by skeletal muscle
CC would be beneficial, for example, diabetes or hyper- or hypo-
CC insulinaemia. They are also useful for treating pericyte-associated
CC tumours and in wound healing. The anti-PRO antibody is useful for the
CC preparation of a medicament useful in the treatment of cancer. The PRO
CC polypeptides are also useful as molecular weight markers, or for
CC chromosome identification. The PRO genes are useful as hybridisation
CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.
CC The PRO genes may also be used in gene therapy, particularly for
CC replacing a defective gene. This sequence encodes a secreted and
CC transmembrane PRO protein.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match          3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACCTTTTCCTTTTATCTTATTATAAATAATGTTGGTCTCCACCACGTG 2180
    ||||| | ||| | ||| | ||| | ||| | ||| | ||| | ||| | ||| | ||| |
Db 2653 CCTTTTCCTTCCCCATCTCTGTACACATTTTAAATAAATAAGGGTTGGCTTCTGAACATA 2712
    ||||| | ||||| | ||||| | ||||| | ||||| | ||||| | ||||| | |||||
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| | ||||| | ||||| | ||||| | ||||| | ||||| | ||||| | |||||
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
    ||||| | ||||| | ||||| | ||||| | ||||| | ||||| | ||||| | |||||
QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 788
ADH34095
ID ADH34095 standard; cDNA; 2846 BP.
XX
AC ADH34095;
XX
```

```
DT 11-MAR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW affinity purification; secreted and transmembrane protein.
XX
OS Homo sapiens.
XX
PN US2003180858-A1.
XX
PD 25-SEP-2003.
XX
PF 08-MAY-2002; 2002US-00063730.
XX
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH ) GENENTECH INC.
XX
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-778508/73.
DR P-PSDB; ADH34096.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in molecular biology, chromosome and gene mapping, in generating
PT antisense RNA and DNA, in various diagnostic assays and in gene therapy.
XX
PS Disclosure; SEQ ID NO 37; 397pp; English.
XX
CC The invention describes an antibody that specifically binds to a PRO
CC polypeptide having a fully defined amino acid sequence given in the
CC specification. The antibody is useful in identifying PRO polypeptides
CC useful for various industrial applications, including pharmaceuticals,
CC diagnostics, biosensors and bioreactors. The antibody is also used for
CC affinity purification of PRO polypeptides from recombinant cell culture
```











KW	hypoglycaemic; antibody therapy; PRO; secreted and transmembrane;
KW	bone disorder; cartilage disorder; sports injury; arthritis;
KW	glucose uptake; skeletal muscle; diabetes; hyper-insulinaemia;
KW	hypo-insulinaemia; pericyte-associated tumour; wound healing; cancer;
KW	chromosome identification; gene therapy; gene; ss; human.
XX	
OS	Homo sapiens.
XX	
PN	US2003180907-A1.
XX	
PD	25-SEP-2003.
XX	
PF	03-MAY-2002; 2002US-00063610.
XX	
PR	30-DEC-1998; 98KR-00062142.
PR	08-MAR-1999; 99WO-US005028.
PR	14-MAY-1999; 99US-00311832.
PR	14-MAY-1999; 99WO-US010733.
PR	25-AUG-1999; 99US-00380137.
PR	25-AUG-1999; 99US-00380138.
PR	25-AUG-1999; 99US-00380139.
PR	25-AUG-1999; 99US-00380142.
PR	15-SEP-1999; 99US-00397342.
PR	18-OCT-1999; 99US-00403297.
PR	12-NOV-1999; 99US-00423844.
PR	30-DEC-1999; 99WO-US031274.
PR	18-FEB-2000; 2000WO-US004341.
PR	01-MAR-2000; 2000WO-US005601.
PR	02-MAR-2000; 2000WO-US005841.
PR	21-MAR-2000; 2000WO-US007532.
PR	22-MAY-2000; 2000WO-US014042.
PR	02-JUN-2000; 2000WO-US015264.
PR	22-AUG-2000; 2000US-00644848.
PR	24-AUG-2000; 2000WO-US023328.
PR	18-SEP-2000; 2000US-00664610.
PR	18-SEP-2000; 2000US-00665350.
PR	08-NOV-2000; 2000US-00709238.
PR	10-NOV-2000; 2000WO-US030873.
PR	01-DEC-2000; 2000WO-US032678.
PR	20-DEC-2000; 2000US-00747259.
PR	20-DEC-2000; 2000WO-US034956.
PR	28-FEB-2001; 2001WO-US006520.
PR	22-MAR-2001; 2001US-00816744.
PR	10-MAY-2001; 2001US-00854208.
PR	10-MAY-2001; 2001US-00854280.
PR	30-MAY-2001; 2001US-00870574.
PR	01-JUN-2001; 2001WO-US017800.
PR	05-JUN-2001; 2001US-00874503.
PR	29-JUN-2001; 2001US-00869599.
PR	18-JUL-2001; 2001US-00908827.
PR	06-DEC-2001; 2001US-00006867.
XX	
PA	(GETH ) GENENTECH INC.
XX	
PI	Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI	Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX	
DR	WPI; 2003-787563/74.
DR	P-PSDB; ADH24580.
XX	
PT	New isolated PRO polypeptide, useful for treating various bone and/or
PT	cartilage disorders, for example, sports injuries and arthritis.
XX	
PS	Disclosure; SEQ ID NO 37; 563pp; English.
XX	
CC	The invention describes an isolated PRO (secreted and transmembrane)
CC	polypeptide comprising the 642 amino acid sequence (S1) defined in the
CC	specification. The PRO polypeptides are useful for treating various bone
CC	and/or cartilage disorders, for example, sports injuries and arthritis.
CC	They are also useful in the therapeutic treatment of disorders where
CC	either the stimulation or inhibition of glucose uptake by skeletal muscle
CC	would be beneficial, for example, diabetes or hyper- or hypo-
CC	insulinaemia. They are also useful for treating pericyte-associated

tumours and in wound healing. The anti-PRO antibody is useful for the preparation of a medicament useful in the treatment of cancer. The PRO polypeptides are also useful as molecular weight markers, or for chromosome identification. The PRO genes are useful as hybridisation probes, or for screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. This sequence encodes a secreted and transmembrane PRO protein.

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

SQ Query Match 3.0%; Score 66.6; DB 10; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTACCACACTCTTTCCCTTTATCTTATTATAAATAAGTGTCCTCACCACGTG 2180  
||| | | | | | | | | | | | | | | | | | | | |  
Db 2653 CCTTTTCTCCCATCTCTTGTAACAATTTAAATAAATAAGGGTGTGCTTCTGAACATA 2712  
  
QY 2181 NCTCCCCAAAAA AAA 2240  
||| | | | | | | | | | | | | | | | | | | | |  
Db 2713 CA AA 2772

QY 2241 AA 2242  
||  
Db 2773 AA 2774

RESULT 794  
ADH37435  
ID ADH37435 standard; cDNA; 2846 BP.  
XX  
AC ADH37435;  
.XX  
DT 11-MAR-2004 (first entry)  
XX Human secreted and transmembrane protein PRO1344 cDNA.  
DE PRO; cytostatic; antidiabetic; antiarthritic; osteopathic; antirheumatic;  
KW secreted and transmembrane polypeptide; cancer; gene therapy; ss; gene;  
KW human.  
XX Homo sapiens.  
OS  
XN US2003181646-A1.  
PD 25-SEP-2003.  
XX  
PF 03-MAY-2002; 2002US-00063607.  
XX  
PR 30-DEC-1998; 98KR-00062142.  
PR 08-MAR-1999; 99WO-US005028.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380139.  
PR 25-AUG-1999; 99US-00380142.  
PR 15-SEP-1999; 99US-00397342.  
PR 18-OCT-1999; 99US-00403297.  
PR 12-NOV-1999; 99US-00423844.  
PR 30-DEC-1999; 99WO-US031274.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 22-AUG-2000; 2000US-00644848.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00664610.  
PR 18-SEP-2000; 2000US-00665350.  
PR 08-NOV-2000; 2000US-00709238.







QY 2181 NCTCCAA 2240  
Db 2713 CAAA 2772  
QY 2241 AA 2242  
Db 2773 AA 2774

RESULT 797  
ADG85643  
ID ADG85643 standard; cDNA; 2846 BP.  
XX  
AC ADG85643;  
XX  
DT 11-MAR-2004 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX  
KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;  
KW affinity purification; secreted and transmembrane protein.  
XX  
OS Homo sapiens.  
XX  
PN US2003180905-A1.  
XX  
PD 25-SEP-2003.  
XX  
PF 03-MAY-2002; 2002US-00063577.  
XX  
PR 30-DEC-1998; 98KR-00062142.  
PR 08-MAR-1999; 99WO-US005028.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380139.  
PR 25-AUG-1999; 99US-00380142.  
PR 15-SEP-1999; 99US-00397342.  
PR 18-OCT-1999; 99US-00403297.  
PR 12-NOV-1999; 99US-00423844.  
PR 30-DEC-1999; 99WO-US031274.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 22-AUG-2000; 2000US-00644848.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00664610.  
PR 18-SEP-2000; 2000US-00665350.  
PR 08-NOV-2000; 2000US-00709238.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 28-FEB-2001; 2000WO-US034956.  
PR 22-MAR-2001; 2001WO-US006520.  
PR 10-MAY-2001; 2001US-00816744.  
PR 10-MAY-2001; 2001US-00854208.  
PR 30-MAY-2001; 2001US-00870574.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 29-JUN-2001; 2001US-00869599.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-DEC-2001; 2001US-00006867.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;  
XX

DR WPI; 2003-802877/75.  
DR P-PSDB; ADG85644.  
XX  
PT New isolated PRO polypeptide, useful for treating various bone and/or  
cartilage disorders, for example, sports injuries and arthritis.  
XX  
PS Disclosure; SEQ ID NO 37; 563pp; English.  
XX  
CC The invention describes an antibody that specifically binds to a PRO  
polypeptide having a fully defined amino acid sequence given in the  
specification. The antibody is useful in identifying PRO polypeptides  
useful for various industrial applications, including pharmaceuticals,  
diagnostics, biosensors and bioreactors. The antibody is also used for  
affinity purification of PRO polypeptides from recombinant cell culture  
or natural sources. The antibody, PRO polypeptide, or its agonists or  
antagonists, may be used for preparing a medicament for diagnosing or  
treating a condition responsive to the antibody, PRO polypeptide, or its  
agonists or antagonists. This sequence encodes a novel human secreted and  
transmembrane PRO polypeptide.  
XX  
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;  
Query Match 3.0%; Score 66.6; DB 10; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACCTCTTCTCTTTATCTTATTAATAATAAATGTTGGTCTCCACCACTG 2180  
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAAGGTTGGCTTCTGAACTA 2712  
QY 2181 NCTCCAA 2240  
Db 2713 CAAA 2772  
QY 2241 AA 2242  
Db 2773 AA 2774

RESULT 798  
ADH24239  
ID ADH24239 standard; cDNA; 2846 BP.  
XX  
AC ADH24239;  
XX  
DT 11-MAR-2004 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX  
KW antiarthritic; antidiabetic; cytostatic; vulnery; hyperglycaemic;  
KW hypoglycaemic; antibody therapy; PRO; secreted and transmembrane;  
KW bone disorder; cartilage disorder; sports injury; arthritis;  
KW glucose uptake; skeletal muscle; diabetes; hyper-insulinaemia;  
KW hypo-insulinaemia; pericyte-associated tumour; wound healing; cancer;  
KW chromosome identification; gene therapy; gene; ss; human.  
XX  
OS Homo sapiens.  
XX  
PN US2003180914-A1.  
XX  
PD 25-SEP-2003.  
XX  
PF 08-MAY-2002; 2002US-00063715.  
XX  
PR 30-DEC-1998; 98KR-00062142.  
PR 08-MAR-1999; 99WO-US005028.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380139.  
PR 25-AUG-1999; 99US-00380142.  
PR 15-SEP-1999; 99US-00397342.







QY		2241 AA 2242 	
Db		2773 AA 2774	
RESULT 801			
ADH29462			
ID	ADH29462 standard; cDNA; 2846 BP.		
XX			
AC	ADH29462;		
XX			
DT	11-MAR-2004 (first entry)		
XX			
DE	Novel human secreted and transmembrane protein PRO1344 cDNA.		
XX			
KW	ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;		
KW	affinity purification; secreted and transmembrane protein.		
XX			
OS	Homo sapiens.		
XX			
PN	US2003180860-A1.		
XX			
PD	25-SEP-2003.		
XX			
PF	08-MAY-2002; 2002US-00063736.		
XX			
PR	30-DEC-1998; 98KR-00062142.		
PR	08-MAR-1999; 99WO-US005028.		
PR	14-MAY-1999; 99US-00311832.		
PR	14-MAY-1999; 99WO-US010733.		
PR	25-AUG-1999; 99US-00380137.		
PR	25-AUG-1999; 99US-00380138.		
PR	25-AUG-1999; 99US-00380139.		
PR	25-AUG-1999; 99US-00380142.		
PR	15-SEP-1999; 99US-00397342.		
PR	18-OCT-1999; 99US-00403297.		
PR	12-NOV-1999; 99US-00423844.		
PR	30-DEC-1999; 99WO-US031274.		
PR	18-FEB-2000; 2000WO-US004341.		
PR	01-MAR-2000; 2000WO-US005601.		
PR	02-MAR-2000; 2000WO-US005841.		
PR	21-MAR-2000; 2000WO-US007532.		
PR	24-AUG-2000; 2000WO-US023328.		
PR	18-SEP-2000; 2000US-00664610.		
PR	18-SEP-2000; 2000US-00665350.		
PR	08-NOV-2000; 2000US-00709238.		
PR	10-NOV-2000; 2000WO-US030873.		
PR	01-DEC-2000; 2000WO-US032678.		
PR	20-DEC-2000; 2000US-00747259.		
PR	28-FEB-2001; 2001WO-US006520.		
PR	22-MAR-2001; 2001US-00816744.		
PR	10-MAY-2001; 2001US-00854208.		
PR	30-MAY-2001; 2001US-00870574.		
PR	01-JUN-2001; 2001WO-US017800.		
PR	05-JUN-2001; 2001US-00874503.		
PR	29-JUN-2001; 2001US-00869599.		
PR	18-JUL-2001; 2001US-00908827.		
PR	06-DEC-2001; 2001US-00006867.		
XX			
PA	(GETH ) GENENTECH INC.		
XX			
PI	Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;		
PI	Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;		
XX			
DR	WPI; 2003-830989/77.		
DR	P-PSDB; ADH29463.		
XX			

PT	New isolated PRO polypeptide, useful for treating various bone and/or cartilage disorders, for example, sports injuries and arthritis.
XX	
PS	Disclosure; SEQ ID NO 37; 397pp; English.
XX	
CC	The invention describes an antibody that specifically binds to a PRO polypeptide having a fully defined amino acid sequence given in the specification. The antibody is useful in identifying PRO polypeptides useful for various industrial applications, including pharmaceuticals, diagnostics, biosensors and bioreactors. The antibody is also used for affinity purification of PRO polypeptides from recombinant cell culture or natural sources. The antibody, PRO polypeptide, or its agonists or antagonists, may be used for preparing a medicament for diagnosing or treating a condition responsive to the antibody, PRO polypeptide, or its agonists or antagonists. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.
XX	
SQ	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match            3.0%; Score 66.6; DB 10; Length 2846; Best Local Similarity   71.3%; Pred. No. 0.00023; Matches   87; Conservative   0; Mismatches   35; Indels   0; Gaps   0;	
QY	2121 CCTTTGCTTTTACCCTCTCTTTTCCTTTATCTATTATAAAAAATGTGGTCTCCACTTG 2180 
Db	2653 CCTTTCTCTCCCACTCTCTTGACACATTTTAATAAAATAAGGTTGCTTCTGAACA 2712 
QY	2181 NCTCCCAA 2240 
Db	2713 CAAA 2772 
QY	2241 AA 2242 
Db	2773 AA 2774
RESULT 802	
ADH27578	
ID	ADH27578 standard; cDNA; 2846 BP.
XX	
AC	ADH27578;
XX	
DT	11-MAR-2004 (first entry)
XX	
DE	Novel human secreted and transmembrane protein PRO1344 cDNA.
XX	
KW	ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW	affinity purification; secreted and transmembrane protein.
XX	
OS	Homo sapiens.
XX	
PN	US2003180906-A1.
XX	
PD	25-SEP-2003.
XX	
PF	03-MAY-2002; 2002US-00063591.
XX	
PR	30-DEC-1998; 98KR-00062142.
PR	08-MAR-1999; 99WO-US005028.
PR	14-MAY-1999; 99US-00311832.
PR	14-MAY-1999; 99WO-US010733.
PR	25-AUG-1999; 99US-00380137.
PR	25-AUG-1999; 99US-00380138.
PR	25-AUG-1999; 99US-00380139.
PR	25-AUG-1999; 99US-00380142.
PR	15-SEP-1999; 99US-00397342.
PR	18-OCT-1999; 99US-00403297.
PR	12-NOV-1999; 99US-00423844.</

```
PR 22-MAY-2000; 200WO-US014042.
PR 02-JUN-2000; 200WO-US015264.
PR 22-AUG-2000; 200US-00644848.
PR 24-AUG-2000; 200WO-US023328.
PR 18-SEP-2000; 200US-00664610.
PR 18-SEP-2000; 200US-00665350.
PR 08-NOV-2000; 200US-00709238.
PR 10-NOV-2000; 200WO-US030873.
PR 01-DEC-2000; 200WO-US032678.
PR 20-DEC-2000; 200US-00747259.
PR 20-DEC-2000; 200WO-US034956.
PR 28-FEB-2001; 200WO-US006520.
PR 22-MAR-2001; 200US-00816744.
PR 10-MAY-2001; 200US-00854208.
PR 10-MAY-2001; 200US-00854280.
PR 10-MAY-2001; 200US-00870574.
PR 01-JUN-2001; 200US-00870574.
PR 30-MAY-2001; 200US-00870574.
PR 01-JUN-2001; 200WO-US017800.
PR 05-JUN-2001; 200US-00874503.
PR 29-JUN-2001; 200US-00869599.
PR 18-JUL-2001; 200US-00908827.
PR 06-DEC-2001; 200US-00006867.
XX
PA (GETH ) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-830991/77.
DR P-PSDB; ADH27579.
XX
PT New isolated PRO polypeptide, useful for treating various bone and/or
PT cartilage disorders, for example, sports injuries and arthritis.
XX
PS Disclosure; SEQ ID NO 37; 398pp; English.
XX
CC The invention describes an antibody that specifically binds to a PRO
CC polypeptide having a fully defined amino acid sequence given in the
CC specification. The antibody is useful in identifying PRO polypeptides
CC useful for various industrial applications, including pharmaceuticals,
CC diagnostics, biosensors and bioreactors. The antibody is also used for
CC affinity purification of PRO polypeptides from recombinant cell culture
CC or natural sources. The antibody, PRO polypeptide, or its agonists or
CC antagonists, may be used for preparing a medicament for diagnosing or
CC treating a condition responsive to the antibody, PRO polypeptide, or its
CC agonists or antagonists. This sequence encodes a novel human secreted and
CC transmembrane PRO polypeptide.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACCTCTTCCCTTTTATCTTATTATAAATAATGTTGGTCTCCACCACCTG 2180
Db ||||| | || | || | || | || | || | || | || | || | || | || | || | || |
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| | || | || | || | || | || | || | || | || | || | || | || | || |
QY 2241 AA 2242
Db |||
QY 2773 AA 2774

RESULT 803
ADH37775
ID ADH37775 standard; cDNA; 2846 BP.
XX
AC ADH37775;
XX
DT 11-MAR-2004 (first entry)
```

```
XX DE
XX
XX KW
KW KW
XX KW
OS OS
XX OS
PN PN
XX PN
PD PD
XX PD
PF PF
XX PF
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 200WO-US004341.
PR 01-MAR-2000; 200WO-US005601.
PR 02-MAR-2000; 200WO-US005841.
PR 21-MAR-2000; 200WO-US007532.
PR 22-MAY-2000; 200WO-US014042.
PR 02-JUN-2000; 200WO-US015264.
PR 22-AUG-2000; 200US-00644848.
PR 24-AUG-2000; 200WO-US023328.
PR 18-SEP-2000; 200US-00664610.
PR 18-SEP-2000; 200US-00665350.
PR 08-NOV-2000; 200US-00709238.
PR 10-NOV-2000; 200WO-US030873.
PR 01-DEC-2000; 200WO-US032678.
PR 20-DEC-2000; 200US-00747259.
PR 20-DEC-2000; 200WO-US034956.
PR 28-FEB-2001; 200WO-US006520.
PR 22-MAR-2001; 200US-00816744.
PR 10-MAY-2001; 200US-00854208.
PR 10-MAY-2001; 200US-00854280.
PR 30-MAY-2001; 200US-00870574.
PR 01-JUN-2001; 200WO-US017800.
PR 05-JUN-2001; 200US-00874503.
PR 29-JUN-2001; 200US-00869599.
PR 18-JUL-2001; 200US-00908827.
PR 06-DEC-2001; 200US-00006867.
XX
XX (GETH ) GENENTECH INC.
PA
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-802901/75.
DR P-PSDB; ADH37776.
XX
PT New secreted and transmembrane PRO polypeptide, useful for preparing a
PT medicament for treating a condition that is responsive to the PRO
PT polypeptide e.g. diabetes.
XX
PS Example 4; SEQ ID NO 37; 397pp; English.
XX
CC This invention describes novel human PRO polypeptides and the
CC polynucleotides encoding them which have cytostatic, antidiabetic,
CC antiarthritic, osteopathic and antirheumatic activity. Specifically
CC claimed are secreted and transmembrane polypeptides, e.g. PRO180, PRO218,
CC PRO263, PRO295, PRO874, PRO300, PRO1864, PRO1282, PRO1063 or PRO1773
CC polypeptide. The PRO polypeptides or anti-PRO antibodies are useful for
```





Db 2773 AA 2774

RESULT 805

ADH57372

ID ADH57372 standard; cDNA; 2846 BP.

XX

AC ADH57372;

XX

DT 25-MAR-2004 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO1344 cDNA.

XX

KW human; PRO; membrane bound protein; membrane bound receptor; cell proliferation; cell migration; cell differentiation; mitogenic factor; survival factor; cytotoxic factor; differentiation factor; neuro peptide; hormone; cell receptor; receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.

OS Homo sapiens.

XX

PN US2003180920-A1.

XX

PD 25-SEP-2003.

XX

PF 08-MAY-2002; 2002US-00063728.

XX

PR 30-DEC-1998; 98KR-00062142.

PR 08-MAR-1999; 99WO-US005028.

PR 14-MAY-1999; 99US-00311832.

PR 14-MAY-1999; 99WO-US010733.

PR 25-AUG-1999; 99US-00380137.

PR 25-AUG-1999; 99US-00380138.

PR 25-AUG-1999; 99US-00380139.

PR 25-AUG-1999; 99US-00380142.

PR 15-SEP-1999; 99US-00397342.

PR 18-OCT-1999; 99US-00403297.

PR 12-NOV-1999; 99US-00423844.

PR 30-DEC-1999; 99WO-US031274.

PR 18-FEB-2000; 2000WO-US004341.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005841.

PR 21-MAR-2000; 2000WO-US007532.

PR 22-MAY-2000; 2000WO-US014042.

PR 02-JUN-2000; 2000WO-US015264.

PR 22-AUG-2000; 2000US-00644848.

PR 24-AUG-2000; 2000WO-US023328.

PR 18-SEP-2000; 2000US-00664610.

PR 18-SEP-2000; 2000US-00665350.

PR 08-NOV-2000; 2000US-00709238.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001WO-US006520.

PR 22-MAR-2001; 2001US-00816744.

PR 10-MAY-2001; 2001US-00854208.

PR 10-MAY-2001; 2001US-00854280.

PR 30-MAY-2001; 2001US-00870574.

PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.

PR 29-JUN-2001; 2001US-00869599.

PR 18-JUL-2001; 2001US-00908827.

PR 06-DEC-2001; 2001US-00006867.

XX

PA (GETH ) GENENTECH INC.

XX

PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX

WPI; 2003-830995/77.

DR P-PSDB; ADH57373.

XX



```
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH ) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-875161/81.
DR P-PSDB; ADH53685.
XX
PT New isolated PRO polypeptide, useful for treating various bone and/or
PT cartilage disorders, for example, sports injuries and arthritis.
XX
XX Disclosure; SEQ ID NO 37; 396pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
XX invention.
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match          3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTATTATAAATAAGTTGGTCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCTCTCCCATCTCTTGACACATTTTAATAAATAAGGTGCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 808
ADH52020
ID ADH52020 standard; cDNA; 2846 BP.
XX
AC ADH52020;
XX
DT 25-MAR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
```

```
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX Homo sapiens.
OS
XX US2003181638-A1.
PN
XX 25-SEP-2003.
PD
XX
XX 03-MAY-2002; 2002US-00063579.
PF
XX
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
XX (GETH ) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
XX WPI; 2003-875158/81.
DR P-PSDB; ADH52021.
XX
XX New isolated PRO polypeptide, useful for treating various bone and/or
PT cartilage disorders, for example, sports injuries and arthritis.
XX
PS Disclosure; SEQ ID NO 37; 397pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC as in the blocking of receptor-ligand interactions. The current invention
```





AD125385  
ID ADI25385 standard; cDNA; 2846 BP.  
XX  
AC ADI25385;  
XX  
DT 15-APR-2004 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX  
KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;  
KW affinity purification; secreted and transmembrane protein.  
XX  
OS Homo sapiens.  
XX  
PN US2003181696-A1.  
XX  
PD 25-SEP-2003.  
XX  
PF 02-MAY-2002; 2002US-00063536.  
XX  
PR 30-DEC-1998; 98KR-00062142.  
PR 08-MAR-1999; 99WO-US005028.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380139.  
PR 25-AUG-1999; 99US-00380142.  
PR 15-SEP-1999; 99US-00397342.  
PR 18-OCT-1999; 99US-00403297.  
PR 12-NOV-1999; 99US-00423844.  
PR 30-DEC-1999; 99WO-US031274.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 22-AUG-2000; 2000US-00644848.  
PR 24-AUG-2000; 2000US-00644848.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00664610.  
PR 18-SEP-2000; 2000US-00665350.  
PR 08-NOV-2000; 2000US-00709238.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001US-00816744.  
PR 10-MAY-2001; 2001US-00854208.  
PR 30-MAY-2001; 2001US-00870574.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 29-JUN-2001; 2001US-00869599.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-DEC-2001; 2001US-00006867.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;  
XX  
XX WPI; 2003-875175/81.  
DR P-PSDB; ADI25386.  
XX  
XX New isolated PRO polypeptide, useful for treating various bone and/or  
PT cartilage disorders, for example, sports injuries and arthritis.  
XX  
XX Disclosure; SEQ ID NO 37; 397pp; English.  
PS  
XX The invention relates to a novel PRO (secreted and transmembrane protei  
CC polypeptide, and the polynucleotide sequence encoding it. Also included

are a vector comprising the novel nucleic acid and a host cell comprising the vector. The polynucleotide sequence is useful in molecular biology as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy. The polynucleotide sequence may also be used in preparing the PRO polypeptide by recombinant techniques, and in generating either transgenic or knock-out animals which, in turn, are useful in the development and screening of therapeutically useful reagents. The PRO polynucleotide sequence is useful in preparing a medicament for treating a condition responsive to the polypeptide or antibody, such as tumours, and in various diagnostic assays. The specification also discloses other PRO proteins and the polynucleotide sequences encoding them. The present sequence encodes a PRO protein.

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTCTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180  
Db 2653 CCTTTTCTTCCCATCTCTTGACACATTTTAAATAAATAGGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAA 2240  
Db 2713 CAAA 2772

QY 2241 AA 2242  
Db 2773 AA 2774

RESULT 811  
ADH90178  
ID ADH90178 standard; cDNA; 2846 BP.  
XX  
AC ADH90178;  
XX  
DT 15-APR-2004 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX  
KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;  
KW affinity purification; secreted and transmembrane protein.  
XX  
OS Homo sapiens.  
XX  
PN US2003181698-A1.  
XX  
PD 25-SEP-2003.  
XX  
PF 07-MAY-2002; 2002US-00063638.  
XX  
PR 30-DEC-1998; 98KR-00062142.  
PR 08-MAR-1999; 99WO-US005028.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380139.  
PR 25-AUG-1999; 99US-00380142.  
PR 15-SEP-1999; 99US-00397342.  
PR 18-OCT-1999; 99US-00403297.  
PR 12-NOV-1999; 99US-00423844.  
PR 30-DEC-1999; 99WO-US031274.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 22-AUG-2000; 2000US-00644848.

PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00664610.  
PR 18-SEP-2000; 2000US-00665350.  
PR 08-NOV-2000; 2000US-00709238.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001US-00816744.  
PR 10-MAY-2001; 2001US-00854208.  
PR 30-MAY-2001; 2001US-00870574.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 29-JUN-2001; 2001US-00869599.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-DEC-2001; 2001US-00006867.  
XX

PA (GETH ) GENENTECH INC.

PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX WPI; 2003-875177/81.  
DR P-PSDB; ADH90179.

PT New isolated PRO polypeptide, useful for treating various bone and/or  
PT cartilage disorders, for example, sports injuries and arthritis.

PS Disclosure; SEQ ID NO 37; 397pp; English.

XX  
CC The invention relates to a novel PRO (secreted and transmembrane protein)  
CC polypeptide, and the polynucleotide sequence encoding it. Also included  
CC are a vector comprising the novel nucleic acid and a host cell comprising  
CC the vector. The polynucleotide sequence is useful in molecular biology as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA, and in gene therapy. The polynucleotide sequence  
CC may also be used in preparing the PRO polypeptide by recombinant  
CC techniques, and in generating either transgenic or knock-out animals  
CC which, in turn, are useful in the development and screening of  
CC therapeutically useful reagents. The PRO polynucleotide sequence is  
CC useful in preparing a medicament for treating a condition responsive to  
CC the polypeptide or antibody, such as tumours, and in various diagnostic  
CC assays. The specification also discloses other PRO proteins and the  
CC polynucleotide sequences encoding them. The present sequence encodes a  
CC PRO protein.  
XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

OY 2121 CCTTTGCTTTACCACTCTTCTCCTTTTATCTTATTATAAATAATGTTGGTCTCCACCACTG 2180  
||||| ||||| ||||| || ||||| ||||| ||||| ||||| ||||| |||||  
Db 2653 CCTTTTCTTCCCACTCTCTGTGTACACATTTTATAATAAATAAGGTTGGCTTCTGAACTA 2712  
  
OY 2181 NCTCCCAA 2240  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 2713 CAAA 2772  
  
OY 2241 AA 2242  
||  
Db 2773 AA 2774

RESULT 812  
ADI25555  
ID ADI25555 standard; cDNA; 2846 BP.  
XX  
AC ADI25555;  
XX

DT 15-APR-2004 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX  
KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;  
KW affinity purification; secreted and transmembrane protein.  
XX  
OS Homo sapiens.  
XX  
PN US2003181669-A1.  
XX  
PD 25-SEP-2003.  
XX  
PF 02-MAY-2002; 2002US-00063570.  
XX  
PR 30-DEC-1998; 98KR-00062142.  
PR 08-MAR-1999; 99WO-US005028.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380139.  
PR 25-AUG-1999; 99US-00380142.  
PR 15-SEP-1999; 99US-00397342.  
PR 18-OCT-1999; 99US-00403297.  
PR 12-NOV-1999; 99US-00423844.  
PR 30-DEC-1999; 99WO-US031274.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 22-AUG-2000; 2000US-00644848.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00664610.  
PR 18-SEP-2000; 2000US-00665350.  
PR 08-NOV-2000; 2000US-00709238.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001US-00816744.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 30-MAY-2001; 2001US-00870574.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 29-JUN-2001; 2001US-00869599.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-DEC-2001; 2001US-00006867.

(GETH ) GENENTECH INC.

Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

WPI; 2003-811661/76.  
P-PSDB; ADI25556.

Novel antibody that binds to a PRO polypeptide, useful for treating  
cancer and in diagnostic assays, for e.g. detecting PRO expression in  
specific cells, tissues, or serum.

Disclosure; SEQ ID NO 37; 396pp; English.

XX  
XX The invention describes an antibody that specifically binds to a PRO  
XX polypeptide having a fully defined amino acid sequence given in the  
XX specification. The antibody is useful in identifying PRO polypeptides  
XX useful for various industrial applications, including pharmaceuticals,  
XX diagnostics, biosensors and bioreactors. The antibody is also used for  
XX affinity purification of PRO polypeptides from recombinant cell culture





KW antidiabetic; antianaemic; cytostatic; cardiant; vulnerary;  
KW antiinflammatory; anorectic.

XX Homo sapiens.

XX US2003050457-A1.

XX 13-MAR-2003.

XX 16-NOV-2001; 2001US-00991172.

XX 16-JUN-1997; 97US-0049787P.

PR 17-OCT-1997; 97US-0062250P.

PR 05-NOV-1997; 97WO-US020069.

PR 12-NOV-1997; 97US-0065186P.

PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0066770P.

PR 25-FEB-1998; 98US-0075945P.

PR 20-MAR-1998; 98US-0078910P.

PR 28-APR-1998; 98US-0083322P.

PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.

PR 02-JUN-1998; 98US-0087607P.

PR 02-JUN-1998; 98US-0087609P.

PR 02-JUN-1998; 98US-0087759P.

PR 03-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088021P.

PR 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088026P.

PR 04-JUN-1998; 98US-0088028P.

PR 04-JUN-1998; 98US-0088029P.

PR 04-JUN-1998; 98US-0088030P.

PR 04-JUN-1998; 98US-0088033P.

PR 04-JUN-1998; 98US-0088326P.

PR 05-JUN-1998; 98US-0088167P.

PR 05-JUN-1998; 98US-0088202P.

PR 05-JUN-1998; 98US-0088212P.

PR 05-JUN-1998; 98US-0088217P.

PR 09-JUN-1998; 98US-0088655P.

PR 10-JUN-1998; 98US-0088734P.

PR 10-JUN-1998; 98US-0088738P.

PR 10-JUN-1998; 98US-0088742P.

PR 10-JUN-1998; 98US-0088810P.

PR 10-JUN-1998; 98US-0088824P.

PR 10-JUN-1998; 98US-0088826P.

PR 11-JUN-1998; 98US-0088858P.

PR 11-JUN-1998; 98US-0088861P.

PR 11-JUN-1998; 98US-0088876P.

PR 12-JUN-1998; 98US-0089105P.

PR 16-JUN-1998; 98US-0089440P.

PR 16-JUN-1998; 98US-0089512P.

PR 16-JUN-1998; 98US-0089514P.

PR 17-JUN-1998; 98US-0089532P.

PR 17-JUN-1998; 98US-0089538P.

PR 17-JUN-1998; 98US-0089598P.

PR 17-JUN-1998; 98US-0089599P.

PR 17-JUN-1998; 98US-0089600P.

PR 17-JUN-1998; 98US-0089653P.

PR 18-JUN-1998; 98US-0089801P.

PR 18-JUN-1998; 98US-0089907P.

PR 18-JUN-1998; 98US-0089908P.

PR 19-JUN-1998; 98US-0089947P.

PR 19-JUN-1998; 98US-0089948P.

PR 19-JUN-1998; 98US-0089952P.

PR 22-JUN-1998; 98US-0090246P.

PR 22-JUN-1998; 98US-0090252P.

PR 22-JUN-1998; 98US-0090254P.

PR 23-JUN-1998; 98US-0090349P.

PR 23-JUN-1998; 98US-0090355P.

PR 24-JUN-1998; 98US-0090429P.

PR 24-JUN-1998; 98US-0090431P.

PR 24-JUN-1998; 98US-0090435P.

PR 24-JUN-1998; 98US-0090444P.

PR 24-JUN-1998; 98US-0090445P.

PR 24-JUN-1998; 98US-0090472P.

PR 24-JUN-1998; 98US-0090535P.

PR 24-JUN-1998; 98US-0090540P.

PR 24-JUN-1998; 98US-0090542P.

PR 24-JUN-1998; 98US-0090557P.

PR 25-JUN-1998; 98US-0090676P.

PR 25-JUN-1998; 98US-0090678P.

PR 25-JUN-1998; 98US-0090690P.

PR 25-JUN-1998; 98US-0090694P.

PR 25-JUN-1998; 98US-0090695P.

PR 25-JUN-1998; 98US-0090696P.

PR 26-JUN-1998; 98US-0090862P.

PR 26-JUN-1998; 98US-0090863P.

PR 01-JUL-1998; 98US-0091360P.

PR 01-JUL-1998; 98US-0091544P.

PR 02-JUL-1998; 98US-0091478P.

PR 02-JUL-1998; 98US-0091519P.

PR 02-JUL-1998; 98US-0091626P.

PR 02-JUL-1998; 98US-0091628P.

PR 02-JUL-1998; 98US-0091633P.

PR 02-JUL-1998; 98US-0091646P.

PR 02-JUL-1998; 98US-0091673P.

PR 07-JUL-1998; 98US-0091978P.

PR 07-JUL-1998; 98US-0091982P.

PR 09-JUL-1998; 98US-0092182P.

PR 10-JUL-1998; 98US-0092472P.

PR 20-JUL-1998; 98US-0093339P.

PR 30-JUL-1998; 98US-0094651P.

PR 04-AUG-1998; 98US-0095282P.

PR 04-AUG-1998; 98US-0095285P.

PR 04-AUG-1998; 98US-0095301P.

PR 04-AUG-1998; 98US-0095302P.

PR 04-AUG-1998; 98US-0095318P.

PR 04-AUG-1998; 98US-0095321P.

PR 04-AUG-1998; 98US-0095325P.

PR 10-AUG-1998; 98US-0095916P.

PR 10-AUG-1998; 98US-0095929P.

PR 10-AUG-1998; 98US-0096012P.

PR 11-AUG-1998; 98US-0096143P.

PR 11-AUG-1998; 98US-0096146P.

PR 12-AUG-1998; 98US-0096329P.

PR 17-AUG-1998; 98US-0096757P.

PR 17-AUG-1998; 98US-0096766P.

PR 17-AUG-1998; 98US-0096768P.

PR 17-AUG-1998; 98US-0096773P.

PR 17-AUG-1998; 98US-0096791P.

PR 17-AUG-1998; 98US-0096867P.

PR 17-AUG-1998; 98US-0096891P.

PR 17-AUG-1998; 98US-0096894P.

PR 17-AUG-1998; 98US-0096895P.

PR 17-AUG-1998; 98US-0096897P.

PR 18-AUG-1998; 98US-0096949P.

PR 18-AUG-1998; 98US-0096950P.

PR 18-AUG-1998; 98US-0096959P.

PR 18-AUG-1998; 98US-0096960P.

PR 18-AUG-1998; 98US-0097022P.

PR 19-AUG-1998; 98US-0097141P.

PR 20-AUG-1998; 98US-0097218P.

PR 24-AUG-1998; 98US-0097661P.

PR 26-AUG-1998; 98US-0097952P.

PR 26-AUG-1998; 98US-0097954P.

PR 26-AUG-1998; 98US-0097955P.

PR 26-AUG-1998; 98US-0097971P.

PR 26-AUG-1998; 98US-0097974P.

PR 26-AUG-1998; 98US-0097978P.

PR 26-AUG-1998; 98US-0097979P.

PR 26-AUG-1998; 98US-0097986P.

PR 26-AUG-1998; 98US-0098014P.

PR 31-AUG-1998; 98US-0098525P.

PR 16-SEP-1998; 98US-0100634P.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98US-0100858P.

```
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

Query Match      3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
```

```
QY 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACTG 2180
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCCTCCCATCTCTTGACACATTTTAATAAAATAAGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
      ||
Db 2773 AA 2774
```

```
RESULT 815
ADI03577
ID ADI03577 standard; cDNA; 2846 BP.
XX
AC ADI03577;
XX
DT 22-APR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW PRO; human; secreted; transmembrane; antiarthritic; antidiabetic;
KW cytostatic; vulnery; hyperglycaemic; hypoglycaemic; bone disorder;
KW cartilage disorder; sports injury; arthritis; glucose uptake; diabetes;
```

```
KW pericyte-associated tumour; wound healing; cancer; gene therapy; ss;
KW gene.
XX
XX Homo sapiens.
XX
PN US2003181656-A1.
XX
XX 25-SEP-2003.
XX
XX 07-MAY-2002; 2002US-00063659.
XX
XX 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
XX (GETH ) GENENTECH INC.
PA
XX
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
XX WPI; 2003-875169/81.
DR P-PSDB; ADI03578.
XX
PT New isolated PRO polypeptide, useful for treating various bone and/or
PT cartilage disorders, for example, sports injuries and arthritis.
XX
XX Example 4; Fig 37; 397pp; English.
PS
XX
CC This invention describes a novel human secreted and transmembrane PRO
CC polypeptide and the polynucleotides encoding it which have antiarthritic,
CC antidiabetic, cytostatic, vulnery, hyperglycaemic and hypoglycaemic
CC activity. The PRO polypeptides are useful for treating various bone
CC and/or cartilage disorders, for example, sports injuries and arthritis.
CC They are also useful in the therapeutic treatment of disorders where
CC either the stimulation or inhibition of glucose uptake by skeletal muscle
CC would be beneficial, for example, diabetes or hyper- or hypo-
CC insulinaemia. They are also useful for treating pericyte-associated
CC tumours and in wound healing. An anti-PRO antibody is useful for the
CC preparation of a medicament useful in the treatment of cancer. The PRO
```













Db 2713 CAAA 2772  
Qy 2241 AA 2242  
Db 2773 AA 2774  
RESULT 821  
ADH98239  
ID ADH98239 standard; cDNA; 2846 BP.  
XX ADH98239;  
AC ADH98239;  
XX ADH98239;  
DT 22-APR-2004 (first entry)  
XX Human PRO polynucleotide #19.  
DE Human; PRO; gene; ss; cancer; affinity purification; cytostatic.  
XX Homo sapiens.  
PN US2003181684-A1.  
XX 25-SEP-2003.  
XX 07-MAY-2002; 2002US-00063660.  
PR 30-DEC-1998; 98KR-00062142.  
PR 08-MAR-1999; 99WO-US005028.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380139.  
PR 25-AUG-1999; 99US-00380142.  
PR 15-SEP-1999; 99US-00397342.  
PR 18-OCT-1999; 99US-00403297.  
PR 12-NOV-1999; 99US-00423844.  
PR 30-DEC-1999; 99WO-US031274.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 22-AUG-2000; 2000US-00644848.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00664610.  
PR 18-SEP-2000; 2000US-00665350.  
PR 08-NOV-2000; 2000US-00709238.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001US-00816744.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 30-MAY-2001; 2001US-00870574.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 29-JUN-2001; 2001US-00869599.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-DEC-2001; 2001US-00006867.  
XX (GETH ) GENENTECH INC.  
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;  
XX WPI; 2003-852269/79.  
DR P-PSDB; ADI11595.

XX Novel antibody that binds to a PRO polypeptide, useful for treating  
PT cancer and in diagnostic assays, for e.g. detecting PRO expression in  
PT specific cells, tissues, or serum.  
XX Disclosure; SEQ ID NO 37; 396pp; English.  
PS The invention relates to an antibody that binds to a human PRO  
XX polypeptide. The invention also relates to human PRO polynucleotides  
CC encoding the PRO polypeptides of the invention. The antibody is  
CC preferably a monoclonal or humanised antibody, or an antibody fragment,  
CC and is used to treat cancer. The anti-PRO antibody can be used in  
CC diagnostic assays, e.g. for detecting PRO expression in specific cells,  
CC tissues or serum. The anti-PRO antibodies are also useful for the  
CC affinity purification of PRO from recombinant cell culture or natural  
CC sources. This sequence represents a human PRO polynucleotide of the  
CC invention.  
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;  
SQ Query Match 3.0%; Score 66.6; DB 10; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;  
QY 2121 CCTTTGCTTTACCACTCTTCTTTTATCTTATTAATAAAAAATGGTCTCCCACTG 2180  
Db 2653 CCTTTTCTTCCCATCTCTTGACACATTTTATAAAATAAGGTTGGCTTCTGACTA 2712  
QY 2181 NCTCCCAA 2240  
Db 2713 CAAA 2772  
QY 2241 AA 2242  
Db 2773 AA 2774  
RESULT 822  
ADH98239  
ID ADH98239 standard; cDNA; 2846 BP.  
XX ADH98239;  
AC ADH98239;  
XX ADH98239;  
DT 22-APR-2004 (first entry)  
XX Novel human secreted and transmembrane protein PRO1344 cDNA.  
DE ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;  
KW affinity purification; secreted and transmembrane protein.  
XX Homo sapiens.  
OS US2003181709-A1.  
XX 25-SEP-2003.  
XX 02-MAY-2002; 2002US-00063529.  
XX 06-DEC-2001; 2001US-00006867.  
XX (GETH ) GENENTECH INC.  
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;  
XX WPI; 2003-802903/75.  
DR P-PSDB; ADH98240.  
XX New isolated PRO polypeptide, useful for treating various bone and/or  
PT cartilage disorders, for example, sports injuries and arthritis.  
XX Disclosure; SEQ ID NO 37; 397pp; English.





```
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH ) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-852264/79.
DR P-PSDB; ADH98070.
XX
PT Novel antibody that binds to a PRO polypeptide, useful for treating
PT cancer and in diagnostic assays, for e.g. detecting PRO expression in
PT specific cells, tissues, or serum.
XX
PS Disclosure; SEQ ID NO 37; 396pp; English.
XX
CC The invention relates to a PRO (secreted and transmembrane protein)
CC polynucleotide appearing as ADH98113 encoding PRO polypeptide having
CC appearing as ADH98113. Also included are a vector comprising the novel
CC nucleic acid and a host cell comprising the vector. The polynucleotide is
CC useful in molecular biology, including uses as hybridisation probes, in
CC chromosome and gene mapping, in generating antisense RNA and DNA, and in
CC gene therapy. The polynucleotide may also be used in preparing PRO
CC polypeptides by recombinant techniques, and in generating either
CC transgenic animals or knock-out animals which, in turn, are useful in the
CC development and screening of therapeutically useful reagents. The PRO
CC polynucleotide is used in preparing a medicament for treating a condition
CC responsive to the polypeptide or antibody, such as tumours, and in
CC various diagnostic assays. The specification discloses 84 PRO proteins
CC and 84 PRO polynucleotides. The present sequence encodes a PRO protein.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match          3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTCTCCCATCTCTGTACACATTTTAAATAAAATAAGGTTGGCTTCTGAACCTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
Db ||
2773 AA 2774

RESULT 825
ABX78612
ID ABX78612 standard; cDNA; 2846 BP.
XX
AC ABX78612;
XX
DT 15-APR-2003 (first entry)
```

```
XX
DE Human PRO polynucleotide #85.
XX
KW Human; PRO; gene; ss; cytostatic; tumour; cancer; breast; lung; stomach;
KW liver; dog; cat; cow; horse; sheep; pig; goat; rabbit; ADEPT;
XX antibody-dependent enzyme mediated prodrug therapy.
OS Homo sapiens.
XX
PN US2003027272-A1.
XX
PD 06-FEB-2003.
XX
PF 21-JUN-2002; 2002US-00176492.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
```

PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.

PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 16-SEP-1998; 98US-0100662P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.  
PR 17-SEP-1998; 98US-0100919P.  
PR 17-SEP-1998; 98US-0100930P.  
PR 18-SEP-1998; 98US-0100849P.  
PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.  
PR 23-SEP-1998; 98US-0101471P.  
PR 23-SEP-1998; 98US-0101472P.  
PR 23-SEP-1998; 98US-0101475P.  
PR 23-SEP-1998; 98US-0101477P.  
PR 24-SEP-1998; 98US-0101738P.  
PR 24-SEP-1998; 98US-0101739P.  
PR 24-SEP-1998; 98US-0101743P.  
PR 24-SEP-1998; 98US-0101922P.  
PR 25-SEP-1998; 98US-0101786P.  
PR 29-SEP-1998; 98US-0102207P.  
PR 29-SEP-1998; 98US-0102240P.  
PR 29-SEP-1998; 98US-0102330P.  
PR 29-SEP-1998; 98US-0102331P.  
PR 30-SEP-1998; 98US-0102487P.  
PR 30-SEP-1998; 98US-0102570P.  
PR 30-SEP-1998; 98US-0102571P.  
PR 01-OCT-1998; 98US-0102684P.  
PR 01-OCT-1998; 98US-0102687P.  
PR 02-OCT-1998; 98US-0102965P.  
PR 06-OCT-1998; 98US-0103258P.  
PR 06-OCT-1998; 98US-0103449P.  
PR 07-OCT-1998; 98US-00168978.

Query Match 3.0%; Score 66.6; DB 10; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACCTCTTTCTCTTTATCTTTATTAATAAAAAATGTTGGTCTCCCACTG 2180

Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAAATAAGGTTGGCTTCTGAACTA 2712

Qy 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 826

ACA75584

ID ACA75584 standard; cDNA; 2846 BP.

XX

AC ACA75584;

XX

DT 07-JUL-2003 (first entry)  
XX Novel human secreted and transmembrane protein PRO1344 cDNA.  
DE  
XX Human; secreted and transmembrane protein: PRO; gene therapy;  
KW tumour necrosis factor-alpha release; TNF-alpha release;  
KW chondrocyte proliferation; chondrocyte differentiation; tumour;  
KW adrenal tumour; lung tumour; colon tumour; breast tumour;  
KW prostate tumour; rectal tumour; cervical tumour; liver tumour; gene; ss.  
XX  
OS Homo sapiens.  
XX  
PN US2003032127-A1.  
XX  
PD 13-FEB-2003.  
XX  
PF 26-JUN-2002; 2002US-00183012.  
XX  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.



PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 16-SEP-1998; 98US-0100662P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.  
PR 17-SEP-1998; 98US-0100919P.  
PR 17-SEP-1998; 98US-0100930P.  
PR 18-SEP-1998; 98US-0100849P.  
PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.  
PR 23-SEP-1998; 98US-0101471P.  
PR 23-SEP-1998; 98US-0101472P.  
PR 23-SEP-1998; 98US-0101475P.  
PR 23-SEP-1998; 98US-0101477P.  
PR 24-SEP-1998; 98US-0101738P.  
PR 24-SEP-1998; 98US-0101739P.  
PR 24-SEP-1998; 98US-0101743P.  
PR 24-SEP-1998; 98US-0101922P.  
PR 25-SEP-1998; 98US-0101786P.  
PR 29-SEP-1998; 98US-0102207P.  
PR 29-SEP-1998; 98US-0102240P.  
PR 29-SEP-1998; 98US-0102330P.  
PR 29-SEP-1998; 98US-0102331P.  
PR 30-SEP-1998; 98US-0102487P.  
PR 30-SEP-1998; 98US-0102570P.  
PR 30-SEP-1998; 98US-0102571P.  
PR 01-OCT-1998; 98US-0102684P.  
PR 01-OCT-1998; 98US-0102687P.  
PR 02-OCT-1998; 98US-0102965P.  
PR 06-OCT-1998; 98US-0103258P.

Query Match 3.0%; Score 66.6; DB 10; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;  
Qy 2121 CCTTTCCTTACCACCTCTTTCCTTTATCTTATTATAAATAAATGTTGGTCTCCACCCTG 2180  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 2653 CCITTTCTCTCCCATCTCTGTACACATTTTATAAATAAATGTTGGTCTCTGAACCTA 2712  
Qy 2181 NCTCCCAA 2240  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 2713 CAAA 2772  
Qy 2241 AA 2242  
||  
Db 2773 AA 2774

RESULT 827  
ACA71064  
ID ACA71064 standard; cDNA; 2846 BP.  
XX  
AC ACA71064;

XX 02-AUG-2003 (first entry)  
DT Human secreted/transmembrane protein (PRO) cDNA #85.  
XX  
DE  
XX  
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;  
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;  
KW tissue typing.  
XX  
OS Homo sapiens.  
XX  
PN US2003032112-A1.  
XX  
PD 13-FEB-2003.  
XX  
PF 21-JUN-2002; 2002US-00176756.  
XX  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-008579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.



AC ACC87592;  
XX  
DT 05-AUG-2003 (first entry)  
XX  
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.  
XX  
KW Human; PRO; secreted protein; transmembrane protein;  
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;  
KW chondrocyte; proliferation; differentiation; cartilage disorder;  
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;  
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;  
KW liver; drug screening; transgenic animal; genetic analysis;  
KW antiarthritic; vulnerary; gene therapy; gene; ss.  
XX  
OS Homo sapiens.  
XX  
PN US2003027278-A1.  
XX  
PD 06-FEB-2003.  
XX  
PF 21-JUN-2002; 2002US-00176987.  
XX  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.

PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.





PR	15-MAY-1998;	98US-0085579P;
PR	15-MAY-1998;	98US-0085580P;
PR	15-MAY-1998;	98US-0085582P;
PR	15-MAY-1998;	98US-0085700P;
PR	18-MAY-1998;	98US-0086023P;
PR	22-MAY-1998;	98US-0086392P;
PR	22-MAY-1998;	98US-0086486P;
PR	28-MAY-1998;	98US-0087098P;
PR	28-MAY-1998;	98US-0087208P;
PR	02-JUN-1998;	98US-0087609P;
PR	02-JUN-1998;	98US-0087759P;
PR	03-JUN-1998;	98US-0087827P;
PR	04-JUN-1998;	98US-0088025P;
PR	04-JUN-1998;	98US-0088028P;
PR	04-JUN-1998;	98US-0088029P;
PR	04-JUN-1998;	98US-0088033P;
PR	04-JUN-1998;	98US-0088326P;
PR	05-JUN-1998;	98US-0088167P;
PR	05-JUN-1998;	98US-0088202P;
PR	05-JUN-1998;	98US-0088212P;
PR	05-JUN-1998;	98US-0088217P;
PR	09-JUN-1998;	98US-0088655P;
PR	10-JUN-1998;	98US-0088722P;
PR	10-JUN-1998;	98US-0088738P;
PR	10-JUN-1998;	98US-0088740P;
PR	10-JUN-1998;	98US-0088811P;
PR	10-JUN-1998;	98US-0088824P;
PR	10-JUN-1998;	98US-0088825P;
PR	10-JUN-1998;	98US-0088826P;
PR	11-JUN-1998;	98US-0088861P;
PR	11-JUN-1998;	98US-0088863P;
PR	11-JUN-1998;	98US-0088876P;
PR	12-JUN-1998;	98US-0089090P;
PR	12-JUN-1998;	98US-0089105P;
PR	16-JUN-1998;	98US-0089512P;
PR	16-JUN-1998;	98US-0089514P;
PR	17-JUN-1998;	98US-0089538P;
PR	17-JUN-1998;	98US-0089598P;
PR	17-JUN-1998;	98US-0089653P;
PR	18-JUN-1998;	98US-0089908P;
PR	19-JUN-1998;	98US-0089952P;
PR	22-JUN-1998;	98US-0090246P;
PR	22-JUN-1998;	98US-0090252P;
PR	22-JUN-1998;	98US-0090254P;
PR	24-JUN-1998;	98US-0090429P;
PR	24-JUN-1998;	98US-0090435P;
PR	24-JUN-1998;	98US-0090444P;
PR	24-JUN-1998;	98US-0090461P;
PR	24-JUN-1998;	98US-0090535P;
PR	24-JUN-1998;	98US-0090540P;
PR	25-JUN-1998;	98US-0090676P;
PR	25-JUN-1998;	98US-0090678P;
PR	25-JUN-1998;	98US-0090688P;
PR	25-JUN-1998;	98US-0090690P;
PR	25-JUN-1998;	98US-0090694P;
PR	25-JUN-1998;	98US-0090695P;
PR	25-JUN-1998;	98US-0090696P;
PR	26-JUN-1998;	98US-00105413;
PR	26-JUN-1998;	98US-0090862P;
PR	26-JUN-1998;	98US-0090863P;
PR	26-JUN-1998;	98US-0091010P;
PR	01-JUL-1998;	98US-0091359P;
PR	01-JUL-1998;	98US-0091544P;
PR	02-JUL-1998;	98US-0091478P;
PR	02-JUL-1998;	98US-0091486P;
PR	02-JUL-1998;	98US-0091626P;
PR	02-JUL-1998;	98US-0091628P;
PR	02-JUL-1998;	98US-0091632P;
PR	24-JUL-1998;	98US-0094006P;
PR	04-AUG-1998;	98US-0095282P;
PR	10-AUG-1998;	98US-0095998P;
PR	10-AUG-1998;	98US-0096012P;
PR	17-AUG-1998;	98US-0096757P;

ID ACD04151 standard; cDNA; 2846 BP.  
XX AC ACD04151;  
XX XX  
DT 09-AUG-2003 (first entry)  
XX XX  
DE Human secreted/transmembrane protein (PRO) cDNA #85.  
XX XX  
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;  
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;  
KW tissue typing.  
XX XX  
OS Homo sapiens.  
XX XX  
PN US2003040070-A1.  
XX XX  
PD 27-FEB-2003.  
XX XX  
PF 27-JUN-2002; 2002US-00184627.  
XX XX  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.

PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.



PR	17-AUG-1998;	98US-0096897P.
PR	18-AUG-1998;	98US-0096949P.
PR	18-AUG-1998;	98US-0096959P.
PR	18-AUG-1998;	98US-0097022P.
PR	26-AUG-1998;	98US-0097952P.
PR	26-AUG-1998;	98US-0097954P.
PR	26-AUG-1998;	98US-0097955P.
PR	26-AUG-1998;	98US-0097971P.
PR	26-AUG-1998;	98US-0097974P.
PR	26-AUG-1998;	98US-0098014P.
PR	01-SEP-1998;	98US-0098716P.
PR	01-SEP-1998;	98US-0098723P.
PR	02-SEP-1998;	98US-0098803P.
PR	02-SEP-1998;	98US-0098821P.
PR	02-SEP-1998;	98US-0098843P.
PR	09-SEP-1998;	98US-0099602P.
PR	10-SEP-1998;	98US-0099741P.
PR	10-SEP-1998;	98US-0099754P.
PR	10-SEP-1998;	98US-0099763P.
PR	10-SEP-1998;	98US-0099812P.
PR	15-SEP-1998;	98US-0100388P.
PR	16-SEP-1998;	98US-0100662P.
PR	16-SEP-1998;	98US-0100664P.
PR	16-SEP-1998;	98US-0101751P.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98US-0100683P.
PR	17-SEP-1998;	98US-0100684P.
PR	17-SEP-1998;	98US-0100919P.
PR	17-SEP-1998;	98US-0100930P.
PR	18-SEP-1998;	98US-0100849P.
PR	18-SEP-1998;	98US-0101014P.
PR	18-SEP-1998;	98US-0101068P.
PR	23-SEP-1998;	98US-0101471P.
PR	23-SEP-1998;	98US-0101472P.
PR	23-SEP-1998;	98US-0101475P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101738P.
PR	24-SEP-1998;	98US-0101739P.
PR	24-SEP-1998;	98US-0101743P.
PR	24-SEP-1998;	98US-0101922P.
PR	25-SEP-1998;	98US-0101786P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
PR	02-OCT-1998;	98US-0102965P.
PR	06-OCT-1998;	98US-0103258P.
PR	06-OCT-1998;	98US-0103449P.
PR	07-OCT-1998;	98US-00168978.

Query Match

Best Local Similarity 3.0%; Score 66.6; DB 10; Length 2846;

Matches 87; Conservative 71.3%; Pred. No. 0.00023; Mismatches 35; Indels 0; Gaps 0;

QY	2121	CCTTTGCTTTACCAC	TCTTTCC	TTTATCTTATTA	ATAAAAA	TGTTGGTCTCC	ACCAC	TG	2180
Db	2653	CCTTTTCC	TTCCCATCTCT	TGTACACAT	TTTAATAA	TAAGGGT	GGCTTCT	GAACTA	2712
QY	2181	NCTCCCA	AAAAA	AAAAA	AAAAA	AAAAA	AAAAA	AAAAA	2240
Db	2713	CAAAAAA	AAAAA	AAAAA	AAAAA	AAAAA	AAAAA	AAAAA	2772
QY	2241	AA	2242						
Db	2773	AA	2774						

ABX77859		ABX77859 standard; cDNA; 2846 BP.
ID	XX	ABX77859;
AC	XX	ABX77859;
DT	XX	14-APR-2003 (first entry)
DE	XX	Human PRO polynucleotide #65.
KW	XX	Human; PRO; gene; ss; cytostatic; tumour; cancer; breast; lung; stomach;
KW	XX	liver; horse; cow; dog; cat; sheep; pig; goat; rabbit; ADEPT;
KW	XX	antibody-dependent enzyme mediated prodrg therapy.
OS	XX	Homo sapiens.
PN	XX	US2003027163-A1.
PD	XX	06-FEB-2003.
PF	XX	15-NOV-2001; 2001US-00997666.
PR	XX	16-JUN-1997; 97US-0049787P.
PR	XX	17-OCT-1997; 97US-0062250P.
PR	XX	05-NOV-1997; 97WO-US020069.
PR	XX	12-NOV-1997; 97US-0065186P.
PR	XX	13-NOV-1997; 97US-0065311P.
PR	XX	24-NOV-1997; 97US-0066770P.
PR	XX	25-FEB-1998; 98US-0075945P.
PR	XX	20-MAR-1998; 98US-0078910P.
PR	XX	28-APR-1998; 98US-0083322P.
PR	XX	07-MAY-1998; 98US-0084600P.
PR	XX	28-MAY-1998; 98US-0087106P.
PR	XX	02-JUN-1998; 98US-0087607P.
PR	XX	02-JUN-1998; 98US-0087609P.
PR	XX	02-JUN-1998; 98US-0087759P.
PR	XX	03-JUN-1998; 98US-0087827P.
PR	XX	04-JUN-1998; 98US-0088021P.
PR	XX	04-JUN-1998; 98US-0088025P.
PR	XX	04-JUN-1998; 98US-0088026P.
PR	XX	04-JUN-1998; 98US-0088028P.
PR	XX	04-JUN-1998; 98US-0088029P.
PR	XX	04-JUN-1998; 98US-0088030P.
PR	XX	04-JUN-1998; 98US-0088033P.
PR	XX	04-JUN-1998; 98US-0088326P.
PR	XX	05-JUN-1998; 98US-0088167P.
PR	XX	05-JUN-1998; 98US-0088202P.
PR	XX	05-JUN-1998; 98US-0088212P.
PR	XX	05-JUN-1998; 98US-0088217P.
PR	XX	09-JUN-1998; 98US-0088655P.
PR	XX	10-JUN-1998; 98US-0088734P.
PR	XX	10-JUN-1998; 98US-0088738P.
PR	XX	10-JUN-1998; 98US-0088742P.
PR	XX	10-JUN-1998; 98US-0088810P.
PR	XX	10-JUN-1998; 98US-0088824P.
PR	XX	10-JUN-1998; 98US-0088826P.
PR	XX	11-JUN-1998; 98US-0088858P.
PR	XX	11-JUN-1998; 98US-0088861P.
PR	XX	11-JUN-1998; 98US-0088876P.
PR	XX	12-JUN-1998; 98US-0089105P.
PR	XX	16-JUN-1998; 98US-0089440P.
PR	XX	16-JUN-1998; 98US-0089512P.
PR	XX	16-JUN-1998; 98US-0089514P.
PR	XX	17-JUN-1998; 98US-0089532P.
PR	XX	17-JUN-1998; 98US-0089538P.
PR	XX	17-JUN-1998; 98US-0089598P.
PR	XX	17-JUN-1998; 98US-0089599P.
PR	XX	17-JUN-1998; 98US-0089600P.
PR	XX	17-JUN-1998; 98US-0089653P.
PR	XX	18-JUN-1998; 98US-0089801P.
PR	XX	18-JUN-1998; 98US-0089907P.
PR	XX	18-JUN-1998; 98US-0089908P.
PR	XX	19-JUN-1998; 98US-0089947P.
PR	XX	19-JUN-1998; 98US-0089948P.



RESULT 832  
ABX80271  
ID ABX80271 standard; DNA; 2846 BP.  
XX  
AC ABX80271;  
XX  
DT 28-APR-2003 (first entry)  
XX  
DE Human secreted or transmembrane protein related PCR primer #50.  
XX  
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;  
KW cardiac insufficiency disorder; cancer; tumour; immune response;  
KW adrenal cortical capillary endothelial growth; c-fos induction;  
KW vascular endothelial growth factor inhibition; VEGF inhibition;  
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;  
KW retinal neurons cell survival; rod photoreceptor cell survival;  
KW retinal disorder; retinitis pigmentosum; kidney disorder;  
KW mammalian kidney mesangial cell proliferation; Berger disease;  
KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;  
KW chondrocyte redifferentiation; sports injury; arthritis; PCR; primer; ss.  
XX  
OS Homo sapiens.  
OS  
XX  
PN US2002132252-A1.  
XX  
PD 19-SEP-2002.  
XX  
PF 14-NOV-2001; 2001US-00990442.  
XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR

PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 02-JUN-1999; 99WO-US012252.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 06-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 28-AUG-2001; 2001US-00941992.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;  
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;  
PI Zhang Z;  
XX  
DR WPI; 2003-247083/24.  
XX  
PT Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346  
PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes  
PT are therapeutically useful for enhancing immune response and in cancer  
PT treatments.  
XX  
PS Example 68; Page 245; 648pp; English.  
XX  
CC The invention describes an isolated human PRO polypeptide. The PRO  
CC polypeptides are useful in detecting PRO polypeptides in a sample, in  
CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and  
CC in modulating at least one biological activity of a cell expressing a PRO  
CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus  
CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186





PR	01-JUL-1998;	98US-0091544P;
PR	02-JUL-1998;	98US-0091478P;
PR	02-JUL-1998;	98US-0091519P;
PR	02-JUL-1998;	98US-0091626P;
PR	02-JUL-1998;	98US-0091628P;
PR	02-JUL-1998;	98US-0091633P;
PR	02-JUL-1998;	98US-0091646P;
PR	02-JUL-1998;	98US-0091673P;
PR	07-JUL-1998;	98US-0091978P;
PR	07-JUL-1998;	98US-0091982P;
PR	09-JUL-1998;	98US-0092182P;
PR	10-JUL-1998;	98US-0092472P;
PR	20-JUL-1998;	98US-0093339P;
PR	30-JUL-1998;	98US-0094651P;
PR	04-AUG-1998;	98US-0095282P;
PR	04-AUG-1998;	98US-0095285P;
PR	04-AUG-1998;	98US-0095301P;
PR	04-AUG-1998;	98US-0095302P;
PR	04-AUG-1998;	98US-0095318P;
PR	04-AUG-1998;	98US-0095321P;
PR	04-AUG-1998;	98US-0095325P;
PR	10-AUG-1998;	98US-0095916P;
PR	10-AUG-1998;	98US-0095929P;
PR	10-AUG-1998;	98US-0096012P;
PR	11-AUG-1998;	98US-0096143P;
PR	11-AUG-1998;	98US-0096146P;
PR	12-AUG-1998;	98US-0096329P;
PR	17-AUG-1998;	98US-0096757P;
PR	17-AUG-1998;	98US-0096766P;
PR	17-AUG-1998;	98US-0096768P;
PR	17-AUG-1998;	98US-0096773P;
PR	17-AUG-1998;	98US-0096791P;
PR	17-AUG-1998;	98US-0096867P;
PR	17-AUG-1998;	98US-0096891P;
PR	17-AUG-1998;	98US-0096894P;
PR	17-AUG-1998;	98US-0096895P;
PR	17-AUG-1998;	98US-0096897P;
PR	18-AUG-1998;	98US-0096949P;
PR	18-AUG-1998;	98US-0096950P;
PR	18-AUG-1998;	98US-0096959P;
PR	18-AUG-1998;	98US-0096960P;
PR	18-AUG-1998;	98US-0097022P;
PR	19-AUG-1998;	98US-0097141P;
PR	20-AUG-1998;	98US-0097218P;
PR	24-AUG-1998;	98US-0097661P;
PR	26-AUG-1998;	98US-0097952P;
PR	26-AUG-1998;	98US-0097954P;
PR	26-AUG-1998;	98US-0097955P;
PR	26-AUG-1998;	98US-0097971P;
PR	26-AUG-1998;	98US-0097974P;
PR	26-AUG-1998;	98US-0097978P;
PR	26-AUG-1998;	98US-0097979P;
PR	26-AUG-1998;	98US-0097986P;
PR	26-AUG-1998;	98US-0098014P;
PR	31-AUG-1998;	98US-0098525P;
PR	16-SEP-1998;	98US-0100634P;
PR	16-SEP-1998;	98WO-US019330;
PR	17-SEP-1998;	98US-0100858P;
PR	17-SEP-1998;	98WO-US019437;
PR	07-OCT-1998;	98WO-US021141;
PR	01-DEC-1998;	98WO-US025108;
PR	22-DEC-1998;	98US-0113296P;
PR	05-JAN-1999;	99WO-US000106;
PR	08-MAR-1999;	99WO-US005028;
PR	12-MAR-1999;	99US-0123957P;
PR	02-JUN-1999;	99WO-US012252;
PR	23-JUN-1999;	99US-0141037P;
PR	07-JUL-1999;	99US-0143048P;
PR	20-JUL-1999;	99US-0144758P;
PR	26-JUL-1999;	99US-0145698P;
PR	28-JUL-1999;	99US-0146222P;
PR	17-AUG-1999;	99US-0149396P;
PR	15-SEP-1999;	99WO-US021090;

PR	15-SEP-1999;	99WO-US021547;
PR	08-OCT-1999;	99US-0158663P.
PR	30-NOV-1999;	99WO-US028313.
PR	01-DEC-1999;	99WO-US028301.
PR	01-DEC-1999;	99WO-US028634.
PR	16-DEC-1999;	99WO-US030095.
PR	20-DEC-1999;	99WO-US030911.
PR	05-JAN-2000;	2000WO-US000219.
PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US003565.
PR	18-FEB-2000;	2000WO-US004341.
PR	22-FEB-2000;	2000WO-US004414.
PR	24-FEB-2000;	2000WO-US004914.
PR	24-FEB-2000;	2000WO-US005004.
PR	02-MAR-2000;	2000WO-US005841.
PR	10-MAR-2000;	2000WO-US006319.
PR	15-MAR-2000;	2000WO-US006884.
PR	20-MAR-2000;	2000WO-US007377.
PR	30-MAR-2000;	2000WO-US008439.
PR	15-MAY-2000;	2000WO-US013358.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	23-JUN-2000;	2000US-0213637P.
PR	28-JUL-2000;	2000WO-US020710.
PR	11-AUG-2000;	2000WO-US022031.

Query Match 3.0%; Score 66.6; DB 10; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0;

[illegible]

RESULT 834

ACA69482  
ID ACA69482 standard; cDNA; 2846 BP.

ACA69482:

DT 27-JUN-2003 (first entry)

DE CDNA encoding human PRO polypeptide #85.

Human; PRO polypeptide; secreted and transmembrane protein; tumour; KW  
 chromosome mapping; gene mapping; cytostatic; gene therapy; gene; ss. KW

OS Homo sapiens.

•

PD 13-FEB-2003.

PF 20-JUN-2002; 2002US-00176911.

PR 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 17-OCT-1997; 97US-0062250P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0063120P.  
PB 24-OCT-1997; 97US-0063121P.  
PB 24-OCT-1997; 97US-0063121P.

PR	24-OCT-1997;	97US-0063121P.
PR	28-OCT-1997:	97US-0063540P.

PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.

PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 16-SEP-1998; 98US-0100662P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.



PR	17-SEP-1998;	98US-0100919P.	
PR	17-SEP-1998;	98US-0100930P.	
PR	18-SEP-1998;	98US-0100849P.	
PR	18-SEP-1998;	98US-0101014P.	
PR	18-SEP-1998;	98US-0101068P.	
PR	23-SEP-1998;	98US-0101471P.	
PR	23-SEP-1998;	98US-0101472P.	
PR	23-SEP-1998;	98US-0101475P.	
PR	23-SEP-1998;	98US-0101477P.	
PR	24-SEP-1998;	98US-0101738P.	
PR	24-SEP-1998;	98US-0101739P.	
PR	24-SEP-1998;	98US-0101743P.	
PR	24-SEP-1998;	98US-0101922P.	
PR	25-SEP-1998;	98US-0101786P.	
PR	29-SEP-1998;	98US-0102207P.	
PR	29-SEP-1998;	98US-0102240P.	
PR	29-SEP-1998;	98US-0102330P.	
PR	29-SEP-1998;	98US-0102331P.	
PR	30-SEP-1998;	98US-0102487P.	
PR	30-SEP-1998;	98US-0102570P.	
PR	30-SEP-1998;	98US-0102571P.	
PR	01-OCT-1998;	98US-0102684P.	
PR	01-OCT-1998;	98US-0102687P.	
PR	02-OCT-1998;	98US-0102965P.	
PR	06-OCT-1998;	98US-0103258P.	
PR	06-OCT-1998;	98US-0103449P.	
PR	07-OCT-1998;	98US-00168978.	
PR	07-OCT-1998;	98US-0103395P.	
Query Match 3.0%; Score 66.6; DB 10; Length 2846;			
Best Local Similarity 71.3%; Pred. No. 0.00023;			
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;			
QY	2121	CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCAC	2180
Db	2653	CCTTTTCCTCCCACTCTCTTGACACATTTTAATAAATAAGGTTGGCTTCTGAAC	2712
QY	2181	NCTCCCAA	2240
Db	2713	CAA	2772
QY	2241	AA	2242
Db	2773	AA	2774
RESULT 835			
ACA90327			
ID	ACA90327 standard; cDNA; 2846 BP.		
XX	ACA90327;		
AC	ACA90327;		
XX	11-AUG-2003 (first entry)		
DT	Novel human secreted and transmembrane protein PRO1344 cDNA.		
DE	Human; gene therapy; tissue typing; tumour; chondrocyte proliferation;		
XX	chondrocyte differentiation; tumour necrosis factor-alpha release; ss;		
KW	affinity purification; gene.		
KW	Homo sapiens.		
XX	US2003036147-A1.		
OS	20-FEB-2003.		
XX	02-JUL-2002; 2002US-00187741.		
PN	18-SEP-1997; 97US-0059263P.		
XX	18-SEP-1997; 97US-0059266P.		
PR	17-OCT-1997; 97US-0062250P.		
PR	21-OCT-1997; 97US-0063486P.		
PR	24-OCT-1997; 97US-0063120P.		

PR	24-OCT-1997;	97US-0063121P.
PR	28-OCT-1997;	97US-0063540P.
PR	28-OCT-1997;	97US-0063541P.
PR	28-OCT-1997;	97US-0063544P.
PR	28-OCT-1997;	97US-0063564P.
PR	29-OCT-1997;	97US-0063734P.
PR	31-OCT-1997;	97US-0063870P.
PR	31-OCT-1997;	97US-0064103P.
PR	13-NOV-1997;	97US-0065311P.
PR	21-NOV-1997;	97US-0066120P.
PR	24-NOV-1997;	97US-0066466P.
PR	24-NOV-1997;	97US-0066772P.
PR	11-DEC-1997;	97US-0069335P.
PR	12-DEC-1997;	97US-0069425P.
PR	17-DEC-1997;	97US-0069870P.
PR	18-DEC-1997;	97US-0068017P.
PR	10-MAR-1998;	98US-0077450P.
PR	11-MAR-1998;	98US-0077632P.
PR	20-MAR-1998;	98US-0078886P.
PR	20-MAR-1998;	98US-0078939P.
PR	27-MAR-1998;	98US-0079664P.
PR	27-MAR-1998;	98US-0079786P.
PR	31-MAR-1998;	98US-0080107P.
PR	31-MAR-1998;	98US-0080194P.
PR	01-APR-1998;	98US-0080327P.
PR	01-APR-1998;	98US-0080333P.
PR	08-APR-1998;	98US-0081049P.
PR	08-APR-1998;	98US-0081070P.
PR	09-APR-1998;	98US-0081195P.
PR	15-APR-1998;	98US-0081838P.
PR	21-APR-1998;	98US-0082568P.
PR	21-APR-1998;	98US-0082569P.
PR	22-APR-1998;	98US-0082704P.
PR	22-APR-1998;	98US-0082797P.
PR	28-APR-1998;	98US-0083322P.
PR	29-APR-1998;	98US-0083495P.
PR	29-APR-1998;	98US-0083496P.
PR	29-APR-1998;	98US-0083499P.
PR	29-APR-1998;	98US-0083559P.
PR	05-MAY-1998;	98US-0084366P.
PR	06-MAY-1998;	98US-0084414P.
PR	07-MAY-1998;	98US-0084639P.
PR	07-MAY-1998;	98US-0084640P.
PR	07-MAY-1998;	98US-0084643P.
PR	15-MAY-1998;	98US-0085579P.
PR	15-MAY-1998;	98US-0085580P.
PR	15-MAY-1998;	98US-0085582P.
PR	15-MAY-1998;	98US-0085700P.
PR	18-MAY-1998;	98US-0086023P.
PR	22-MAY-1998;	98US-0086392P.
PR	22-MAY-1998;	98US-0086486P.
PR	28-MAY-1998;	98US-0087098P.
PR	28-MAY-1998;	98US-0087208P.
PR	02-JUN-1998;	98US-0087609P.
PR	02-JUN-1998;	98US-0087759P.
PR	03-JUN-1998;	98US-0087827P.
PR	04-JUN-1998;	98US-0088025P.
PR	04-JUN-1998;	98US-0088028P.
PR	04-JUN-1998;	98US-0088029P.
PR	04-JUN-1998;	98US-0088033P.
PR	04-JUN-1998;	98US-0088326P.
PR	05-JUN-1998;	98US-0088167P.
PR	05-JUN-1998;	98US-0088202P.
PR	05-JUN-1998;	98US-0088212P.
PR	05-JUN-1998;	98US-0088217P.
PR	09-JUN-1998;	98US-0088655P.
PR	10-JUN-1998;	98US-0088722P.
PR	10-JUN-1998;	98US-0088738P.
PR	10-JUN-1998;	98US-0088740P.
PR	10-JUN-1998;	98US-0088811P.
PR	10-JUN-1998;	98US-0088824P.
PR	10-JUN-1998;	98US-0088825P.



PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.

PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.



```
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 24-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACCTCTTCTCTTTATCTTATTATAAAAAATGTTGGTCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTATAATAAATAAGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 837
ABX90248
ID ABX90248 standard; cDNA; 2846 BP.
XX
AC ABX90248;
XX
DT 01-MAY-2003 (first entry)
XX
DE Human secreted/transmembrane protein cDNA, #94.
XX
KW Human; gene; ss; PRO; secreted; transmembrane; signal peptide;
KW pharmaceutical; diagnostic; therapeutic; gene therapy.
XX
OS Homo sapiens.
XX
PN US2002160384-A1.
XX
PD 31-OCT-2002.
XX
PF 14-NOV-2001; 2001US-00992598.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
```

```
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
```







RESULT 839  
ACA93867  
ID ACA93867 standard; cDNA; 2846 BP.  
XX  
AC ACA93867;  
XX  
DT 18-JUL-2003 (first entry)  
XX  
DE Human secreted/transmembrane protein (PRO) cDNA #85.  
XX  
KW Human; ss: gene; secreted protein; transmembrane protein; PRO; tumour;  
KW proliferation; differentiation; chondrocyte cell; TNF-alpha;  
KW tumour necrosis factor-alpha; gene therapy.  
XX  
OS Homo sapiens.  
XX  
PN US2003036149-A1.  
XX  
PD 20-FEB-2003.  
XX  
PF 02-JUL-2002; 2002US-00187746.  
XX  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083599P.  
PR 29-APR-1998; 98US-0083599P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.

PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 16-SEP-1998; 98US-0100662P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.  
PR 17-SEP-1998; 98US-0100919P.  
PR 17-SEP-1998; 98US-0100930P.  
PR 18-SEP-1998; 98US-0100849P.  
PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.  
PR 23-SEP-1998; 98US-0101471P.  
PR 23-SEP-1998; 98US-0101472P.  
PR 23-SEP-1998; 98US-0101475P.  
PR 23-SEP-1998; 98US-0101477P.  
PR 24-SEP-1998; 98US-0101738P.  
PR 24-SEP-1998; 98US-0101739P.  
PR 24-SEP-1998; 98US-0101743P.  
PR 25-SEP-1998; 98US-0101922P.  
PR 29-SEP-1998; 98US-0101786P.  
PR 29-SEP-1998; 98US-0102207P.  
PR 29-SEP-1998; 98US-0102240P.  
PR 29-SEP-1998; 98US-0102330P.  
PR 29-SEP-1998; 98US-0102331P.  
PR 30-SEP-1998; 98US-0102487P.  
PR 30-SEP-1998; 98US-0102570P.  
PR 30-SEP-1998; 98US-0102571P.  
PR 01-OCT-1998; 98US-0102684P.  
PR 01-OCT-1998; 98US-0102687P.  
PR 02-OCT-1998; 98US-0102965P.  
PR 06-OCT-1998; 98US-0103258P.  
PR 06-OCT-1998; 98US-0103449P.  
PR 07-OCT-1998; 98US-00168978.

Query Match 3.0%; Score 66.6; DB 10; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;  
QY 2121 CCTTGTCTTACCACCTCTTCTCTTTATCTTATTAATAAAATGTTGGTCTCCACCACGTG 2180  
D5 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAAGGTTGGCTTCTGAACATA 2712  
QY 2181 NCTCCCAAA 2240  
D5 2713 CAA 2772

QY 2241 AA 2242  
D5 2773 AA 2774

RESULT 840  
ACD15260  
ID ACD15260 standard; cDNA; 2846 BP.  
XX  
AC ACD15260;  
XX  
DT 17-AUG-2003 (first entry)  
XX  
DE Human secreted/transmembrane protein (PRO) cDNA #85.  
XX  
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;  
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;  
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;  
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.  
XX  
OS Homo sapiens.  
XX  
PN US2003044923-A1.  
XX  
PD 06-MAR-2003.  
XX  
PF 24-JUN-2002; 2002US-00179522.  
XX  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.





RESULT 841  
ACD08847  
ID ACD08847 standard; cDNA; 2846 BP.  
XX  
AC ACD08847;  
XX  
DT 09-AUG-2003 (first entry)  
XX  
DE Human secreted/transmembrane protein (PRO) cDNA #85.  
XX  
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;  
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;  
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;  
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.  
XX  
OS Homo sapiens.  
XX  
PN US2003040062-A1.  
XX  
PD 27-FEB-2003.  
XX  
PF 25-JUN-2002; 2002US-00180545.  
XX  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 11-DEC-1997; 97US-0066772P.  
PR 12-DEC-1997; 97US-0069335P.  
PR 17-DEC-1997; 97US-0069425P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-007886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.



PR 29-APR-1998; 98US-00835559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.

PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 16-SEP-1998; 98US-0100662P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.  
PR 17-SEP-1998; 98US-0100919P.  
PR 17-SEP-1998; 98US-0100930P.  
PR 18-SEP-1998; 98US-0100849P.  
PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.  
PR 23-SEP-1998; 98US-0101471P.  
PR 23-SEP-1998; 98US-0101472P.  
PR 23-SEP-1998; 98US-0101475P.  
PR 23-SEP-1998; 98US-0101477P.  
PR 24-SEP-1998; 98US-0101738P.  
PR 24-SEP-1998; 98US-0101739P.  
PR 24-SEP-1998; 98US-0101743P.  
PR 24-SEP-1998; 98US-0101922P.  
PR 25-SEP-1998; 98US-0101786P.  
PR 29-SEP-1998; 98US-0102207P.  
PR 29-SEP-1998; 98US-0102240P.  
PR 29-SEP-1998; 98US-0102330P.  
PR 29-SEP-1998; 98US-0102331P.  
PR 30-SEP-1998; 98US-0102487P.  
PR 30-SEP-1998; 98US-0102570P.  
PR 30-SEP-1998; 98US-0102571P.  
PR 01-OCT-1998; 98US-0102684P.  
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 10; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCCACTG 2180

Db 2653 CCTTTTCCTTCCCATCTCTGTACACATTTTAATAAATAAGGTTGGCTTCTGAACTA 2712

Qy 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

Qy 2241 AA 2242



Db 2773 AA 2774 |||

RESULT 843

ACF15488

ID ACF15488 standard; cDNA; 2846 BP.

XX AC ACF15488;

XX AC ACF15488;

DT 13-SEP-2003 (first entry)

XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

DE Human; PRO; secreted protein; transmembrane protein;

XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;

KW chondrocyte; proliferation; differentiation; cartilage disorder;

KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;

KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;

KW liver; drug screening; transgenic animal; genetic analysis;

KW antiarthritic; vulnerary; gene therapy; gene; ss.

XX Homo sapiens.

OS US2003044926-A1.

XX 06-MAR-2003.

PF 26-JUN-2002; 2002US-00183015.

XX 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 17-OCT-1997; 97US-0062250P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0063120P.

PR 24-OCT-1997; 97US-0063121P.

PR 28-OCT-1997; 97US-0063540P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063544P.

PR 28-OCT-1997; 97US-0063564P.

PR 29-OCT-1997; 97US-0063734P.

PR 31-OCT-1997; 97US-0063870P.

PR 31-OCT-1997; 97US-0064103P.

PR 13-NOV-1997; 97US-0065311P.

PR 21-NOV-1997; 97US-0066120P.

PR 24-NOV-1997; 97US-0066466P.

PR 24-NOV-1997; 97US-0066772P.

PR 11-DEC-1997; 97US-0069335P.

PR 12-DEC-1997; 97US-0069425P.

PR 17-DEC-1997; 97US-0069870P.

PR 18-DEC-1997; 97US-0068017P.

PR 10-MAR-1998; 98US-0077450P.

PR 11-MAR-1998; 98US-0077632P.

PR 11-MAR-1998; 98US-0077649P.

PR 20-MAR-1998; 98US-0078886P.

PR 20-MAR-1998; 98US-0078939P.

PR 27-MAR-1998; 98US-0079664P.

PR 27-MAR-1998; 98US-0079786P.

PR 31-MAR-1998; 98US-0080107P.

PR 31-MAR-1998; 98US-0080194P.

PR 01-APR-1998; 98US-0080327P.

PR 01-APR-1998; 98US-0080333P.

PR 08-APR-1998; 98US-0081049P.

PR 08-APR-1998; 98US-0081070P.

PR 09-APR-1998; 98US-0081195P.

PR 15-APR-1998; 98US-0081838P.

PR 21-APR-1998; 98US-0082568P.

PR 21-APR-1998; 98US-0082569P.

PR 22-APR-1998; 98US-0082704P.

PR 22-APR-1998; 98US-0082797P.

PR 28-APR-1998; 98US-0083322P.

PR 29-APR-1998; 98US-0083495P.

PR 29-APR-1998; 98US-0083496P.

PR 29-APR-1998; 98US-0083499P.

PR 29-APR-1998; 98US-0083559P.

PR 05-MAY-1998; 98US-0084366P.

PR 06-MAY-1998; 98US-0084414P.

PR 07-MAY-1998; 98US-0084639P.

PR 07-MAY-1998; 98US-0084640P.

PR 07-MAY-1998; 98US-0084643P.

PR 15-MAY-1998; 98US-0085579P.

PR 15-MAY-1998; 98US-0085580P.

PR 15-MAY-1998; 98US-0085582P.

PR 15-MAY-1998; 98US-0085700P.

PR 18-MAY-1998; 98US-0086023P.

PR 22-MAY-1998; 98US-0086392P.

PR 22-MAY-1998; 98US-0086486P.

PR 28-MAY-1998; 98US-0087098P.

PR 28-MAY-1998; 98US-0087208P.

PR 02-JUN-1998; 98US-0087609P.

PR 02-JUN-1998; 98US-0087759P.

PR 03-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088028P.

PR 04-JUN-1998; 98US-0088029P.

PR 04-JUN-1998; 98US-0088033P.

PR 04-JUN-1998; 98US-0088326P.

PR 05-JUN-1998; 98US-0088167P.

PR 05-JUN-1998; 98US-0088202P.

PR 05-JUN-1998; 98US-0088212P.

PR 05-JUN-1998; 98US-0088217P.

PR 09-JUN-1998; 98US-0088655P.

PR 10-JUN-1998; 98US-0088722P.

PR 10-JUN-1998; 98US-0088738P.

PR 10-JUN-1998; 98US-0088740P.

PR 10-JUN-1998; 98US-0088811P.

PR 10-JUN-1998; 98US-0088824P.

PR 10-JUN-1998; 98US-0088825P.

PR 10-JUN-1998; 98US-0088826P.

PR 11-JUN-1998; 98US-0088861P.

PR 11-JUN-1998; 98US-0088863P.

PR 11-JUN-1998; 98US-0088876P.

PR 12-JUN-1998; 98US-0089090P.

PR 12-JUN-1998; 98US-0089105P.

PR 16-JUN-1998; 98US-0089512P.

PR 16-JUN-1998; 98US-0089514P.

PR 17-JUN-1998; 98US-0089538P.

PR 17-JUN-1998; 98US-0089598P.

PR 17-JUN-1998; 98US-0089653P.

PR 18-JUN-1998; 98US-0089908P.

PR 19-JUN-1998; 98US-0089952P.

PR 22-JUN-1998; 98US-0090246P.

PR 22-JUN-1998; 98US-0090252P.

PR 22-JUN-1998; 98US-0090254P.

PR 24-JUN-1998; 98US-0090429P.

PR 24-JUN-1998; 98US-0090435P.

PR 24-JUN-1998; 98US-0090444P.

PR 24-JUN-1998; 98US-0090461P.

PR 24-JUN-1998; 98US-0090535P.

PR 24-JUN-1998; 98US-0090540P.

PR 25-JUN-1998; 98US-0090676P.

PR 25-JUN-1998; 98US-0090678P.

PR 25-JUN-1998; 98US-0090688P.

PR 25-JUN-1998; 98US-0090690P.

PR 25-JUN-1998; 98US-0090694P.

PR 25-JUN-1998; 98US-0090695P.

PR 25-JUN-1998; 98US-0090696P.

PR 26-JUN-1998; 98US-00105413.

PR 26-JUN-1998; 98US-0090862P.

PR 26-JUN-1998; 98US-0090863P.

PR 26-JUN-1998; 98US-0091010P.

PR 01-JUL-1998; 98US-0091359P.

PR 01-JUL-1998; 98US-0091544P.

PR 02-JUL-1998; 98US-0091478P.

PR 02-JUL-1998; 98US-0091486P.

PR 02-JUL-1998; 98US-0091626P.

```
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
```

Query Match 3.0%; Score 66.6; DB 10; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

```
QY 2121 CCTTTGCTTTACCACCTCTTCTCTTTTATCTTTATTAATAAAATGTTGGTCTCCCACTG 2180
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAAATAAGGTTGGCTTCTGAACTA 2712
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
```

```
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 844
ABX64094
ID ABX64094 standard; cDNA; 2846 BP.
XX
AC ABX64094;
XX
DT 26-FEB-2003 (first entry)
XX cDNA encoding human PRO1344 polypeptide.
DE
XX Human; PRO polypeptide; secreted protein; transmembrane protein;
KW genetic disorder; antibacterial; immunosuppressive; transgenic;
KW gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2002103125-A1.
XX
PD 01-AUG-2002.
XX
PF 20-NOV-2001; 2001US-00989731.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
```







PR	31-MAR-1998;	98US-0080194P.
PR	01-APR-1998;	98US-0080327P.
PR	01-APR-1998;	98US-0080333P.
PR	08-APR-1998;	98US-0081049P.
PR	08-APR-1998;	98US-0081070P.
PR	09-APR-1998;	98US-0081195P.
PR	15-APR-1998;	98US-0081838P.
PR	21-APR-1998;	98US-0082568P.
PR	21-APR-1998;	98US-0082569P.
PR	22-APR-1998;	98US-0082704P.
PR	22-APR-1998;	98US-0082797P.
PR	28-APR-1998;	98US-0083322P.
PR	29-APR-1998;	98US-0083495P.
PR	29-APR-1998;	98US-0083496P.
PR	29-APR-1998;	98US-0083499P.
PR	29-APR-1998;	98US-0083559P.
PR	05-MAY-1998;	98US-0084366P.
PR	06-MAY-1998;	98US-0084414P.
PR	07-MAY-1998;	98US-0084639P.
PR	07-MAY-1998;	98US-0084640P.
PR	07-MAY-1998;	98US-0084643P.
PR	15-MAY-1998;	98US-0085579P.
PR	15-MAY-1998;	98US-0085580P.
PR	15-MAY-1998;	98US-0085582P.
PR	15-MAY-1998;	98US-0085700P.
PR	18-MAY-1998;	98US-0086023P.
PR	22-MAY-1998;	98US-0086392P.
PR	22-MAY-1998;	98US-0086486P.
PR	28-MAY-1998;	98US-0087098P.
PR	28-MAY-1998;	98US-0087208P.
PR	02-JUN-1998;	98US-0087609P.
PR	02-JUN-1998;	98US-0087759P.
PR	03-JUN-1998;	98US-0087827P.
PR	04-JUN-1998;	98US-0088025P.
PR	04-JUN-1998;	98US-0088028P.
PR	04-JUN-1998;	98US-0088029P.
PR	04-JUN-1998;	98US-0088033P.
PR	04-JUN-1998;	98US-0088326P.
PR	05-JUN-1998;	98US-0088167P.
PR	05-JUN-1998;	98US-0088202P.
PR	05-JUN-1998;	98US-0088212P.
PR	05-JUN-1998;	98US-0088217P.
PR	09-JUN-1998;	98US-0088655P.
PR	10-JUN-1998;	98US-0088722P.
PR	10-JUN-1998;	98US-0088738P.
PR	10-JUN-1998;	98US-0088740P.
PR	10-JUN-1998;	98US-0088811P.
PR	10-JUN-1998;	98US-0088824P.
PR	10-JUN-1998;	98US-0088825P.
PR	10-JUN-1998;	98US-0088826P.
PR	11-JUN-1998;	98US-0088861P.
PR	11-JUN-1998;	98US-0088863P.
PR	11-JUN-1998;	98US-0088876P.
PR	12-JUN-1998;	98US-0089090P.
PR	16-JUN-1998;	98US-0089512P.
PR	16-JUN-1998;	98US-0089514P.
PR	17-JUN-1998;	98US-0089538P.
PR	17-JUN-1998;	98US-0089598P.
PR	17-JUN-1998;	98US-0089653P.
PR	18-JUN-1998;	98US-0089908P.
PR	19-JUN-1998;	98US-0089952P.
PR	22-JUN-1998;	98US-0090246P.
PR	22-JUN-1998;	98US-0090252P.
PR	22-JUN-1998;	98US-0090254P.
PR	24-JUN-1998;	98US-0090429P.
PR	24-JUN-1998;	98US-0090435P.
PR	24-JUN-1998;	98US-0090444P.
PR	24-JUN-1998;	98US-0090461P.
PR	24-JUN-1998;	98US-0090535P.
PR	24-JUN-1998;	98US-0090540P.
PR	25-JUN-1998;	98US-0090676P.
PR	25-JUN-1998;	98US-0090678P.
PR	25-JUN-1998;	98US-0090680P.
PR	25-JUN-1998;	98US-0090694P.
PR	25-JUN-1998;	98US-0090695P.
PR	25-JUN-1998;	98US-0090696P.
PR	26-JUN-1998;	98US-00105413.
PR	26-JUN-1998;	98US-0090862P.
PR	26-JUN-1998;	98US-0090863P.
PR	26-JUN-1998;	98US-0091010P.
PR	01-JUL-1998;	98US-0091359P.
PR	01-JUL-1998;	98US-0091544P.
PR	02-JUL-1998;	98US-0091478P.
PR	02-JUL-1998;	98US-0091486P.
PR	02-JUL-1998;	98US-0091626P.
PR	02-JUL-1998;	98US-0091628P.
PR	02-JUL-1998;	98US-0091632P.
PR	24-JUL-1998;	98US-0094006P.
PR	04-AUG-1998;	98US-0095282P.
PR	10-AUG-1998;	98US-0095998P.
PR	10-AUG-1998;	98US-0096012P.
PR	17-AUG-1998;	98US-0096757P.
PR	17-AUG-1998;	98US-0096766P.
PR	17-AUG-1998;	98US-0096867P.
PR	17-AUG-1998;	98US-0096891P.
PR	17-AUG-1998;	98US-0096897P.
PR	18-AUG-1998;	98US-0096949P.
PR	18-AUG-1998;	98US-0096959P.
PR	18-AUG-1998;	98US-0097022P.
PR	26-AUG-1998;	98US-0097952P.
PR	26-AUG-1998;	98US-0097954P.
PR	26-AUG-1998;	98US-0097955P.
PR	26-AUG-1998;	98US-0097971P.
PR	26-AUG-1998;	98US-0097974P.
PR	26-AUG-1998;	98US-0098014P.
PR	01-SEP-1998;	98US-0098716P.
PR	01-SEP-1998;	98US-0098723P.
PR	02-SEP-1998;	98US-0098803P.
PR	02-SEP-1998;	98US-0098821P.
PR	02-SEP-1998;	98US-0098843P.
PR	09-SEP-1998;	98US-0099602P.
PR	10-SEP-1998;	98US-0099741P.
PR	10-SEP-1998;	98US-0099754P.
PR	10-SEP-1998;	98US-0099763P.
PR	10-SEP-1998;	98US-0099812P.
PR	15-SEP-1998;	98US-0100388P.
PR	16-SEP-1998;	98US-0100662P.
PR	16-SEP-1998;	98US-0100664P.
PR	16-SEP-1998;	98US-0101751P.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98US-0100683P.
PR	17-SEP-1998;	98US-0100684P.
PR	17-SEP-1998;	98US-0100919P.
PR	17-SEP-1998;	98US-0100930P.
PR	18-SEP-1998;	98US-0100849P.
PR	18-SEP-1998;	98US-0101014P.
PR	18-SEP-1998;	98US-0101068P.
PR	23-SEP-1998;	98US-0101471P.
PR	23-SEP-1998;	98US-0101472P.
PR	23-SEP-1998;	98US-0101475P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101738P.
PR	24-SEP-1998;	98US-0101739P.
PR	24-SEP-1998;	98US-0101743P.
PR	24-SEP-1998;	98US-0101922P.
PR	25-SEP-1998;	98US-0101786P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.

```
PR 01-OCT-1998; 98US-0102687P.
Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCTTTTATCTTATTATAATAAATGTTGGTCTCCACCACTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAATAAGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
||
Db 2773 AA 2774

RESULT 847
ACD01842
ID ACD01842 standard; cDNA; 2846 BP.
XX
AC ACD01842;
XX
DT 30-JUL-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; cytostatic; gene therapy;
KW chondrocyte stimulator; tumour; adrenal tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome identification; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003017544-A1.
XX
PD 23-JAN-2003.
XX
PF 21-JUN-2002; 2002US-00176915.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
```





PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.

PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 24-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 18-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 16-SEP-1998; 98US-0100662P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.  
PR 17-SEP-1998; 98US-0100919P.  
PR 17-SEP-1998; 98US-0100930P.  
PR 18-SEP-1998; 98US-0100849P.  
PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.  
PR 23-SEP-1998; 98US-0101471P.  
PR 23-SEP-1998; 98US-0101472P.  
PR 23-SEP-1998; 98US-0101475P.  
PR 23-SEP-1998; 98US-0101477P.  
PR 24-SEP-1998; 98US-0101738P.  
PR 24-SEP-1998; 98US-0101739P.  
PR 24-SEP-1998; 98US-0101743P.  
PR 24-SEP-1998; 98US-0101922P.  
PR 25-SEP-1998; 98US-0101786P.  
PR 29-SEP-1998; 98US-0102207P.  
PR 29-SEP-1998; 98US-0102240P.  
PR 29-SEP-1998; 98US-0102330P.  
PR 29-SEP-1998; 98US-0102331P.  
PR 30-SEP-1998; 98US-0102487P.  
PR 30-SEP-1998; 98US-0102570P.  
PR 30-SEP-1998; 98US-0102571P.  
PR 01-OCT-1998; 98US-0102684P.  
PR 01-OCT-1998; 98US-0102687P.  
PR 02-OCT-1998; 98US-0102965P.  
PR 06-OCT-1998; 98US-0103258P.  
PR 06-OCT-1998; 98US-0103449P.

```
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103401P.

Query Match      3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTAATAAAATAAGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 849
ADI05057
ID ADI05057 standard; cDNA; 2846 BP.
XX AC ADI05057;
XX DT 06-MAY-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX KW antibody; human; secreted; transmembrane; PRO; cytostatic; cancer; ss;
XX OS Homo sapiens.
XX PN US2003180848-A1.
XX PD 25-SEP-2003.
XX PF 08-MAY-2002; 2002US-00063694.
XX 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
```

```
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX (GETH ) GENENTECH INC.
PA Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-802876/75.
DR P-PSDB; ADI05058.
XX
PT Novel antibody that binds to a PRO polypeptide, useful for treating
PT cancer and in diagnostic assays, for e.g. detecting PRO expression in
PT specific cells, tissues, or serum.
XX
PS Example 4; SEQ ID NO 37; 397pp; English.
XX
CC This invention describes a novel antibody that binds to a human secreted
CC and transmembrane PRO polypeptide which is a monoclonal antibody, a
CC humanised antibody, or antibody fragment and is preferably labelled. The
CC antibody has cytostatic activity and can be used to treat cancer. The
CC anti-PRO antibody can be used in diagnostic assays, for e.g. detecting
CC PRO expression in specific cells, tissues, or serum. The anti-PRO
CC antibodies are also useful for the affinity purification of PRO from
CC recombinant cell culture or natural sources. ADI05021-ADI05188 represent
CC human PRO polynucleotides and polypeptides described in the disclosure of
CC the invention.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match      3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTAATAAAATAAGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 850
ADI03407
ID ADI03407 standard; cDNA; 2846 BP.
XX AC ADI03407;
XX DT 06-MAY-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX KW PRO; human; secreted; transmembrane; antiarthritic; antidiabetic;
KW cytostatic; vulnerary; hyperglycaemic; hypoglycaemic; bone disorder;
KW cartilage disorder; sports injury; arthritis; glucose uptake; diabetes;
KW pericyte-associated tumour; wound healing; cancer; gene therapy; ss;
KW gene.
XX OS Homo sapiens.
XX PN US2003181654-A1.
XX PD 25-SEP-2003.
XX
```











```
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000WO-US023328.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-875178/81.
DR P-PSDB; ADH90349.
XX
PT New isolated PRO polypeptide, useful for treating various bone and/or
PT cartilage disorders, for example, sports injuries and arthritis.
XX
PS Disclosure; SEQ ID NO 37; 397pp; English.
XX
CC The invention relates to a novel PRO (secreted and transmembrane protein)
CC polypeptide, and the polynucleotide sequence encoding it. Also included
CC are a vector comprising the novel nucleic acid and a host cell comprising
CC the vector. The polynucleotide sequence is useful in molecular biology as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, and in gene therapy. The polynucleotide sequence
CC may also be used in preparing the PRO polypeptide by recombinant
CC techniques, and in generating either transgenic or knock-out animals
CC which, in turn, are useful in the development and screening of
CC therapeutically useful reagents. The PRO polynucleotide sequence is
CC useful in preparing a medicament for treating a condition responsive to
CC the polypeptide or antibody, such as tumours, and in various diagnostic
CC assays. The specification also discloses other PRO proteins and the
CC polynucleotide sequences encoding them. The present sequence encodes a
CC PRO protein.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match          3.0%;  Score 66.6;  DB 10;  Length 2846;
Best Local Similarity 71.3%;  Pred. No. 0.00023;
Matches 87;  Conservative 0;  Mismatches 35;  Indels 0;  Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
DB 2653 CCTTTTCTTCCCATCTCTTGTACACATTTTAATAAAATAAGGTTGCTTCTGAACTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
```

```
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
      ||
Db 2773 AA 2774

RESULT 855
AD103067
ID AD103067 standard; cDNA; 2846 BP.
XX
AC AD103067;
XX
DT 06-MAY-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW PRO; human; secreted; transmembrane; antiarthritic; antidiabetic;
KW cytostatic; vulnery; hyperglycaemic; hypoglycaemic; bone disorder;
KW cartilage disorder; sports injury; arthritis; glucose uptake; diabetes;
KW pericyte-associated tumour; wound healing; cancer; gene therapy; ss;
KW gene.
XX
OS Homo sapiens.
XX
PN US2003181653-A1.
XX
PD 25-SEP-2003.
XX
PF 07-MAY-2002; 2002US-00063650.
XX
PR 30-DEC-1998; 98XR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
```



Db 2773 AA 2774

RESULT 857

ADH97899

ID ADH97899 standard; cDNA; 2846 BP.

XX AC ADH97899;

XX DT 06-MAY-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.

XX KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;

XX KW affinity purification; secreted and transmembrane protein.

XX OS Homo sapiens.

XX PN US2003181674-A1.

XX PD 25-SEP-2003.

XX PF 03-MAY-2002; 2002US-00063602.

XX PR 30-DEC-1998; 98KR-00062142.

PR 08-MAR-1999; 99WO-US005028.

PR 14-MAY-1999; 99US-00311832.

PR 14-MAY-1999; 99WO-US010733.

PR 25-AUG-1999; 99US-00380137.

PR 25-AUG-1999; 99US-00380138.

PR 25-AUG-1999; 99US-00380139.

PR 25-AUG-1999; 99US-00380142.

PR 15-SEP-1999; 99US-00397342.

PR 18-OCT-1999; 99US-00403297.

PR 12-NOV-1999; 99US-00423844.

PR 30-DEC-1999; 99WO-US031274.

PR 18-FEB-2000; 2000WO-US004341.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005841.

PR 21-MAR-2000; 2000WO-US007532.

PR 22-MAY-2000; 2000WO-US014042.

PR 02-JUN-2000; 2000WO-US015264.

PR 22-AUG-2000; 2000US-00644848.

PR 24-AUG-2000; 2000WO-US023328.

PR 18-SEP-2000; 2000US-00664610.

PR 18-SEP-2000; 2000US-00665350.

PR 08-NOV-2000; 2000US-00709238.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001WO-US006520.

PR 22-MAR-2001; 2001US-00816744.

PR 10-MAY-2001; 2001US-00854208.

PR 10-MAY-2001; 2001US-00854280.

PR 30-MAY-2001; 2001US-00870574.

PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.

PR 29-JUN-2001; 2001US-00869599.

PR 18-JUL-2001; 2001US-00908827.

PR 06-DEC-2001; 2001US-00006867.

XX PA (GETH ) GENENTECH INC.

XX PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX WPI; 2003-852265/79.

DR P-PSDB; ADH97900.

XX Novel antibody that binds to a PRO polypeptide, useful for treating

PT cancer and in diagnostic assays, for e.g. detecting PRO expression in

PT specific cells, tissues, or serum.

XX Disclosure; SEQ ID NO 37; 396pp; English.

XX The invention relates to a PRO (secreted and transmembrane protein)

CC polynucleotide appearing as ADH97943 encoding PRO polypeptide having

CC appearing as ADH97943. Also included are a vector comprising the novel

CC nucleic acid and a host cell comprising the vector. The polynucleotide is

CC useful in molecular biology, including uses as hybridisation probes, in

CC chromosome and gene mapping, in generating antisense RNA and DNA, and in

CC gene therapy. The polynucleotide may also be used in preparing PRO

CC polypeptides by recombinant techniques, and in generating either

CC transgenic animals or knock-out animals which, in turn, are useful in the

CC development and screening of therapeutically useful reagents. The PRO

CC polynucleotide is used in preparing a medicament for treating a condition

CC responsive to the polypeptide or antibody, such as tumours, and in

CC various diagnostic assays. The specification discloses 84 PRO proteins

CC and 84 PRO polynucleotides. The present sequence encodes a PRO protein.

XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGCTTTACCACTCTTCTCTTTATCTTATTATAATAAATGTTGGTCTCCACCTG 2180

Db 2653 CCTTCTCTCCCATCTCTGTACACATTTTAAATAAAGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 858

AD101284

ID AD101284 standard; cDNA; 2846 BP.

XX AC AD101284;

XX DT 06-MAY-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.

XX KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;

XX KW affinity purification; secreted and transmembrane protein.

XX OS Homo sapiens.

XX PN US20031906659-A1.

XX PD 09-OCT-2003.

XX PF 01-MAY-2002; 2002US-00063521.

XX PR 30-DEC-1998; 98KR-00062142.

PR 08-MAR-1999; 99WO-US005028.

PR 14-MAY-1999; 99US-00311832.

PR 14-MAY-1999; 99WO-US010733.

PR 25-AUG-1999; 99US-00380137.

PR 25-AUG-1999; 99US-00380138.

PR 25-AUG-1999; 99US-00380139.

PR 25-AUG-1999; 99US-00380142.

PR 15-SEP-1999; 99US-00397342.

PR 18-OCT-1999; 99US-00403297.

PR 12-NOV-1999; 99US-00423844.

PR 30-DEC-1999; 99WO-US031274.

PR 18-FEB-2000; 2000WO-US004341.

PR 01-MAR-2000; 2000WO-US005601.



```
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH ) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-803322/75.
DR P-PSDB; ADI01285.
XX
XX Novel antibody that binds to a PRO polypeptide, useful for treating
PT cancer and in diagnostic assays, for e.g. detecting PRO expression in
PT specific cells, tissues, or serum.
XX
PS Disclosure; Fig 37; 562pp; English.
XX
CC The invention describes an antibody that specifically binds to a PRO
CC polypeptide having a fully defined amino acid sequence given in the
CC specification. The antibody is useful in identifying PRO polypeptides
CC useful for various industrial applications, including pharmaceuticals,
CC diagnostics, biosensors and bioreactors. The antibody is also used for
CC affinity purification of PRO polypeptides from recombinant cell culture
CC or natural sources. The antibody, PRO polypeptide, or its agonists or
CC antagonists, may be used for preparing a medicament for diagnosing or
CC treating a condition responsive to the antibody, PRO polypeptide, or its
CC agonists or antagonists. This sequence encodes a novel human secreted and
CC transmembrane PRO polypeptide.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
Db ||||| ||||| ||||| || ||||| ||||| ||||| ||||| |||||
2653 CCTTTTCTTCCCATCTCTTGACACATTTTAAATAAAGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
Db ||
2773 AA 2774

RESULT 859
ADI01979
ID ADI01979 standard; cDNA; 2846 BP.
XX
```

```
AC ADI01979;
XX
DT 06-MAY-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW antiarthritic; antidiabetic; cytostatic; vulnery; hyperglycaemic;
KW hypoglycaemic; antibody therapy; PRO; secreted and transmembrane;
KW bone disorder; cartilage disorder; sports injury; arthritis;
KW glucose uptake; skeletal muscle; diabetes; hyper-insulinaemia;
KW hypo-insulinaemia; pericyte-associated tumour; wound healing; cancer;
KW chromosome identification; gene therapy; gene; ss; human.
XX
OS Homo sapiens.
XX
PN US2003181652-A1.
XX
PD 25-SEP-2003.
XX
PF 07-MAY-2002; 2002US-00063649.
XX
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH ) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-875165/81.
DR P-PSDB; ADI01980.
XX
PT New isolated PRO polypeptide, useful for treating various bone and/or
PT cartilage disorders, for example, sports injuries and arthritis.
XX
PS Disclosure; SEQ ID NO 37; 397pp; English.
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
```



RESULT 861	
ADII11424	
ID	ADII1424 standard; cDNA; 2846 BP.
XX AC	ADII1424;
XX DT	06-MAY-2004 (first entry)
XX DE	Human PRO polynucleotide #19.
XX KW	Human; PRO; gene; ss; cancer; affinity purification; cytostatic.
XX OS	Homo sapiens.
XX PN	US2003181681-A1.
XX PD	25-SEP-2003.
XX PF	07-MAY-2002; 2002US-00063646.
XX PR	30-DEC-1998; 98KR-00062142.
PR	08-MAR-1999; 99WO-US005028.
PR	14-MAY-1999; 99US-00311832.
PR	14-MAY-1999; 99WO-US010733.
PR	25-AUG-1999; 99US-00380137.
PR	25-AUG-1999; 99US-00380138.
PR	25-AUG-1999; 99US-00380139.
PR	25-AUG-1999; 99US-00380142.
PR	15-SEP-1999; 99US-00397342.
PR	18-OCT-1999; 99US-00403297.
PR	12-NOV-1999; 99US-00423844.
PR	30-DEC-1999; 99WO-US031274.
PR	18-FEB-2000; 2000WO-US004341.
PR	01-MAR-2000; 2000WO-US005601.
PR	02-MAR-2000; 2000WO-US005841.
PR	21-MAR-2000; 2000WO-US007532.
PR	22-MAY-2000; 2000WO-US014042.
PR	02-JUN-2000; 2000WO-US015264.
PR	22-AUG-2000; 2000US-00644848.
PR	24-AUG-2000; 2000WO-US023328.
PR	18-SEP-2000; 2000US-00664610.
PR	18-SEP-2000; 2000US-00665350.
PR	08-NOV-2000; 2000US-00709238.
PR	10-NOV-2000; 2000WO-US030873.
PR	01-DEC-2000; 2000WO-US032678.
PR	20-DEC-2000; 2000US-00747259.
PR	20-DEC-2000; 2000WO-US034956.
PR	28-FEB-2001; 2001WO-US006520.
PR	22-MAR-2001; 2001US-00816744.
PR	10-MAY-2001; 2001US-00854208.
PR	10-MAY-2001; 2001US-00854280.
PR	30-MAY-2001; 2001US-00870574.
PR	01-JUN-2001; 2001WO-US017800.
PR	05-JUN-2001; 2001US-00874503.
PR	29-JUN-2001; 2001US-00869599.
PR	18-JUL-2001; 2001US-00908827.
PR	06-DEC-2001; 2001US-00006867.
XX PA	(GETH ) GENENTECH INC.
XX PI	Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI	Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX WPI	WPI; 2003-898871/82.
DR P-PSDB	P-PSDB; ADII1425.
XX PT	Novel antibody that binds to a PRO polypeptide, useful for treat-
PT	cancer and in diagnostic assays, for e.g. detecting PRO expressi-
PT	specific cells, tissues, or serum.
XX PS	Disclosure; SEQ ID NO 37; 396pp; English.

```

XX
CC The invention relates to an antibody that binds to a human PRO
CC polypeptide. The invention also relates to human PRO polynucleotides
CC encoding the PRO polypeptides of the invention. The antibody is
CC preferably a monoclonal or humanised antibody, or an antibody fragment,
CC and is used to treat cancer. The anti-PRO antibody can be used in
CC diagnostic assays, e.g. for detecting PRO expression in specific cells,
CC tissues or serum. The anti-PRO antibodies are also useful for the
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. This sequence represents a human PRO polynucleotide of the
CC invention.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match          3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGCCTTTACCACCTCTTTCCCTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACCTG 2180
Db 2653 CCGTTTCCTTCCCATCTCTGTGACACATTTTAATAAAAAATAAGGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 862
ADI02326
ID ADI02326 standard; cDNA; 2846 BP.
AC ADI02326;
XX
DT 06-MAY-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW antiarthritic; antidiabetic; cytostatic; vulnerary; hyperglycaemic;
KW hypoglycaemic; antibody therapy; PRO; secreted and transmembrane;
KW bone disorder; cartilage disorder; sports injury; arthritis;
KW glucose uptake; skeletal muscle; diabetes; hyper-insulinaemia;
KW hypo-insulinaemia; pericyte-associated tumour; wound healing; cancer;
KW chromosome identification; gene therapy; gene; ss; human.
XX
OS Homo sapiens.
XX
PN US2003181650-A1.
XX
PD 25-SEP-2003.
XX
PF 07-MAY-2002; 2002US-00063642.
XX
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.

```





```
CC and is used to treat cancer. The anti-PRO antibody can be used in
CC diagnostic assays, e.g. for detecting PRO expression in specific cells,
CC tissues or serum. The anti-PRO antibodies are also useful for the
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. This sequence represents a human PRO polynucleotide of the
CC invention.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match          3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTTACCACTCTTTCTCTTTATCTTATTATAATAAATGTTGGTCTCCACCACTG 2180
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTATAATAAATAGGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
      ||
Db 2773 AA 2774

RESULT 864
ADI05401
ID ADI05401 standard; cDNA; 2846 BP.
XX
AC ADI05401;
XX
DT 06-MAY-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW PRO; human; secreted; transmembrane; antiarthritic; antidiabetic;
KW cytosstatic; vulnery; hyperglycaemic; hypoglycaemic; bone disorder;
KW cartilage disorder; sports injury; arthritis; glucose uptake; diabetes;
KW pericyte-associated tumour; wound healing; cancer; gene therapy; ss;
KW gene.
XX
OS Homo sapiens.
XX
PN US2003190716-A1.
XX
PD 09-OCT-2003.
XX
PF 03-MAY-2002; 2002US-00063617.
XX
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
```

```
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
XX (GETH ) GENENTECH INC.
PA
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
XX WPI; 2003-831627/77.
DR P-PSDB; ADI05402.
XX
PT New isolated PRO polypeptide, useful for treating various bone and/or
PT cartilage disorders, for example, sports injuries and arthritis.
XX
XX Example 4; SEQ ID NO 37; 395pp; English.
XX
CC This invention describes a novel human secreted and transmembrane PRO
CC polypeptide and the polynucleotides encoding it which have antiarthritic,
CC antidiabetic, cytosstatic, vulnery, hyperglycaemic and hypoglycaemic
CC activity. The PRO polypeptides are useful for treating various bone
CC and/or cartilage disorders, for example, sports injuries and arthritis.
CC They are also useful in the therapeutic treatment of disorders where
CC either the stimulation or inhibition of glucose uptake by skeletal muscle
CC would be beneficial, for example, diabetes or hyper- or hypo-
CC insulinemia. They are also useful for treating pericyte-associated
CC tumours and in wound healing. An anti-PRO antibody is useful for the
CC preparation of a medicament useful in the treatment of cancer. The PRO
CC polypeptides are also useful as molecular weight markers, or for
CC chromosome identification. The PRO genes are useful as hybridisation
CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.
CC The PRO genes may also be used in gene therapy, particularly for
CC replacing a defective gene. ADI05365-ADI05532 represent the PRO
CC polynucleotides and polypeptides described in the disclosure of the
CC invention.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match          3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTTACCACTCTTTCTCTTTATCTTATTATAATAAATGTTGGTCTCCACCACTG 2180
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTATAATAAATAGGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
      ||
Db 2773 AA 2774

RESULT 865
ADH79473
ID ADH79473 standard; cDNA; 2846 BP.
XX
AC ADH79473;
XX
DT 06-MAY-2004 (first entry)
```





```
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH ) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-852266/79.
DR P-PSDB; ADI19431.
XX
PT Novel antibody that binds to a PRO polypeptide, useful for treating
PT cancer and in diagnostic assays, for e.g. detecting PRO expression in
PT specific cells, tissues, or serum.
XX
PS Disclosure; SEQ ID NO 37; 396pp; English.
XX
CC The invention relates to a PRO (secreted and transmembrane protein)
CC polynucleotide appearing as ADI19474 encoding PRO polypeptide having
CC appearing as ADI19474. Also included are a vector comprising the novel
CC nucleic acid and a host cell comprising the vector. The polynucleotide is
CC useful in molecular biology, including uses as hybridisation probes, in
CC chromosome and gene mapping, in generating antisense RNA and DNA, and in
CC gene therapy. The polynucleotide may also be used in preparing PRO
CC polypeptides by recombinant techniques, and in generating either
CC transgenic animals or knock-out animals which, in turn, are useful in the
CC development and screening of therapeutically useful reagents. The PRO
CC polynucleotide is used in preparing a medicament for treating a condition
CC responsive to the polypeptide or antibody, such as tumours, and in
CC various diagnostic assays. The specification discloses 84 PRO proteins
CC and 84 PRO polynucleotides. The present sequence encodes a PRO protein.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match          3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTTCTTTTATCTTATTATAATAAATGTTGGTCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CTTTTCCTTCCCATCTCTGTACACATTTTATAATAAATAGGTTGGTCTTCGAACATA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 867
ADI05231
ID ADI05231 standard; cDNA; 2846 BP.
XX
AC ADI05231;
XX
DT 06-MAY-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW PRO; human; secreted; transmembrane; antiarthritic; antidiabetic;
KW cytostatic; vulnery; hyperglycaemic; hypoglycaemic; bone disorder;
KW cartilage disorder; sports injury; arthritis; glucose uptake; diabetes;
KW pericyte-associated tumour; wound healing; cancer; gene therapy; ss;
KW gene.
```

```
XX
OS Homo sapiens.
XX
PN US2003181677-A1.
XX
PD 25-SEP-2003.
XX
PF 03-MAY-2002; 2002US-00063611.
XX
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH ) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-875172/81.
DR P-PSDB; ADI05232.
XX
PT New isolated PRO polypeptide, useful for treating various bone and/or
PT cartilage disorders, for example, sports injuries and arthritis.
XX
PS Example 4; SEQ ID NO 37; 397pp; English.
XX
CC This invention describes a novel human secreted and transmembrane PRO
CC polypeptide and the polynucleotides encoding it which have antiarthritic,
CC antidiabetic, cytostatic, vulnery, hyperglycaemic and hypoglycaemic
CC activity. The PRO polypeptides are useful for treating various bone
CC and/or cartilage disorders, for example, sports injuries and arthritis.
CC They are also useful in the therapeutic treatment of disorders where
CC either the stimulation or inhibition of glucose uptake by skeletal muscle
CC would be beneficial, for example, diabetes or hyper- or hypo-
CC insulinemia. They are also useful for treating pericyte-associated
CC tumours and in wound healing. An anti-PRO antibody is useful for the
CC preparation of a medicament useful in the treatment of cancer. The PRO
CC polypeptides are also useful as molecular weight markers, or for
CC chromosome identification. The PRO genes are useful as hybridisation
```









Db 2773 AA 2774

RESULT 872

ADH79813

ID ADH79813 standard; cDNA; 2846 BP.

XX

AC ADH79813;

XX

DT 06-MAY-2004 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO1344 cDNA.

XX

KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;

KW affinity purification; secreted and transmembrane protein.

XX

OS Homo sapiens.

XX

PN US2003191289-A1.

XX

PD 09-OCT-2003.

XX

PF 07-MAY-2002; 2002US-00063657.

XX

PR 30-DEC-1998; 98KR-00062142.

PR 08-MAR-1999; 99WO-US005028.

PR 14-MAY-1999; 99US-00311832.

PR 14-MAY-1999; 99WO-US010733.

PR 25-AUG-1999; 99US-00380137.

PR 25-AUG-1999; 99US-00380138.

PR 25-AUG-1999; 99US-00380139.

PR 25-AUG-1999; 99US-00380142.

PR 15-SEP-1999; 99US-00397342.

PR 18-OCT-1999; 99US-00403297.

PR 12-NOV-1999; 99US-00423844.

PR 30-DEC-1999; 99WO-US031274.

PR 18-FEB-2000; 2000WO-US004341.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005841.

PR 21-MAR-2000; 2000WO-US007532.

PR 22-MAY-2000; 2000WO-US014042.

PR 02-JUN-2000; 2000WO-US015264.

PR 22-AUG-2000; 2000US-00644848.

PR 24-AUG-2000; 2000WO-US023328.

PR 18-SEP-2000; 2000US-00664610.

PR 18-SEP-2000; 2000US-00665350.

PR 08-NOV-2000; 2000US-00709238.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001WO-US006520.

PR 22-MAR-2001; 2001US-00816744.

PR 10-MAY-2001; 2001US-00854208.

PR 10-MAY-2001; 2001US-00854280.

PR 30-MAY-2001; 2001US-00870574.

PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.

PR 29-JUN-2001; 2001US-00869599.

PR 18-JUL-2001; 2001US-00908827.

PR 06-DEC-2001; 2001US-00006867.

XX

PA (GETH ) GENENTECH INC.

XX

PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX

DR WPI; 2003-803331/75.

DR P-PSDB; ADH79814.

XX

PT Novel antibody that binds to a PRO polypeptide, useful for treating

PT cancer and in diagnostic assays, for e.g. detecting PRO expression in

PT specific cells, tissues, or serum.

XX

PS Disclosure; SEQ ID NO 37; 394pp; English.

XX

CC The invention describes an antibody that specifically binds to a PRO

CC polypeptide having a fully defined amino acid sequence given in the

CC specification. The antibody is useful in identifying PRO polypeptides

CC useful for various industrial applications, including pharmaceuticals,

CC diagnostics, biosensors and bioreactors. The antibody is also used for

CC affinity purification of PRO polypeptides from recombinant cell culture

CC or natural sources. The antibody, PRO polypeptide, or its agonists or

CC antagonists, may be used for preparing a medicament for diagnosing or

CC treating a condition responsive to the antibody, PRO polypeptide, or its

CC agonists or antagonists. This sequence encodes a novel human secreted and

CC transmembrane PRO polypeptide.

XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTATTAATAAAATGTTGGTCTCCCACTG 2180

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAAGGTTGGCTTCTGAAC TA 2712

QY 2181 NCTCCCAA 2240

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

2713 CAAA 2772

QY 2241 AA 2242

Db ||

2773 AA 2774

RESULT 873

ADI04631

ID ADI04631 standard; cDNA; 2846 BP.

XX

AC ADI04631;

XX

DT 06-MAY-2004 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO1344 cDNA.

XX

KW antibody; human; secreted; transmembrane; PRO; cytostatic; cancer; ss;

KW gene.

XX

OS Homo sapiens.

XX

PN US2003171550-A1.

XX

PD 11-SEP-2003.

XX

PF 02-MAY-2002; 2002US-00063526.

XX

PR 30-DEC-1998; 98KR-00062142.

PR 08-MAR-1999; 99WO-US005028.

PR 14-MAY-1999; 99US-00311832.

PR 14-MAY-1999; 99WO-US010733.

PR 25-AUG-1999; 99US-00380137.

PR 25-AUG-1999; 99US-00380138.

PR 25-AUG-1999; 99US-00380139.

PR 25-AUG-1999; 99US-00380142.

PR 15-SEP-1999; 99US-00397342.

PR 18-OCT-1999; 99US-00403297.

PR 12-NOV-1999; 99US-00423844.

PR 30-DEC-1999; 99WO-US031274.

PR 18-FEB-2000; 2000WO-US004341.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005841.

PR 21-MAR-2000; 2000WO-US007532.

PR 22-MAY-2000; 2000WO-US014042.

PR 02-JUN-2000; 2000WO-US015264.

PR 22-AUG-2000; 2000US-00644848.

PR 24-AUG-2000; 2000WO-US023328.

PR 18-SEP-2000; 2000US-00664610.

PR 18-SEP-2000; 2000US-00665350.

PR 08-NOV-2000; 2000US-00709238.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001WO-US006520.

PR 22-MAR-2001; 2001US-00816744.

PR 10-MAY-2001; 2001US-00854208.

PR 10-MAY-2001; 2001US-00854280.

PR 30-MAY-2001; 2001US-00870574.

PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.

PR 29-JUN-2001; 2001US-00869599.

PR 18-JUL-2001; 2001US-00908827.

PR 06-DEC-2001; 2001US-00006867.

XX

PA (GETH ) GENENTECH INC.

XX

PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX

DR WPI; 2003-803331/75.

DR P-PSDB; ADH79814.

XX

PT Novel antibody that binds to a PRO polypeptide, useful for treating

PT cancer and in diagnostic assays, for e.g. detecting PRO expression in

PT specific cells, tissues, or serum.

```
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH ) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-787554/74.
DR P-PSDB; ADI04632.
XX
PT Novel antibody that binds to a PRO polypeptide, useful for treating
PT cancer and in diagnostic assays, for e.g. detecting PRO expression in
PT specific cells, tissues, or serum.
XX
PS Example 4; SEQ ID NO 37; 396pp; English.
XX
CC This invention describes a novel antibody that binds to a human secreted
CC and transmembrane PRO polypeptide which is a monoclonal antibody, a
CC humanised antibody, or antibody fragment and is preferably labelled. The
CC antibody has cytostatic activity and can be used to treat cancer. The
CC anti-PRO antibody can be used in diagnostic assays, for e.g. detecting
CC PRO expression in specific cells, tissues, or serum. The anti-PRO
CC antibodies are also useful for the affinity purification of PRO from
CC recombinant cell culture or natural sources. ADI04595-ADI04762 represent
CC human PRO polynucleotides and polypeptides described in the disclosure of
CC the invention.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match          3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCCTTCCCATCTCTTGACACATTTTAATAAAATAAGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 874
ADI02767
ID ADI02767 standard; cDNA; 2846 BP.
XX
AC ADI02767;
XX
DT 06-MAY-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
```

```
XX
KW antiarthritic; antidiabetic; cytostatic; vulnerary; hyperglycaemic;
KW hypoglycaemic; antibody therapy; PRO; secreted and transmembrane;
KW bone disorder; cartilage disorder; sports injury; arthritis;
KW glucose uptake; skeletal muscle; diabetes; hyper-insulinaemia;
KW hypo-insulinaemia; pericyte-associated tumour; wound healing; cancer;
KW chromosome identification; gene therapy; gene; ss; human.
XX
OS Homo sapiens.
XX
PN US2003181651-A1.
XX
PD 25-SEP-2003.
XX
PF 07-MAY-2002; 2002US-00063644.
XX
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH ) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-875164/81.
DR P-PSDB; ADI02768.
XX
PT New isolated PRO polypeptide, useful for treating various bone and/or
PT cartilage disorders, for example, sports injuries and arthritis.
XX
PS Disclosure; SEQ ID NO 37; 397pp; English.
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide comprising the 642 amino acid sequence (S1) defined in the
CC specification. The PRO polypeptides are useful for treating various bone
CC and/or cartilage disorders, for example, sports injuries and arthritis.
CC They are also useful in the therapeutic treatment of disorders where
CC either the stimulation or inhibition of glucose uptake by skeletal muscle
```













PR	18-FEB-2000; 2000WO-US004341.	ADL32775 standard; cDNA; 2846 BP.	ID
PR	01-MAR-2000; 2000WO-US005601.		XX
PR	02-MAR-2000; 2000WO-US005841.	ADL32775;	AC
PR	21-MAR-2000; 2000WO-US007532.		XX
PR	22-MAY-2000; 2000WO-US014042.	20-MAY-2004 (first entry)	DT
PR	02-JUN-2000; 2000WO-US015264.		XX
PR	22-AUG-2000; 2000US-00644848.	Novel human secreted and transmembrane protein PRO1344 cDNA.	DE
PR	24-AUG-2000; 2000WO-US023328.		XX
PR	18-SEP-2000; 2000US-00664610.	Human; ss; gene; cytostatic; gene therapy; chondrocyte stimulator;	KW
PR	18-SEP-2000; 2000US-00665350.	secreted and transmembrane protein; PRO; chromosome mapping;	KW
PR	08-NOV-2000; 2000US-00709238.	gene mapping; tumour.	KW
PR	10-NOV-2000; 2000WO-US030873.		XX
PR	01-DEC-2000; 2000WO-US032678.	Homo sapiens.	OS
PR	20-DEC-2000; 2000US-00747259.		XX
PR	20-DEC-2000; 2000WO-US034956.	US2003207396-A1.	PN
PR	28-FEB-2001; 2001WO-US006520.		XX
PR	22-MAR-2001; 2001US-00816744.	06-NOV-2003.	PD
PR	10-MAY-2001; 2001US-00854208.		XX
PR	10-MAY-2001; 2001US-00854280.	11-JUL-2002; 2002US-00194486.	PF
PR	30-MAY-2001; 2001US-00870574.		XX
PR	01-JUN-2001; 2001WO-US017800.	05-JUN-2000; 2000US-0209832P.	PR
PR	05-JUN-2001; 2001US-00874503.	28-FEB-2001; 2001WO-US006520.	PR
PR	29-JUN-2001; 2001US-00869599.	15-JAN-2002; 2002US-00052586.	PR
PR	18-JUL-2001; 2001US-00908827.		XX
PR	06-DEC-2001; 2001US-00006867.	(GETH ) GENENTECH INC.	PA
XX			XX
PA	(GETH ) GENENTECH INC.	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;	PI
XX		Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;	PI
PI	Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;		XX
PI	Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;	WPI; 2003-864789/80.	DR
XX		P-PSDB; ADL32776.	DR
DR	WPI; 2003-803329/75.		XX
DR	P-PSDB; ADH79991.	Three hundred and five nucleic acids encoding PRO polypeptides, useful	PT
XX		for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation,	PT
PT	Novel antibody that binds to a PRO polypeptide, useful for treating	particularly for treating e.g. lung or breast tumors, or arthritis in a	PT
PT	cancer and in diagnostic assays, for e.g. detecting PRO expression in	mammal.	XX
PT	specific cells, tissues, or serum.		XX
XX		Claim 2; SEQ ID NO 169; 707pp; English.	PS
PS	Disclosure; SEQ ID NO 37; 394pp; English.		XX
XX		The invention describes 305 nucleic acids encoding PRO polypeptides	CC
CC	The invention describes an antibody that specifically binds to a PRO	(secreted and transmembrane). The polynucleotide is useful in molecular	CC
CC	polypeptide having a fully defined amino acid sequence given in the	biology, including uses as hybridisation probes, in chromosome and gene	CC
CC	specification. The antibody is useful in identifying PRO polypeptides	mapping, in generating antisense RNA and DNA, and in gene therapy. The	CC
CC	useful for various industrial applications, including pharmaceuticals,	polynucleotide may also be used in preparing PRO polypeptides by	CC
CC	diagnostics, biosensors and bioreactors. The antibody is also used for	recombinant techniques, and in generating either transgenic animals or	CC
CC	affinity purification of PRO polypeptides from recombinant cell culture	knock-out animals which, in turn, are useful in the development and	CC
CC	or natural sources. The antibody, PRO polypeptide, or its agonists or	screening of therapeutically useful reagents. The PRO polypeptide or the	CC
CC	antagonists, may be used for preparing a medicament for diagnosing or	antibody is used in preparing a medicament for treating a condition	CC
CC	treating a condition responsive to the antibody, PRO polypeptide, or its	responsive to the polypeptide or antibody, such as tumours, and in	CC
CC	agonists or antagonists. This sequence encodes a novel human secreted and	various diagnostic assays. This sequence encodes a novel human secreted	CC
CC	transmembrane PRO polypeptide.	and transmembrane PRO polypeptide.	CC
XX			XX
SQ	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;	SQ
Query Match 3.0%; Score 66.6; DB 10; Length 2846;			
Best Local Similarity 71.3%; Pred. No. 0.00023;			
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;			
QY	2121 CCTTTGCTTTACCACTCTTTCTTTATCTTTATTAATAAAAAATGTTGGTCTCCACCACTG 2180	2121 CCTTTGCTTTACCACTCTTTCTTTATCTTTATTAATAAAAAATGTTGGTCTCCACCACTG 2180	QY
Db			Db
Db	2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAAATAAGGGTTGGCTTCTGAACTA 2712	2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAAATAAGGGTTGGCTTCTGAACTA 2712	Db
QY	2181 NCTCCCAAA 2240	2181 NCTCCCAAA 2240	QY
Db			Db
QY	2241 AA 2242	2241 AA 2242	QY
Db			Db
Db	2773 AA 2774	2773 AA 2774	Db
RESULT 881			
ADL32775			
RESULT 882			
ADM30309			







```
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
XX (GETH ) GENENTECH INC.
XX
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
XX WPI; 2004-020352/02.
DR P-PSDB; ADC52176.
XX
PT New isolated PRO polypeptide, for use in diagnosing and treating cancer
PT and tumor conditions, in particular stomach, lung, esophageal or kidney
PT tumors, and melanoma.
XX
PS Disclosure; SEQ ID NO 37; 409pp; English.
XX
CC The invention describes an antibody that specifically binds to a PRO
CC polypeptide having a fully defined amino acid sequence given in the
CC specification. The antibody is useful in identifying PRO polypeptides
CC useful for various industrial applications, including pharmaceuticals,
CC diagnostics, biosensors and bioreactors. The antibody is also used for
CC affinity purification of PRO polypeptides from recombinant cell culture
CC or natural sources. The antibody, PRO polypeptide, or its agonists or
CC antagonists, may be used for preparing a medicament for diagnosing or
CC treating a condition responsive to the antibody, PRO polypeptide, or its
CC agonists or antagonists. This sequence encodes a novel human secreted and
CC transmembrane PRO polypeptide.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGGCTTTACCACTCTTTCCTTTTATCTTATTATAAAATGTTGTCCTCCACCACTG 2180
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2653 CCTTTTCCTTCCCATCTCTTGACACATTTTAATAAAATAGGGTTGGCTTCTGAACTA 2712
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 2181 NCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 2241 AA 2242
||
Db 2773 AA 2774

RESULT 885
ADE74306
ID ADE74306 standard; cDNA; 2846 BP.
XX
AC ADE74306;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour; tumour.
XX
OS Homo sapiens.
XX
PN US2003211572-A1.
XX
PD 13-NOV-2003.
XX
PF 18-JUN-2002; 2002US-00174570.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
```

```
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-00631120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
```





PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082569P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 05-MAY-1998; 98US-0083559P.  
PR 06-MAY-1998; 98US-0084366P.  
PR 07-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.

PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 15-SEP-1998; 98US-0100388P.

PR	16-SEP-1998;	98US-0100662P;
PR	16-SEP-1998;	98US-0100664P;
PR	16-SEP-1998;	98US-0101753P.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98US-0100683P.
PR	17-SEP-1998;	98US-0100684P.
PR	17-SEP-1998;	98US-0100919P.
PR	17-SEP-1998;	98US-0100930P.
PR	18-SEP-1998;	98US-0100849P.
PR	18-SEP-1998;	98US-0101014P.
PR	18-SEP-1998;	98US-0101068P.
PR	23-SEP-1998;	98US-0101471P.
PR	23-SEP-1998;	98US-0101472P.
PR	23-SEP-1998;	98US-0101475P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101738P.
PR	24-SEP-1998;	98US-0101739P.
PR	24-SEP-1998;	98US-0101743P.
PR	24-SEP-1998;	98US-0101922P.
PR	25-SEP-1998;	98US-0101786P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
PR	02-OCT-1998;	98US-0102965P.
PR	06-OCT-1998;	98US-0103258P.
PR	06-OCT-1998;	98US-0103449P.

[illegible]

RESULT 887	
ADF35356	
ID	ADF35356 standard; cDNA; 2846 BP.
XX	
AC	ADF35356;
XX	
DT	12-FEB-2004 (first entry)
XX	
DE	cDNA encoding human PRO1344 polypeptide.
XX	
KW	Human; PRO polypeptide; secreted protein; transmembrane protein;
KW	transgenic; tumour; cytostatic; gene therapy; gene; ss.
XX	
OS	Homo sapiens.
XX	
PN	US2003194760-A1.
XX	
PD	16-OCT-2003.
XX	
PF	16-NOV-2001; 2001US-00991150.
XX	
PR	16-JUN-1997; 97US-0049787P.
PR	17-OCT-1997; 97US-0062250P.





```
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 28-AUG-2001; 2001US-00941992.
XX
XX (GETH ) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
XX WPI; 2004-081070/08.
DR P-PSDB; ADG11607.
DR
XX
PT New PRO polypeptide useful in diagnosing or treating cardiac
PT insufficiency disorders, retinal disorders, kidney disorders, obesity,
PT diabetes, cancer, thalassemia, or arthritis.
XX
PS Claim 2; SEQ ID NO 230; 648pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for linking
CC bioactive molecules to cells expressing PRO polypeptides, for modulating
CC biological activities of cells expressing PRO polypeptides, and for
CC identifying agonists or antagonists. The PRO polypeptide or the antibody
CC may be used in preparing a medicament for treating a condition responsive
CC to the polypeptide or antibody, such as tumours, and in various
CC diagnostic assays. The polynucleotide sequences encoding PRO polypeptides
CC are useful as hybridisation probes, in chromosome and gene mapping, in
CC the generation of antisense RNA and DNA, in the preparation of PRO
CC polypeptides, for generating transgenic animals or knockout animals, and
CC in gene therapy. The present sequence encodes a human PRO polypeptide of
CC the invention. Note: The sequence data for this patent was obtained in
CC electronic format directly from the USPTO web site at
CC seqdata.uspto.gov/psipsDIDentry.html.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTCTCTTTTATCTTTATTAATAAAATGTTGCTCTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTCTCTCCCATCTCTGTGTACACATTTTATAAAATAAGGTTGCTCTGAACATA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db ||
2773 AA 2774

RESULT 889
ADF96131
ID ADF96131 standard; cDNA; 2846 BP.
XX
AC ADF96131;
XX
DT 26-FEB-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW Human; ss; gene; cytostatic; gene therapy; chondrocyte stimulator;
KW secreted and transmembrane protein; PRO; chromosome mapping;
KW gene mapping; tumour.
```

```
XX
OS Homo sapiens.
XX
PN US2003215909-A1.
XX
PD 20-NOV-2003.
XX
PF 24-JUN-2002; 2002US-00179523.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-007886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
```







XX ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;  
KW affinity purification; secreted and transmembrane protein.  
XX Homo sapiens.  
XX US2003180852-A1.  
XX 25-SEP-2003.  
XX 08-MAY-2002; 2002US-00063705.  
XX 30-DEC-1998; 98KR-00062142.  
XX 08-MAR-1999; 99WO-US005028.  
XX 14-MAY-1999; 99US-00311832.  
XX 14-MAY-1999; 99WO-US010733.  
XX 25-AUG-1999; 99US-00380137.  
XX 25-AUG-1999; 99US-00380138.  
XX 25-AUG-1999; 99US-00380139.  
XX 25-AUG-1999; 99US-00380142.  
XX 15-SEP-1999; 99US-00397342.  
XX 18-OCT-1999; 99US-00403297.  
XX 12-NOV-1999; 99US-00423844.  
XX 30-DEC-1999; 99WO-US031274.  
XX 18-FEB-2000; 2000WO-US004341.  
XX 01-MAR-2000; 2000WO-US005601.  
XX 02-MAR-2000; 2000WO-US005841.  
XX 21-MAR-2000; 2000WO-US007532.  
XX 22-MAY-2000; 2000WO-US014042.  
XX 22-AUG-2000; 2000US-00644848.  
XX 24-AUG-2000; 2000WO-US023328.  
XX 18-SEP-2000; 2000US-00664610.  
XX 18-SEP-2000; 2000US-00665350.  
XX 08-NOV-2000; 2000US-00709238.  
XX 10-NOV-2000; 2000WO-US030873.  
XX 01-DEC-2000; 2000WO-US032678.  
XX 20-DEC-2000; 2000US-00747259.  
XX 20-DEC-2000; 2000WO-US034956.  
XX 28-FEB-2001; 2001WO-US006520.  
XX 22-MAR-2001; 2001US-00816744.  
XX 10-MAY-2001; 2001US-00854208.  
XX 10-MAY-2001; 2001US-00854280.  
XX 30-MAY-2001; 2001US-00870574.  
XX 01-JUN-2001; 2001WO-US017800.  
XX 05-JUN-2001; 2001US-00874503.  
XX 29-JUN-2001; 2001US-00869599.  
XX 18-JUL-2001; 2001US-00908827.  
XX 06-DEC-2001; 2001US-00006867.  
XX (GETH ) GENENTECH INC.  
XX Baton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;  
XX WPI; 2004-020807/02.  
DR P-PSDB; ADH06608.  
XX New secreted and transmembrane PRO nucleic acid, for use in molecular  
PT biology, chromosome and gene mapping, in generating antisense RNA and  
PT DNA, in various diagnostic assays and in gene therapy.  
XX Disclosure; SEQ ID NO 37; 398pp; English.  
XX The invention relates to a novel PRO (secreted and transmembrane protein)  
CC polypeptide, and the polynucleotide sequence encoding it. Also included  
CC are a vector comprising the novel nucleic acid and a host cell comprising  
CC the vector. The polynucleotide sequence is useful in molecular biology as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA, and in gene therapy. The polynucleotide sequence  
CC may also be used in preparing the PRO polypeptide by recombinant  
CC techniques, and in generating either transgenic or knock-out animals  
CC which, in turn, are useful in the development and screening of

CC therapeutically useful reagents. The PRO polynucleotide sequence is  
CC useful in preparing a medicament for treating a condition responsive to  
CC the polypeptide or antibody, such as tumours, and in various diagnostic  
CC assays. The specification also discloses other PRO proteins and the  
CC polynucleotide sequences encoding them. The present sequence encodes a  
CC PRO protein.  
XX  
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;  
Query Match 3.0%; Score 66.6; DB 12; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;  
QY 2121 CCTTGGCTTTACCACCTCTTTCCTTTTATCTTATTAAATAAAATGTTGGTCTCCACCACCTG 2180  
Db 2653 CCTTTCCTTCCCCATCTCTGTACACATTTTAATAAAATAAGGGTTGGCTTCTGAACCTA 2712  
QY 2181 NCTCCCAA 2240  
Db 2713 CAAA 2772  
QY 2241 AA 2242  
Db 2773 AA 2774  
RESULT 893  
ADH06437  
ID ADH06437 standard; cDNA; 2846 BP.  
XX  
AC ADH06437;  
XX  
DT 11-MAR-2004 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;  
KW affinity purification; secreted and transmembrane protein.  
KW  
XX Homo sapiens.  
XX US2003180853-A1.  
XX 25-SEP-2003.  
XX 08-MAY-2002; 2002US-00063707.  
XX 30-DEC-1998; 98KR-00062142.  
XX 08-MAR-1999; 99WO-US005028.  
XX 14-MAY-1999; 99US-00311832.  
XX 14-MAY-1999; 99WO-US010733.  
XX 25-AUG-1999; 99US-00380137.  
XX 25-AUG-1999; 99US-00380138.  
XX 25-AUG-1999; 99US-00380139.  
XX 25-AUG-1999; 99US-00380142.  
XX 15-SEP-1999; 99US-00397342.  
XX 18-OCT-1999; 99US-00403297.  
XX 12-NOV-1999; 99US-00423844.  
XX 30-DEC-1999; 99WO-US031274.  
XX 18-FEB-2000; 2000WO-US004341.  
XX 01-MAR-2000; 2000WO-US005601.  
XX 02-MAR-2000; 2000WO-US005841.  
XX 21-MAR-2000; 2000WO-US007532.  
XX 22-MAY-2000; 2000WO-US014042.  
XX 02-JUN-2000; 2000WO-US015264.  
XX 22-AUG-2000; 2000US-00644848.  
XX 24-AUG-2000; 2000WO-US023328.  
XX 18-SEP-2000; 2000US-00664610.  
XX 18-SEP-2000; 2000US-00665350.  
XX 08-NOV-2000; 2000US-00709238.  
XX 10-NOV-2000; 2000WO-US030873.  
XX 01-DEC-2000; 2000WO-US032678.  
XX 20-DEC-2000; 2000US-00747259.

```
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
'DR WPI; 2004-020808/02.
DR P-PSDB; ADH06438.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in molecular biology, chromosome and gene mapping, in generating
PT antisense RNA and DNA, in various diagnostic assays and in gene therapy.
XX
PS Disclosure; SEQ ID NO 37; 398pp; English.
XX
CC The invention relates to a novel PRO (secreted and transmembrane protein)
CC polypeptide, and the polynucleotide sequence encoding it. Also included
CC are a vector comprising the novel nucleic acid and a host cell comprising
CC the vector. The polynucleotide sequence is useful in molecular biology as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, and in gene therapy. The polynucleotide sequence
CC may also be used in preparing the PRO polypeptide by recombinant
CC techniques, and in generating either transgenic or knock-out animals
CC which, in turn, are useful in the development and screening of
CC therapeutically useful reagents. The PRO polynucleotide sequence is
CC useful in preparing a medicament for treating a condition responsive to
CC the polypeptide or antibody, such as tumours, and in various diagnostic
CC assays. The specification also discloses other PRO proteins and the
CC polynucleotide sequences encoding them. The present sequence encodes a
CC PRO protein.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match          3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACCTCTTCCCTTTTATCTTATTATAATAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAATAAGGTTGGCTTCTGAACATA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 894
ADG68858
ID ADG68858 standard; cDNA; 2846 BP.
XX
AC ADG68858;
XX
DT 11-MAR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW affinity purification; secreted and transmembrane protein.
```

```
XX OS Homo sapiens.
XX PN US2003180855-A1.
XX PD 25-SEP-2003.
XX PF 08-MAY-2002; 2002US-00063713.
XX PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH ) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2004-020810/02.
DR P-PSDB; ADG68859.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in molecular biology, chromosome and gene mapping, in generating
PT antisense RNA and DNA, in various diagnostic assays and in gene therapy.
XX
PS Disclosure; SEQ ID NO 37; 398pp; English.
XX
CC The invention relates to a PRO (secreted and transmembrane protein)
CC polynucleotide appearing as ADG68902 encoding PRO polypeptide having
CC appearing as ADG68902. Also included are a vector comprising the novel
CC nucleic acid and a host cell comprising the vector. The polynucleotide is
CC useful in molecular biology, including uses as hybridisation probes, in
CC chromosome and gene mapping, in generating antisense RNA and DNA, and in
CC gene therapy. The polynucleotide may also be used in preparing PRO
CC polypeptides by recombinant techniques, and in generating either
CC transgenic animals or knock-out animals which, in turn, are useful in the
CC development and screening of therapeutically useful reagents. The PRO
CC polynucleotide is used in preparing a medicament for treating a condition
CC responsive to the polypeptide or antibody, such as tumours, and in
```





PD 25-SEP-2003.

XX 08-MAY-2002; 2002US-00063714.

PF 30-DEC-1998; 98KR-00062142.

XX 08-MAR-1999; 99WO-US005028.

PR 14-MAY-1999; 99US-00311832.

PR 14-MAY-1999; 99WO-US010733.

PR 25-AUG-1999; 99US-00380137.

PR 25-AUG-1999; 99US-00380138.

PR 25-AUG-1999; 99US-00380139.

PR 25-AUG-1999; 99US-00380142.

PR 15-SEP-1999; 99US-00397342.

PR 18-OCT-1999; 99US-00403297.

PR 12-NOV-1999; 99US-00423844.

PR 30-DEC-1999; 99WO-US031274.

PR 18-FEB-2000; 2000WO-US004341.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005841.

PR 21-MAR-2000; 2000WO-US007532.

PR 22-MAY-2000; 2000WO-US014042.

PR 02-JUN-2000; 2000WO-US015264.

PR 22-AUG-2000; 2000US-00644848.

PR 24-AUG-2000; 2000WO-US023328.

PR 18-SEP-2000; 2000US-00664610.

PR 18-SEP-2000; 2000US-00665350.

PR 08-NOV-2000; 2000US-00709238.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.

PR 28-FEB-2001; 2000WO-US034956.

PR 22-MAR-2001; 2001WO-US006520.

PR 10-MAY-2001; 2001US-00816744.

PR 10-MAY-2001; 2001US-00854208.

PR 30-MAY-2001; 2001US-00870574.

PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.

PR 29-JUN-2001; 2001US-00869599.

PR 18-JUL-2001; 2001US-00908827.

PR 06-DEC-2001; 2001US-00006867.

XX (GETH ) GENENTECH INC.

XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX WPI; 2004-020826/02.

DR P-PSDB; ADH25090.

XX New nucleic acids encoding PRO polypeptides, useful in diagnosing and treating disorders that affect glucose or free fatty acid in skeletal muscle, such as diabetes, hypoinsulinemia or hyperinsulinemia.

XX Disclosure; SEQ ID NO 37; 398pp; English.

XX The invention describes an isolated PRO (secreted and transmembrane) polypeptide comprising the 642 amino acid sequence (S1) defined in the specification. The PRO polypeptides are useful for treating various bone and/or cartilage disorders, for example, sports injuries and arthritis. They are also useful in the therapeutic treatment of disorders where either the stimulation or inhibition of glucose uptake by skeletal muscle would be beneficial, for example, diabetes or hyper- or hypo-insulinaemia. They are also useful for treating pericyte-associated tumours and in wound healing. The anti-PRO antibody is useful for the preparation of a medicament useful in the treatment of cancer. The PRO polypeptides are also useful as molecular weight markers, or for chromosome identification. The PRO genes are useful as hybridisation probes, or for screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. This sequence encodes a secreted and transmembrane PRO protein.

XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACCTCTTTCCTTTTATCTTTATTTAATAAAAAATGTTGGTCTCCACCACTG 2180

Db 2653 CCTTTTCCTTCCCATCTCTGTACACATTTTAAATAAAATAAGGGTTGGCTTCTGAACTA 2712

Qy 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 897

ADH33721

ID ADH33721 standard; cDNA; 2846 BP.

XX

AC ADH33721;

XX 11-MAR-2004 (first entry)

DE Human PRO polynucleotide #19.

XX

KW Human; PRO; gene; ss; tumour necrosis factor-alpha; TNF-alpha; blood;

KW chondrocyte cell; tumour; cancer.

XX

OS Homo sapiens.

XX

PN US2003181645-A1.

XX

PD 25-SEP-2003.

XX

PF 03-MAY-2002; 2002US-00063604.

XX

PR 30-DEC-1998; 98KR-00062142.

PR 08-MAR-1999; 99WO-US005028.

PR 14-MAY-1999; 99US-00311832.

PR 14-MAY-1999; 99WO-US010733.

PR 25-AUG-1999; 99US-00380137.

PR 25-AUG-1999; 99US-00380138.

PR 25-AUG-1999; 99US-00380139.

PR 25-AUG-1999; 99US-00380142.

PR 15-SEP-1999; 99US-00397342.

PR 18-OCT-1999; 99US-00403297.

PR 12-NOV-1999; 99US-00423844.

PR 30-DEC-1999; 99WO-US031274.

PR 18-FEB-2000; 2000WO-US004341.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005841.

PR 21-MAR-2000; 2000WO-US007532.

PR 22-MAY-2000; 2000WO-US014042.

PR 02-JUN-2000; 2000WO-US015264.

PR 22-AUG-2000; 2000US-00644848.

PR 24-AUG-2000; 2000WO-US023328.

PR 18-SEP-2000; 2000US-00664610.

PR 18-SEP-2000; 2000US-00665350.

PR 08-NOV-2000; 2000US-00709238.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.

PR 20-DEC-2000; 2000US-00747259.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001WO-US006520.

PR 22-MAR-2001; 2001US-00816744.

PR 10-MAY-2001; 2001US-00854208.

PR 10-MAY-2001; 2001US-00854280.

PR 30-MAY-2001; 2001US-00870574.

PR 01-JUN-2001; 2001WO-US017800.



ADH02364	standard; cDNA; 2846 BP.
ADH02364;	
11-MAR-2004	(first entry)
Human PRO	polynucleotide #19.
Human; PRO; gene; ss;	tumour necrosis factor-alpha; TNF-alpha; blood;
chondrocyte cell;	tumour; cancer.
Homo sapiens.	
US2003180839-A1.	
25-SEP-2003.	
07-MAY-2002;	2002US-00063670.
30-DEC-1998;	98KR-00062142.
08-MAR-1999;	99WO-US005028.
14-MAY-1999;	99US-00311832.
14-MAY-1999;	99WO-US010733.
25-AUG-1999;	99US-00380137.
25-AUG-1999;	99US-00380138.
25-AUG-1999;	99US-00380139.
25-AUG-1999;	99US-00380142.
15-SEP-1999;	99US-00397342.
18-OCT-1999;	99US-00403297.
12-NOV-1999;	99US-00423844.
30-DEC-1999;	99WO-US031274.
18-FEB-2000;	2000WO-US004341.
01-MAR-2000;	2000WO-US005601.
02-MAR-2000;	2000WO-US005841.
21-MAR-2000;	2000WO-US007532.
22-MAY-2000;	2000WO-US014042.
02-JUN-2000;	2000WO-US015264.
22-AUG-2000;	2000US-00644848.
24-AUG-2000;	2000WO-US023328.
18-SEP-2000;	2000US-00664610.
18-SEP-2000;	2000US-00665350.
08-NOV-2000;	2000US-00709238.
10-NOV-2000;	2000WO-US030873.
01-DEC-2000;	2000WO-US032678.
20-DEC-2000;	2000US-00747259.
20-DEC-2000;	2000WO-US034956.
28-FEB-2001;	2001WO-US006520.
22-MAR-2001;	2001US-00816744.
10-MAY-2001;	2001US-00854208.
10-MAY-2001;	2001US-00854280.
30-MAY-2001;	2001US-00870574.
01-JUN-2001;	2001WO-US017800.
05-JUN-2001;	2001US-00874503.
29-JUN-2001;	2001US-00869599.
18-JUL-2001;	2001US-00908827.
06-DEC-2001;	2001US-00006867.
(GETH )	GENENTECH INC.
Eaton DL, Filvaroff E,	Gerritsen ME, Goddard A, Godowski PJ;
Grimaldi JC, Gurney AL,	Watanabe CK, Wood WI;
WPI; 2004-020796/02.	
P-PSDB; ADH02365.	
New PRO polypeptide	and nucleic acid encoding the polypeptides, useful in
gene therapy, chromosome	identification, tissue typing, or as
hybridization probes	in chromosome and gene mapping.
Disclosure; SEQ ID NO	37; 398pp; English.
The invention relates	to human PRO polypeptides and the PRO
polynucleotides	encoding them. The invention also relates to an antibody

that specifically binds to the polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal comprising comparing the level of expression of any PRO polypeptide, given in the specification, in a test sample of cells taken from the mammal with a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptide in the test sample as compared to the control sample indicates the presence of a tumour in the mammal. The polynucleotides are useful as hybridisation probes in chromosome and gene mapping or in generating antisense RNA and DNA, for preparing PRO polypeptides, in assays to identify other proteins or molecules involved in binding reactions, to generate transgenic animals or knockout animals, which in turn are useful in the development and screening of therapeutically useful reagents, for chromosome identification and in tissue typing. The PRO polypeptides and polynucleotides are also useful in gene therapy and as molecular weight markers for protein electrophoresis. The anti-PRO antibodies may be used in diagnostic assays for PRO or for the affinity purification of PRO from recombinant cell culture or natural sources. This sequence represents a human PRO polynucleotide of the invention.

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

```
Query Match      3.0%;      Score 66.6;  DB 12;      Length 2846;
Best Local Similarity 71.3%;      Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
```

Qy	2121	CCTTTGCTTTACCACTCTTTCCTTTTATCTATTATAAAAAAAGTTGGTCTCCACCACGTG	2180
Dδ	2653	CCTTTTCCTTCCCACATCTCTTGTAACAATTTAAATAAAAATGAAGGGTTCCTGAACATA	2712

[illegible]

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 900

ADH07971

ID ADH07971 standard; cDNA; 2846 BP.

AC ADH07971;

DT 11-MAR-2004 (first entry)

DE Novel human secreted and transmembrane protein PRO1344 cDNA.

ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;  
KW affinity purification; secreted and transmembrane protein.

OS Homo sapiens.

PN US2003180845-A1.

PD 25-SEP-2003.

PF 08-MAY-2002; 2002US-00063689.

PR 30-DEC-1998; 98KR-00062142.

PR 08-MAR-1999; 99WO-US005028.

PR 14-MAY-1999; 99US-00311832.

PR 14-MAY-1999; 99WO-US010733.

PR 25-AUG-1999; 99US-00380137.  
 PR 25-AUG-1999; 99US-00380138  
 PR 25-AUG-1999; 99US-00380139

PR 25-AUG-1999; 99US=00380138.  
PR 25-AUG-1999: 99US=00380139

PK 23-AUG-1999; 99US-00380139;  
PK 25-AUG-1999; 99US-00380142;  
PK 25-AUG-1999; 99US-00380142;

PR 99US-00397342.  
15-SEP-1999;  
23-SEP-1999;

PR 18-OCT-1999; 99US-00403297.

PR 12-NOV-1999; 99US-00423844.



PR	30-DEC-1999;	99WO-US031274;
PR	18-FEB-2000;	2000WO-US004341;
PR	01-MAR-2000;	2000WO-US005601;
PR	02-MAR-2000;	2000WO-US005841;
PR	21-MAR-2000;	2000WO-US007532;
PR	22-MAY-2000;	2000WO-US014042;
PR	02-JUN-2000;	2000WO-US015264;
PR	22-AUG-2000;	2000US-00644848;
PR	24-AUG-2000;	2000WO-US023328;
PR	18-SEP-2000;	2000US-00664610;
PR	18-SEP-2000;	2000US-00665350;
PR	08-NOV-2000;	2000US-00709238;
PR	10-NOV-2000;	2000WO-US030873;
PR	01-DEC-2000;	2000WO-US032678;
PR	20-DEC-2000;	2000US-00747259;
PR	20-DEC-2000;	2000WO-US0043956;
PR	28-FEB-2001;	2001WO-US006520;
PR	22-MAR-2001;	2001US-00816744;
PR	10-MAY-2001;	2001US-00854208;
PR	10-MAY-2001;	2001US-00854280;
PR	30-MAY-2001;	2001US-00870574;
PR	01-JUN-2001;	2001WO-US017800;
PR	05-JUN-2001;	2001US-00874503;
PR	29-JUN-2001;	2001US-00869599;
PR	18-JUL-2001;	2001US-00908827;
PR	06-DEC-2001;	2001US-00006867;

The invention relates to a novel PRO (secreted and transmembrane protein) polypeptide, and the polynucleotide sequence encoding it. Also included are a vector comprising the novel nucleic acid and a host cell comprising the vector. The polynucleotide sequence is useful in molecular biology as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy. The polynucleotide sequence may also be used in preparing the PRO polypeptide by recombinant techniques, and in generating either transgenic or knock-out animals which, in turn, are useful in the development and screening of therapeutically useful reagents. The PRO polynucleotide sequence is useful in preparing a medicament for treating a condition responsive to the polypeptide or antibody, such as tumours, and in various diagnostic assays. The specification also discloses other PRO proteins and the polynucleotide sequences encoding them. The present sequence encodes a PRO protein.

Db 2773 AA 2774

RESULT 901  
ADG69368

ID ADG69368 standard; cDNA; 2846 BP.

XX AC ADG69368;

XX DT 11-MAR-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.

XX DE ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;

KW affinity purification; secreted and transmembrane protein.

KW KW Homo sapiens.

XX OS US2003180846-A1.

XX PN 25-SEP-2003.

XX PD 08-MAY-2002; 2002US-00063692.

XX PF 30-DEC-1998; 98KR-00062142.

XX PR 08-MAR-1999; 99WO-US005028.

PR 14-MAY-1999; 99US-00311832.

PR 14-MAY-1999; 99WO-US010733.

PR 25-AUG-1999; 99US-00380137.

PR 25-AUG-1999; 99US-00380138.

PR 25-AUG-1999; 99US-00380139.

PR 25-AUG-1999; 99US-00380142.

PR 15-SEP-1999; 99US-00397342.

PR 18-OCT-1999; 99US-00403297.

PR 12-NOV-1999; 99US-00423844.

PR 30-DEC-1999; 99WO-US031274.

PR 18-FEB-2000; 2000WO-US004341.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005841.

PR 21-MAR-2000; 2000WO-US007532.

PR 22-MAY-2000; 2000WO-US014042.

PR 02-JUN-2000; 2000WO-US015264.

PR 22-AUG-2000; 2000US-00644848.

PR 24-AUG-2000; 2000WO-US023328.

PR 18-SEP-2000; 2000US-00664610.

PR 18-SEP-2000; 2000US-00665350.

PR 08-NOV-2000; 2000US-00709238.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001WO-US006520.

PR 22-MAR-2001; 2001US-00816744.

PR 10-MAY-2001; 2001US-00854208.

PR 10-MAY-2001; 2001US-00854280.

PR 30-MAY-2001; 2001US-00870574.

PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.

PR 29-JUN-2001; 2001US-00869599.

PR 18-JUL-2001; 2001US-00908827.

PR 06-DEC-2001; 2001US-00006867.

XX XX

PA (GETH ) GENENTECH INC.

XX PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX WPI; 2004-020803/02.

DR P-PSDB; ADG69369.

XX

PT New secreted and transmembrane PRO nucleic acid, for use in molecular

PT biology, chromosome and gene mapping, in generating antisense RNA and

PT DNA, in various diagnostic assays and in gene therapy.

XX Claim 1; SEQ ID NO 37; 398pp; English.

XX The invention relates to a PRO (secreted and transmembrane protein)

CC polynucleotide appearing as ADG69412 encoding PRO polypeptide having

CC appearing as ADG69412. Also included are a vector comprising the novel

CC nucleic acid and a host cell comprising the vector. The polynucleotide is

CC useful in molecular biology, including uses as hybridisation probes, in

CC chromosome and gene mapping, in generating antisense RNA and DNA, and in

CC gene therapy. The polynucleotide may also be used in preparing PRO

CC polypeptides by recombinant techniques, and in generating either

CC transgenic animals or knock-out animals which, in turn, are useful in the

CC development and screening of therapeutically useful reagents. The PRO

CC polynucleotide is used in preparing a medicament for treating a condition

CC responsive to the polypeptide or antibody, such as tumours, and in

CC various diagnostic assays. The specification discloses 84 PRO proteins

CC and 84 PRO polynucleotides. The present sequence encodes a PRO protein.

XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180

Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAACATA 2712

Qy 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 902

ADH39189

ID ADH39189 standard; cDNA; 2846 BP.

XX

AC ADH39189;

DT 11-MAR-2004 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO1344 cDNA.

XX

KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;

KW affinity purification; secreted and transmembrane protein.

XX

OS Homo sapiens.

XX

PN US2003180917-A1.

XX

PD 25-SEP-2003.

XX

PF 08-MAY-2002; 2002US-00063720.

XX

PR 30-DEC-1998; 98KR-00062142.

PR 08-MAR-1999; 99WO-US005028.

PR 14-MAY-1999; 99US-00311832.

PR 14-MAY-1999; 99WO-US010733.

PR 25-AUG-1999; 99US-00380137.

PR 25-AUG-1999; 99US-00380138.

PR 25-AUG-1999; 99US-00380139.

PR 25-AUG-1999; 99US-00380142.

PR 15-SEP-1999; 99US-00397342.

PR 18-OCT-1999; 99US-00403297.

PR 12-NOV-1999; 99US-00423844.

PR 30-DEC-1999; 99WO-US031274.

PR 18-FEB-2000; 2000WO-US004341.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005841.

PR 21-MAR-2000; 2000WO-US007532.

PR 22-MAY-2000; 2000WO-US014042.

PR 02-JUN-2000; 2000WO-US015264.

PR 22-AUG-2000; 2000US-00644848.

PR 24-AUG-2000; 2000WO-US023328.

PR 18-SEP-2000; 2000US-00664610.

PR 18-SEP-2000; 2000US-00665350.

PR 08-NOV-2000; 2000US-00709238.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001WO-US006520.

PR 22-MAR-2001; 2001US-00816744.

PR 10-MAY-2001; 2001US-00854208.

PR 10-MAY-2001; 2001US-00854280.

PR 30-MAY-2001; 2001US-00870574.

PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.

PR 29-JUN-2001; 2001US-00869599.

PR 18-JUL-2001; 2001US-00908827.

PR 06-DEC-2001; 2001US-00006867.

XX (GETH ) GENENTECH INC.

PA

XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX

DR WPI; 2004-020829/02.

DR P-PSDB; ADH39190.

XX

PT New PRO nucleic acid, useful for preparing a medicament for treating a

PT condition associated with a PRO nucleic acid e.g., cancer, by gene

PT therapy.

XX

PS Disclosure; SEQ ID NO 37; 396pp; English.

XX

CC The invention relates to a novel PRO (secreted and transmembrane protein)

CC polypeptide, and the polynucleotide sequence encoding it. Also included

CC are a vector comprising the novel nucleic acid and a host cell comprising

CC the vector. The polynucleotide sequence is useful in molecular biology as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA, and in gene therapy. The polynucleotide sequence

CC may also be used in preparing the PRO polypeptide by recombinant

CC techniques, and in generating either transgenic or knock-out animals

CC which, in turn, are useful in the development and screening of

CC therapeutically useful reagents. The PRO polynucleotide sequence is

CC useful in preparing a medicament for treating a condition responsive to

CC the polypeptide or antibody, such as tumours, and in various diagnostic

CC assays. The specification also discloses other PRO proteins and the

CC polynucleotide sequences encoding them. The present sequence encodes a

CC PRO protein.

XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180

Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAACATA 2712

Qy 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 903

ADH26099	ADH26099 standard; cDNA; 2846 BP.	ID	ADG83929 standard; cDNA; 2846 BP.
XX	ADH26099;	XX	ADG83929;
AC	ADH26099;	AC	
XX		XX	
DT	11-MAR-2004 (first entry)	DT	11-MAR-2004 (first entry)
XX		XX	Human PRO polynucleotide #19.
DE	Novel human secreted and transmembrane protein PRO1344 cDNA.	DE	
XX		XX	
KW	Human; ss; gene; cytostatic; gene therapy; chondrocyte stimulator;	KW	Human; PRO; gene; ss; tumour necrosis factor-alpha; TNF-alpha; blood;
KW	secreted and transmembrane protein; PRO; chromosome mapping;	KW	chondrocyte cell; tumour; cancer.
KW	gene mapping; tumour.	XX	
XX		OS	Homo sapiens.
OS	Homo sapiens.	XX	
XX		PN	US2003180842-A1.
XX		XX	
PN	US2003068770-A1.	PD	25-SEP-2003.
XX		XX	
PD	10-APR-2003.	XX	
XX		PF	07-MAY-2002; 2002US-00063675.
XX		XX	
PF	29-JUL-2002; 2002US-00207925.	PR	30-DEC-1998; 98KR-00062142.
XX		PR	08-MAR-1999; 99WO-US005028.
XX		PR	14-MAY-1999; 99US-00311832.
PR	29-MAR-2000; 2000US-0193032P.	PR	14-MAY-1999; 99WO-US010733.
PR	28-FEB-2001; 2001WO-US006520.	PR	25-AUG-1999; 99US-00380137.
PR	15-JAN-2002; 2002US-00052586.	PR	25-AUG-1999; 99US-00380138.
XX		PR	25-AUG-1999; 99US-00380139.
PA	(GETH ) GENENTECH INC.	PR	25-AUG-1999; 99US-00380142.
XX		PR	15-SEP-1999; 99US-00397342.
PI	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;	PR	18-OCT-1999; 99US-00403297.
PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;	PR	12-NOV-1999; 99US-00423844.
XX		PR	30-DEC-1999; 99WO-US031274.
DR	WPI; 2004-080156/08.	PR	18-FEB-2000; 2000WO-US004341.
DR	P-PSDB; ADH26100.	PR	01-MAR-2000; 2000WO-US005601.
XX		PR	02-MAR-2000; 2000WO-US005841.
PT	Isolated secreted and transmembrane PRO nucleic acids and polypeptides,	PR	21-MAR-2000; 2000WO-US007532.
PT	useful for preventing, diagnosing and treating disorders associated with	PR	22-MAY-2000; 2000WO-US014042.
PT	their aberrant expression.	PR	02-JUN-2000; 2000WO-US015264.
XX		PR	22-AUG-2000; 2000US-00644848.
PS	Claim 2; SEQ ID NO 169; 1pp; English.	PR	24-AUG-2000; 2000WO-US023328.
XX		PR	18-SEP-2000; 2000US-00664610.
CC	The invention describes 305 nucleic acids encoding PRO polypeptides	PR	18-SEP-2000; 2000US-00665350.
CC	(secreted and transmembrane). The polynucleotide is useful in molecular	PR	08-NOV-2000; 2000US-00709238.
CC	biology, including uses as hybridisation probes, in chromosome and gene	PR	10-NOV-2000; 2000WO-US030873.
CC	mapping, in generating antisense RNA and DNA, and in gene therapy. The	PR	01-DEC-2000; 2000WO-US032678.
CC	polynucleotide may also be used in preparing PRO polypeptides by	PR	20-DEC-2000; 2000US-00747259.
CC	recombinant techniques, and in generating either transgenic animals or	PR	20-DEC-2000; 2000WO-US034956.
CC	knock-out animals which, in turn, are useful in the development and	PR	28-FEB-2001; 2001WO-US006520.
CC	screening of therapeutically useful reagents. The PRO polypeptide or the	PR	22-MAR-2001; 2001US-00816744.
CC	antibody is used in preparing a medicament for treating a condition	PR	10-MAY-2001; 2001US-00854208.
CC	responsive to the polypeptide or antibody, such as tumours, and in	PR	10-MAY-2001; 2001US-00854280.
CC	various diagnostic assays. This sequence encodes a novel human secreted	PR	30-MAY-2001; 2001US-00870574.
CC	and transmembrane PRO polypeptide.	PR	01-JUN-2001; 2001WO-US017800.
XX		PR	05-JUN-2001; 2001US-00874503.
SQ	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;	PR	29-JUN-2001; 2001US-00869599.
		PR	18-JUL-2001; 2001US-00908827.
		PR	06-DEC-2001; 2001US-00006867.
		XX	
		PA	(GETH ) GENENTECH INC.
		XX	
		XX	Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
		PI	Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
		PI	
		XX	
		DR	WPI; 2004-020799/02.
		DR	P-PSDB; ADG83930.
		XX	
		PT	New PRO polypeptide and nucleic acid encoding the polypeptide, for use in
		PT	gene therapy, chromosome identification, tissue typing, or as
		PT	hybridization probes in chromosome and gene mapping.
		XX	
		PS	Disclosure; SEQ ID NO 37; 398pp; English.
		XX	
		CC	The invention relates to human PRO polypeptides and the PRO
		CC	polynucleotides encoding them. The invention also relates to an antibody







```
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH ) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2004-020809/02.
DR P-PSDB; ADH06268.
XX
PT New PRO polypeptide and nucleic acid encoding the polypeptide, for use in
PT gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX
PS Disclosure; SEQ ID NO 37; 398pp; English.
XX
CC The invention relates to a novel PRO (secreted and transmembrane protein)
CC polypeptide, and the polynucleotide sequence encoding it. Also included
CC are a vector comprising the novel nucleic acid and a host cell comprising
CC the vector. The polynucleotide sequence is useful in molecular biology as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, and in gene therapy. The polynucleotide sequence
CC may also be used in preparing the PRO polypeptide by recombinant
CC techniques, and in generating either transgenic or knock-out animals
CC which, in turn, are useful in the development and screening of
CC therapeutically useful reagents. The PRO polynucleotide sequence is
CC useful in preparing a medicament for treating a condition responsive to
CC the polypeptide or antibody, such as tumours, and in various diagnostic
CC assays. The specification also discloses other PRO proteins and the
CC polynucleotide sequences encoding them. The present sequence encodes a
CC PRO protein.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match      3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCCCTTTATCTTATTAATAAATAATGTTGGTCTCCCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTCTCTCCCATCTCTGTACACATTTTAATAAATAAGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
Db ||
2773 AA 2774

RESULT 908
ADH30097
ID ADH30097 standard; cDNA; 2846 BP.
XX
AC ADH30097;
XX
DT 11-MAR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW affinity purification; secreted and transmembrane protein.
XX
```

```
XX OS Homo sapiens.
XX PN US2003180856-A1.
XX PD 25-SEP-2003.
XX PF 08-MAY-2002; 2002US-00063724.
XX PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH ) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2004-020811/02.
DR P-PSDB; ADH30098.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in molecular biology, chromosome and gene mapping, in generating
PT antisense RNA and DNA, in various diagnostic assays and in gene therapy.
XX
PS Disclosure; SEQ ID NO 37; 398pp; English.
XX
CC The invention describes an antibody that specifically binds to a PRO
CC polypeptide having a fully defined amino acid sequence given in the
CC specification. The antibody is useful in identifying PRO polypeptides,
CC useful for various industrial applications, including pharmaceuticals,
CC diagnostics, biosensors and bioreactors. The antibody is also used for
CC affinity purification of PRO polypeptides from recombinant cell culture
CC or natural sources. The antibody, PRO polypeptide, or its agonists or
CC antagonists, may be used for preparing a medicament for diagnosing or
CC treating a condition responsive to the antibody, PRO polypeptide, or its
CC agonists or antagonists. This sequence encodes a novel human secreted and
CC transmembrane PRO polypeptide.
XX
```



```
SQ      Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

      Query Match          3.0%; Score 66.6; DB 12; Length 2846;
      Best Local Similarity 71.3%; Pred. No. 0.00023;
      Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY      2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAAAATGGTGTCTCCACCACTG 2180
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db      2653 CCTTTTCCTTCCCATCTCTTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAACTA 2712

QY      2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db      2713 CAAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY      2241 AA 2242
      ||
Db      2773 AA 2774

RESULT 909
ADH24409
ID      ADH24409 standard; cDNA; 2846 BP.
XX
AC      ADH24409;
XX
DT      11-MAR-2004 (first entry)
XX
DE      Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW      cytosstatic; antidiabetic; antiarthritic; osteopathic; antirheumatic;
KW      human; secreted and transmembrane; PRO; PRO180; PRO218; PRO263; PRO295;
KW      PRO874; PRO300; PRO1864; PRO1282; PRO1063; PRO1773; cancer; diabetes;
KW      osteoarthritis; rheumatoid arthritis; PRO1063; chromosome mapping; gene mapping;
KW      chromosome identification; tissue typing; gene; ss.
XX
OS      Homo sapiens.
XX
PN      US2003180910-A1.
XX
PD      25-SEP-2003.
XX
PF      08-MAY-2002; 2002US-00063710.
XX
PR      30-DEC-1998; 98XR-00062142.
PR      08-MAR-1999; 99WO-US005028.
PR      14-MAY-1999; 99US-00311832.
PR      14-MAY-1999; 99WO-US010733.
PR      25-AUG-1999; 99US-00380137.
PR      25-AUG-1999; 99US-00380138.
PR      25-AUG-1999; 99US-00380139.
PR      25-AUG-1999; 99US-00380142.
PR      15-SEP-1999; 99US-00397342.
PR      18-OCT-1999; 99US-00403297.
PR      12-NOV-1999; 99US-00423844.
PR      30-DEC-1999; 99WO-US031274.
PR      18-FEB-2000; 2000WO-US004341.
PR      01-MAR-2000; 2000WO-US005601.
PR      02-MAR-2000; 2000WO-US005841.
PR      21-MAR-2000; 2000WO-US007532.
PR      22-MAY-2000; 2000WO-US014042.
PR      02-JUN-2000; 2000WO-US015264.
PR      22-AUG-2000; 2000US-00644848.
PR      24-AUG-2000; 2000WO-US023328.
PR      18-SEP-2000; 2000US-00664610.
PR      18-SEP-2000; 2000US-00665350.
PR      08-NOV-2000; 2000US-00709238.
PR      10-NOV-2000; 2000WO-US030873.
PR      01-DEC-2000; 2000WO-US032678.
PR      20-DEC-2000; 2000US-00747259.
PR      20-DEC-2000; 2000WO-US034956.
PR      28-FEB-2001; 2001WO-US006520.
PR      22-MAR-2001; 2001US-00816744.
PR      10-MAY-2001; 2001US-00854208.
```

```
PR      10-MAY-2001; 2001US-00854280.
PR      30-MAY-2001; 2001US-00870574.
PR      01-JUN-2001; 2001WO-US017800.
PR      05-JUN-2001; 2001US-00874503.
PR      29-JUN-2001; 2001US-00869599.
PR      18-JUL-2001; 2001US-00908827.
PR      06-DEC-2001; 2001US-00006867.
XX      (GETH ) GENENTECH INC.
XX      PA
PI      Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI      Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX      WPI; 2004-020823/02.
DR      P-PSDB; ADH24410.
XX
XX      New secreted and transmembrane PRO polypeptides and nucleic acid
PT      molecules, useful in gene therapy or preparing a medicament for treating
PT      a condition that is responsive to the PRO polypeptide or anti-PRO
PT      antibody, e.g. diabetes.
XX
XX      Disclosure; SEQ ID NO 37; 398pp; English.
XX
CC      The invention describes a novel isolated nucleic acid encoding a human
CC      secreted and transmembrane PRO portein. Specifically claimed are secreted
CC      and transmembrane polypeptides, e.g. PRO180, PRO218, PRO263, PRO295,
CC      PRO874, PRO300, PRO1864, PRO1282, PRO1063, or PRO1773 polypeptide. The
CC      PRO polypeptides or anti-PRO antibodies are useful in preparing a
CC      medicament for treating a condition that is responsive to the PRO
CC      polypeptide or anti-PRO antibody, e.g. cancer, diabetes, osteoarthritis
CC      or rheumatoid arthritis. The PRO nucleotide sequences may be used as
CC      hybridization probes in chromosome and gene mapping, or in generating
CC      antisense RNA and DNA. The PRO nucleic acids are also useful in preparing
CC      PRO polypeptides, in assays to identify other proteins or molecules
CC      involved in binding reaction, in generating transgenic animals or
CC      knockout animals, which in turn are useful in the development and
CC      screening of therapeutically useful reagents, for chromosome
CC      identification, and tissue typing. The PRO polypeptides and nucleic acid
CC      molecules are also useful in gene therapy, and as molecular weight
CC      markers for protein electrophoresis purposes. The anti-PRO antibodies may
CC      be used in diagnostic assays for PRO, or for the affinity purification of
CC      PRO from recombinant cell culture or natural sources. This sequence
CC      encodes a novel human secreted and transmembrane PRO protein.
XX
SQ      Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

      Query Match          3.0%; Score 66.6; DB 12; Length 2846;
      Best Local Similarity 71.3%; Pred. No. 0.00023;
      Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY      2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAATGGTGTCTCCACCACTG 2180
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db      2653 CCTTTTCCTTCCCATCTCTTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAACTA 2712

QY      2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db      2713 CAAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY      2241 AA 2242
      ||
Db      2773 AA 2774

RESULT 910
ADH33068
ID      ADH33068 standard; cDNA; 2846 BP.
XX
AC      ADH33068;
XX
DT      11-MAR-2004 (first entry)
XX
DE      Human PRO polynucleotide #85.
XX
```

KW	Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide; cancer; tumour; adrenal; lung; colon; breast; prostate; rectum; cervix; liver; tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell.
KX	Homo sapiens.
OS	US2003068768-A1.
XX	10-APR-2003.
PN	29-JUL-2002; 2002US-00207919.
XX	29-MAR-2000; 2000US-0193053P.
PF	28-FEB-2001; 2001WO-US006520.
XX	15-JAN-2002; 2002US-00052586.
PR	(GETH ) GENENTECH INC.
XX	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL; Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
PI	WPI; 2004-080155/08.
PI	P-PSDB; ADH33069.
XX	Three hundred and five nucleic acids encoding PRO polypeptides, useful for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation, particularly for treating e.g. lung or breast tumors, or arthritis in a mammal.
DR	Claim 2; SEQ ID NO 169; 700pp; English.
XX	The invention relates to human PRO polypeptides (secreted and transmembrane polypeptides) and the PRO polynucleotides encoding them. The PRO polypeptides and polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. They are particularly useful for detecting tumours (e.g. adrenal tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour, cervical tumour, or liver tumour) in a mammal, for stimulating the release of tumour necrosis factor (TNF)-alpha from human blood or for stimulating the proliferation or differentiation of chondrocyte cells. The PRO nucleic acids are useful as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, in preparing PRO polypeptides by recombinant technology, in generating transgenic animals or knock-out animals which may be used in the development and screening of therapeutically useful reagents, in gene therapy, in chromosome identification, as chromosome markers and in generating probes. The PRO polypeptides, or anti-PRO antibodies, are useful for preparing a medicament for treating a condition which is responsive to the PRO polypeptides or anti-PRO antibodies. The PRO polypeptides are useful as molecular markers for protein electrophoresis, and in tissue typing. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.
CC	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
XX	Query Match            3.0%; Score 66.6; DB 12; Length 2846;
SQ	Best Local Similarity    71.3%; Pred. No. 0.00023;
	Matches    87; Conservative    0; Mismatches    35; Indels    0; Gaps    0
QY	2121 CCTTTGGCTTACCACACTCTTCCTTTATCTTATTATAAAAAATGTTGGTCTCCCACTG 218 
Db	2653 CCTTTTCCTCCCCCATCTCTGTACACATTTTAATAAAATAAGGGTTGGCTTCTGAACA 271 
QY	2181 NCTCCCAA 224 
Db	2713 CAAAAAANAANAANAANAANAANAANAANAANAANAANAANAANAANAANAANA 277 
QY	2241 AA 2242 
Db	2773 AA 2774

RESULT 911  
ADG69538  
ID ADG69538 standard; cDNA; 2846 BP.  
XX AC ADG69538;  
XX AC  
XX DT 11-MAR-2004 (first entry)  
XX DE 11-MAR-2004 (first entry)  
XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;  
KW affinity purification; secreted and transmembrane protein.  
XX OS Homo sapiens.  
XX PN US2003180844-A1.  
XX PD 25-SEP-2003.  
XX PF 08-MAY-2002; 2002US-00063686.  
XX PR 30-DEC-1998; 98KR-00062142.  
PR 08-MAR-1999; 99WO-US005028.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380139.  
PR 25-AUG-1999; 99US-00380142.  
PR 15-SEP-1999; 99US-00397342.  
PR 18-OCT-1999; 99US-00403297.  
PR 12-NOV-1999; 99US-00423844.  
PR 30-DEC-1999; 99WO-US031274.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 22-AUG-2000; 2000US-00644848.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00664610.  
PR 18-SEP-2000; 2000US-00665350.  
PR 08-NOV-2000; 2000US-00709238.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001US-00816744.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 30-MAY-2001; 2001US-00870574.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 29-JUN-2001; 2001US-00869599.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-DEC-2001; 2001US-00006867.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;  
XX  
DR WPI; 2004-020801/02.  
DR P-PSDB; ADG69539.  
XX  
XX  
PT New secreted and transmembrane PRO nucleic acid, for use in molecular  
PT biology, chromosome and gene mapping, in generating antisense RNA and  
PT DNA, in various diagnostic assays and in gene therapy.  
XX  
XX Disclosure; SEQ ID NO 37; 398pp; English.  
XX





```
XX
AC  ADG85813;
XX
DT  11-MAR-2004 (first entry)
XX
DE  Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW  ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW  affinity purification; secreted and transmembrane protein.
XX
OS  Homo sapiens.
XX
PN  US2003180861-A1.
XX
PD  25-SEP-2003.
XX
PF  09-MAY-2002; 2002US-00063742.
XX
PR  30-DEC-1998; 98KR-00062142.
PR  08-MAR-1999; 99WO-US005028.
PR  14-MAY-1999; 99US-00311832.
PR  14-MAY-1999; 99WO-US010733.
PR  25-AUG-1999; 99US-00380137.
PR  25-AUG-1999; 99US-00380138.
PR  25-AUG-1999; 99US-00380139.
PR  25-AUG-1999; 99US-00380142.
PR  15-SEP-1999; 99US-00397342.
PR  18-OCT-1999; 99US-00403297.
PR  12-NOV-1999; 99US-00423844.
PR  30-DEC-1999; 99WO-US031274.
PR  18-FEB-2000; 2000WO-US004341.
PR  01-MAR-2000; 2000WO-US005601.
PR  02-MAR-2000; 2000WO-US005841.
PR  21-MAR-2000; 2000WO-US007532.
PR  22-MAY-2000; 2000WO-US014042.
PR  02-JUN-2000; 2000WO-US015264.
PR  22-AUG-2000; 2000US-00644848.
PR  24-AUG-2000; 2000US-00644848.
PR  18-SEP-2000; 2000US-00664610.
PR  18-SEP-2000; 2000US-00665350.
PR  08-NOV-2000; 2000US-00709238.
PR  10-NOV-2000; 2000WO-US030873.
PR  01-DEC-2000; 2000WO-US032678.
PR  20-DEC-2000; 2000US-00747259.
PR  20-DEC-2000; 2000WO-US034956.
PR  28-FEB-2001; 2001WO-US006520.
PR  22-MAR-2001; 2001US-00816744.
PR  10-MAY-2001; 2001US-00854208.
PR  10-MAY-2001; 2001US-00854280.
PR  30-MAY-2001; 2001US-00870574.
PR  01-JUN-2001; 2001WO-US017800.
PR  05-JUN-2001; 2001US-00874503.
PR  29-JUN-2001; 2001US-00869599.
PR  18-JUL-2001; 2001US-00908827.
PR  06-DEC-2001; 2001US-00006867.
XX
PA  (GETH ) GENENTECH INC.
XX
PI  Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI  Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR  WPI; 2004-020813/02.
DR  P-PSDB; ADG85814.
XX
PT  New PRO polypeptide and nucleic acid encoding the polypeptide, for use in
PT  gene therapy, chromosome identification, tissue typing, or as
PT  hybridization probes in chromosome and gene mapping.
XX
PS  Disclosure; SEQ ID NO 37; 398pp; English.
XX
CC  The invention describes an antibody that specifically binds to a PRO
CC  polypeptide having a fully defined amino acid sequence given in the
CC  specification. The antibody is useful in identifying PRO polypeptides
```

CC useful for various industrial applications, including pharmaceuticals,  
CC diagnostics, biosensors and bioreactors. The antibody is also used for  
CC affinity purification of PRO polypeptides from recombinant cell culture  
CC or natural sources. The antibody, PRO polypeptide, or its agonists or  
CC antagonists, may be used for preparing a medicament for diagnosing or  
CC treating a condition responsive to the antibody, PRO polypeptide, or its  
CC agonists or antagonists. This sequence encodes a novel human secreted and  
CC transmembrane PRO polypeptide.

XX  
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTCTTTTATCTTATTAATAAAAAATGTTGGTCTCCCACTG 2180  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 2653 CCTTTCTCTCCCACTCTCTGTACACATTTTAATAAAAAATAAGGTTGGCTTCTGAACTA 2712  
  
QY 2181 NCTCCCAAAAAA AA 2240  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 2713 CAAAAA AA 2772  
  
QY 2241 AA 2242  
||  
Db 2773 AA 2774

RESULT 914

ADH39359  
ID ADH39359 standard; cDNA; 2846 BP.

XX AC ADH39359;

XX DT 11-MAR-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.

KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;  
KW affinity purification; secreted and transmembrane protein.

XX OS Homo sapiens.

XX PN US2003180916-A1.

XX PD 25-SEP-2003.

XX PF 08-MAY-2002; 2002US-00063717.

XX PR 30-DEC-1998; 98KR-00062142.

XX PR 08-MAR-1999; 99WO-US005028.

XX PR 14-MAY-1999; 99US-00311832.

XX PR 14-MAY-1999; 99WO-US010733.

XX PR 25-AUG-1999; 99US-00380137.

XX PR 25-AUG-1999; 99US-00380138.

XX PR 25-AUG-1999; 99US-00380139.

XX PR 25-AUG-1999; 99US-00380142.

XX PR 15-SEP-1999; 99US-00397342.

XX PR 18-OCT-1999; 99US-00403297.

XX PR 12-NOV-1999; 99US-00423844.

XX PR 30-DEC-1999; 99WO-US031274.

XX PR 18-FEB-2000; 2000WO-US004341.

XX PR 01-MAR-2000; 2000WO-US005601.

XX PR 02-MAR-2000; 2000WO-US005841.

XX PR 21-MAR-2000; 2000WO-US007532.

XX PR 22-MAY-2000; 2000WO-US014042.

XX PR 02-JUN-2000; 2000WO-US015264.

XX PR 22-AUG-2000; 2000US-00644848.

XX PR 24-AUG-2000; 2000WO-US023328.

XX PR 18-SEP-2000; 2000US-00664610.

XX PR 18-SEP-2000; 2000US-00665350.

XX PR 08-NOV-2000; 2000US-00709238.

XX PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001US-00816744.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 30-MAY-2001; 2001US-00870574.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 29-JUN-2001; 2001US-00869599.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-DEC-2001; 2001US-00006867.  
XX  
PA (GETH ) GENENTECH INC.

PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX  
DR WPI; 2004-020828/02.  
DR P-PSDB; ADH39360.

XX  
PT New nucleic acids encoding PRO polypeptides, useful in diagnosing and  
PT treating disorders that affect glucose or free fatty acid in skeletal  
PT muscle, such as diabetes, hypoinsulinemia or hyperinsulinemia.

XX  
PS Disclosure; SEQ ID NO 37; 398pp; English.

XX  
CC The invention relates to a novel PRO (secreted and transmembrane protein)  
CC polypeptide, and the polynucleotide sequence encoding it. Also included  
CC are a vector comprising the novel nucleic acid and a host cell comprising  
CC the vector. The polynucleotide sequence is useful in molecular biology as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA, and in gene therapy. The polynucleotide sequence  
CC may also be used in preparing the PRO polypeptide by recombinant  
CC techniques, and in generating either transgenic or knock-out animals  
CC which, in turn, are useful in the development and screening of  
CC therapeutically useful reagents. The PRO polynucleotide sequence is  
CC useful in preparing a medicament for treating a condition responsive to  
CC the polypeptide or antibody, such as tumours, and in various diagnostic  
CC assays. The specification also discloses other PRO proteins and the  
CC polynucleotide sequences encoding them. The present sequence encodes a  
CC PRO protein.

XX  
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;  
QY 2121 CCTTGTCTTACCACTCTTTCTCTTTTATCTTATTAATAAATGTTGGTCTCCACCACTG 2180  
DB 2653 CCTTTCTCCCATCTCTTGTACACATTTTAATAAATAAGGGTTGGCTTCTGAACATA 2712  
QY 2181 NCTCCCAA 2240  
DB 2713 CAAAAAATAA 2772  
QY 2241 AA 2242  
DB 2773 AA 2774

RESULT 915  
ADH33551  
ID ADH33551 standard; cDNA; 2846 BP.  
XX  
AC ADH33551;  
XX  
DT 11-MAR-2004 (first entry)  
XX  
DE Human PRO polynucleotide #19.  
XX

KW Human; PRO; gene; ss; tumour necrosis factor-alpha; TNF-alpha; blood;  
KW chondrocyte cell; tumour; cancer.  
XX Homo sapiens.  
OS  
PN US2003181637-A1.  
XX  
PD 25-SEP-2003.  
XX  
PF 02-MAY-2002; 2002US-00063527.  
XX  
PR 30-DEC-1998; 98KR-00062142.  
PR 08-MAR-1999; 99WO-US005028.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380139.  
PR 25-AUG-1999; 99US-00380142.  
PR 15-SEP-1999; 99US-00397342.  
PR 18-OCT-1999; 99US-00403297.  
PR 12-NOV-1999; 99US-00423844.  
PR 30-DEC-1999; 99WO-US031274.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 22-AUG-2000; 2000US-00644848.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00664610.  
PR 18-SEP-2000; 2000US-00665350.  
PR 08-NOV-2000; 2000US-00709238.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001US-00816744.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 30-MAY-2001; 2001US-00870574.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 29-JUN-2001; 2001US-00869599.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-DEC-2001; 2001US-00006867.  
XX  
XX (GETH ) GENENTECH INC.  
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;  
XX  
XX WPI; 2004-059332/06.  
DR P-PSDB; ADH33552.  
XX  
PT New isolated PRO polypeptide, useful for treating various bone and/or  
PT cartilage disorders, for example, sports injuries and arthritis.  
XX  
PS Disclosure; SEQ ID NO 37; 335pp; English.  
XX  
CC The invention relates to human PRO polypeptides and the PRO  
CC polynucleotides encoding them. The invention also relates to an antibody  
CC that specifically binds to the polypeptide, a method for stimulating the  
CC release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a  
CC method for stimulating proliferation or differentiation of chondrocyte  
CC cells and a method for detecting the presence of a tumour in a mammal  
CC comprising comparing the level of expression of any PRO polypeptide,  
CC given in the specification, in a test sample of cells taken from the  
CC mammal with a control sample of normal cells of the same cell type, where  
CC a higher level of expression of the PRO polypeptide in the test sample as  
CC compared to the control sample indicates the presence of a tumour in the

mammal. The polynucleotides are useful as hybridisation probes in chromosome and gene mapping or in generating antisense RNA and DNA, for preparing PRO polypeptides, in assays to identify other proteins or molecules involved in binding reactions, to generate transgenic animals or knockout animals, which in turn are useful in the development and screening of therapeutically useful reagents, for chromosome identification and in tissue typing. The PRO polypeptides and polynucleotides are also useful in gene therapy and as molecular weight markers for protein electrophoresis. The anti-PRO antibodies may be used in diagnostic assays for PRO or for the affinity purification of PRO from recombinant cell culture or natural sources. This sequence represents a human PRO polynucleotide of the invention.

Query Match 3.0%; Score 66.6; DB 12; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

[illegible]

RESULT 916	
ADH33891	
ID	ADH33891 standard; cDNA; 2846 BP.
XX	
XX	
AC	ADH33891;
XX	
DT	11-MAR-2004 (first entry)
XX	
DE	Human PRO polynucleotide #19.
XX	
XX	
KW	Human; PRO; gene; ss; tumour necrosis factor-alpha; TNF-alpha; blood;
KW	chondrocyte cell; tumour; cancer.

PR	18-SEP-2000;	2000US-00664610.
PR	18-SEP-2000;	2000US-00665350.
PR	08-NOV-2000;	2000US-00709238.
PR	10-NOV-2000;	2000WO-US030873.
PR	01-DEC-2000;	2000WO-US032678.
PR	20-DEC-2000;	2000US-00747259.
PR	20-DEC-2000;	2000WO-US034956.
PR	28-FEB-2001;	2001WO-US006520.
PR	22-MAR-2001;	2001US-00816744.
PR	10-MAY-2001;	2001US-00854208.
PR	10-MAY-2001;	2001US-00854280.
PR	30-MAY-2001;	2001US-00870574.
PR	01-JUN-2001;	2001WO-US017800.
PR	05-JUN-2001;	2001US-00874503.
PR	29-JUN-2001;	2001US-00869599.
PR	18-JUL-2001;	2001US-00908827.
XX	06-DEC-2001;	2001US-00006867.
PA	(GETH )	GENENTECH INC.

AA  
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

DR WPI; 2004-059334/06.  
DR P-PSDB; ADH33892.

New isolated PRO polypeptide, useful for treating various bone and/or cartilage disorders, for example, sports injuries and arthritis.

PS Disclosure; SEQ ID NO 37; 397pp; English.

The invention relates to human PRO polypeptides and the PRO polynucleotides encoding them. The invention also relates to an antibody that specifically binds to the polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal comprising comparing the level of expression of any PRO polypeptide, given in the specification, in a test sample of cells taken from the mammal with a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptide in the test sample as compared to the control sample indicates the presence of a tumour in the mammal. The polynucleotides are useful as hybridisation probes in chromosome and gene mapping or in generating antisense RNA and DNA, for preparing PRO polypeptides, in assays to identify other proteins or molecules involved in binding reactions, to generate transgenic animals or knockout animals, which in turn are useful in the development and screening of therapeutically useful reagents, for chromosome identification and in tissue typing. The PRO polypeptides and polynucleotides are also useful in gene therapy and as molecular weight markers for protein electrophoresis. The anti-PRO antibodies may be used in diagnostic assays for PRO or for the affinity purification of PRO from recombinant cell culture or natural sources. This sequence represents a human PRO polynucleotide of the invention.

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match	3.0%;	Score 66.6;	DB 12;	Length 2846
Best Local Similarity	71.3%;	Pred. No. 0.00023;		
Matches 87;	Conservative	0;	Mismatches 35;	Indels 0

Qy	2121	CCTTTGGCTTTACCACTCTTTTCC	TTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACTG	2180
D $\bar{b}$	2653	CCTTTCCCTTCCCATCTCTTGTACACATTTTAAATAAAATAAGGGTTGGCTTCTGAACTA	2712	
Qy	2181	NCCTCCAAAAA	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	2240
D $\bar{b}$	2713	CAAAAAA	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	2772
Qy	2241	AA	2242	
D $\bar{b}$	2773	AA	2774	



RESULT	917
ADH01101	
ID	ADH01101 standard; cDNA; 2846 BP.
XX	
AC	ADH01101;
XX	
DT	11-MAR-2004 (first entry)
XX	
DE	Human PRO polynucleotide #19.
XX	
KW	Human; PRO; gene; ss; tumour necr
KW	chondrocyte cell; tumour; cancer.
XX	
OS	Homo sapiens.
XX	
PN	US2003180838-A1.
XX	
PD	25-SEP-2003.
XX	
PF	07-MAY-2002; 2002US-00063669.
XX	
PR	30-DEC-1998; 98KR-00062142.
PR	08-MAR-1999; 99WO-US005028.
PR	14-MAY-1999; 99US-00311832.
PR	14-MAY-1999; 99WO-US010733.
PR	25-AUG-1999; 99US-00380137.
PR	25-AUG-1999; 99US-00380138.
PR	25-AUG-1999; 99US-00380139.
PR	25-AUG-1999; 99US-00380142.
PR	15-SEP-1999; 99US-00397342.
PR	18-OCT-1999; 99US-00403297.
PR	12-NOV-1999; 99US-00423844.
PR	30-DEC-1999; 99WO-US001274.
PR	18-FEB-2000; 2000WO-US004341.
PR	01-MAR-2000; 2000WO-US005601.
PR	02-MAR-2000; 2000WO-US005841.
PR	21-MAR-2000; 2000WO-US007532.
PR	22-MAY-2000; 2000WO-US014042.
PR	02-JUN-2000; 2000WO-US015264.
PR	22-AUG-2000; 2000US-00644848.
PR	24-AUG-2000; 2000WO-US023328.
PR	18-SEP-2000; 2000US-00664610.
PR	18-SEP-2000; 2000US-00665350.
PR	08-NOV-2000; 2000US-00709238.
PR	10-NOV-2000; 2000WO-US030873.
PR	01-DEC-2000; 2000WO-US032678.
PR	20-DEC-2000; 2000US-00747259.
PR	20-DEC-2000; 2000WO-US034956.
PR	28-FEB-2001; 2001WO-US006520.
PR	22-MAR-2001; 2001US-00816744.
PR	10-MAY-2001; 2001US-00854208.
PR	10-MAY-2001; 2001US-00854280.
PR	30-MAY-2001; 2001US-00870574.
PR	01-JUN-2001; 2001WO-US017800.
PR	05-JUN-2001; 2001US-00874503.
PR	29-JUN-2001; 2001US-00869599.
PR	18-JUL-2001; 2001US-00908827.
PR	06-DEC-2001; 2001US-00908667.

The invention relates to human PRO polypeptides and the PRO polynucleotides encoding them. The invention also relates to an antibody that specifically binds to the polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal comprising comparing the level of expression of any PRO polypeptide, given in the specification, in a test sample of cells taken from the mammal with a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptide in the test sample as compared to the control sample indicates the presence of a tumour in the mammal. The polynucleotides are useful as hybridisation probes in chromosome and gene mapping or in generating antisense RNA and DNA, for preparing PRO polypeptides, in assays to identify other proteins or molecules involved in binding reactions, to generate transgenic animals or knockout animals, which in turn are useful in the development and screening of therapeutically useful reagents, for chromosome identification and in tissue typing. The PRO polypeptides and polynucleotides are also useful in gene therapy and as molecular weight markers for protein electrophoresis. The anti-PRO antibodies may be used in diagnostic assays for PRO or for the affinity purification of PRO from recombinant cell culture or natural sources. This sequence represents a human PRO polynucleotide of the invention.

Sequence 2846 BP: 768 A: 696 C: 745 G: 637 T: 0 U: 0 Other: 0

```
Query Match      3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87: Conservative 0; Mismatches 35; Indels 0;
```

QY	2121	CCTTTGCTTTACCACTCTTTTCCCTTTATCTTAATAAATAAGTTGGTCTCCACCACGTG	2180
D <sub>b</sub>	2653	CCTTTTCCTTCCCACATCTTTGTACACATTTTAATAAAAAAAGGGTTGGCTTCGAACTA	2712
QY	2181	NCTCCCCAA	2240
D <sub>b</sub>	2713	CAA	2772
QY	2241	AA	2242
D <sub>b</sub>	2773	AA	2774

RESIII.T 918

ADG69708 standard: cDNA: 2846 BP.

AC ADG69708:

11-MAR-2004 (first entry)

Novel human secreted and transmembrane protein PRO1344 cDNA.

ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;  
xx  
kw affinity purification; secreted and transmembrane protein.  
xx

XX Homo sapiens.

XX PN US2003180843-A1.

PD 25-SEP-2003.

07-MAY-2002; 2002US-00063676.

PR 30-DEC-1998; 98KR-00062142.

PR 14-MAY-1999; 99US-00311832.

PR 25-AUG-1999; 99US-00380137.

PR 25-AUG-1999; 99US-00380139.

100



PR	17-JUN-1998;	98US-0089532P;
PR	17-JUN-1998;	98US-0089538P;
PR	17-JUN-1998;	98US-0089598P;
PR	17-JUN-1998;	98US-0089599P;
PR	17-JUN-1998;	98US-0089600P;
PR	17-JUN-1998;	98US-0089653P;
PR	18-JUN-1998;	98US-0089801P;
PR	18-JUN-1998;	98US-0089907P;
PR	18-JUN-1998;	98US-0089908P;
PR	19-JUN-1998;	98US-0089948P;
PR	19-JUN-1998;	98US-0089952P;
PR	22-JUN-1998;	98US-0090246P;
PR	22-JUN-1998;	98US-0090252P;
PR	22-JUN-1998;	98US-0090254P;
PR	23-JUN-1998;	98US-0090349P;
PR	23-JUN-1998;	98US-0090355P;
PR	24-JUN-1998;	98US-0090429P;
PR	24-JUN-1998;	98US-0090431P;
PR	24-JUN-1998;	98US-0090435P;
PR	24-JUN-1998;	98US-0090444P;
PR	24-JUN-1998;	98US-0090445P;
PR	24-JUN-1998;	98US-0090472P;
PR	24-JUN-1998;	98US-0090535P;
PR	24-JUN-1998;	98US-0090540P;
PR	24-JUN-1998;	98US-0090542P;
PR	24-JUN-1998;	98US-0090557P;
PR	25-JUN-1998;	98US-0090676P;
PR	25-JUN-1998;	98US-0090678P;
PR	25-JUN-1998;	98US-0090690P;
PR	25-JUN-1998;	98US-0090694P;
PR	25-JUN-1998;	98US-0090695P;
PR	25-JUN-1998;	98US-0090696P;
PR	26-JUN-1998;	98US-0090862P;
PR	26-JUN-1998;	98US-0090863P;
PR	01-JUL-1998;	98US-0091360P;
PR	01-JUL-1998;	98US-0091544P;
PR	02-JUL-1998;	98US-0091478P;
PR	02-JUL-1998;	98US-0091519P;
PR	02-JUL-1998;	98US-0091626P;
PR	02-JUL-1998;	98US-0091628P;
PR	02-JUL-1998;	98US-0091633P;
PR	02-JUL-1998;	98US-0091646P;
PR	02-JUL-1998;	98US-0091673P;
PR	07-JUL-1998;	98US-0091978P;
PR	07-JUL-1998;	98US-0091982P;
PR	09-JUL-1998;	98US-0092182P;
PR	10-JUL-1998;	98US-0092472P;
PR	20-JUL-1998;	98US-0093339P;
PR	30-JUL-1998;	98US-0094651P;
PR	04-AUG-1998;	98US-0095325P;
PR	04-AUG-1998;	98US-0095285P;
PR	04-AUG-1998;	98US-0095301P;
PR	04-AUG-1998;	98US-0095302P;
PR	04-AUG-1998;	98US-0095318P;
PR	04-AUG-1998;	98US-0095321P;
PR	04-AUG-1998;	98US-0095325P;
PR	10-AUG-1998;	98US-0095916P;
PR	10-AUG-1998;	98US-0095929P;
PR	10-AUG-1998;	98US-0096012P;
PR	11-AUG-1998;	98US-0096143P;
PR	11-AUG-1998;	98US-0096146P;
PR	12-AUG-1998;	98US-0096329P;
PR	17-AUG-1998;	98US-0096757P;
PR	17-AUG-1998;	98US-0096768P;
PR	17-AUG-1998;	98US-0096773P;
PR	17-AUG-1998;	98US-0096791P;
PR	17-AUG-1998;	98US-0096867P;
PR	17-AUG-1998;	98US-0096891P;
PR	17-AUG-1998;	98US-0096894P;
PR	17-AUG-1998;	98US-0096895P;
PR	17-AUG-1998;	98US-0096897P;
PR	18-AUG-1998;	98US-0096949P;

PR	18-AUG-1998;	98US-0096950P
PR	18-AUG-1998;	98US-0096959P
PR	18-AUG-1998;	98US-0096960P
PR	18-AUG-1998;	98US-0097022P
PR	19-AUG-1998;	98US-0097141P
PR	20-AUG-1998;	98US-0097218P
PR	24-AUG-1998;	98US-0097661P
PR	26-AUG-1998;	98US-0097952P
PR	26-AUG-1998;	98US-0097954P
PR	26-AUG-1998;	98US-0097955P
PR	26-AUG-1998;	98US-0097971P
PR	26-AUG-1998;	98US-0097974P
PR	26-AUG-1998;	98US-0097978P
PR	26-AUG-1998;	98US-0097979P
PR	26-AUG-1998;	98US-0097986P
PR	26-AUG-1998;	98US-0098014P
PR	31-AUG-1998;	98US-0098525P
PR	16-SEP-1998;	98US-0100634P
PR	16-SEP-1998;	98WO-US019330
PR	17-SEP-1998;	98US-0100858P
PR	17-SEP-1998;	98WO-US019437
PR	07-OCT-1998;	98WO-US021141
PR	01-DEC-1998;	98WO-US025108
PR	22-DEC-1998;	98US-0113296P
PR	05-JAN-1999;	99WO-US000106
PR	20-FEB-1999;	99WO-US030911
PR	08-MAR-1999;	99WO-US005028
PR	12-MAR-1999;	99US-0123957P
PR	02-JUN-1999;	99WO-US012252
PR	23-JUN-1999;	99US-0141037P
PR	07-JUL-1999;	99US-0143048P
PR	20-JUL-1999;	99US-0144758P
PR	26-JUL-1999;	99US-0145698P
PR	28-JUL-1999;	99US-0146222P
PR	17-AUG-1999;	99US-0149396P
PR	15-SEP-1999;	99WO-US021090
PR	15-SEP-1999;	99WO-US021547
PR	08-OCT-1999;	99US-0158663P
PR	30-NOV-1999;	99WO-US028313
PR	01-DEC-1999;	99WO-US028301
PR	01-DEC-1999;	99WO-US028634
PR	16-DEC-1999;	99WO-US030095
PR	05-JAN-2000;	2000WO-US000219
PR	06-JAN-2000;	2000WO-US000376
PR	11-FEB-2000;	2000WO-US003565
PR	18-FEB-2000;	2000WO-US004341
PR	22-FEB-2000;	2000WO-US004414
PR	24-FEB-2000;	2000WO-US004914
PR	24-FEB-2000;	2000WO-US005004
PR	02-MAR-2000;	2000WO-US005841
PR	10-MAR-2000;	2000WO-US006319
PR	15-MAR-2000;	2000WO-US006884
PR	20-MAR-2000;	2000WO-US007377
PR	30-MAR-2000;	2000WO-US008439
PR	15-MAY-2000;	2000WO-US013358
PR	17-MAY-2000;	2000WO-US013705
PR	22-MAY-2000;	2000WO-US014042
PR	30-MAY-2000;	2000WO-US014941
PR	02-JUN-2000;	2000WO-US015264
PR	23-JUN-2000;	2000US-0213637P
PR	28-JUN-2000;	2000WO-US020710

		Query Match	3.0%;	Score 66.6;	DB 12;	Length 2846;
		Best Local Similarity	71.3%;	Pred. No. 0.00023;		
		Matches 87;	Conservative	0;	Mismatches 35;	Indels 0; Gaps 0;
Qy	2121	CCTTTGCTTTACCACTCTTTCC	TTTTATCTTATTAATAAAAAATGTTGGTCTCCACCAC	TG	2180	
Db	2653	CCTTTTCCTTCCCCATCTCTTG	TACACATTTTAATAAAAAAAGGGTTGGCTTC	TGAACTA	2712	
Qy	2181	NTCCCAAAAA	AAAAA	AAAAA	AAAAA	AAAAA
Db	2713	CAAAAA	AAAAA	AAAAA	AAAAA	AAAAA











Db 2713 CAAA 2772  
QY 2241 AA 2242  
Db - 2773 AA 2774

RESULT 924  
ADH39536  
ID ADH39536 standard; cDNA; 2846 BP.  
XX  
AC ADH39536;  
DT 11-MAR-2004 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;  
KW affinity purification; secreted and transmembrane protein.  
XX  
OS Homo sapiens.  
XX  
PN US2003180915-A1.  
XX  
PD 25-SEP-2003.  
XX  
PF 08-MAY-2002; 2002US-00063716.  
XX  
PR 30-DEC-1998; 98XR-00062142.  
PR 08-MAR-1999; 99WO-US005028.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380139.  
PR 25-AUG-1999; 99US-00380142.  
PR 15-SEP-1999; 99US-00397342.  
PR 18-OCT-1999; 99US-00403297.  
PR 12-NOV-1999; 99US-00423844.  
PR 30-DEC-1999; 99WO-US031274.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 22-AUG-2000; 2000US-00644848.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00664610.  
PR 18-SEP-2000; 2000US-00665350.  
PR 08-NOV-2000; 2000US-00709238.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001US-00816744.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 30-MAY-2001; 2001US-00870574.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 29-JUN-2001; 2001US-00869599.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-DEC-2001; 2001US-00006867.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;  
XX  
DR WPI; 2004-020827/02.

DR P-PSDB; ADH39537.  
XX  
PT New secreted and transmembrane PRO nucleic acid molecule, useful in gene therapy or preparing a medicament for treating a condition that is responsive to a PRO polypeptide or anti-PRO antibody, e.g. diabetes.  
PT  
XX  
PS Disclosure; SEQ ID NO 37; 398pp; English.  
XX  
CC The invention relates to a novel PRO (secreted and transmembrane protein) polypeptide, and the polynucleotide sequence encoding it. Also included are a vector comprising the novel nucleic acid and a host cell comprising the vector. The polynucleotide sequence is useful in molecular biology as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy. The polynucleotide sequence may also be used in preparing the PRO polypeptide by recombinant techniques, and in generating either transgenic or knock-out animals which, in turn, are useful in the development and screening of therapeutically useful reagents. The PRO polynucleotide sequence is useful in preparing a medicament for treating a condition responsive to the polypeptide or antibody, such as tumours, and in various diagnostic assays. The specification also discloses other PRO proteins and the polynucleotide sequences encoding them. The present sequence encodes a PRO protein.  
XX  
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;  
Query Match 3.0%; Score 66.6; DB 12; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;  
QY 2121 CCTTGCCTTACCACCTCTTCCCTTTATCTTATTAATAAAATGTTGGTCTCCACCCTG 2180  
Db 2653 CCTTTCCTTCCCCATCTCTGTACACATTTTAATAAATAGGTTGGCTTCTGAACATA 2712  
QY 2181 NCTCCCAA 2240  
Db 2713 CAAA 2772  
QY 2241 AA 2242  
Db 2773 AA 2774  
RESULT 925  
ADH20009  
ID ADH20009 standard; cDNA; 2846 BP.  
XX  
AC ADH20009;  
XX  
DT 11-MAR-2004 (first entry)  
XX  
DE Human cDNA encoding secreted/transmembrane protein PRO1344.  
XX  
KW PRO; secreted protein; transmembrane protein;  
KW hypertrophy of neonatal heart; angiogenesis;  
KW vascular endothelial growth factor; VEGF-stimulated proliferation;  
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;  
KW c-fos induction; adipocyte cell; chondrocyte differentiation;  
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;  
KW cancer; human; ss; gene; colon cancer; lung cancer; breast cancer;  
KW rod photoreceptor cell.  
XX  
OS Homo sapiens.  
XX  
PN US2003219856-A1.  
XX  
PD 27-NOV-2003.  
XX  
PF 14-AUG-2002; 2002US-00219538.  
XX  
PR 09-JUL-1998; 98US-0092182P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.

PR 30-MAR-2000; 2000WO-US008439.  
PR 28-AUG-2001; 2001US-00941992.  
XX (GETH ) GENENTECH INC.  
PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
XX Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;  
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;  
PI Zhang Z;  
XX WPI; 2004-021947/02.  
DR P-PSDB; ADH20010.  
DR  
XX New genes and secreted and transmembrane polypeptides, useful for  
PT treating or diagnosing e.g. cancers or tumors in mammals, or as  
PT diagnostics, biosensors or bioreactors.  
XX  
PS Claim 2; SEQ ID NO 230; 648pp; English.  
XX  
CC The invention relates to an isolated nucleic acid molecule comprising the  
CC full-length coding sequence of the DNA ATCC Accession Numbers given in  
CC the specification, or comprising a sequence with at least 80% identity  
CC to: (a) a nucleotide encoding any of 147 PRO polypeptides, or an  
CC extracellular domain of the polypeptide; or (b) any of 147 nucleotide  
CC sequences fully defined in the specification. Also included are the PRO  
CC proteins (or their extracellular domains with or without their associated  
CC extracellular domains), expression vectors, host cells, PRO chimaeric  
CC proteins, anti-PRO antibodies, methods of detecting polypeptide in a  
CC sample, methods of linking a bioactive molecule to a cell expressing a  
CC polypeptide and methods of modulating at least one biological activity of  
CC a cell expressing the polypeptide. The PRO polypeptides or  
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
CC heart, promoting angiogenesis, inhibiting vascular endothelial growth  
CC factor (VEGF)-stimulated proliferation of endothelial cells, modulating  
CC the proliferation of stimulated T-lymphocytes, enhancing the survival or  
CC proliferation of retinal neurons or rod photoreceptor cells, inducing c-  
CC fos in endothelial cells, modulating glucose or FFA uptake by adipocyte  
CC cells, inducing proliferation and/or re-differentiation of chondrocytes,  
CC or inducing pancreatic beta-cell precursor differentiation. In  
CC particular, these are useful for detecting or treating tumours and  
CC certain cancers (colon, lung or breast cancers) in mammals, e.g. humans,  
CC dogs, cats, cattle, horses, sheep, pigs, goats, or rabbits. The PRO genes  
CC may also be used in gene therapy, particularly for replacing a defective  
CC gene. The present sequence is a cDNA encoding a PRO protein.  
XX  
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;  
Query Match 3.0%; Score 66.6; DB 12; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;  
QY 2121 CCTTGGCTTTACCACCTCTTCTTTTATCTTATTATAAATAATGTTGGTCTCCACCACTG 2180  
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
2653 CCTTTCCTTCCCCATCTCTGTACACATTTTATAATAAATAAGGTTGGCTTCTGAACATA 2712  
QY 2181 NCTCCCAAA 2240  
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
2713 CAA 2772  
QY 2241 AA 2242  
Db ||  
2773 AA 2774  
RESULT 926  
ADH02534  
ID ADH02534 standard; cDNA; 2846 BP.  
XX  
AC ADH02534;  
XX  
DT 11-MAR-2004 (first entry)

XX Human PRO polynucleotide #19.  
DE  
XX Human; PRO; gene; ss; tumour necrosis factor-alpha; TNF-alpha; blood;  
KW chondrocyte cell; tumour; cancer.  
KW Homo sapiens.  
OS  
XX US2003180840-A1.  
PN  
XX  
PD 25-SEP-2003.  
XX  
XX 07-MAY-2002; 2002US-00063671.  
XX  
PR 30-DEC-1998; 98XR-00062142.  
PR 08-MAR-1999; 99WO-US005028.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380139.  
PR 25-AUG-1999; 99US-00380142.  
PR 15-SEP-1999; 99US-00397342.  
PR 18-OCT-1999; 99US-00403297.  
PR 12-NOV-1999; 99US-00423844.  
PR 30-DEC-1999; 99WO-US031274.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 22-AUG-2000; 2000US-00644848.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00664610.  
PR 18-SEP-2000; 2000US-00665350.  
PR 08-NOV-2000; 2000US-00709238.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001US-00816744.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 30-MAY-2001; 2001US-00870574.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 29-JUN-2001; 2001US-00869599.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-DEC-2001; 2001US-00006867.  
XX (GETH ) GENENTECH INC.  
PA  
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;  
PI  
XX WPI; 2004-020797/02.  
DR P-PSDB; ADH02535.  
XX  
PT New PRO polypeptide and nucleic acid encoding the polypeptide, for use in  
PT gene therapy, chromosome identification, tissue typing, or as  
PT hybridization probes in chromosome and gene mapping.  
XX  
PS Disclosure; SEQ ID NO 37; 398pp; English.  
XX  
CC The invention relates to human PRO polypeptides and the PRO  
CC polynucleotides encoding them. The invention also relates to an antibody  
CC that specifically binds to the polypeptide, a method for stimulating the  
CC release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a  
CC method for stimulating proliferation or differentiation of chondrocyte  
CC cells and a method for detecting the presence of a tumour in a mammal  
CC comprising comparing the level of expression of any PRO polypeptide,

given in the specification, in a test sample of cells taken from the mammal with a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptide in the test sample as compared to the control sample indicates the presence of a tumour in the mammal. The polynucleotides are useful as hybridisation probes in chromosome and gene mapping or in generating antisense RNA and DNA, for preparing PRO polypeptides, in assays to identify other proteins or molecules involved in binding reactions, to generate transgenic animals or knockout animals, which in turn are useful in the development and screening of therapeutically useful reagents, for chromosome identification and in tissue typing. The PRO polypeptides and polynucleotides are also useful in gene therapy and as molecular weight markers for protein electrophoresis. The anti-PRO antibodies may be used in diagnostic assays for PRO or for the affinity purification of PRO from recombinant cell culture or natural sources. This sequence represents a human PRO polynucleotide of the invention.

```
Query Match      3.0%;      Score 66.6;  DB 12;  Length 2846;
Best Local Similarity 71.3%;      Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
```

Qy	2121	CCTTTGCTTTACACTCTTTTCCTTTTATCTTATTAAATAAAAAATGTTGGTCTCCACCACTG	2180
Db	2653	CCTTTTCCTTCCCATCTCTTGACACATTTTATAAAAAATAAGGGTTGGCTTCTGAACATA	2712
Qy	2181	NTCCCCAAAAAATAA	2240
Db	2713	CAAAAAAATAA	2772
Qy	2241	AA	2242
Db	2773	AA	2774

RESULT 927  
ADG69028  
ID ADG69028 standard; cDNA; 2846 BP.

AC ADG69028;  
XX  
XX  
DT 11-MAR-2004 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX  
ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;  
KW affinity purification; secreted and transmembrane protein.  
KW

XX	US2003180849-A1.
PN	
XX	25-SEP-2003.
PD	
XX	08-MAY-2002; 2002US-00063698.
PF	

PR	30-DEC-1998;	98KR-00062142.
PR	08-MAR-1999;	99WO-US005028.
PR	14-MAY-1999;	99US-00311832.
PR	14-MAY-1999;	99WO-US010733.
PR	25-AUG-1999;	99US-00380137.
PR	25-AUG-1999;	99US-00380138.
PR	25-AUG-1999;	99US-00380139.
PR	25-AUG-1999;	99US-00380142.
PR	15-SEP-1999;	99US-00397342.
PR	18-OCT-1999;	99US-00403297.
PR	12-NOV-1999;	99US-00423844.
PR	30-DEC-1999;	99WO-US031274.
PR	18-FEB-2000;	2000WO-US004341.
PR	01-MAR-2000;	2000WO-US005601.
PR	02-MAR-2000;	2000WO-US005841.
PR	21-MAR-2000;	2000WO-US007532.

PR	22-MAY-2000;	2000WO-US014042.
PR	02-JUN-2000;	2000WO-US015264.
PR	22-AUG-2000;	2000US-0064848.
PR	24-AUG-2000;	2000WO-US023328.
PR	18-SEP-2000;	2000US-00664610.
PR	18-SEP-2000;	2000US-00665350.
PR	08-NOV-2000;	2000US-00709238.
PR	10-NOV-2000;	2000WO-US030873.
PR	01-DEC-2000;	2000WO-US032678.
PR	20-DEC-2000;	2000US-00747259.
PR	20-DEC-2000;	2000WO-US034956.
PR	28-FEB-2001;	2001WO-US005520.
PR	22-MAR-2001;	2001US-00816744.
PR	10-MAY-2001;	2001US-00854208.
PR	10-MAY-2001;	2001US-00854280.
PR	30-MAY-2001;	2001US-00870574.
PR	01-JUN-2001;	2001WO-US017800.
PR	05-JUN-2001;	2001US-00874503.
PR	29-JUN-2001;	2001US-00869599.
PR	18-JUL-2001;	2001US-00908827.
PR	06-DEC-2001;	2001US-00006867.

(GETH ) GENENTECH INC.

PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

DR WPI; 2004-020805/02.  
DR P-PSDB; ADG69029.

New PRO polypeptides and nucleic acids encoding the polypeptides, useful in gene therapy, chromosome identification, tissue typing, or as hybridization probes in chromosome and gene mapping.

PS Disclosure: SEO ID NO 37: 398pp: English.

The invention relates to a PRO (secreted and transmembrane protein) polynucleotide appearing as ADG69072 encoding PRO polypeptide having appearing as ADG69072. Also included are a vector comprising the novel nucleic acid and a host cell comprising the vector. The polynucleotide is useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy. The polynucleotide may also be used in preparing PRO polypeptides by recombinant techniques, and in generating either transgenic animals or knock-out animals which, in turn, are useful in the development and screening of therapeutically useful reagents. The PRO polynucleotide is used in preparing a medicament for treating a condition responsive to the polypeptide or antibody, such as tumours, and in various diagnostic assays. The specification discloses 84 PRO proteins and 84 PRO polynucleotides. The present sequence encodes a PRO protein.

Sequence 2846 BP: 768 A: 696 C: 745 G: 637 T: 0 U: 0 Other: 0

```
Query Match      3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
```

Qy	2121	CCTTTGCTTTACCACTCTTTTCCCTTTTATCTTATTAAATAAAAAATGTTGGTCTCCACCACCTG	2180
Db	2653	CCTTTTCCTTCCCTCCCATCTCTTGACACATTTTAAATAAAAAATAAGGGTTGGCTTCTGAACATA	2712
Qy	2181	NCTCCCAAA	2240
Db	2713	CAAA	2772
Qy	2241	AA	2242
Db	2773	AA	2774

RESULT 928  
ADH07631  
ID ADH07631 standard; cDNA; 2846 BP.













```
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
XX (GETH ) GENENTECH INC.
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2004-059333/06.
DR P-PSDB; ADH57203.
XX
PT New isolated PRO polypeptide, useful for treating various bone and/or
PT cartilage disorders, for example, sports injuries and arthritis.
XX
PS Disclosure; Fig 37; 395pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACCTCTTCTCTTTTATCTTATTATAATAAAATGTTGGTCTCCACCACTG 2180
DB ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTTCCTTCCCCATCTCTGTACACATTTTAAATAAAATAAGGGTTGGCTTCTGAACCTA 2712
```

```
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
Db ||
2773 AA 2774

RESULT 934
ADH52190
ID ADH52190 standard; cDNA; 2846 BP.
XX
AC ADH52190;
XX
DT 25-MAR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
OS Homo sapiens.
XX
PN US2003180921-A1.
XX
PD 25-SEP-2003.
XX
PF 08-MAY-2002; 2002US-00063731.
XX
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH ) GENENTECH INC.
```













```
CC transmembrane PRO protein.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match      3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTATAAAATGTTGGTCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCCTTCCCATCTCTTGACACATTTTATAAAATAGGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 940
ADH90688
ID ADH90688 standard; cDNA; 2846 BP.
XX
AC ADH90688;
XX
DT 22-APR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW affinity purification; secreted and transmembrane protein.
XX
OS Homo sapiens.
XX
PN US2003181701-A1.
XX
PD 25-SEP-2003.
XX
PF 08-MAY-2002; 2002US-00063682.
XX
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
```

```
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
XX (GETH ) GENENTECH INC.
XX
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2004-020836/02.
DR P-PSDB; ADH90689.
XX
PT New PRO nucleic acid, useful for preparing a medicament for treating a
PT condition associated with PRO nucleic acid e.g. cancer.
XX
XX PS Disclosure; SEQ ID NO 37; 398pp; English.
XX
CC The invention relates to a novel PRO (secreted and transmembrane protein)
CC polypeptide, and the polynucleotide sequence encoding it. Also included
CC are a vector comprising the novel nucleic acid and a host cell comprising
CC the vector. The polynucleotide sequence is useful in molecular biology as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, and in gene therapy. The polynucleotide sequence
CC may also be used in preparing the PRO polypeptide by recombinant
CC techniques, and in generating either transgenic or knock-out animals
CC which, in turn, are useful in the development and screening of
CC therapeutically useful reagents. The PRO polynucleotide sequence is
CC useful in preparing a medicament for treating a condition responsive to
CC the polypeptide or antibody, such as tumours, and in various diagnostic
CC assays. The specification also discloses other PRO proteins and the
CC polynucleotide sequences encoding them. The present sequence encodes a
CC PRO protein.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match      3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTATAAAATGTTGGTCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCCTTCCCATCTCTTGACACATTTTATAAAATAGGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 941
ADJ54807
ID ADJ54807 standard; cDNA; 2846 BP.
XX
AC ADJ54807;
XX
XX 06-MAY-2004 (first entry)
XX
DE Human PRO polynucleotide #85.
XX
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW cancer; tumour; adrenal; lung; colon; breast; prostate; rectum; cervix;
KW liver; tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW bone disorder; cartilage disorder; arthritis.
XX
OS Homo sapiens.
XX
PN US2004023321-A1.
```

```
XX 05-FEB-2004.
XX 17-JUL-2002; 2002US-00197709.
XX 18-DEC-1997; 97US-0068017P.
PR 01-DEC-1998; 98WO-US025108.
PR 03-MAR-1999; 99US-00254311.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX (GETH ) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-224694/21.
DR P-PSDB; ADJ54808.
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, as diagnostic markers for the presence of cancerous
PT tumors, and as therapeutic targets for treating the tumors.
XX Claim 2; SEQ ID NO 169; 700pp; English.
XX The invention relates to human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. They are particularly useful for
CC detecting tumors (e.g. adrenal tumour, lung tumour, colon tumour, breast
CC tumour, prostate tumour, rectal tumour, cervical tumour, or liver tumour)
CC in a mammal, for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood or for stimulating the proliferation or
CC differentiation of chondrocyte cells. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as bone or cartilage disorders (e.g. arthritis) and
CC cancer. The PRO polypeptides are useful as molecular markers for protein
CC electrophoresis, and in tissue typing. This sequence represents a human
CC PRO polynucleotide of the invention. Note: The sequence data for this
CC patent is also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match      3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTCTCTTTATCTTATTAATAAAATGTTGCTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTCTCTCCCACTCTCTGTACACATTTTAAATAAAATAAGGGTTGGCTTCTGAAC 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db ||
2773 AA 2774

RESULT 942
ADJ98563
ID ADJ98563 standard; cDNA; 2846 BP.
XX
AC ADJ98563;
```

```
XX 06-MAY-2004 (first entry)
XX Novel human secreted and transmembrane protein PRO1344 cDNA.
DE
XX antiarthritic; antidiabetic; cytostatic; vulnerrary; hyperglycaemic;
KW hypoglycaemic; antibody therapy; PRO; secreted and transmembrane;
KW bone disorder; cartilage disorder; sports injury; arthritis;
KW glucose uptake; skeletal muscle; diabetes; hyper-insulinaemia;
KW hypo-insulinaemia; pericyte-associated tumour; wound healing; cancer;
KW chromosome identification; gene therapy; gene; ss; human.
XX Homo sapiens.
OS
XX US2003187197-A1.
PN
XX 02-OCT-2003.
XX
XX 07-MAY-2002; 2002US-00063647.
XX
XX 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00655350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX (GETH ) GENENTECH INC.
PA
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
XX WPI; 2004-009972/01.
DR P-PSDB; ADJ98564.
XX
XX New isolated PRO polypeptide, useful for treating various bone and/or
PT cartilage disorders, for example, sports injuries and arthritis.
XX Disclosure; SEQ ID NO 37; 397pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide comprising the 642 amino acid sequence (S1) defined in the
```





RESULT 944  
ADH78892  
ID ADH78892 standard; cDNA; 2846 BP.  
XX  
AC ADH78892;  
XX  
DT 06-MAY-2004 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX  
KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;  
KW affinity purification; secreted and transmembrane protein.  
XX  
OS Homo sapiens.  
XX  
PN US2003181703-A1.  
XX  
PD 25-SEP-2003.  
XX  
PF 08-MAY-2002; 2002US-00063723.  
XX  
PR 30-DEC-1998; 98KR-00062142.  
PR 08-MAR-1999; 99WO-US005028.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380139.  
PR 25-AUG-1999; 99US-00380142.  
PR 15-SEP-1999; 99US-00397342.  
PR 18-OCT-1999; 99US-00403297.  
PR 12-NOV-1999; 99US-00423844.  
PR 30-DEC-1999; 99WO-US031274.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 22-AUG-2000; 2000US-00644848.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00664610.  
PR 18-SEP-2000; 2000US-00665350.  
PR 08-NOV-2000; 2000US-00709238.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001US-00816744.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 30-MAY-2001; 2001US-00870574.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 29-JUN-2001; 2001US-00869599.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-DEC-2001; 2001US-00006867.  
XX  
(GETH ) GENENTECH INC.  
XX  
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;  
XX  
DR WPI; 2004-088894/09.  
DR P-PSDB; ADH78893.  
XX  
PT New PRO nucleic acid, useful for preparing a medicament for treating a  
PT condition associated with the PRO nucleic acid e.g., cancer, by gene  
PT therapy.  
XX  
PS Disclosure; SEQ ID NO 37; 398pp; English.

The invention relates to a PRO (secreted and transmembrane protein) polynucleotide appearing as ADH78958 encoding PRO polypeptide having appearing as ADH78959. Also included are a vector comprising the novel nucleic acid and a host cell comprising the vector. The polynucleotide is useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy. The polynucleotide may also be used in preparing PRO transgenic animals or knock-out animals which, in turn, are useful in the development and screening of therapeutically useful reagents. The PRO polynucleotide is used in preparing a medicament for treating a condition responsive to the polypeptide or antibody, such as tumours, and in various diagnostic assays. The specification discloses 84 PRO proteins and 84 PRO polynucleotides. The present sequence encodes a PRO protein.

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match	3.0%;	Score 66.6;	DB 12;	Length 2846;
Best Local Similarity	71.3%;	Pred. No. 0.00023;		
Matches 87;	Conservative 0;	Mismatches 35;	Indels 0;	Gaps 0;

```

QY      2121 CCTTTGGCTTTACCACTCTTTTCCTTTTATCTTATAATAAAATGTTGGTCTCCACCACGTG 21800
          ||||| | ||| | ||| | ||| | ||| | ||| | ||| | ||| | ||| | ||| | ||| |
Db      2653 CCTTTTCCTTCCCACATCTCTTGACACATTTTAATAAATAAGGGTTGGCTTCTGAACATA 27120

QY      2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 22400
          ||||| | ||| | ||| | ||| | ||| | ||| | ||| | ||| | ||| | ||| | ||| |
Db      2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 22400

QY      2241 AA 2242
          ||
Db      2773 AA 2774

RESULT 945
ADJ99126
ID   ADJ99126 standard; cDNA; 2846 BP.
XX
AC   ADJ99126;
XX
DT   06-MAY-2004 (first entry)
DE   Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW   antiarthritic; antidiabetic; cytostatic; vulnerary; hyperglycaemic;
KW   hypoglycaemic; antibody therapy; PRO; secreted and transmembrane;
KW   bone disorder; cartilage disorder; sports injury; arthritis;
KW   glucose uptake; skeletal muscle; diabetes; hyper-insulinaemia;
KW   hypo-insulinaemia; pericyte-associated tumour; wound healing; cancer;
KW   chromosome identification; gene therapy; gene; ss; human.
XX
OS   Homo sapiens.
XX
PN   US2003186408-A1.
XX
PD   02-OCT-2003.
XX
PF   08-MAY-2002; 2002US-00063688.
XX
PR   30-DEC-1998; 98KR-00062142.
PR   08-MAR-1999; 99WO-US005028.
PR   14-MAY-1999; 99US-00311832.
PR   14-MAY-1999; 99WO-US010733.
PR   25-AUG-1999; 99US-00380137.
PR   25-AUG-1999; 99US-00380138.
PR   25-AUG-1999; 99US-00380139.
PR   25-AUG-1999; 99US-00380142.
PR   15-SEP-1999; 99US-00397342.
PR   18-OCT-1999; 99US-00403297.
PR   12-NOV-1999; 99US-00423844.
PR   30-DEC-1999; 99WO-US031274.
PR   18-FEB-2000; 2000WO-US004341.

```

PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 22-AUG-2000; 2000US-00644848.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00664610.  
PR 18-SEP-2000; 2000US-00665350.  
PR 08-NOV-2000; 2000US-00709238.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 28-FEB-2001; 2001WO-US034956.  
PR 22-MAR-2001; 2001US-00816744.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 30-MAY-2001; 2001US-00870574.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 29-JUN-2001; 2001US-00869599.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-DEC-2001; 2001US-00006867.  
XX  
PA (GETH ) GENENTECH INC.

XX  
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX  
DR WPI; 2004-032011/03.  
DR P-PSDB; ADJ99127.

XX  
PT Isolated nucleic acid useful in molecular biology, has nucleic acid  
PT sequence identity to: e.g. nucleic acid sequence encoding polypeptide  
PT having specified amino acid sequence, and specified nucleic acid  
PT sequence.

XX  
PS Disclosure; SEQ ID NO 37; 398pp; English.

XX  
CC The invention describes an isolated PRO (secreted and transmembrane)  
CC polypeptide comprising the 642 amino acid sequence (S1) defined in the  
CC specification. The PRO polypeptides are useful for treating various bone  
CC and/or cartilage disorders, for example, sports injuries and arthritis.  
CC They are also useful in the therapeutic treatment of disorders where  
CC either the stimulation or inhibition of glucose uptake by skeletal muscle  
CC would be beneficial, for example, diabetes or hyper- or hypo-  
CC insulinaemia. They are also useful for treating pericyte-associated  
CC tumours and in wound healing. The anti-PRO antibody is useful for the  
CC preparation of a medicament useful in the treatment of cancer. The PRO  
CC polypeptides are also useful as molecular weight markers, or for  
CC chromosome identification. The PRO genes are useful as hybridisation  
CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.  
CC The PRO genes may also be used in gene therapy, particularly for  
CC replacing a defective gene. This sequence encodes a secreted and  
CC transmembrane PRO protein.

XX  
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACCTCTTTCCCTTTTATCTTATTATAATAAAATGTGGTCTCCACCACTG 2180  
||||| ||||| ||||| || ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Db 2653 CCTTTTCCTCCCATCTCTTGTACACATTTTAATAAAATAAGGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAA 2240  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Db 2713 CAAAAA  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 2241 AA 2242  
||

Db 2773 AA 2774  
RESULT 946  
ADJ99296  
ID ADJ99296 standard; cDNA; 2846 BP.  
XX  
AC ADJ99296;  
XX  
DT 06-MAY-2004 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX  
KW antiarthritic; antidiabetic; cytostatic; vulnerary; hyperglycaemic;  
KW hypoglycaemic; antibody therapy; PRO; secreted and transmembrane;  
KW bone disorder; cartilage disorder; sports injury; arthritis;  
KW glucose uptake; skeletal muscle; diabetes; hyper-insulinaemia;  
KW hypo-insulinaemia; pericyte-associated tumour; wound healing; cancer;  
KW chromosome identification; gene therapy; gene; ss; human.  
XX  
OS Homo sapiens.  
XX  
PN US2003187196-A1.  
XX  
PD 02-OCT-2003.  
XX  
PF 01-MAY-2002; 2002US-00063520.  
XX  
PR 30-DEC-1998; 98KR-00062142.  
PR 08-MAR-1999; 99WO-US005028.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380139.  
PR 25-AUG-1999; 99US-00380142.  
PR 15-SEP-1999; 99US-00397342.  
PR 18-OCT-1999; 99US-00403297.  
PR 12-NOV-1999; 99US-00423844.  
PR 30-DEC-1999; 99WO-US031274.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 22-AUG-2000; 2000US-00644848.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00664610.  
PR 18-SEP-2000; 2000US-00665350.  
PR 08-NOV-2000; 2000US-00709238.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001US-00816744.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 30-MAY-2001; 2001US-00870574.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 29-JUN-2001; 2001US-00869599.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-DEC-2001; 2001US-00006867.  
XX  
(GETH ) GENENTECH INC.  
XX  
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;  
XX  
DR WPI; 2004-009971/01.  
DR P-PSDB; ADJ99297.





Db 2773 AA 2774

RESULT 948

ADH79062

ID ADH79062 standard; cDNA; 2846 BP.

XX

AC ADH79062;

DT 06-MAY-2004 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO1344 cDNA.

XX

KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;

KW affinity purification; secreted and transmembrane protein.

XX

OS Homo sapiens.

XX

PN US2003181702-A1.

XX

PD 25-SEP-2003.

XX

PF 08-MAY-2002; 2002US-00063721.

XX

PR 30-DEC-1998; 98KR-00062142.

PR 08-MAR-1999; 99WO-US005028.

PR 14-MAY-1999; 99US-00311832.

PR 14-MAY-1999; 99WO-US010733.

PR 25-AUG-1999; 99US-00380137.

PR 25-AUG-1999; 99US-00380138.

PR 25-AUG-1999; 99US-00380139.

PR 25-AUG-1999; 99US-00380142.

PR 15-SEP-1999; 99US-00397342.

PR 18-OCT-1999; 99US-00403297.

PR 12-NOV-1999; 99US-00423844.

PR 30-DEC-1999; 99WO-US031274.

PR 18-FEB-2000; 2000WO-US004341.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005841.

PR 21-MAR-2000; 2000WO-US007532.

PR 22-MAY-2000; 2000WO-US014042.

PR 02-JUN-2000; 2000WO-US015264.

PR 22-AUG-2000; 2000US-00644848.

PR 24-AUG-2000; 2000WO-US023328.

PR 18-SEP-2000; 2000US-00664610.

PR 18-SEP-2000; 2000US-00665350.

PR 08-NOV-2000; 2000US-00709238.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001WO-US006520.

PR 22-MAR-2001; 2001US-00816744.

PR 10-MAY-2001; 2001US-00854208.

PR 30-MAY-2001; 2001US-00870574.

PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.

PR 29-JUN-2001; 2001US-00869599.

PR 18-JUL-2001; 2001US-00908827.

PR 06-DEC-2001; 2001US-00006867.

XX

PA (GETH ) GENENTECH INC.

XX

PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX

DR WPI; 2004-080359/08.

DR P-PSDB; ADH79063.

XX

PT New PRO nucleic acid, useful for preparing a medicament for treating a

PT condition associated with the PRO nucleic acid e.g., cancer, by gene

PT therapy.

XX Disclosure; SEQ ID NO 37; 398pp; English.

PS

XX

CC The invention relates to a PRO (secreted and transmembrane protein)

CC polynucleotide appearing as ADH79123 encoding PRO polypeptide having

CC appearing as ADH79124. Also included are a vector comprising the novel

CC nucleic acid and a host cell comprising the vector. The polynucleotide is

CC useful in molecular biology, including uses as hybridisation probes, in

CC chromosome and gene mapping, in generating antisense RNA and DNA, and in

CC gene therapy. The polynucleotide may also be used in preparing PRO

CC polypeptides by recombinant techniques, and in generating either

CC transgenic animals or knock-out animals which, in turn, are useful in the

CC development and screening of therapeutically useful reagents. The PRO

CC polynucleotide is used in preparing a medicament for treating a condition

CC responsive to the polypeptide or antibody, such as tumours, and in

CC various diagnostic assays. The specification discloses 84 PRO proteins

CC and 84 PRO polynucleotides. The present sequence encodes a PRO protein.

XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTATAATAAATGTTGGTCTCCACCACTG 2180

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

2653 CCTTTTCCTTCCCATCTCTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAA 2240

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

2713 CAAA 2772

QY 2241 AA 2242

Db ||

2773 AA 2774

RESULT 949

ADK00922

ID ADK00922 standard; cDNA; 2846 BP.

XX

AC ADK00922;

XX

DT 06-MAY-2004 (first entry)

XX

DE Human PRO polynucleotide #19.

XX

KW Human; PRO; gene; ss; tumour necrosis factor-alpha; TNF-alpha; blood;

KW chondrocyte cell; tumour; cancer.

XX

OS Homo sapiens.

XX

PN US2003186407-A1.

XX

PD 02-OCT-2003.

XX

PF 08-MAY-2002; 2002US-00063684.

XX

PR 30-DEC-1998; 98KR-00062142.

PR 08-MAR-1999; 99WO-US005028.

PR 14-MAY-1999; 99US-00311832.

PR 14-MAY-1999; 99WO-US010733.

PR 25-AUG-1999; 99US-00380137.

PR 25-AUG-1999; 99US-00380138.

PR 25-AUG-1999; 99US-00380139.

PR 25-AUG-1999; 99US-00380142.

PR 15-SEP-1999; 99US-00397342.

PR 18-OCT-1999; 99US-00403297.

PR 12-NOV-1999; 99US-00423844.

PR 30-DEC-1999; 99WO-US031274.

PR 18-FEB-2000; 2000WO-US004341.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005841.

PR 21-MAR-2000; 2000WO-US007532.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 22-AUG-2000; 2000US-00644848.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00664610.  
PR 18-SEP-2000; 2000US-00665350.  
PR 08-NOV-2000; 2000US-00709238.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001US-00816744.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 30-MAY-2001; 2001US-00870574.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 29-JUN-2001; 2001US-00869599.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-DEC-2001; 2001US-00006867.

XX (GETH ) GENENTECH INC.

XX PA  
XX PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX DR WPI; 2004-032010/03.  
DR P-PSDB; ADK00923.

XX PT Isolated nucleic acid useful for e.g. chromosome identification, has  
PT nucleic acid sequence identity to: e.g. nucleic acid sequence encoding  
PT polypeptide having specified amino acid sequence, and specified nucleic  
PT acid sequence.

XX PS Disclosure; SEQ ID NO 37; 397pp; English.

XX CC The invention relates to human PRO polypeptides and the PRO  
CC polynucleotides encoding them. The invention also relates to an antibody  
CC that specifically binds to the polypeptide, a method for stimulating the  
CC release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a  
CC method for stimulating proliferation or differentiation of chondrocyte  
CC cells and a method for detecting the presence of a tumour in a mammal  
CC comprising comparing the level of expression of any PRO polypeptide,  
CC given in the specification, in a test sample of cells taken from the  
CC mammal with a control sample of normal cells of the same cell type, where  
CC a higher level of expression of the PRO polypeptide in the test sample as  
CC compared to the control sample indicates the presence of a tumour in the  
CC mammal. The polynucleotides are useful as hybridisation probes in  
CC chromosome and gene mapping or in generating antisense RNA and DNA, for  
CC preparing PRO polypeptides, in assays to identify other proteins or  
CC molecules involved in binding reactions, to generate transgenic animals  
CC or knockout animals, which in turn are useful in the development and  
CC screening of therapeutically useful reagents, for chromosome  
CC identification and in tissue typing. The PRO polypeptides and  
CC polynucleotides are also useful in gene therapy and as molecular weight  
CC markers for protein electrophoresis. The anti-PRO antibodies may be used  
CC in diagnostic assays for PRO or for the affinity purification of PRO from  
CC recombinant cell culture or natural sources. This sequence represents a  
CC human PRO polynucleotide of the invention.

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACCTCTTCTCCTTTTATCTTATTAATAAATGTTGGTCTCCACCACTG 2180  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 2653 CCTTTTCTTCCCATCTCTTGTACACATTTTAAATAAATAAGGTTGGCTTCTGAACTA 2712  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
QY 2181 NCTCCCAA 2240

Db 2713 CAAA 2772  
|||  
QY 2241 AA 2242  
||  
Db 2773 AA 2774  
||  
RESULT 950  
ADK14443  
ID ADK14443 standard; cDNA; 2846 BP.  
XX AC ADK14443;  
XX DT 06-MAY-2004 (first entry)  
XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX KW PRO; human; secreted; transmembrane; cancer; antibody; ss; gene.  
XX OS Homo sapiens.  
XX PN US2003187229-A1.  
XX PD 02-OCT-2003.  
XX PF 03-MAY-2002; 2002US-00063578.  
XX PR 30-DEC-1998; 98KR-00062142.  
PR 08-MAR-1999; 99WO-US005028.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380139.  
PR 25-AUG-1999; 99US-00380142.  
PR 15-SEP-1999; 99US-00397342.  
PR 18-OCT-1999; 99US-00403297.  
PR 12-NOV-1999; 99US-00423844.  
PR 30-DEC-1999; 99WO-US031274.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000US-0015264.  
PR 22-AUG-2000; 2000US-00644848.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00664610.  
PR 18-SEP-2000; 2000US-00665350.  
PR 08-NOV-2000; 2000US-00709238.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001US-00816744.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 30-MAY-2001; 2001US-00870574.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 29-JUN-2001; 2001US-00869599.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-DEC-2001; 2001US-00006867.  
XX (GETH ) GENENTECH INC.  
XX PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;  
XX DR WPI; 2004-009981/01.  
DR P-PSDB; ADK14444.

XX Novel antibody that binds to a PRO polypeptide, useful for treating  
PT cancer and in diagnostic assays, for e.g. detecting PRO expression in  
PT specific cells, tissues, or serum.  
XX  
PS Example 4; SEQ ID NO 37; 396pp; English.  
XX  
CC This invention describes a novel antibody that binds to a human secreted  
CC and transmembrane PRO polypeptide. The antibody is preferably a  
CC monoclonal or humanised antibody, or an antibody fragment. It is  
CC preferably labelled. The antibody can be used to treat cancer. The anti-  
CC PRO antibody can be used in diagnostic assays, for e.g. detecting PRO  
CC expression in specific cells, tissues, or serum. The anti-PRO antibodies  
CC are also useful for the affinity purification of PRO from recombinant  
CC cell culture or natural sources. ADK14407-ADK14574 represent human PRO  
CC polynucleotides and polypeptides described in the disclosure of the  
CC invention.  
XX  
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;  
Query Match 3.0%; Score 66.6; DB 12; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;  
QY 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180  
Db 2653 CCTTTTCCTTCCCATCTCTTGACACATTTTAATAAATAAGGTTGGCTTCTGAACTA 2712  
QY 2181 NCTCCCAA 2240  
Db 2713 CAAA 2772  
QY 2241 AA 2242  
Db 2773 AA 2774  
RESULT 951  
ID ADJ64578 standard; cDNA; 2846 BP.  
XX  
AC ADJ64578;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Human PRO polynucleotide #85.  
XX  
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;  
KW cancer; tumour; adrenal; lung; colon; breast; prostate; rectum; cervix;  
KW liver; tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;  
KW bone disorder; cartilage disorder; arthritis.  
XX  
OS Homo sapiens.  
XX  
PN US2004038337-A1.  
XX  
PD 26-FEB-2004.  
XX  
PF 23-JUL-2002; 2002US-00201858.  
XX  
PR 17-NOV-1998; 98US-0108788P.  
PR 01-SEP-1999; 99WO-US020111.  
PR 18-OCT-1999; 99US-00403297.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 15-JAN-2002; 2002US-00052586.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;  
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR WPI; 2004-203227/19.  
DR P-PSDB; ADJ64579.

XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
PT for detecting the presence of a tumor in a mammal and as therapeutic  
PT targets for treating a tumor.  
XX  
PS Claim 2; SEQ ID NO 169; 700pp; English.  
XX  
CC The invention relates to human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the PRO polynucleotides encoding them.  
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,  
CC diagnostics, biosensors or bioeffectors. They are particularly useful for  
CC detecting tumours (e.g. adrenal tumour, lung tumour, colon tumour, breast  
CC tumour, prostate tumour, rectal tumour, cervical tumour, or liver tumour)  
CC in a mammal, for stimulating the release of tumour necrosis factor (TNF)-  
CC alpha from human blood or for stimulating the proliferation or  
CC differentiation of chondrocyte cells. The PRO nucleic acids are useful as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant  
CC technology, in generating transgenic animals or knock-out animals which  
CC may be used in the development and screening of therapeutically useful  
CC reagents, in gene therapy, in chromosome identification, as chromosome  
CC markers and in generating probes. The PRO polypeptides, or anti-PRO  
CC antibodies, are useful for preparing a medicament for treating a  
CC condition which is responsive to the PRO polypeptides or anti-PRO  
CC antibodies, such as bone or cartilage disorders (e.g. arthritis) and  
CC cancer. The PRO polypeptides are useful as molecular markers for protein  
CC electrophoresis, and in tissue typing. This sequence represents a human  
CC PRO polynucleotide of the invention. Note: The sequence data for this  
CC patent is also available in electronic format from USPTO at  
CC seqdata.uspto.gov/sequence.html.  
XX  
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;  
Query Match 3.0%; Score 66.6; DB 12; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;  
QY 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180  
Db 2653 CCTTTTCCTTCCCATCTCTTGACACATTTTAATAAATAAGGTTGGCTTCTGAACTA 2712  
QY 2181 NCTCCCAA 2240  
Db 2713 CAAA 2772  
QY 2241 AA 2242  
Db 2773 AA 2774  
RESULT 952  
ID ADM31474 standard; cDNA; 2846 BP.  
XX  
AC ADM31474;  
XX  
DT 03-JUN-2004 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX  
KW Human; ss; gene; cytostatic; gene therapy; chondrocyte stimulator;  
KW secreted and transmembrane protein; PRO; chromosome mapping;  
KW gene mapping; tumour.  
XX  
OS Homo sapiens.  
XX  
PN US2004048334-A1.  
XX  
PD 11-MAR-2004.  
XX  
PF 26-JUL-2002; 2002US-00205890.  
XX  
PR 15-SEP-2000; 2000US-0232887P.



PR 28-FEB-2001; 2001WO-US0006520.  
PR 15-JAN-2002; 2002US-00052586.  
XX  
PA (GETH ) GENENTECH INC.  
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;  
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR WPI; 2004-238495/22.  
DR P-PSDB; ADM31475.  
XX  
PT New isolated nucleic acids encoding secreted and transmembrane PRO  
PT polypeptides, useful for stimulating the release of tumor necrosis factor  
PT alpha from human blood and detecting the presence of a tumor in a mammal.  
XX  
PS Claim 2; SEQ ID NO 169; 706pp; English.  
XX  
CC The invention describes 305 nucleic acids encoding PRO polypeptides  
CC (secreted and transmembrane). The polynucleotide is useful in molecular  
CC biology, including uses as hybridisation probes, in chromosome and gene  
CC mapping, in generating antisense RNA and DNA, and in gene therapy. The  
CC polynucleotide may also be used in preparing PRO polypeptides by  
CC recombinant techniques, and in generating either transgenic animals or  
CC knock-out animals which, in turn, are useful in the development and  
CC screening of therapeutically useful reagents. The PRO polypeptide or the  
CC antibody is used in preparing a medicament for treating a condition  
CC responsive to the polypeptide or antibody, such as tumours, and in  
CC various diagnostic assays. This sequence encodes a novel human secreted  
CC and transmembrane PRO polypeptide. Note: This sequence is also available  
CC in electronic format from the US patent office at  
CC ftp.segdata.uspto.gov/sequence.html?DocID=20040048334.  
XX  
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;  
  
Query Match 3.0%; Score 66.6; DB 12; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;  
  
QY 2121 CCTTGGCTTTACCACTCTTCTCTTTATCTTTATTAATAAAATGTTGGTCTCCCACTG 2180  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAAATAGGGTTGGCTTCTGAACTA 2712  
  
QY 2181 NCTCCCAA 2240  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 2713 CAAAAA  
2241 AA 2242  
2773 AA 2774  
  
RESULT 953  
ADM36521  
ID ADM36521 standard; cDNA; 2846 BP.  
XX  
AC ADM36521;  
XX  
DT 03-JUN-2004 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX  
KW Human; ss; gene; cytostatic; gene therapy; chondrocyte stimulator;  
KW secreted and transmembrane protein; PRO; chromosome mapping;  
KW gene mapping; tumour.  
XX  
OS Homo sapiens.  
XX  
PN US2004053358-A1.  
XX  
PD 18-MAR-2004.  
XX  
PF 23-JUL-2002; 2002US-00201853.  
XX

PR 18-NOV-1998; 98US-0108851P.  
PR 01-SEP-1999; 99WO-US020111.  
PR 18-OCT-1999; 99US-00403297.  
PR 28-FEB-2001; 2001WO-US0006520.  
PR 15-JAN-2002; 2002US-00052586.  
XX  
XX (GETH ) GENENTECH INC.  
PA  
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;  
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2004-247725/23.  
DR P-PSDB; ADM36522.  
XX  
PT New secreted and transmembrane PRO polypeptide and nucleic acid, for use  
PT in gene therapy, as diagnostic markers for the presence of cancerous  
PT tumors, and as therapeutic targets for treating the tumors.  
XX  
PS Claim 2; SEQ ID NO 169; 700pp; English.  
XX  
CC The invention describes 305 nucleic acids encoding PRO polypeptides  
CC (secreted and transmembrane). The polynucleotide is useful in molecular  
CC biology, including uses as hybridisation probes, in chromosome and gene  
CC mapping, in generating antisense RNA and DNA, and in gene therapy. The  
CC polynucleotide may also be used in preparing PRO polypeptides by  
CC recombinant techniques, and in generating either transgenic animals or  
CC knock-out animals which, in turn, are useful in the development and  
CC screening of therapeutically useful reagents. The PRO polypeptide or the  
CC antibody is used in preparing a medicament for treating a condition  
CC responsive to the polypeptide or antibody, such as tumours, and in  
CC various diagnostic assays. This sequence encodes a novel human secreted  
CC and transmembrane PRO polypeptide. Note: This sequence is also available  
CC in electronic format from the US patent office at  
CC ftp.segdata.uspto.gov/sequence.html?DocID=20040053358.  
XX  
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;  
  
Query Match 3.0%; Score 66.6; DB 12; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;  
  
QY 2121 CCTTGGCTTTACCACTCTTCTCTTTATCTTTATTAATAAAATGTTGGTCTCCCACTG 2180  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAAATAGGGTTGGCTTCTGAACTA 2712  
  
QY 2181 NCTCCCAA 2240  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 2713 CAAAAA  
2241 AA 2242  
2773 AA 2774  
  
RESULT 954  
ADM40326  
ID ADM40326 standard; cDNA; 2846 BP.  
XX  
AC ADM40326;  
XX  
DT 03-JUN-2004 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX  
KW Human; ss; gene; cytostatic; gene therapy; chondrocyte stimulator;  
KW secreted and transmembrane protein; PRO; chromosome mapping;  
KW gene mapping; tumour.  
XX  
OS Homo sapiens.  
XX  
PN US2004048335-A1.  
XX  
PD 11-MAR-2004.



Db 2713 CAA 2772  
QY 2241 AA 2242  
Db 2773 AA 2774

RESULT 956  
ADN37934  
ID ADN37934 standard; cDNA; 2846 BP.  
XX  
AC ADN37934;  
XX  
DT 29-JUL-2004 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX  
KW Human; ss; gene; cytostatic; gene therapy; chondrocyte stimulator;  
KW secreted and transmembrane protein; PRO; chromosome mapping;  
KW gene mapping; tumour.  
XX  
OS Homo sapiens.  
XX  
PN US2004091959-A1.  
XX  
PD 13-MAY-2004.  
XX  
PF 26-JUL-2002; 2002US-00206916.  
XX  
PR 05-JUN-2000; 2000US-0209832P.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 15-JAN-2002; 2002US-00052586.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;  
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR WPI; 2004-374950/35.  
DR P-PSDB; ADN37935.  
XX  
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic  
PT acids, useful for diagnosing, preventing and/or treating tumors, such as  
PT adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.  
XX  
PS Claim 2; SEQ ID NO 169; 706pp; English.  
XX  
CC The invention describes 305 nucleic acids encoding PRO polypeptides  
CC (secreted and transmembrane). The polynucleotide is useful in molecular  
CC biology, including uses as hybridisation probes, in chromosome and gene  
CC mapping, in generating antisense RNA and DNA, and in gene therapy. The  
CC polynucleotide may also be used in preparing PRO polypeptides by  
CC recombinant techniques, and in generating either transgenic animals or  
CC knock-out animals which, in turn, are useful in the development and  
CC screening of therapeutically useful reagents. The PRO polypeptide or the  
CC antibody is used in preparing a medicament for treating a condition  
CC responsive to the polypeptide or antibody, such as tumours, and in  
CC various diagnostic assays. This sequence encodes a novel human secreted  
CC and transmembrane PRO polypeptide.  
XX  
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;  
Best Local Similarity 71.3%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACCTCTTCTCTTTATCTTATTATAATAAAATGTTGGTCTCCACCACTG 2180  
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTATAATAAATAAGGTTGGCTTCTGAACTA 2712  
QY 2181 NCTCCCAAA 2240

Db 2713 CAA 2772  
QY 2241 AA 2242  
Db 2773 AA 2774

RESULT 957  
ACA67289  
ID ACA67289 standard; cDNA; 2848 BP.  
XX  
AC ACA67289;  
XX  
DT 23-JUN-2003 (first entry)  
XX  
DE cDNA encoding human secreted polypeptide PRO1344.  
XX  
KW Human; gene; ss; affinity purification.  
XX  
OS Homo sapiens.  
XX  
PN US2003027212-A1.  
XX  
PD 06-FEB-2003.  
XX  
PF 02-MAY-2002; 2002US-00063544.  
XX  
PR 30-DEC-1998; 98KR-00062142.  
PR 08-MAR-1999; 99WO-US005028.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380139.  
PR 25-AUG-1999; 99US-00380142.  
PR 15-SEP-1999; 99US-00397342.  
PR 18-OCT-1999; 99US-00403297.  
PR 12-NOV-1999; 99US-00423844.  
PR 30-DEC-1999; 99WO-US031274.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 22-AUG-2000; 2000US-00644848.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00664610.  
PR 18-SEP-2000; 2000US-00665350.  
PR 08-NOV-2000; 2000US-00709238.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001US-00816744.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 30-MAY-2001; 2001US-00870574.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 29-JUN-2001; 2001US-00869599.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-DEC-2001; 2001US-00006867.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;  
XX  
DR WPI; 2003-341840/32.  
DR P-PSDB; ABU81164.  
XX





XX (META-) METAGEN GES GENOMFORSCHUNG MBH.  
PA Rosenthal A, Hinzmann B, Schaefer R, Zuber J, Tchernitsa O;  
PI Grips M, Hellriegel M, Schmitz A, Sers C;  
XX WPI; 2001-483415/52.  
DR Nucleic acids differentially expressed between tumor and normal cells,  
XX useful for diagnosis or therapy of tumors and for screening active  
PT agents.  
PT Disclosure; Page 548; 579pp; German.  
XX This invention describes a nucleic acid (I) with differential expression  
CC between tumour and normal cells and which has cytostatic activity. (I)  
CC work as modulators of Ras activity by inducing expression of tumour  
CC suppressor genes. (I), and polypeptides encoded by them, are useful as  
CC targets for diagnosis or therapy and in screening to determine the  
CC effects of an active compound (potential pharmaceutical) on a cell line,  
CC particularly for diagnosis and treatment of tumors, especially by  
CC modulating expression of (I) (by gene therapy, antisense RNA or ribozyme  
CC methods) or by modulating the amount and/or location of (I)-encoded  
CC polypeptides (by administration of the polypeptide or its activator,  
CC antibody (optionally as a conjugate) or inhibitor). The method allows  
CC identification of many Class II tumour suppressor genes (i.e. genes that  
CC are not primary targets for tumour-initiating mutations). AAH81492-  
CC AAH82376 represent the human and rat derived nucleic acid fragments  
CC described in the method of the invention  
XX  
SQ Sequence 255 BP; 82 A; 35 C; 30 G; 105 T; 0 U; 3 Other;  
Query Match 3.0%; Score 66.4; DB 5; Length 255;  
Best Local Similarity 66.7%; Pred. No. 0.00012;  
Matches 94; Conservative 0; Mismatches 47; Indels 0; Gaps 0;  
QY 2102 TCATTCCATCCAATGATCGCCTTTGCTTTACCACTCTTCTTTTATCTTATTAATAAAA 2161  
Db 147 TAACTGTATTATTGCTGCTATTTTCAGCATAAATTTTCCATTGTTTTTTTATAAAT 88  
QY 2162 ATGTTGGTCTCCACCACCTGCTCCCAAAAAA 2221  
Db 87 AAATATTTTGTGAACCTTTAAAAA 7  
QY 2222 AAAAAA 2242  
Db 27 AAAAAA 7  
RESULT 960  
ABV07596/c  
ID ABV07596 standard; cDNA; 266 BP.  
XX  
AC ABV07596;  
XX  
DT 13-SEP-2002 (first entry)  
XX  
DE Human prostate expression marker cDNA 7587.  
XX  
KW Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;  
KW pharmacogenomic marker; gene; ss.  
XX Homo sapiens.  
OS  
XX WO200160860-A2.  
PN  
XX 23-AUG-2001.  
PD  
XX 20-FEB-2001; 2001WO-US005171.  
PF  
XX 17-FEB-2000; 2000US-0183319P.  
PR  
XX 16-MAR-2000; 2000US-0189862P.  
PR  
XX 25-MAY-2000; 2000US-0207454P.

PR 09-JUN-2000; 2000US-0211314P.  
PR 18-JUL-2000; 2000US-0219007P.  
PR 13-DEC-2000; 2000US-0255281P.  
XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.  
PA  
XX Schlegel R, Endege WO, Monahan JE;  
PI WPI; 2001-662795/76.  
XX  
DR Novel isolated nucleic acid molecule associated with cancerous state of  
XX prostate cells and correlating with presence of prostate cancer, useful  
PT for detecting presence of prostate cancer, stage of prostate cancer.  
PT  
XX  
PS Claim 1; Page 1223; 11750pp; English.  
XX  
CC The invention relates to an isolated nucleic acid molecule (I) comprising  
CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the  
CC specification or its complement. (I) is useful for: (a) assessing whether  
CC a patient is afflicted with prostate cancer; (b) monitoring the  
CC progression of prostate cancer in a patient; (c) assessing the efficacy  
CC of a test compound to inhibit prostate cancer in a patient; (d) assessing  
CC the efficacy of a therapy for inhibiting prostate cancer in a patient;  
CC (e) selecting a composition for inhibiting prostate cancer in a patient;  
CC (f) assessing the prostate cell carcinogenic potential of a compound; (g)  
CC determining whether prostate cancer has metastasized in a patient; (h)  
CC assessing the aggressiveness or indolence of prostate cancer in a patient  
CC ; (I) is also useful as a pharmacodynamic or pharmacogenomic marker  
XX  
SQ Sequence 266 BP; 86 A; 15 C; 16 G; 114 T; 0 U; 35 Other;  
Query Match 3.0%; Score 66.4; DB 5; Length 266;  
Best Local Similarity 65.4%; Pred. No. 0.00012;  
Matches 85; Conservative 0; Mismatches 45; Indels 0; Gaps 0;  
QY 2113 AATGATCGCCTTTGCTTTACCACTCTTCTTTTATCTTATTAATAAATGTTGCTCTC 2172  
Db 170 AATTTTNTNTNTNTNTNAANANANCCNNNTTTTAAATTAANAATTTTNTTTT 111  
QY 2173 CACCACCTGCTCCCAAAAAA 2242  
Db 110 NGTTAAAAA 41  
QY 2233 AAAAAA 2242  
Db 50 AAAAAA 41  
RESULT 961  
ABV04310/c  
ID ABV04310 standard; cDNA; 300 BP.  
XX  
AC ABV04310;  
XX  
DT 13-SEP-2002 (first entry)  
XX  
DE Human prostate expression marker cDNA 4301.  
XX  
KW Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;  
KW pharmacogenomic marker; gene; ss.  
XX Homo sapiens.  
OS  
XX WO200160860-A2.  
PN  
XX 23-AUG-2001.  
PD  
XX 20-FEB-2001; 2001WO-US005171.  
PF  
XX 17-FEB-2000; 2000US-0183319P.  
PR  
XX 16-MAR-2000; 2000US-0189862P.  
PR  
XX 25-MAY-2000; 2000US-0207454P.  
PR  
XX 09-JUN-2000; 2000US-0211314P.







QY 2138 TTTCCCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACCTGNCCTCCCAAAAAA 2197  
Db 64 AAAATCCTTCTCGAAAAA 123  
QY 2198 AAAAAA 2242  
Db 124 AAAAAA 168

RESULT 965  
AAL02457  
ID AAL02457 standard; cDNA; 823 BP.  
XX  
AC AAL02457;  
XX  
DT 21-NOV-2001 (first entry)  
XX  
DE Human reproductive system related antigen cDNA SEQ ID NO: 2458.  
XX  
KW Human; reproductive system related antigen; reproductive system disorder;  
KW cancer; gene therapy; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200155320-A2.  
XX  
PD 02-AUG-2001.  
XX  
PF 17-JAN-2001; 2001WO-US001339.  
XX  
PR 31-JAN-2000; 2000US-0179065P.  
PR 04-FEB-2000; 2000US-0180628P.  
PR 24-FEB-2000; 2000US-0184664P.  
PR 02-MAR-2000; 2000US-0186350P.  
PR 16-MAR-2000; 2000US-0189874P.  
PR 17-MAR-2000; 2000US-0190076P.  
PR 18-APR-2000; 2000US-0198123P.  
PR 19-MAY-2000; 2000US-0205515P.  
PR 07-JUN-2000; 2000US-0209467P.  
PR 28-JUN-2000; 2000US-0214886P.  
PR 30-JUN-2000; 2000US-0215135P.  
PR 07-JUL-2000; 2000US-0216647P.  
PR 07-JUL-2000; 2000US-0216880P.  
PR 11-JUL-2000; 2000US-0217487P.  
PR 11-JUL-2000; 2000US-0217496P.  
PR 14-JUL-2000; 2000US-0218290P.  
PR 26-JUL-2000; 2000US-0220963P.  
PR 26-JUL-2000; 2000US-0220964P.  
PR 14-AUG-2000; 2000US-0224518P.  
PR 14-AUG-2000; 2000US-0224519P.  
PR 14-AUG-2000; 2000US-0225213P.  
PR 14-AUG-2000; 2000US-0225214P.  
PR 14-AUG-2000; 2000US-0225266P.  
PR 14-AUG-2000; 2000US-0225267P.  
PR 14-AUG-2000; 2000US-0225268P.  
PR 14-AUG-2000; 2000US-0225270P.  
PR 14-AUG-2000; 2000US-0225447P.  
PR 14-AUG-2000; 2000US-0225757P.  
PR 14-AUG-2000; 2000US-0225758P.  
PR 14-AUG-2000; 2000US-0225759P.  
PR 18-AUG-2000; 2000US-0226279P.  
PR 22-AUG-2000; 2000US-0226681P.  
PR 22-AUG-2000; 2000US-0226686P.  
PR 22-AUG-2000; 2000US-0227182P.  
PR 23-AUG-2000; 2000US-0227009P.  
PR 30-AUG-2000; 2000US-0228924P.  
PR 01-SEP-2000; 2000US-0229287P.  
PR 01-SEP-2000; 2000US-0229343P.  
PR 01-SEP-2000; 2000US-0229344P.  
PR 01-SEP-2000; 2000US-0229345P.  
PR 05-SEP-2000; 2000US-0229509P.  
PR 06-SEP-2000; 2000US-0229513P.  
PR 06-SEP-2000; 2000US-0230437P.

PR 06-SEP-2000; 2000US-0230438P.  
PR 08-SEP-2000; 2000US-0231242P.  
PR 08-SEP-2000; 2000US-0231243P.  
PR 08-SEP-2000; 2000US-0231244P.  
PR 08-SEP-2000; 2000US-0231413P.  
PR 08-SEP-2000; 2000US-0231414P.  
PR 08-SEP-2000; 2000US-0232080P.  
PR 08-SEP-2000; 2000US-0232081P.  
PR 12-SEP-2000; 2000US-0231968P.  
PR 14-SEP-2000; 2000US-0232397P.  
PR 14-SEP-2000; 2000US-0232398P.  
PR 14-SEP-2000; 2000US-0232399P.  
PR 14-SEP-2000; 2000US-0232400P.  
PR 14-SEP-2000; 2000US-0232401P.  
PR 14-SEP-2000; 2000US-0233063P.  
PR 14-SEP-2000; 2000US-0233064P.  
PR 14-SEP-2000; 2000US-0233065P.  
PR 21-SEP-2000; 2000US-0234223P.  
PR 21-SEP-2000; 2000US-0234274P.  
PR 25-SEP-2000; 2000US-0234997P.  
PR 25-SEP-2000; 2000US-0234998P.  
PR 26-SEP-2000; 2000US-0235484P.  
PR 27-SEP-2000; 2000US-0235834P.  
PR 27-SEP-2000; 2000US-0235836P.  
PR 29-SEP-2000; 2000US-0236327P.  
PR 29-SEP-2000; 2000US-0236367P.  
PR 29-SEP-2000; 2000US-0236368P.  
PR 29-SEP-2000; 2000US-0236369P.  
PR 29-SEP-2000; 2000US-0236370P.  
PR 02-OCT-2000; 2000US-0236802P.  
PR 02-OCT-2000; 2000US-0237037P.  
PR 02-OCT-2000; 2000US-0237038P.  
PR 02-OCT-2000; 2000US-0237039P.  
PR 13-OCT-2000; 2000US-0239935P.  
PR 13-OCT-2000; 2000US-0239937P.  
PR 20-OCT-2000; 2000US-0240960P.  
PR 20-OCT-2000; 2000US-0241221P.  
PR 20-OCT-2000; 2000US-0241785P.  
PR 20-OCT-2000; 2000US-0241786P.  
PR 20-OCT-2000; 2000US-0241787P.  
PR 20-OCT-2000; 2000US-0241808P.  
PR 20-OCT-2000; 2000US-0241809P.  
PR 20-OCT-2000; 2000US-0241826P.  
PR 01-NOV-2000; 2000US-0244617P.  
PR 08-NOV-2000; 2000US-0246474P.  
PR 08-NOV-2000; 2000US-0246475P.  
PR 08-NOV-2000; 2000US-0246476P.  
PR 08-NOV-2000; 2000US-0246477P.  
PR 08-NOV-2000; 2000US-0246478P.  
PR 08-NOV-2000; 2000US-0246523P.  
PR 08-NOV-2000; 2000US-0246524P.  
PR 08-NOV-2000; 2000US-0246525P.  
PR 08-NOV-2000; 2000US-0246526P.  
PR 08-NOV-2000; 2000US-0246527P.  
PR 08-NOV-2000; 2000US-0246528P.  
PR 08-NOV-2000; 2000US-0246532P.  
PR 08-NOV-2000; 2000US-0246609P.  
PR 08-NOV-2000; 2000US-0246610P.  
PR 08-NOV-2000; 2000US-0246611P.  
PR 08-NOV-2000; 2000US-0246613P.  
PR 17-NOV-2000; 2000US-0249207P.  
PR 17-NOV-2000; 2000US-0249208P.  
PR 17-NOV-2000; 2000US-0249209P.  
PR 17-NOV-2000; 2000US-0249210P.  
PR 17-NOV-2000; 2000US-0249211P.  
PR 17-NOV-2000; 2000US-0249212P.  
PR 17-NOV-2000; 2000US-0249213P.  
PR 17-NOV-2000; 2000US-0249214P.  
PR 17-NOV-2000; 2000US-0249215P.  
PR 17-NOV-2000; 2000US-0249216P.  
PR 17-NOV-2000; 2000US-0249217P.  
PR 17-NOV-2000; 2000US-0249218P.





PR 29-SEP-2000; 2000US-0236367P.  
PR 29-SEP-2000; 2000US-0236368P.  
PR 29-SEP-2000; 2000US-0236369P.  
PR 29-SEP-2000; 2000US-0236370P.  
PR 02-OCT-2000; 2000US-0236802P.  
PR 02-OCT-2000; 2000US-0237037P.  
PR 02-OCT-2000; 2000US-0237038P.  
PR 02-OCT-2000; 2000US-0237039P.  
PR 02-OCT-2000; 2000US-0237040P.  
PR 13-OCT-2000; 2000US-0239935P.  
PR 13-OCT-2000; 2000US-0239937P.  
PR 20-OCT-2000; 2000US-0240960P.  
PR 20-OCT-2000; 2000US-0241221P.  
PR 20-OCT-2000; 2000US-0241785P.  
PR 20-OCT-2000; 2000US-0241786P.  
PR 20-OCT-2000; 2000US-0241787P.  
PR 20-OCT-2000; 2000US-0241808P.  
PR 20-OCT-2000; 2000US-0241809P.  
PR 20-OCT-2000; 2000US-0241826P.  
PR 01-NOV-2000; 2000US-0244617P.  
PR 08-NOV-2000; 2000US-0246474P.  
PR 08-NOV-2000; 2000US-0246475P.  
PR 08-NOV-2000; 2000US-0246476P.  
PR 08-NOV-2000; 2000US-0246477P.  
PR 08-NOV-2000; 2000US-0246478P.  
PR 08-NOV-2000; 2000US-0246523P.  
PR 08-NOV-2000; 2000US-0246524P.  
PR 08-NOV-2000; 2000US-0246525P.  
PR 08-NOV-2000; 2000US-0246526P.  
PR 08-NOV-2000; 2000US-0246527P.  
PR 08-NOV-2000; 2000US-0246528P.  
PR 08-NOV-2000; 2000US-0246532P.  
PR 08-NOV-2000; 2000US-0246609P.  
PR 08-NOV-2000; 2000US-0246610P.  
PR 08-NOV-2000; 2000US-0246611P.  
PR 08-NOV-2000; 2000US-0246613P.  
PR 17-NOV-2000; 2000US-0249207P.  
PR 17-NOV-2000; 2000US-0249208P.  
PR 17-NOV-2000; 2000US-0249209P.  
PR 17-NOV-2000; 2000US-0249210P.  
PR 17-NOV-2000; 2000US-0249211P.  
PR 17-NOV-2000; 2000US-0249212P.  
PR 17-NOV-2000; 2000US-0249213P.  
PR 17-NOV-2000; 2000US-0249214P.  
PR 17-NOV-2000; 2000US-0249215P.  
PR 17-NOV-2000; 2000US-0249216P.  
PR 17-NOV-2000; 2000US-0249217P.  
PR 17-NOV-2000; 2000US-0249218P.  
PR 17-NOV-2000; 2000US-0249244P.  
PR 17-NOV-2000; 2000US-0249245P.  
PR 17-NOV-2000; 2000US-0249264P.  
PR 17-NOV-2000; 2000US-0249265P.  
PR 17-NOV-2000; 2000US-0249297P.  
PR 17-NOV-2000; 2000US-0249299P.  
PR 17-NOV-2000; 2000US-0249300P.  
PR 01-DEC-2000; 2000US-0250160P.  
PR 01-DEC-2000; 2000US-0250391P.  
PR 05-DEC-2000; 2000US-0251030P.  
PR 05-DEC-2000; 2000US-0251988P.  
PR 05-DEC-2000; 2000US-0256719P.  
PR 06-DEC-2000; 2000US-0251479P.  
PR 08-DEC-2000; 2000US-0251856P.  
PR 08-DEC-2000; 2000US-0251868P.  
PR 08-DEC-2000; 2000US-0251869P.  
PR 08-DEC-2000; 2000US-0251989P.  
PR 08-DEC-2000; 2000US-0251990P.  
PR 11-DEC-2000; 2000US-0254097P.  
PR 05-JAN-2001; 2001US-0259678P.  
XX  
PA (HUMA-) HUMAN GENOME SCI INC.  
XX  
XX Rosen CA, Barash SC, Ruben SM;  
PI  
XX

DR WPI; 2001-498786/53.  
DR P-PSDB; ABB10953.  
XX  
PT New isolated ovarian and/or breast cancer related nucleic acids and  
PT polypeptides, useful for diagnosing, treating and/or preventing human  
PT diseases and disorders, particularly ovarian and/or breast cancer.  
XX  
PS Claim 1; SEQ ID NO 221; 577pp + Sequence Listing; English.  
XX  
CC The invention relates to novel genes (ABA07454-ABA08224) and proteins  
CC (ABB10743-ABB10980) useful for preventing, treating or ameliorating  
CC medical conditions e.g. by protein or gene therapy. The genes are  
CC isolated from a range of human tissues disclosed in the specification.  
CC The nucleic acids, proteins, antibodies and (ant)agonists are useful in  
CC the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and  
CC ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,  
CC breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune  
CC disorders e.g. Addison's disease, allergies, autoimmune haemolytic  
CC anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,  
CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)  
CC cardiovascular disorders such as myocardial ischaemias; (d) wound healing  
CC ; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)  
CC infectious diseases such as viral, bacterial, fungal and parasitic  
CC infections. Note: The sequence data for this patent did not form part of  
CC the printed specification, but was obtained in electronic format directly  
CC from WIPO at ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 823 BP; 327 A; 147 C; 154 G; 195 T; 0 U; 0 Other;  
  
Query Match 3.0%; Score 66.4; DB 4; Length 823;  
Best Local Similarity 75.2%; Pred. No. 0.00017;  
Matches 82; Conservative 0; Mismatches 27; Indels 0; Gaps 0;  
  
QY 2134 ACTCTTCTCTTTATCTTATTAATAAAATGTTGGTCTCCACCACCTGCCAAAAAA 2193  
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
689 ACTATACGTATATTTTCTGAATAAAATATTTTCTTAAATAAAAAAA 748  
  
QY 2194 AA 2242  
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
749 AA 797  
  
RESULT 967  
ABX15518  
ID ABX15518 standard; cDNA; 1781 BP.  
XX  
AC ABX15518;  
XX  
DT 27-MAR-2003 (first entry)  
XX  
DE cDNA encoding human tyrosylprotein sulphotransferase 1 related protein.  
XX  
KW ss; gene; human; tyrosylprotein sulphotransferase; transferase;  
KW transgenic; alternative splice variant.  
XX  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers  
FT CDS 241..1371  
FT /\*tag= a  
FT /product= "Tyrosylprotein sulphotransferase related  
FT protein"  
XX  
PN US2002142416-A1.  
XX  
PD 03-OCT-2002.  
XX  
PF 28-MAR-2001; 2001US-00818512.  
XX  
PR 28-MAR-2001; 2001US-00818512.  
XX  
PA (BEAS/) BEASLEY E M.  
PA (KETC/) KETCHUM K A.

PA (DFRA/) DI FRANCESCO V.  
XX Beasley EM, Ketchum KA, Di Francesco V;  
XX WPI; 2003-165811/16.  
DR P-PSDB; ABG73827.  
XX Novel human enzyme protein related to transferase enzyme subfamily and  
PT nucleic acid molecule encoding the protein for diagnosing, treating  
PT disease or condition mediated by enzyme protein and for identifying  
PT modulators.  
XX Claim 4; Fig 1; 132pp; English.  
PS  
XX The invention relates to an isolated human enzyme peptide belonging to  
CC the transferase enzyme subfamily. The polypeptide is useful for  
CC identifying a modulator of the expression of the peptide, identifying an  
CC agent that binds to the peptide, to identify the peptides binding  
CC partner/ligand, in competition binding assays. The enzyme-modulating  
CC agents are useful in an animal or other model to determine the efficacy,  
CC toxicity, mechanism of action or side effects of treatment with such an  
CC agent. The enzyme proteins also provide a target for diagnosing a disease  
CC or predisposition to a disease mediated by the peptide, in  
CC pharmacogenomic analysis and for treating disorders characterised by an  
CC absence or inappropriate, or unwanted expression of the protein. A  
CC pharmacological composition containing an agent identified from the peptide  
CC is useful for treating a disease or condition mediated by a human enzyme  
CC protein. The peptide and its corresponding nucleic acid are useful as  
CC models for the development of human therapeutic targets, aid in the  
CC identification of therapeutic proteins and serve as targets for the  
CC development of human therapeutic agents that modulate enzyme activity in  
CC cells and tissues that express the enzyme, as a query sequence to perform  
CC a search against sequence databases to identify other family members or  
CC related sequences. The nucleic acid is useful designing ribozymes,  
CC constructing transgenic animals, for monitoring the effectiveness of  
CC modulating compounds on the expression or activity of the enzyme gene in  
CC clinical trials or in a treatment regimen, in diagnostic assays for  
CC qualitative change in enzyme nucleic acid expression and for testing an  
CC individual for a genotype. A host cell expressing the peptide is useful  
CC for producing a enzyme protein or peptide, conducting cell-based assays  
CC involving the enzyme protein, identifying enzyme protein mutants and to  
CC produce non-human transgenic animals which are useful for studying the  
CC function of a enzyme protein and identifying and evaluating modulators of  
CC enzyme protein activity. The present sequence represents cDNA encoding a  
CC human transferase which may be an alternative splice form of human  
CC tyrosylprotein sulphotransferase 1  
XX  
SQ Sequence 1781 BP; 571 A; 366 C; 408 G; 436 T; 0 U; 0 Other;  
  
Query Match 3.0%; Score 66.4; DB 8; Length 1781;  
Best Local Similarity 81.7%; Pred. No. 0.00022;  
Matches 76; Conservative 0; Mismatches 17; Indels 0; Gaps 0;  
  
QY 2150 TTATTAATAAAAAATGTTGGTCTCCACCACCTGNCCTCCAAAAA 2209  
Db 1661 TTTGAAATAAAAAATGTTTCAGCGACCTCTCTGTTCTTAAAAA 1720  
  
QY 2210 AAAAAA 2242  
Db 1721 AAAAAA 1753  
  
RESULT 968  
AAD47901  
ID AAD47901 standard; cDNA; 1781 BP.  
XX  
AC AAD47901;  
XX  
DT 12-FEB-2004 (first entry)  
XX  
DE Human transferase-related enzyme encoding cDNA.  
XX  
KW Human; gene; transferase; tyrosylprotein sulphotransferase; chromosome 7;

KW therapeutic; drug target; inflammatory disorder; haemological disorder;  
KW single nucleotide polymorphism; SNP; ss.  
XX Homo sapiens.  
XX  
FH Key Location/Qualifiers  
FT 5'UTR i. .240  
FT /\*tag= a  
FT CDS 241. .1371  
FT /\*tag= b  
FT /\*product= "Transferase-related enzyme"  
FT 3'UTR 1372. .1781  
FT /\*tag= c  
XX  
PN US2003138837-A1.  
XX  
PD 24-JUL-2003.  
XX  
PF 30-JAN-2003; 2003US-00354065.  
XX  
PR 28-MAR-2001; 2001US-00818512.  
XX  
PA (APPL-) APPLERA CORP.  
XX  
XX Beasley EM, Ketchum KA, Di Francesco V;  
PI WPI; 2003-851726/79.  
DR P-PSDB; ABW01917.  
DR  
XX New isolated human enzyme proteins, useful for developing therapeutic or  
PT diagnostic compositions, particularly for developing modulators of  
PT transferase enzyme activity in cells or tissues.  
XX  
PS Claim 4; SEQ ID NO 1; 135pp; English.  
XX  
CC The present invention relates to human enzyme and gene related to  
CC transferases in general, specifically sulphotransferase and tyrosylprotein  
CC sulphotransferase in particular. The transferase-related gene of the  
CC invention is located on human chromosome 7. The enzyme and nucleic acid  
CC molecules of the invention are useful in the development of human  
CC therapeutics and diagnostic compositions. These molecules serve as  
CC potential targets for the development of therapeutics to treat disorders  
CC associated with transferases (e.g. inflammatory or haemological  
CC disorders). The single nucleotide polymorphisms (SNPs) identified in the  
CC gene are valuable markers for the diagnosis, prognosis, prevention and/or  
CC treatment of the disorders. The enzyme is also useful for raising  
CC antibodies or eliciting an immune response; as a reagent in assays  
CC designed to quantitatively determine levels of the protein (or its  
CC binding partner or ligand) in biological fluids; and as markers for  
CC tissues in which the corresponding protein is preferentially expressed.  
CC The present sequence is human transferase-related enzyme encoding cDNA  
XX  
SQ Sequence 1781 BP; 571 A; 366 C; 408 G; 436 T; 0 U; 0 Other;  
  
Query Match 3.0%; Score 66.4; DB 10; Length 1781;  
Best Local Similarity 81.7%; Pred. No. 0.00022;  
Matches 76; Conservative 0; Mismatches 17; Indels 0; Gaps 0;  
  
QY 2150 TTATTAATAAAAAATGTTGGTCTCCACCACCTGNCCTCCAAAAA 2209  
Db 1661 TTTGAAATAAAAAATGTTTCAGCGACCTCTCTGTTCTTAAAAA 1720  
  
QY 2210 AAAAAA 2242  
Db 1721 AAAAAA 1753  
  
RESULT 969  
ADI62940  
ID ADI62940 standard; cDNA; 1874 BP.  
XX  
AC ADI62940;  
XX

```
DT 22-APR-2004 (first entry)
DE Human apoptosis-associated cDNA SEQ ID 383.
XX
KW apoptosis; cell death; cytostatic; neuroprotective; immunosuppressive;
KW antiarheumatic; antiarthritic; dermatological; antiinflammatory;
KW hepatotropic; virucide; nootropic; anticonvulsant; antiparkinsonian;
KW vasotropic; cerebroprotective; antialcoholic; gene therapy; tumour;
KW autoimmune disease; degenerative disease; viral infection; leukaemia;
KW carcinoma; sarcoma; multiple sclerosis; rheumatoid arthritis; diabetes;
KW lupus; hepatitis; influenza viruses; Alzheimer's disease;
KW Huntington's disease; Parkinson's diseases; reperfusion injury; stroke;
KW alcoholic liver disease; human; gene; ss.
XX
OS Homo sapiens.
XX
XX WO2003058021-A2.
XX
XX 17-JUL-2003.
XX
XX 13-JAN-2003; 2003WO-EP000270.
XX
XX 11-JAN-2002; 2002DE-01000856.
XX
XX (XANT-) XANTOS BIOMEDICINE AG.
XX
XX Koenig-Hoffman K, Kazinski M, Schaefer R, Kesper B;
XX WPI; 2003-542134/51.
XX
XX New nucleic acids involved in apoptosis, useful for diagnosis and
XX treatment of e.g. tumors and degenerative disease, also related proteins,
XX antibodies and modulators.
XX
XX Claim 1b; SEQ ID NO 383; 517pp; German.
XX
XX This invention describes novel nucleic acid molecules that are associated
XX with apoptosis and encode a polypeptide and are derived from a normalised
XX gene library (embryonic or liver) or clone collections, and the extent of
XX apoptosis measured by cell death detection assay or the CPG assay
XX (measuring loss of membrane integrity). The products of the invention
XX have cytostatic, neuroprotective, immunosuppressive, antirheumatic,
XX antiarthritic, dermatological, antiinflammatory, hepatotropic, virucide,
XX nootropic, anticonvulsant, antiparkinsonian, vasotropic,
XX cerebroprotective and antialcoholic activity and can be used for gene
XX therapy. The polynucleotides also related vectors, hosts (or their
XX extracts), encoded polypeptide (or their receptors) and/or agents that
XX inhibit their activity (including antisense sequences) are used for
XX treatment or prevention of tumours, autoimmune or degenerative diseases
XX and viral infections, specifically leukaemia, carcinoma, sarcoma,
XX multiple sclerosis, rheumatoid arthritis, diabetes, lupus, or infection
XX with hepatitis or influenza viruses, Alzheimer's, Huntington's or
XX Parkinson's diseases, reperfusion injury, stroke and alcoholic liver
XX disease. Detection of the polynucleotides and derived polypeptides can
XX also be used for diagnosis of these diseases. This sequence encodes an
XX apoptosis-associated protein described in the disclosure of the
XX invention.
XX
XX Sequence 1874 BP; 343 A; 632 C; 546 G; 353 T; 0 U; 0 Other;
XX
XX Query Match 3.0%; Score 66.4; DB 10; Length 1874;
XX Best Local Similarity 65.1%; Pred. No. 0.00022;
XX Matches 97; Conservative 0; Mismatches 52; Indels 0; Gaps 0;
XX
QY 2094 ACACATATCATTCATCCCAATGATCGCCTTTGCTTTACCACTCTTTCCTTTTATCTTAT 2153
DB 1712 AGACGGCAGCAGTCCCAGCTCTGGTTTCCTTCTCGGTTTATTCGTAGATGAATGGT 1771
XX
QY 2154 TAATAAATAATGTTGGTCTCCACCACCTGCTCCCAAAAAAATAAAAAA 2213
DB 1772 TCCCATAAATAAGGGGCATGAGCCCTTCTTCAGAAAAAATAAAAAA 1831
XX
QY 2214 AAAAAAATAAAAAAATAAAAAA 2242
```

```
Db 1832 AAAAAAATAAAAAAATAAAAAA 1860
XX
RESULT 970
AAF44987
ID AAF44987 standard; cDNA; 1927 BP.
XX
AC AAF44987;
XX
DT 28-MAR-2001 (first entry)
XX
DE Human Gene 64 SEQ ID NO: 66.
XX
KW Human; mouse; secreted protein; TANGO253; TANGO 257; TANGO 281;
KW INTERCEPT 258; coronary disorder; olfactory disorder;
KW neurological disorder; pulmonary disorder; immunological disorder;
KW developmental disorder; kidney disorder; ss.
XX
OS Homo sapiens.
XX
XX WO200078808-A1.
XX
XX 28-DEC-2000.
XX
XX 19-JUN-2000; 2000WO-US016883.
XX
XX 18-JUN-1999; 99US-00336536.
XX
XX (MILL-) MILLENNIUM PHARM INC.
XX
XX Leiby KR, McKay C, Bossone S;
XX WPI; 2001-050109/06.
XX
XX New nucleic acids for treating diseases and disorders, e.g.
XX atherosclerosis, infection, autoimmune diseases, obesity, ear disorders,
XX brain disorders, tumors, diabetes, arthritis, multiple sclerosis and
XX asthma.
XX
XX Disclosure; Page 250-251; 332pp; English.
XX
XX The present invention provides the protein and coding sequences of the
XX human and murine secreted or transmembrane proteins TANGO 253, TANGO 257,
XX TANGO 281 and INTERCEPT 258. These are useful in the treatment of
XX coronary, pulmonary, olfactory, immunological, neurological,
XX developmental and kidney disorders
XX
XX Sequence 1927 BP; 491 A; 515 C; 483 G; 434 T; 0 U; 4 Other;
XX
XX Query Match 3.0%; Score 66.4; DB 4; Length 1927;
XX Best Local Similarity 62.0%; Pred. No. 0.00023;
XX Matches 103; Conservative 0; Mismatches 63; Indels 0; Gaps 0;
XX
QY 2077 GTCCTCAAGTCTCGTGACACATAATCATTCATCCCAATGATCGCCTTTGCTTTACCACT 2136
DB 1678 GACGTCCAGCTCTGTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1737
XX
QY 2137 CTTTCCTTTTATCTTATTATAATAAAATGTTGGTCTCCACCACCTGCTCCCAAAAAA 2196
DB 1738 TTCTCCACATTTGTTTGTATTGCAACATTTTGCATTAAAAAGGAAATCCANAAAAA 1797
XX
QY 2197 AAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2242
DB 1798 AAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 1843
XX
RESULT 971
ADE15662
ID ADE15662 standard; DNA; 4816 BP.
XX
AC ADE15662;
XX
```





ID AAI89390 standard; cDNA; 388 BP.  
XX AC AAI89390;  
AC AAI89390;  
XX DT 06-NOV-2001 (first entry)  
XX DE Human polynucleotide SEQ ID NO 9450.  
DE Human; cytokine; cell proliferation; cell differentiation; gene therapy;  
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;  
KW tissue growth factor; immunomodulatory; cancer; leukaemia;  
KW nervous system disorders; arthritis; inflammation; ss.  
XX OS Homo sapiens.  
OS XX WO200164835-A2.  
XX PN 07-SEP-2001.  
XX PD 26-FEB-2001; 2001WO-US004927.  
XX PF 28-FEB-2000; 2000US-00515126.  
XX PR 18-MAY-2000; 2000US-00577409.  
XX PA (HYSE-) HYSEQ INC.  
XX PI Tang YT, Liu C, Drmanac RT;  
XX WPI; 2001-514838/56.  
DR P-PSDB; AAO09459.  
XX Isolated nucleic acids and polypeptides, useful for preventing diagnosing  
PT and treating e.g. leukemia, inflammation and immune disorders.  
PT  
XX Claim 1; SEQ ID NO 9450; 1399pp + Sequence Listing; English.  
PS  
XX The invention relates to human polynucleotides (AAI79941-AAI93841) and  
CC the encoded proteins (AAO00010-AAO13910) that exhibit activity elating to  
CC cytokine, cell proliferation or cell differentiation or which may induce  
CC production of other cytokines in other cell populations. The  
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or  
CC peptide therapy. The polypeptides have various cytokine-like activities,  
CC e.g. stem cell growth factor activity, haematopoiesis regulating  
CC activity, tissue growth factor activity, immunomodulatory activity and  
CC activin/inhibin activity and may be useful in the diagnosis and/or  
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and  
CC inflammation. Note: The sequence data for this patent did not form part  
CC of the printed specification, but was obtained in electronic format  
CC directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 388 BP; 128 A; 67 C; 105 G; 82 T; 0 U; 6 Other;  
  
Query Match 3.0%; Score 66.2; DB 4; Length 388;  
Best Local Similarity 69.5%; Pred. No. 0.00015;  
Matches 89; Conservative 0; Mismatches 39; Indels 0; Gaps 0;  
  
QY 2115 TGATCGCCTTGGCTTTACCACTCTTTCTTTTATCTTATTAATAAAATGTTGGTCTCCA 2174  
||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 168 TGCTTTGCTTTGGGGTTCTCTATTATTACTTTGTTTCTCGAAGACAAACTTTCCTCTAAA 227  
  
QY 2175 CCACTGNCCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2234  
| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 228 AAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAA 287  
  
QY 2235 AAAAAAAA 2242  
|||||||  
Db 288 AAAAAAAA 295  
  
RESULT 974  
ACN51900  
ID ACN51900 standard; cDNA; 433 BP.  
XX

AC ACN51900;  
XX 02-DEC-2004 (first entry)  
XX Cotton androecium tissue EST Clone ID: LIB3828-009-Q1-N6-D11, SEQ:6681.  
DE  
XX Cotton; plant; EST; expressed sequence tag; transgenic plant; androecium;  
KW variety Nucotton33B; library LIB3828; molecular tag; molecular marker;  
KW genetic mapping; molecular mapping; seed germination; plant growth;  
KW plant quality; plant yield; plant breeding; tissue printing; ss.  
XX Gossypium hirsutum.  
OS  
XX US2004123340-A1.  
XX 24-JUN-2004.  
XX 12-DEC-2001; 2001US-00021323.  
XX 14-DEC-2000; 2000US-02555619P.  
XX (DEIK/) DEIKMAN J.  
PA (FENG/) FENG P C C.  
PA (FINC/) FINCHER K L.  
PA (ZIEG/) ZIEGLER T E.  
XX Deikman J, Feng PCC, Fincher KL, Ziegler TE;  
PI WPI; 2004-479808/45.  
XX  
DR New isolated nucleic acid molecule that encodes a plant protein or its  
PT fragment, useful for isolating a variety of agronomically significant  
PT genes associated with plant growth, quality or yield, and as molecular  
PT tags to map genes.  
XX  
PS Claim 1; SEQ ID NO 6681; 34pp; English.  
XX  
CC The invention relates to 17880 cotton expressed sequence tags (ESTs;  
CC ACN45220-ACN63099). The ESTs were isolated from cDNA libraries generated  
CC from primed or non-primed seeds from variety DP50B, mature seeds from  
CC variety Coker 312 Boswell 96 Field, and androecium tissue, gynoecium  
CC tissue, developing fibres, carpel walls and septa from variety  
CC Nucotton33B. The invention also relates to substantially purified  
CC proteins or their fragments encoded by nucleic acid molecules of the  
CC invention, and to transformed plants having a nucleic acid construct  
CC comprising a nucleic acid of the invention. The cotton ESTs are useful as  
CC molecular tags to isolate genetic regions, to isolate genes, to map  
CC genes, to determine gene function and to determining whether genes are  
CC members of a particular gene family. The nucleic acid molecules may be  
CC used for isolating a variety of agronomically significant genes  
CC associated with plant growth, quality, yield, and could also serve as  
CC links in metabolic and catabolic pathways. The nucleic acid molecules are  
CC also useful for identifying genes important in initiating and maintaining  
CC seed germination or that may be used to mitigate stresses encountered  
CC during seed germination. The ESTs additionally enable the acquisition of  
CC promoters and cis-regulatory elements which will be useful to express  
CC agronomically significant genes in these tissues and/or other tissues,  
CC and also permits the acquisition of molecular markers useful in breeding  
CC schemes, genetic and molecular mapping, and in cloning of agronomically  
CC significant genes. The nucleic acid molecules are further useful for  
CC detecting the expression level or pattern of a protein or mRNA and for  
CC detecting the presence or quantity of a protein by tissue printing. The  
CC present sequence represents a specifically claimed EST isolated from a  
CC cotton variety Nucotton33B androecium tissue cDNA library (LIB3828). The  
CC sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from the US  
CC patent office at seqdata.uspto.gov/sequence.html?DocID=US20040123340  
XX  
SQ Sequence 433 BP; 297 A; 12 C; 35 G; 89 T; 0 U; 0 Other;  
  
Query Match 3.0%; Score 66.2; DB 13; Length 433;  
Best Local Similarity 71.7%; Pred. No. 0.00016;  
Matches 86; Conservative 0; Mismatches 34; Indels 0; Gaps 0;





CC sample at a first point in time, repeating the method at a subsequent  
CC time and comparing the level of expression. The method is carried out  
CC using an ovarian tissue sample. A composition comprising a marker,  
CC polypeptide or antibody of the invention is used to treat ovarian cancer.  
CC This sequence represents a human ovarian cancer DNA marker of the  
CC invention. Note: The sequence data for this patent did not form part of  
CC the printed specification, but was obtained in electronic format directly  
CC from WIPO at ftp.wipo.int/pub/published\_pct\_sequences.

XX  
SQ Sequence 476 BP; 146 A; 13 C; 38 G; 184 T; 0 U; 95 Other;

Query Match 3.0%; Score 66.2; DB 5; Length 476;  
Best Local Similarity 50.4%; Pred. No. 0.00016;  
Matches 114; Conservative 0; Mismatches 112; Indels 0; Gaps 0;

QY 2017 TTTTAGCATATCTCAACCTTGCAATTGATTGGCATAATCACCTCCGGTTTGCTTTCTAG 2076  
Db ||||| - - - - - ||||| - - - - - ||||| - - - - - ||||| - - - - -  
302 TTTTATTAAANAACACACNNNTTATNTTTTATNCANTTAATTATTTTATAAA 243  
QY 2077 GTCCTCAAGTCTCGTGACACATAATCATTCATCCATCCATGATCGCCTTTGCTTTACCACT 2136  
Db - - - - - ||||| - - - - - ||||| - - - - - ||||| - - - - - ||||| - - - - -  
242 AAATTNNTGNNTGNNNCCCCNTTTTNTTTTNNCNTTAAANNNTTTTNTTTT 183  
QY 2137 CTTTCCTTTTATCTTATTAAATAAAAAATGTTGGTCTCCACCACCTGNCCTCCAAAAAAA 2196  
Db - - - - - ||||| - - - - - ||||| - - - - - ||||| - - - - - ||||| - - - - -  
182 TAATNNANTTTTNTTNTAATTNNAANTTTTNTTNNAAANTTNNAAANAAAAAAA 123  
QY 2197 AAAAAA 2242  
Db ||||| - - - - - ||||| - - - - - ||||| - - - - - ||||| - - - - -  
122 AAAAAA 77

RESULT 977  
ADI71958/c  
ID ADI71958 standard; DNA; 476 BP.  
XX  
AC ADI71958;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Human ovarian cancer DNA marker #4700.  
XX  
KW Human; ovarian cancer; ds; tumour; cytostatic; DNA marker.  
XX  
OS Homo sapiens.  
XX  
PN WO200170979-A2.  
XX  
PD 27-SEP-2001.  
XX  
PF 21-MAR-2001; 2001WO-US009126.  
XX  
PR 21-MAR-2000; 2000US-0191031P.  
PR 25-MAY-2000; 2000US-0207124P.  
PR 15-JUN-2000; 2000US-0211940P.  
PR 07-JUL-2000; 2000US-0216820P.  
PR 25-JUL-2000; 2000US-0220661P.  
PR 21-DEC-2000; 2000US-0257672P.  
XX  
PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.  
XX  
PI Lee J, Lillie J;  
XX  
WPI; 2001-611502/70.  
DR  
XX Novel isolated nucleic acid molecules (markers) overexpressed in ovarian  
PT cancer cells as compared to their normal non-cancerous ovarian cells are  
PT used to characterize stage, grade, histological type of ovarian cancer.  
XX  
PS Disclosure; SEQ ID NO 4700; 106pp; English.  
XX  
CC The invention relates to nucleic acid markers which are overexpressed in  
CC ovarian cancer cells as compared to their expression in normal (i.e. non-

CC cancerous) ovarian cells. The invention also relates to polypeptides  
CC encoded by the markers, antibodies that selectively bind to the  
CC polypeptides, a method of inhibiting ovarian cancer in a patient at risk  
CC of developing ovarian cancer involving inhibiting expression of a gene  
CC corresponding to a marker of the invention and a method of treating a  
CC patient afflicted with ovarian cancer comprising providing to cells of  
CC the patient an antisense oligonucleotide complementary to a marker of the  
CC invention. The markers are useful for assessing if a patient is afflicted  
CC with ovarian cancer, which involves comparing the level of expression of  
CC a marker in a patient sample and a normal level of expression of the  
CC marker in a control non-ovarian cancer sample. A difference between the  
CC expression levels indicates ovarian cancer. The level of expression of a  
CC marker corresponds to a secreted protein or to a transcribed  
CC polynucleotide or its portion. The level of expression of the marker is  
CC assessed by detecting the presence in the sample, a protein or protein  
CC fragment corresponding to the marker. The presence of protein or protein  
CC fragment is detected using an antibody that specifically binds with the  
CC protein or protein fragment. Alternatively, the level of expression of  
CC the marker is assessed by detecting the presence of a transcribed  
CC polynucleotide which anneals with the marker or anneals with a portion of  
CC the polynucleotide comprising the marker, under stringent conditions. The  
CC marker is also used for monitoring the progression of ovarian cancer in a  
CC patient which involves detecting expression of the marker in a patient  
CC sample at a first point in time, repeating the method at a subsequent  
CC time and comparing the level of expression. The method is carried out  
CC using an ovarian tissue sample. A composition comprising a marker,  
CC polypeptide or antibody of the invention is used to treat ovarian cancer.  
CC This sequence represents a human ovarian cancer DNA marker of the  
CC invention.

XX  
SQ Sequence 476 BP; 146 A; 13 C; 38 G; 184 T; 0 U; 95 Other;

Query Match 3.0%; Score 66.2; DB 5; Length 476;  
Best Local Similarity 50.4%; Pred. No. 0.00016;  
Matches 114; Conservative 0; Mismatches 112; Indels 0; Gaps 0;

QY 2017 TTTTAGCATATCTCAACCTTGCAATTGATTGGCATAATCACCTCCGGTTTGCTTTCTAG 2076  
Db ||||| - - - - - ||||| - - - - - ||||| - - - - - ||||| - - - - -  
302 TTTTATTAAANAACACACNNNTTATNTTTTATNCANTTAATTATTTTATAAA 243  
QY 2077 GTCCTCAAGTCTCGTGACACATAATCATTCATCCATCCATGATCGCCTTTGCTTTACCACT 2136  
Db - - - - - ||||| - - - - - ||||| - - - - - ||||| - - - - - ||||| - - - - -  
242 AAATTNNTGNNTGNNNCCCCNTTTTNTTTTNNCNTTAAANNNTTTTNTTTT 183  
QY 2137 CTTTCCTTTTATCTTATTAAATAAAAAATGTTGGTCTCCACCACCTGNCCTCCAAAAAAA 2196  
Db - - - - - ||||| - - - - - ||||| - - - - - ||||| - - - - - ||||| - - - - -  
182 TAATNNANTTTTNTTNTAATTNNAANTTTTNTTNNAAANTTNNAAANAAAAAAA 123  
QY 2197 AAAAAA 2242  
Db ||||| - - - - - ||||| - - - - - ||||| - - - - - ||||| - - - - -  
122 AAAAAA 77

RESULT 978  
ACN46735/c  
ID ACN46735 standard; cDNA; 486 BP.  
XX  
AC ACN46735;

XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Cotton primed seed EST Clone ID: LIB3825-003-Q1-N6-E5, SEQ:1516.  
XX  
KW Cotton; plant; EST; expressed sequence tag; transgenic plant; seed;  
KW variety DP50B; library LIB3825; molecular tag; molecular marker;  
KW genetic mapping; molecular mapping; seed germination; plant growth;  
KW plant quality; plant yield; plant breeding; tissue printing; ss.  
XX  
OS Gossypium hirsutum.

XX  
PN US2004123340-A1.  
XX  
PD 24-JUN-2004.











XX PR 14-JAN-2000; 2000US-0176077P.  
PR 14-MAR-2000; 2000US-0189167P.  
PR 24-MAR-2000; 2000US-0192099P.  
PR 29-MAR-2000; 2000US-0193480P.  
PR 15-MAY-2000; 2000US-0205230P.  
PR 09-JUN-2000; 2000US-0211315P.  
PR 25-JUL-2000; 2000US-0220534P.  
XX PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.  
XX PI Lillie J, Xu Y, Wang Y, Steinmann K;  
XX DR WPI; 2001-451856/48.  
XX PT New peptide useful as a marker for the diagnosis of breast cancer.  
XX PS Claim 1; Page 1311; 3695pp; English.  
XX CC The invention relates to human breast cancer expressed polynucleotides  
CC (AAL07544-AAL26789) and methods of assessing whether a patient is  
CC afflicted with breast cancer by examining the correlation between the  
CC expression of certain markers and the cancerous state of breast cells.  
CC The polynucleotides and encoded polypeptides are potential markers for  
CC detecting, diagnosing, monitoring, characterising treating and  
CC potentially preventing breast cancer. The polynucleotides and encoded  
CC polypeptides are also useful for isolating compounds with cytostatic  
CC activity  
XX SQ Sequence 693 BP; 167 A; 108 C; 69 G; 223 T; 0 U; 126 Other;  
Query Match 3.0%; Score 66.2; DB 4; Length 693;  
Best Local Similarity 69.2%; Pred. No. 0.00018;  
Matches 83; Conservative 0; Mismatches 37; Indels 0; Gaps 0;  
QY 2123 TTGTGCTTTACCACTCTTTCCCTTTATCTTATTAATAAAATGTTGGTCTCCACCACTGNC 2182  
Db 170 TTTTNTNNAANNAANCCNTTTTNTTTTAAATAAAATTTTAAATAAA 111  
QY 2183 TCCCAA 2242  
Db 110 AA 51  
RESULT 984  
ADI71984/c  
ID ADI71984 standard; DNA; 723 BP.  
XX AC ADI71984;  
XX DT 20-MAY-2004 (first entry)  
XX DE Human ovarian cancer DNA marker #4726.  
XX KW Human; ovarian cancer; ds; tumour; cytostatic; DNA marker.  
XX OS Homo sapiens.  
XX PN WO200170979-A2.  
XX PD 27-SEP-2001.  
XX PF 21-MAR-2001; 2001WO-US009126.  
XX PR 21-MAR-2000; 2000US-0191031P.  
PR 25-MAY-2000; 2000US-0207124P.  
PR 15-JUN-2000; 2000US-0211940P.  
PR 07-JUL-2000; 2000US-0216820P.  
PR 25-JUL-2000; 2000US-0220661P.  
PR 21-DEC-2000; 2000US-0257672P.  
XX PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.  
XX

PI Lee J, Lillie J;  
XX DR WPI; 2001-611502/70.  
XX PT Novel isolated nucleic acid molecules (markers) overexpressed in ovarian  
PT cancer cells as compared to their normal non-cancerous ovarian cells are  
PT used to characterize stage, grade, histological type of ovarian cancer.  
XX PS Disclosure; SEQ ID NO 4726; 106pp; English.  
XX CC The invention relates to nucleic acid markers which are overexpressed in  
CC ovarian cancer cells as compared to their expression in normal (i.e. non-  
CC cancerous) ovarian cells. The invention also relates to polypeptides  
CC encoded by the markers, antibodies that selectively bind to the  
CC polypeptides, a method of inhibiting ovarian cancer in a patient at risk  
CC of developing ovarian cancer involving inhibiting expression of a gene  
CC corresponding to a marker of the invention and a method of treating a  
CC patient afflicted with ovarian cancer comprising providing to cells of  
CC the patient an antisense oligonucleotide complementary to a marker of the  
CC invention. The markers are useful for assessing if a patient is afflicted  
CC with ovarian cancer, which involves comparing the level of expression of  
CC a marker in a patient sample and a normal level of expression of the  
CC marker in a control non-ovarian cancer sample. A difference between the  
CC expression levels indicates ovarian cancer. The level of expression of a  
CC marker corresponds to a secreted protein or to a transcribed  
CC polynucleotide or its portion. The level of expression of the marker is  
CC assessed by detecting the presence in the sample, a protein or protein  
CC fragment corresponding to the marker. The presence of protein or protein  
CC fragment is detected using an antibody that specifically binds with the  
CC protein or protein fragment. Alternatively, the level of expression of  
CC the marker is assessed by detecting the presence of a transcribed  
CC polynucleotide which anneals with the marker or anneals with a portion of  
CC the polynucleotide comprising the marker, under stringent conditions. The  
CC marker is also used for monitoring the progression of ovarian cancer in a  
CC patient which involves detecting expression of the marker in a patient  
CC sample at a first point in time, repeating the method at a subsequent  
CC time and comparing the level of expression. The method is carried out  
CC using an ovarian tissue sample. A composition comprising a marker,  
CC polypeptide or antibody of the invention is used to treat ovarian cancer.  
CC This sequence represents a human ovarian cancer DNA marker of the  
CC invention.  
XX SQ Sequence 723 BP; 229 A; 56 C; 74 G; 251 T; 0 U; 113 Other;  
Query Match 3.0%; Score 66.2; DB 5; Length 723;  
Best Local Similarity 69.2%; Pred. No. 0.00018;  
Matches 83; Conservative 0; Mismatches 37; Indels 0; Gaps 0;  
QY 2123 TTTGCTTTACCACTCTTTCCCTTTATCTTATTAATAAAATGTTGGTCTCCACCACTGNC 2182  
Db 181 TTTTNTNCCNCNTTTTNTTAANAATTTTNNAAAAAATNTTTTTTTTAA 122  
QY 2183 TCCCAA 2242  
Db 121 AA 62  
RESULT 985  
ADL37134/c  
ID ADL37134 standard; DNA; 723 BP.  
XX AC ADL37134;  
XX DT 20-MAY-2004 (first entry)  
XX DE Human ovarian cancer DNA marker #11024.  
XX KW Human; ovarian cancer; ds; tumour; cytostatic; DNA marker.  
XX OS Homo sapiens.  
XX PN WO200170979-A2.  
XX







```

CC the polynucleotide comprising the marker, under stringent conditions. The
CC marker is also used for monitoring the progression of ovarian cancer in a
CC patient which involves detecting expression of the marker in a patient
CC sample at a first point in time, repeating the method at a subsequent
CC time and comparing the level of expression. The method is carried out
CC using an ovarian tissue sample. A composition comprising a marker,
CC polypeptide or antibody of the invention is used to treat ovarian cancer.
CC This sequence represents a human ovarian cancer DNA marker of the
CC invention.
XX
SQ Sequence 810 BP; 225 A; 35 C; 137 G; 283 T; 0 U; 130 Other;

Query Match 3.0%; Score 66.2; DB 5; Length 810;
Best Local Similarity 77.0%; Pred. No. 0.00019;
Matches 77; Conservative 0; Mismatches 23; Indels 0; Gaps 0;

QY 2143 TTTTATCTTATTATAAAAAATGTTGGTCTCCACCACCTGCTCCCAAAAAA 2202
XX ||||| ||| ||||| ||| ||||| ||| ||||| ||| ||||| ||| |||||
AC ADI73104;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human ovarian cancer DNA marker #5846.
XX
KW Human; ovarian cancer; ds; tumour; cytostatic; DNA marker.
XX
OS Homo sapiens.
XX
PN WO200170979-A2.
XX
PD 27-SEP-2001.
XX
PF 21-MAR-2001; 2001WO-US009126.
XX
PR 21-MAR-2000; 2000US-0191031P.
PR 25-MAY-2000; 2000US-0207124P.
PR 15-JUN-2000; 2000US-0211940P.
PR 07-JUL-2000; 2000US-0216820P.
PR 25-JUL-2000; 2000US-0220661P.
PR 21-DEC-2000; 2000US-0257672P.
XX
PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
PI Lee J; Lillie J;
XX
DR WPI; 2001-611502/70.
XX
PT Novel isolated nucleic acid molecules (markers) overexpressed in ovarian
PT cancer cells as compared to their normal non-cancerous ovarian cells are
PT used to characterize stage, grade, histological type of ovarian cancer.
XX
PS Disclosure; SEQ ID NO 5846; 106pp; English.
XX
CC The invention relates to nucleic acid markers which are overexpressed in
CC ovarian cancer cells as compared to their expression in normal (i.e. non-
CC cancerous) ovarian cells. The invention also relates to polypeptides
CC encoded by the markers, antibodies that selectively bind to the
CC polypeptides, a method of inhibiting ovarian cancer in a patient at risk
CC of developing ovarian cancer involving inhibiting expression of a gene
CC corresponding to a marker of the invention and a method of treating a
CC patient afflicted with ovarian cancer comprising providing to cells of
CC the patient an antisense oligonucleotide complementary to a marker of the
CC invention. The markers are useful for assessing if a patient is afflicted
CC with ovarian cancer, which involves comparing the level of expression of
CC a marker in a patient sample and a normal level of expression of the
CC marker in a control non-ovarian cancer sample. A difference between the
CC expression levels indicates ovarian cancer. The level of expression of a
CC marker corresponds to a secreted protein or to a transcribed
CC polynucleotide or its portion. The level of expression of the marker is
CC assessed by detecting the presence in the sample, a protein or protein
CC fragment corresponding to the marker. The presence of protein or protein
CC fragment is detected using an antibody that specifically binds with the
CC protein or protein fragment. Alternatively, the level of expression of
CC the marker is assessed by detecting the presence of a transcribed
CC polynucleotide which anneals with the marker or anneals with a portion of
CC
```







XX 21-MAR-2001; 2001US-0277340P.  
PR 19-JUL-2001; 2001US-0306171P.  
PR 13-NOV-2001; 2001US-0331287P.  
XX (HUMA-) HUMAN GENOME SCI INC.  
PA Rosen CA, Ruben SM;  
XX WPI; 2003-175238/17.  
XX New human secreted proteins and nucleic acid molecules, useful for  
PT preparing a diagnostic or pharmaceutical composition for diagnosing,  
PT preventing or treating cancer or other hyperproliferative disorder,  
PT asthma, allergies or AIDS.  
XX Claim 9; SEQ ID NO 934; 3205pp; English.  
XX The invention relates to novel genes ADA39629-ADA40565 and proteins  
CC ADA40566-ADA41501 for human secreted proteins, useful for preventing,  
CC treating or ameliorating medical conditions e.g. by protein or gene  
CC therapy. The polypeptides, nucleic acid molecules, antibodies or gene  
CC fragments, and agonists or antagonists that bind to the polypeptide are  
CC useful for preparing a diagnostic or pharmaceutical composition for  
CC diagnosing or treating cancer or other hyperproliferative disorder. The  
CC polypeptides and nucleic acid molecules are also useful for detecting,  
CC preventing, diagnosing, prognosticating, treating or ameliorating cancer  
CC or other hyperproliferative disorders including neoplasms, autoimmune  
CC disorders (e.g. diabetes, rheumatoid arthritis, systemic lupus  
CC erythematosus, multiple sclerosis, neurodegenerative disorders (e.g.  
CC anaemia), haematopoietic or haematological disorders (e.g. anaemia,  
CC thrombocytopenia), allergic reactions including asthma or eczema,  
CC inflammatory disorders (e.g. ischaemia-reperfusion injury, inflammatory  
CC bowel disease or Crohn's disease), neurodegenerative disorders (e.g.  
CC Alzheimer's disease or Parkinson's disease), cardiovascular disorders  
CC (e.g. atherosclerosis, myocarditis), infectious diseases (bacterial,  
CC fungal or viral infections including HIV/AIDS), or wound healing and  
CC disorders of epithelial cell proliferation. The nucleic acids are also  
CC useful for chromosome identification, radiation hybrid mapping or long-  
CC range restriction mapping, as molecular weight markers, or as  
CC hybridization or diagnostic probes. The polypeptides and antibodies are  
CC useful for providing immunological probes for differential identification  
CC of the tissues immunohistochemistry assays. Note: The sequence data for  
CC this patent did not form part of the printed specification, but was  
CC obtained in electronic format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences.  
XX  
SQ Sequence 1315 BP; 419 A; 329 C; 290 G; 277 T; 0 U; 0 Other;  
  
Query Match 3.0%; Score 66.2; DB 8; Length 1315;  
Best Local Similarity 84.1%; Pred. No. 0.00022;  
Matches 74; Conservative 0; Mismatches 14; Indels 0; Gaps 0;  
  
QY 2155 AATAAAATGTTGGTCTCCACACTGNCCTCCAAAAA 2214  
Db 1200 AATAAAATGAAAGTATCCTCTCAAAAAA 1259  
  
QY 2215 AAAAAA 2242  
Db 1260 AAAAAA 1287  
  
RESULT 993  
ACC50854  
ID ACC50854 standard; cDNA; 1315 BP.  
XX ACC50854;  
XX  
DT 12-JUN-2003 (first entry)  
XX  
DE Human secreted protein coding sequence, SEQ ID 521.  
XX  
KW Cardiant; antiarrhythmic; antiarteriosclerotic; vasotropic; cytostatic;

KW vulnery; antiinflammatory; nootropic; neuroprotective;  
KW antiparkinsonian; gene therapy; human; cardiovascular disorder; gene; ss.  
XX Homo sapiens.  
XX WO200295010-A2.  
XX 28-NOV-2002.  
XX 19-MAR-2002; 2002WO-US009785.  
XX 21-MAR-2001; 2001US-0277340P.  
PR 19-JUL-2001; 2001US-0306171P.  
PR 13-NOV-2001; 2001US-0331287P.  
XX (HUMA-) HUMAN GENOME SCI INC.  
XX Rosen CA, Ruben SM;  
PI WPI; 2003-129429/12.  
XX Novel human secreted proteins, useful for detecting, preventing,  
PT diagnosing, prognosticating, treating and/or ameliorating cardiovascular  
PT disorders such as arrhythmia.  
XX Claim 21; SEQ ID NO 521; 1881pp; English.  
XX The present invention relates to novel human secreted proteins (ABR47633-  
CC ABR48145) and their coding sequences (ACC50344-ACC50856). The proteins  
CC or their coding sequences are useful for the preparation of a diagnostic  
CC or pharmaceutical composition for diagnosing or treating a cardiovascular  
CC disorder (e.g., arrhythmia, tachycardia, cardiac arrest, coronary  
CC arteriosclerosis and myocardial ischaemia), neural disorders, immune  
CC system disorders, muscular disorders, reproductive disorders,  
CC gastrointestinal disorders, pulmonary disorders, renal disorders,  
CC proliferative disorders and/or cancerous diseases and conditions, for  
CC wound healing and epithelial cell proliferation, to treat inflammation or  
CC infection, for treating thrombosis and arteriosclerosis, for treating or  
CC preventing neural damage which occurs in neuronal disorders or  
CC neurodegenerative conditions such as Alzheimer's disease and Parkinson's  
CC disease, to enhance bone and periodontal regeneration and aid in tissue  
CC transplants or bone grafts, to prevent skin aging or hair loss, to  
CC stimulate growth and differentiation of haematopoietic cells and bone  
CC marrow cells when used in combination with other cytokines, to maintain  
CC organs before transplantation or for supporting cell culture of primary  
CC tissues, to increase or decrease differentiation or proliferation of  
CC embryonic stem cells, or to modulate mammalian characteristics or  
CC metabolism. Note: The sequence data for this patent was published in  
CC electronic format and is available from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 1315 BP; 419 A; 329 C; 290 G; 277 T; 0 U; 0 Other;  
  
Query Match 3.0%; Score 66.2; DB 8; Length 1315;  
Best Local Similarity 84.1%; Pred. No. 0.00022;  
Matches 74; Conservative 0; Mismatches 14; Indels 0; Gaps 0;  
  
QY 2155 AATAAAATGTTGGTCTCCACACTGNCCTCCAAAAA 2214  
Db 1200 AATAAAATGAAAGTATCCTCTCAAAAAA 1259  
  
QY 2215 AAAAAA 2242  
Db 1260 AAAAAA 1287  
  
RESULT 994  
ADC73986  
ID ADC73986 standard; DNA; 1315 BP.  
XX  
AC ADC73986;  
XX  
DT 01-JAN-2004 (first entry)

XX Human secreted protein-related DNA - SEQ ID 619.  
DE antianaemic; antirheumatic; antiarthritic; antiinflammatory; antithyroid;  
XX antidiabetic; immunosuppressive; dermatological; nephrotropic;  
KW antiparkinsonian; neuroprotective; nootropic; antibacterial; virucide;  
KW fungicide; antiparasitic; antiarteriosclerotic; vulnery; cytostatic;  
KW haemopoietic; haematologic; anaemia; autoimmune disorder;  
KW rheumatoid arthritis; inflammation; Grave's disease; diabetes;  
KW systemic lupus erythematosus; glomerulonephritis; neurodegenerative;  
KW Parkinson's; Alzheimer's; wound; hyperproliferative; atherosclerosis;  
KW cancer; bacterial; viral; fungal; parasitic infection; gene therapy;  
KW human; gene; ds.  
XX Homo sapiens.  
OS  
XX WO2003038063-A2.  
PN  
XX  
PD 08-MAY-2003.  
XX  
PF 19-MAR-2002; 2002WO-US008277.  
XX  
PR 21-MAR-2001; 2001US-0277340P.  
PR 19-JUL-2001; 2001US-0306171P.  
PR 13-NOV-2001; 2001US-0331287P.  
XX (HUMA-) HUMAN GENOME SCI INC.  
PA  
XX  
XX Rosen CA, Ruben SM;  
PI  
XX WPI; 2003-430516/40.  
DR P-PSDB; ADC74601.  
XX  
PT New human secreted polypeptide for diagnosing, preventing or treating  
PT hematopoietic or hematologic disorders (e.g. anemia), autoimmune  
PT disorders (e.g. diabetes) or hyperproliferative disorders (e.g. cancer or  
PT atherosclerosis).  
XX  
PS Claim 27; SEQ ID NO 619; 2272pp; English.  
XX  
CC The invention relates to a novel human secreted polypeptide comprising a  
CC defined sequence given in the specification. The polypeptide, nucleic  
CC acid molecule, antibody, agonist or antagonist of the invention may be  
CC useful for preparing a composition for diagnosing or treating a  
CC haemopoietic or haematologic disorder such as anaemia, autoimmune  
CC disorders such as rheumatoid arthritis, inflammation, Grave's disease,  
CC diabetes, systemic lupus erythematosus or glomerulonephritis,  
CC neurodegenerative disorders including Parkinson's disease and Alzheimer's  
CC disease, wounds and hyperproliferative disorders including  
CC atherosclerosis or cancer, as well as bacterial, viral, fungal or  
CC parasitic infections. The polypeptide may also be used during gene  
CC therapy procedures and for identifying a binding partner by contacting  
CC the polypeptide with a binding partner and determining whether the  
CC binding partner increases or decreases the activity of the polypeptide.  
CC The current sequence is that of the human secreted protein-related DNA of  
CC the invention.  
XX  
SQ Sequence 1315 BP; 419 A; 329 C; 290 G; 277 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.2; DB 10; Length 1315;  
Best Local Similarity 84.1%; Pred. No. 0.00022;  
Matches 74; Conservative 0; Mismatches 14; Indels 0; Gaps 0;  
QY 2155 AATAAAATGTTGGTCTCCACCACCTGCTCCCAAAAAAAAAAAAAAAAAAAAA 2214  
Db 1200 AATAAAATGAAAGTATCTCTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1259  
QY 2215 AAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242  
Db 1260 AAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1287

ADD37810  
ID ADD37810 standard; cDNA; 1315 BP.  
XX  
AC ADD37810;  
XX  
DT 15-JAN-2004 (first entry)  
XX  
DE Human secreted protein encoding sequence #292.  
XX  
KW human secreted protein; Antiallergic; Antiinflammatory; Antibacterial;  
KW Anti-HIV; Cytostatic; Immunosuppressive; Hemostatic; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200290526-A2.  
XX  
PD 14-NOV-2002.  
XX  
PF 19-MAR-2002; 2002WO-US008279.  
XX  
PR 21-MAR-2001; 2001US-0277340P.  
PR 19-JUL-2001; 2001US-0306171P.  
PR 13-NOV-2001; 2001US-0331287P.  
XX (HUMA-) HUMAN GENOME SCI INC.  
PA  
XX Rosen CA, Ruben SM;  
PI  
XX WPI; 2003-140218/13.  
DR  
XX  
PT New human secreted proteins and nucleic acid molecules, useful for  
PT preparing a diagnostic or pharmaceutical composition for diagnosing or  
PT treating allergic or asthmatic disorders, or related immediate  
PT hypersensitivity disorders.  
XX  
PS Claim 7; SEQ ID NO 292; 1323pp; English.  
XX  
CC The present invention relates to an isolated polypeptide or human  
CC secreted protein. The polypeptides, nucleic acid molecules, antibodies or  
CC their fragments, and agonists or antagonists that bind are useful for  
CC preparing a diagnostic or pharmaceutical composition for diagnosing or  
CC treating allergic or asthmatic disorders. The polypeptide is also useful  
CC for identifying a binding partner by contacting the polypeptide with a  
CC binding partner, and determining whether the binding partner increases or  
CC decreases the activity of the polypeptide. The polypeptides and nucleic  
CC acid molecules are also useful for detecting, preventing, diagnosing,  
CC prognosticating, treating or ameliorating inflammatory disorders  
CC neoplastic diseases, wound healing and disorders of epithelial cell  
CC proliferation, immune disorders, cardiovascular disorders, blood-related  
CC disorders, infectious diseases, endocrine disorders, or gastrointestinal  
CC disorders. The nucleic acids are also useful for chromosome  
CC identification, radiation hybrid mapping or long-range restriction  
CC mapping, as molecular weight markers, or as hybridization or diagnostic  
CC probes. The polypeptides and antibodies are useful for providing  
CC immunological probes for differential identification of the tissues  
CC immunohistochemistry assays. The present sequence represents a human  
CC secreted protein encoding sequence.  
XX  
SQ Sequence 1315 BP; 419 A; 329 C; 290 G; 277 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.2; DB 10; Length 1315;  
Best Local Similarity 84.1%; Pred. No. 0.00022;  
Matches 74; Conservative 0; Mismatches 14; Indels 0; Gaps 0;  
QY 2155 AATAAAATGTTGGTCTCCACCACCTGCTCCCAAAAAAAAAAAAAAAAAAAAA 2214  
Db 1200 AATAAAATGAAAGTATCTCTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1259  
QY 2215 AAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242  
Db 1260 AAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1287

CC sequence data for this patent did form part of the printed specification  
CC but was obtained in electronic format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences.

XX

SQ Sequence 1315 BP; 419 A; 329 C; 290 G; 277 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.2; DB 10; Length 1315;  
Best Local Similarity 84.1%; Pred. No. 0.00022;  
Matches 74; Conservative 0; Mismatches 14; Indels 0; Gaps 0

QY 2155 AATAAAATGTTGGTCTCCACCACCTGNCTCCCAAAAAA 221  
||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 1200 AATAAAATGAAGTATCCTCTCAAAAAA 125  
QY 2215 AAAAAAAAAAAAAAAAAAAAAA 2242  
||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 1260 AAAAAAAAAAAAAAAAAAAAAA 1287

RESULT 997  
ADA40234  
ID ADA40234 standard; cDNA; 1317 BP.  
XX  
AC ADA40234;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human secreted protein encoding cDNA.  
XX  
KW Human; secreted protein; cancer; hyperproliferative disorder;  
KW rheumatoid arthritis; autoimmune disorder; haematopoietic disorder;  
KW anaemia; allergic reaction; asthma; cardiovascular disorder;  
KW wound healing; cytostatic; immunosuppressive; neuroprotective;  
KW antiviral; anti-allergic; hepatotropic; antidiabetic; anti-inflammatory;  
KW vulnery; cardiant; gene therapy; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO2002102993-A2.  
XX  
PD 27-DEC-2002.  
XX  
PF 19-MAR-2002; 2002WO-US008123.  
XX  
PR 21-MAR-2001; 2001US-0277340P.  
PR 19-JUL-2001; 2001US-0306171P.  
PR 13-NOV-2001; 2001US-0331287P.  
XX  
PA (HUMA-) HUMAN GENOME SCI INC.  
XX  
PI Rosen CA, Ruben SM;  
XX  
DR WPI; 2003-175238/17.  
XX  
PT New human secreted proteins and nucleic acid molecules, useful for  
PT preparing a diagnostic or pharmaceutical composition for diagnosing,  
PT preventing or treating cancer or other hyperproliferative disorder,  
PT asthma, allergies or AIDS.  
XX  
PS Claim 9; SEQ ID NO 616; 3205pp; English.  
XX  
CC The invention relates to novel genes ADA39629-ADA40565 and proteins  
CC ADA40566-ADA41501 for human secreted proteins, useful for preventing,  
CC treating or ameliorating medical conditions e.g. by protein or gene  
CC therapy. The polypeptides, nucleic acid molecules, antibodies or their  
CC fragments, and agonists or antagonists that bind to the polypeptide are  
CC useful for preparing a diagnostic or pharmaceutical composition for  
CC diagnosing or treating cancer or other hyperproliferative disorder. The  
CC polypeptides and nucleic acid molecules are also useful for detecting,  
CC preventing, diagnosing, prognosticating, treating or ameliorating cancer  
CC or other hyperproliferative disorders including neoplasms, autoimmune  
CC disorders (e.g. diabetes, rheumatoid arthritis, systemic lupus  
CC erythematosus, multiple sclerosis, autoimmunethyroiditis or haemolytic

ADA56701 standard; DNA; 1315 BP.

ADA56701;

20-NOV-2003 (first entry)

Gene encoding human secreted protein #574.

immunosuppressive; antiinflammatory; antiasthmatic; antiallergic;  
cytostatic; cerebroprotective; neuroprotective; nootropic;  
cardiovascular; antiarteriosclerotic; gene therapy;  
human secreted protein; immune disorder; inflammation;  
respiratory disorder; cancer; CNS disorder; neurodegenerative disorders;  
inflammatory bowel disease; nephritis; Crohn's disease; asthma; allergy;  
multiple sclerosis; ischaemic brain injury; Parkinson's disease;  
Alzheimer's disease; atherosclerosis; myocarditis; chromosome mapping;  
triple helix formation; antisense gene therapy; forensic biology; ds;  
gene.

Homo sapiens.

WO2002102994-A2.

27-DEC-2002.

19-MAR-2002; 2002WO-US008278.

21-MAR-2001; 2001US-0277340P.  
19-JUL-2001; 2001US-0306171P.  
13-NOV-2001; 2001US-0331287P.

(HUMA-) HUMAN GENOME SCI INC.

Rosen CA, Ruben SM;  
WPI; 2003-167512/16.  
P-PSDB; ADA57594.

New human secreted polypeptides and polynucleotides, useful for  
diagnosing, treating or preventing e.g. immune disorders, inflammatory  
conditions, respiratory disorders, cancers, CNS disorders, or  
neurodegenerative disorders.

Claim 21; SEQ ID NO 890; 1754pp; English.

The invention relates to 592 new human secreted polypeptides useful for  
diagnosing, treating or preventing e.g. immune disorders, inflammatory  
conditions, respiratory disorders, cancers, CNS disorders, or  
neurodegenerative disorders, or polypeptides comprising an amino acid  
sequence at least 95% identical to the new sequences. The polypeptides,  
antibodies or antibody fragments that bind to the polypeptides, nucleic  
acids encoding the polypeptides, agonists or antagonists that binds to  
the polypeptide, are useful in preparing diagnostic or pharmaceutical  
compositions for diagnosing, treating or preventing an e.g. immune  
disorders, inflammatory conditions (e.g. inflammatory bowel disease,  
nephritis or Crohn's disease), respiratory disorders (e.g. asthma and  
allergy), cancers (e.g. gastric, ovarian or lung cancer), CNS disorders  
(e.g. multiple sclerosis or ischaemic brain injury), neurodegenerative  
disorders (e.g. Parkinson's disease or Alzheimer's disease), and  
cardiovascular disorders (e.g. atherosclerosis or myocarditis). The  
polynucleotides are useful for chromosome identification, chromosome  
mapping, for controlling gene expression through triple helix formation  
or antisense DNA or RNA, in gene therapy, for identifying individuals  
from minute biological samples, in forensic biology, and as hybridization  
probes. The polypeptides are useful for as molecular weight markers on  
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)  
gels, to raise antibodies, for testing biological activities, and for  
treating or preventing neural disorders, immune system disorders,  
muscular, reproductive, gastrointestinal, pulmonary, cardiovascular,  
renal, proliferative and/or cancerous diseases. This sequence corresponds  
to a gene encoding one of the polypeptide of the invention. Note: The



anaemia), haematopoietic or haematological disorders (e.g. anaemia, thrombocytopenia), allergic reactions including asthma or eczema, inflammatory disorders (e.g. ischaemia-reperfusion injury, inflammatory bowel disease or Crohn's disease), neurodegenerative disorders (e.g. Alzheimer's disease or Parkinson's disease), cardiovascular disorders (e.g. atherosclerosis, myocarditis), infectious diseases (bacterial, fungal or viral infections including HIV/AIDS), or wound healing and disorders of epithelial cell proliferation. The nucleic acids are also useful for chromosome identification, radiation hybrid mapping or long-range restriction mapping, as molecular weight markers, or as hybridization or diagnostic probes. The polypeptides and antibodies are useful for providing immunological probes for differential identification of the tissues immunohistochemistry assays. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences.

Sequence 1317 BP; 419 A; 331 C; 290 G; 277 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.2; DB 8; Length 1317;  
Best Local Similarity 84.1%; Pred. No. 0.00022;  
Matches 74; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 2155 AATAAAATGTTGGTCTCCACCACCTGNCCTCCAAAAA 2214  
Db 1202 AATAAAATGAAAGTATCTCTCAAAAAA 1261

QY 2215 AAAAAA 2242  
Db 1262 AAAAAA 1289

RESULT 998  
ACC50674  
ID ACC50674 standard; cDNA; 1317 BP.  
XX ACC50674;  
DT 12-JUN-2003 (first entry)  
XX Human secreted protein coding sequence, SEQ ID 341.  
DE Cardiant; antiarrhythmic; antiarteriosclerotic; vasotropic; cytostatic;  
XX vulnerable; antiinflammatory; nootropic; neuroprotective;  
KW antiparkinsonian; gene therapy; human; cardiovascular disorder; gene; ss.  
XX Homo sapiens.  
OS WO200295010-A2.  
XX 28-NOV-2002.  
PD 19-MAR-2002; 2002WO-US009785.  
XX 21-MAR-2001; 2001US-0277340P.  
PF 19-JUL-2001; 2001US-0306171P.  
XX 13-NOV-2001; 2001US-0331287P.  
XX (HUMA-) HUMAN GENOME SCI INC.  
PA Rosen CA, Ruben SM;  
XX WPI; 2003-129429/12.  
XX Novel human secreted proteins, useful for detecting, preventing,  
PT diagnosing, prognosticating, treating and/or ameliorating cardiovascular  
PT disorders such as arrhythmia.  
XX Claim 21; SEQ ID NO 341; 1881pp; English.  
PS The present invention relates to novel human secreted proteins (ABR47633-  
XX ABR48145) and their coding sequences (ACC50344-ACC50856). The proteins  
CC and their coding sequences are useful for the preparation of a diagnostic  
CC

or pharmaceutical composition for diagnosing or treating a cardiovascular disorder (e.g., arrhythmia, tachycardia, cardiac arrest, coronary arteriosclerosis and myocardial ischaemia), neural disorders, immune system disorders, muscular disorders, reproductive disorders, gastrotestinal disorders, pulmonary disorders, renal disorders, proliferative disorders and/or cancerous diseases and conditions, for wound healing and epithelial cell proliferation, to treat inflammation or infection, for treating thrombosis and arteriosclerosis, for treating or preventing neural damage which occurs in neuronal disorders or neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease, to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts, to prevent skin aging or hair loss, to stimulate growth and differentiation of haematopoietic cells and bone marrow cells when used in combination with other cytokines, to maintain organs before transplantation or for supporting cell culture of primary tissues, to increase or decrease differentiation or proliferation of embryonic stem cells, or to modulate mammalian characteristics or metabolism. Note: The sequence data for this patent was published in electronic format and is available from WIPO at ftp.wipo.int/pub/published\_pct\_sequences

Sequence 1317 BP; 419 A; 331 C; 290 G; 277 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.2; DB 8; Length 1317;  
Best Local Similarity 84.1%; Pred. No. 0.00022;  
Matches 74; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 2155 AATAAAATGTTGGTCTCCACCACCTGNCCTCCAAAAA 2214  
Db 1202 AATAAAATGAAAGTATCTCTCAAAAAA 1261

QY 2215 AAAAAA 2242  
Db 1262 AAAAAA 1289

RESULT 999  
ADC73758  
ID ADC73758 standard; DNA; 1317 BP.  
XX AC ADC73758;  
XX 01-JAN-2004 (first entry)  
DT Human secreted protein-related DNA - SEQ ID 391.  
XX antianaemic; antirheumatic; antiarthritic; antiinflammatory; antithyroid;  
KW antidiabetic; immunosuppressive; dermatological; nephrotropic;  
KW antiparkinsonian; neuroprotective; nootropic; antibacterial; virucide;  
KW fungicide; antiparasitic; antiarteriosclerotic; vulnery; cytostatic;  
KW haemopoietic; haematologic; anaemia; autoimmune disorder;  
KW rheumatoid arthritis; inflammation; Grave's disease; diabetes;  
KW systemic lupus erythematosus; glomerulonephritis; neurodegenerative;  
KW Parkinson's; Alzheimer's; wound; hyperproliferative; atherosclerosis;  
KW cancer; bacterial; viral; fungal; parasitic infection; gene therapy;  
XX human; gene; ds.  
XX Homo sapiens.  
OS WO2003038063-A2.  
XX 08-MAY-2003.  
XX 19-MAR-2002; 2002WO-US008277.  
PF 21-MAR-2001; 2001US-0277340P.  
XX 19-JUL-2001; 2001US-0306171P.  
PR 13-NOV-2001; 2001US-0331287P.  
XX (HUMA-) HUMAN GENOME SCI INC.  
PA Rosen CA, Ruben SM;  
XX and their coding sequences are useful for the preparation of a diagnostic  
CC









PA	(REUB/) REUBER T L.	CC	orthologue of a thalecress transcription factor isolated from Soybean.
PA	(KEDD/) KEDDIE J S.	XX	
PA	(YUGG/) YU G.	SQ	Sequence 1337 BP; 437 A; 296 C; 239 G; 365 T; 0 U; 0 Other;
PA	(JIAN/) JIANG C.		Query Match 3.0%; Score 66.2; DB 12; Length 1337;
PA	(SAMA/) SAMAHA R S.		Best Local Similarity 58.0%; Pred. No. 0.00022;
PA	(PILG/) PILGRIM M L.		Matches 116; Conservative 0; Mismatches 84; Indels 0; Gaps 0;
PA	(CREE/) CREELMAN R A.	QY	2043 TTGATTGGCATAATCACTCCGGTTTGCTTTCTAGGTCCTCAAGTCGCTCGTGACACATAAT 2102
PA	(DUBE/) DUBELL A N.	Db	1122 TTATTGTATAAATAATTAGTCGCTGATATGCATAATATATATAGTACCGGTACAGTTGAAC 1181
PA	(RATC/) RATCLIFFE O.	QY	2103 CATTCCATCCAATGATCGCCTTTGCTTTTACCACCTCTTTTCCTTTTATCTTATTAATAAAAA 2162
PA	(KUMI/) KUMIMOTO R.	Db	1182 ATTTTGGCCCAATTTTCCCTTTTGTGTTACTCTTTCACCTTTTCTTCTCCGGCAATTGA 1241
PA	(SHER/) SHERMAN B K.	QY	2163 TGTTGGTCTCCACCACCTGNCTCCCAAAAAA 2222
XX		Db	1242 TGGTAGTCATAAAGAAAAA 1301
PI	Zhang J, Fromm ME, Heard JE, Riechmann JL, Adam LJ, Broun PE;	QY	2223 AAAAAAAAAAAAAAAAAA 2242
PI	Pineda O, Reuber TL, Keddle JS, Yu G, Jiang C, Samaha RS;	Db	1302 AAAAAAAAAAAAAAAAAA 1321
PI	Pilgrim ML, Creelman RA, Dubell AN, Ratcliffe O, Kumimoto R;		
PI	Sherman BK;		
DR	WPI; 2004-225755/21.		
XX			
PT	New transgenic plant, useful in developing phenotypes with altered or		
PT	improved characteristics or traits.		
XX			
PS	Claim 1; SEQ ID NO 1297; 213pp; English.		
XX			
CC	The invention relates to a transgenic plant comprises a recombinant	RESULT 1005	
CC	polynucleotide having a polynucleotide sequence or its complementary	AAV59706	
CC	sequence comprising a sequence encoding a polypeptide, that initiates	ID	AAV59706 standard; DNA; 1378 BP.
CC	transcription (i.e. a transcription factor) from Arabidopsis, Soybean,	XX	
CC	Rice, Rape or Corn, comprising any of the sequences appearing as ADO01588	AC	AAV59706;
CC	-ADO03527 or ADO03530-ADO03559. Also included are using a transgenic	XX	
CC	plant to grow a progeny plant, an expression cassette (comprising a	DT	19-JAN-1999 (first entry)
CC	constitutive, inducible or tissue-specific promoter and a recombinant	XX	
CC	polynucleotide described above), a host cell comprising the expression	DE	Human secreted protein gene 14 clone HPMFD84.
CC	cassette, producing a modified plant having a modified trait, identifying	XX	
CC	a factor that is modulated by or interacts with a polypeptide encoded by	KW	Human; secreted protein; fusion protein; gene therapy; protein therapy;
CC	the polynucleotide sequence and identifying at least one downstream	KW	diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
CC	polynucleotide sequence that is subject to a regulatory effect of any of	KW	developmental abnormality; foetal deficiency; blood; allergy; renal; ds;
CC	the polypeptides encoded by the polynucleotide described above. The	KW	immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
CC	transgenic plant is useful for producing a plant that has an altered	KW	inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
CC	trait e.g. an enhanced tolerance to abiotic stress (increased tolerance	KW	cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
CC	to chilling, germination in cold conditions,freezing tolerance, tolerance	KW	osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
CC	to heat, tolerance to drought, tolerance to osmotic stress, tolerance to	KW	endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
CC	salt, tolerance to phosphate limitation, tolerance to potassium	XX	
CC	limitation, decreased sensitivity to nitrogen limitation), altered	OS	Homo sapiens.
CC	hormone sensitivity, reduced sensitivity to abscisic acid, an altered	XX	
CC	response to ethylene, disease resistance, altered susceptibility to	PN	WO9839448-A2.
CC	Botrytis, altered susceptibility to Fusarium, altered susceptibility to	XX	
CC	Erysiphe, altered susceptibility to Pseudomonas syringae, altered	PD	11-SEP-1998.
CC	susceptibility to Sclerotinia, altered sugar sensing, improved seed	XX	
CC	germination and seedling vigor, early flowering, late flowering, extended	PF	06-MAR-1998; 98WO-US004493.
CC	period of flowering, an inflorescence architectural change, a change in	XX	
CC	stem bifurcations, a lack of a shoot meristem, reduced meristem cell	PR	07-MAR-1997; 97US-0038621P.
CC	differentiation, altered phyllotaxy, altered branching pattern, reduced	PR	07-MAR-1997; 97US-0040161P.
CC	apical dominance, reduced trichome density, ectopic trichome development,	PR	07-MAR-1997; 97US-0040162P.
CC	altered trichome development, altered stem morphology, increased root	PR	07-MAR-1997; 97US-0040163P.
CC	growth, increased root hairs, altered seed development, altered cell	PR	07-MAR-1997; 97US-0040333P.
CC	proliferation/cell differentiation, premature senescence, delayed	PR	07-MAR-1997; 97US-0040334P.
CC	senescence, lethality, increased necrosis, an increase in seedling or	PR	07-MAR-1997; 97US-0040336P.
CC	plant size, decreased plant size, a change in leaf morphology, increased	PR	07-MAR-1997; 97US-0040626P.
CC	altered leaf development, increased leaf size and mass, glossy leaves,	PR	07-MAR-1997; 97US-0043311P.
CC	leaf cell expansion, change in seed morphology, altered seed coloration,	PR	11-APR-1997; 97US-0043312P.
CC	increased seed size, decreased seed size, altered seed shape, change in	PR	11-APR-1997; 97US-0043313P.
CC	leaf biochemistry, increased leaf wax, an alteration in leaf prenyl lipid	PR	11-APR-1997; 97US-0043314P.
CC	content, increased leaf insoluble sugars, decreased leaf insoluble	PR	11-APR-1997; 97US-0043315P.
CC	sugars, increased leaf anthocyanins, an alteration of leaf fatty acid	PR	11-APR-1997; 97US-0043568P.
CC	content, an alteration of leaf glucosinolate content, change in seed	PR	11-APR-1997; 97US-0043569P.
CC	biochemistry, an increase in seed oil content, decrease in seed oil	PR	11-APR-1997; 97US-0043576P.
CC	content, increase in seed fatty acid content, decrease in seed fatty acid	PR	11-APR-1997; 97US-0043578P.
CC	content, increase in seed protein content, decrease in seed protein	PR	11-APR-1997; 97US-0043580P.
CC	content, alteration in seed prenyl lipid content, increase in seed	PR	11-APR-1997; 97US-0043669P.
CC	sterols, upregulation of genes involved in secondary metabolism, increase	PR	11-APR-1997; 97US-0043670P.
CC	in root anthocyanins, increase in plant anthocyanins, and alteration in	PR	
CC	light response or shade avoidance. The present sequence encodes an	PR	





OS Homo sapiens.  
XX  
PN US6420526-B1.  
XX  
PD 16-JUL-2002.  
XX  
PF 08-SEP-1998; 98US-00149476.  
XX  
PR 07-MAR-1997; 97US-0038621P.  
PR 07-MAR-1997; 97US-0040161P.  
PR 07-MAR-1997; 97US-0040162P.  
PR 07-MAR-1997; 97US-0040163P.  
PR 07-MAR-1997; 97US-0040333P.  
PR 07-MAR-1997; 97US-0040334P.  
PR 07-MAR-1997; 97US-0040336P.  
PR 07-MAR-1997; 97US-0040626P.  
PR 11-APR-1997; 97US-0043311P.  
PR 11-APR-1997; 97US-0043312P.  
PR 11-APR-1997; 97US-0043313P.  
PR 11-APR-1997; 97US-0043314P.  
PR 11-APR-1997; 97US-0043315P.  
PR 11-APR-1997; 97US-0043568P.  
PR 11-APR-1997; 97US-0043569P.  
PR 11-APR-1997; 97US-0043576P.  
PR 11-APR-1997; 97US-0043578P.  
PR 11-APR-1997; 97US-0043580P.  
PR 11-APR-1997; 97US-0043669P.  
PR 11-APR-1997; 97US-0043670P.  
PR 11-APR-1997; 97US-0043671P.  
PR 11-APR-1997; 97US-0043672P.  
PR 11-APR-1997; 97US-0043674P.  
PR 23-MAY-1997; 97US-0047492P.  
PR 23-MAY-1997; 97US-0047500P.  
PR 23-MAY-1997; 97US-0047501P.  
PR 23-MAY-1997; 97US-0047502P.  
PR 23-MAY-1997; 97US-0047503P.  
PR 23-MAY-1997; 97US-0047581P.  
PR 23-MAY-1997; 97US-0047582P.  
PR 23-MAY-1997; 97US-0047583P.  
PR 23-MAY-1997; 97US-0047584P.  
PR 23-MAY-1997; 97US-0047585P.  
PR 23-MAY-1997; 97US-0047586P.  
PR 23-MAY-1997; 97US-0047587P.  
PR 23-MAY-1997; 97US-0047588P.  
PR 23-MAY-1997; 97US-0047589P.  
PR 23-MAY-1997; 97US-0047590P.  
PR 23-MAY-1997; 97US-0047592P.  
PR 23-MAY-1997; 97US-0047593P.  
PR 23-MAY-1997; 97US-0047594P.  
PR 23-MAY-1997; 97US-0047595P.  
PR 23-MAY-1997; 97US-0047596P.  
PR 23-MAY-1997; 97US-0047597P.  
PR 23-MAY-1997; 97US-0047598P.  
PR 23-MAY-1997; 97US-0047599P.  
PR 23-MAY-1997; 97US-0047600P.  
PR 23-MAY-1997; 97US-0047601P.  
PR 23-MAY-1997; 97US-0047612P.  
PR 23-MAY-1997; 97US-0047613P.  
PR 23-MAY-1997; 97US-0047614P.  
PR 23-MAY-1997; 97US-0047615P.  
PR 23-MAY-1997; 97US-0047617P.  
PR 23-MAY-1997; 97US-0047618P.  
PR 23-MAY-1997; 97US-0047632P.  
PR 23-MAY-1997; 97US-0047633P.  
PR 06-JUN-1997; 97US-0048964P.  
PR 06-JUN-1997; 97US-0048974P.  
PR 13-JUN-1997; 97US-0049610P.  
PR 08-JUL-1997; 97US-0051926P.  
PR 16-JUL-1997; 97US-0052874P.  
PR 18-AUG-1997; 97US-0055724P.  
PR 22-AUG-1997; 97US-0056630P.  
PR 22-AUG-1997; 97US-0056631P.  
PR 22-AUG-1997; 97US-0056632P.

PR 22-AUG-1997; 97US-0056636P.  
PR 22-AUG-1997; 97US-0056637P.  
PR 22-AUG-1997; 97US-0056662P.  
PR 22-AUG-1997; 97US-0056664P.  
PR 22-AUG-1997; 97US-0056845P.  
PR 22-AUG-1997; 97US-0056862P.  
PR 22-AUG-1997; 97US-0056864P.  
PR 22-AUG-1997; 97US-0056872P.  
PR 22-AUG-1997; 97US-0056874P.  
PR 22-AUG-1997; 97US-0056875P.  
PR 22-AUG-1997; 97US-0056876P.  
PR 22-AUG-1997; 97US-0056877P.  
PR 22-AUG-1997; 97US-0056878P.  
PR 22-AUG-1997; 97US-0056879P.  
PR 22-AUG-1997; 97US-0056880P.  
PR 22-AUG-1997; 97US-0056881P.  
PR 22-AUG-1997; 97US-0056882P.  
PR 22-AUG-1997; 97US-0056884P.  
PR 22-AUG-1997; 97US-0056886P.  
PR 22-AUG-1997; 97US-0056887P.  
PR 22-AUG-1997; 97US-0056888P.  
PR 22-AUG-1997; 97US-0056889P.  
PR 22-AUG-1997; 97US-0056892P.  
PR 22-AUG-1997; 97US-0056893P.  
PR 22-AUG-1997; 97US-0056894P.  
PR 22-AUG-1997; 97US-0056903P.  
PR 22-AUG-1997; 97US-0056908P.  
PR 22-AUG-1997; 97US-0056909P.  
PR 22-AUG-1997; 97US-0056910P.  
PR 22-AUG-1997; 97US-0056911P.  
PR 05-SEP-1997; 97US-0057650P.  
PR 05-SEP-1997; 97US-0057669P.  
PR 05-SEP-1997; 97US-0057761P.  
PR 12-SEP-1997; 97US-0058785P.  
PR 02-OCT-1997; 97US-0061060P.  
PR 06-MAR-1998; 98WO-US004493.  
XX  
(HUMA-) HUMAN GENOME SCI INC.

PI Ruben SM, Rosen CA, Fischer CL, Soppet DP, Carter KC;  
PI Bednarik DR, Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM;  
PI Ferrie AM, Duan R, Hu J, Florence KA, Olsen HS, Ebner R, Brewer LA;  
PI Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;

XX WPI; 2002-634796/68.  
DR P-PSDB; ABG95377.

XX New isolated human secreted protein for diagnosing, preventing, treating  
PT or ameliorating medical conditions and used as a food additive or  
PT preservative.

XX Example 1; SEQ ID NO 208; 129pp; English.

PS The invention relates to an isolated protein that is one of 186 human  
XX secreted proteins, given in the specification, encoded by one of 309 cDNA  
CC sequences also given in the specification. The protein is used in a  
CC pharmaceutical composition used to prevent, treat or ameliorate a medical  
CC condition in e.g. humans, mice, rabbits, goats, horses, cats, dogs,  
CC chickens or sheep. Disorders which are diagnosed or treated include  
CC autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative  
CC disorders e.g. neoplasms of the breast or liver, cardiovascular disorders  
CC e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,  
CC angiogenesis, nervous system disorders e.g. Alzheimer's disease,  
CC infections caused by bacteria, viruses and fungi and ocular disorders  
CC e.g. corneal infection. The polypeptides can also be used to aid wound  
CC healing and epithelial cell proliferation, to prevent skin aging due to  
CC sunburn, to maintain organs before transplantation, for supporting cell  
CC culture of primary tissues, to regenerate tissues and in chemotaxis. The  
CC polypeptides can also be used as a food additive or preservative to  
CC increase or decrease storage capabilities, fat content, lipid, protein,  
CC carbohydrate, vitamins, minerals, cofactors and other nutritional  
CC components. The present sequence represents a cDNA derived from a gene  
CC encoding one of the novel human secreted proteins of the invention. Note:

PR	11-APR-1997;	97US-00436722;
PR	11-APR-1997;	97US-0043674P;
PR	23-MAY-1997;	97US-0047492P;
PR	23-MAY-1997;	97US-0047500P;
PR	23-MAY-1997;	97US-0047501P;
PR	23-MAY-1997;	97US-0047502P;
PR	23-MAY-1997;	97US-0047503P;
PR	23-MAY-1997;	97US-0047581P;
PR	23-MAY-1997;	97US-0047582P;
PR	23-MAY-1997;	97US-0047583P;
PR	23-MAY-1997;	97US-0047584P;
PR	23-MAY-1997;	97US-0047585P;
PR	23-MAY-1997;	97US-0047586P;
PR	23-MAY-1997;	97US-0047587P;
PR	23-MAY-1997;	97US-0047588P;
PR	23-MAY-1997;	97US-0047589P;
PR	23-MAY-1997;	97US-0047590P;
PR	23-MAY-1997;	97US-0047592P;
PR	23-MAY-1997;	97US-0047593P;
PR	23-MAY-1997;	97US-0047594P;
PR	23-MAY-1997;	97US-0047595P;
PR	23-MAY-1997;	97US-0047596P;
PR	23-MAY-1997;	97US-0047597P;
PR	23-MAY-1997;	97US-0047598P;
PR	23-MAY-1997;	97US-0047599P;
PR	23-MAY-1997;	97US-0047600P;
PR	23-MAY-1997;	97US-0047601P;
PR	23-MAY-1997;	97US-0047612P;
PR	23-MAY-1997;	97US-0047613P;
PR	23-MAY-1997;	97US-0047614P;
PR	23-MAY-1997;	97US-0047615P;
PR	23-MAY-1997;	97US-0047617P;
PR	23-MAY-1997;	97US-0047618P;
PR	23-MAY-1997;	97US-0047632P;
PR	23-MAY-1997;	97US-0047633P;
PR	06-JUN-1997;	97US-0048964P;
PR	06-JUN-1997;	97US-0048974P;
PR	13-JUN-1997;	97US-0049610P;
PR	08-JUL-1997;	97US-0051926P;
PR	16-JUL-1997;	97US-0052874P;
PR	18-AUG-1997;	97US-0055724P;
PR	22-AUG-1997;	97US-0056630P;
PR	22-AUG-1997;	97US-0056631P;
PR	22-AUG-1997;	97US-0056632P;
PR	22-AUG-1997;	97US-0056636P;
PR	22-AUG-1997;	97US-0056637P;
PR	22-AUG-1997;	97US-0056662P;
PR	22-AUG-1997;	97US-0056664P;
PR	22-AUG-1997;	97US-0056845P;
PR	22-AUG-1997;	97US-0056862P;
PR	22-AUG-1997;	97US-0056864P;
PR	22-AUG-1997;	97US-0056872P;
PR	22-AUG-1997;	97US-0056874P;
PR	22-AUG-1997;	97US-0056875P;
PR	22-AUG-1997;	97US-0056876P;
PR	22-AUG-1997;	97US-0056877P;
PR	22-AUG-1997;	97US-0056878P;
PR	22-AUG-1997;	97US-0056879P;
PR	22-AUG-1997;	97US-0056880P;
PR	22-AUG-1997;	97US-0056881P;
PR	22-AUG-1997;	97US-0056882P;
PR	22-AUG-1997;	97US-0056884P;
PR	22-AUG-1997;	97US-0056886P;
PR	22-AUG-1997;	97US-0056887P;
PR	22-AUG-1997;	97US-0056888P;
PR	22-AUG-1997;	97US-0056889P;
PR	22-AUG-1997;	97US-0056892P;
PR	22-AUG-1997;	97US-0056893P;
PR	22-AUG-1997;	97US-0056894P;
PR	22-AUG-1997;	97US-0056903P;
PR	22-AUG-1997;	97US-0056908P;
PR	22-AUG-1997;	97US-0056909P;
PR	22-AUG-1997;	97US-0056910P;

```
PR 22-AUG-1997; 97US-0056911P.
PR 05-SEP-1997; 97US-0057650P.
PR 05-SEP-1997; 97US-0057669P.
PR 05-SEP-1997; 97US-0057761P.
PR 12-SEP-1997; 97US-0058785P.
PR 09-OCT-1997; 97US-0061660P.
PR 06-MAR-1998; 98WO-US004493.
PR 08-SEP-1998; 98US-00149476.
PR 17-MAR-2000; 2000US-0190068P.
XX
PA (RUBE/) RUBEN S M.
PA (ROSE/) ROSEN C A.
PA (SOPP/) SOPPET D R.
PA (CART/) CARTER K C.
PA (BEDN/) BEDNARIK D P.
PA (ENDR/) ENDRESS G A.
PA (YUGG/) YU G.
PA (NIJJ/) NI J.
PA (FENG/) FENG P.
PA (YOUN/) YOUNG P E.
PA (GREE/) GREENE J M.
PA (FERR/) FERRIE A M.
PA (DUAN/) DUAN D R.
PA (HUJJ/) HU J.
PA (FLOR/) FLORENCE K A.
PA (OLSE/) OLSEN H S.
PA (FISC/) FISCHER C L.
PA (EBNE/) EBNER R.
PA (BREW/) BREWER L A.
PA (MOOR/) MOORE P A.
PA (SHIY/) SHI Y.
PA (LAFI/) LAFLEUR D W.
PA (LIYY/) LI Y.
PA (ZENG/) ZENG Z.
PA (KYAW/) KYAW H.
XX
PI Ruben SM, Rosen CA, Soppet DR, Carter KC, Bednarik DP;
PI Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM, Ferrie AM;
PI Duan DR, Hu J, Florence KA, Olsen HS, Fischer CL, Ebner R;
PI Brewer LA, Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;
XX
DR WPI; 2003-521800/49.
DR P-PSDB; ABO34571.
XX
PT New genes and its encoded prostate cancer antigen proteins, useful for
PT preventing, treating, ameliorating or diagnosing e.g. prostate cancers,
PT thymic hypoplasia, multiple sclerosis, AIDS, angina pectoris or cerebral
PT ischemia.
XX
PS Claim 4; SEQ ID NO 208; 260pp; English.
XX
CC The present invention relates to the isolation of novel human secreted
CC proteins and the polynucleotide sequences encoding them. The invention
CC also discloses vectors, host cells, antibodies, and recombinant methods
CC for producing human secreted proteins. The polypeptide and polynucleotide
CC sequences for the secreted proteins are useful for preventing, treating,
CC ameliorating or diagnosing medical conditions such as hyperproliferative
CC disorders (e.g. leukaemia or breast cancers), wounds, reproductive
CC disorders, blood-related disorders (e.g. haemophilia or
CC thrombocytopaenia), immunodeficiencies (e.g. Wiskott-Aldrich syndrome or
CC thymic hypoplasia), autoimmune disorders (e.g. graft-versus-host disease,
CC multiple sclerosis or Hashimoto's thyroiditis), allergies (e.g. asthma),
CC viral or bacterial or fungal infections (e.g. AIDS or sepsis), renal
CC disorders (e.g. kidney failure), cardiovascular disorders (e.g. angina
CC pectoris, cerebral ischaemia or congenital heart defects), respiratory
CC disorders, neurological disorders (e.g. Alzheimer's disease or
CC Parkinson's disease), and inflammations (e.g. Crohn's disease). The
CC polynucleotide or polypeptide may also be used as vaccine adjuvants.
CC ACD82641-ACD82950 encode human secreted proteins or their fragments.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from the
CC USPTO web site at seqdata.uspto.gov/psipdsIDEntry.html
XX
```

```
SQ Sequence 1378 BP; 494 A; 254 C; 248 G; 377 T; 0 U; 5 Other;
Query Match 3.0%; Score 66.2; DB 9; Length 1378;
Best Local Similarity 71.7%; Pred. No. 0.00023;
Matches 86; Conservative 0; Mismatches 34; Indels 0; Gaps 0;
Qy 2123 TTTGCTTTACCACCTCTTCCCTTTATCTTATTATAATAAATGTTGGTCTCCACCACGTGNC 2182
Db 1245 TTCTATGTACAACACTGATGCTTGTCTTATTATTTTAATAAATTATCAGAGTGAATAAAAAA 1304
Qy 2183 TCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
Db 1305 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1364
RESULT 1008
ADI22923
ID ADI22923 standard; cDNA; 1378 BP.
XX
AC ADI22923;
XX
DT 22-APR-2004 (first entry)
XX
DE cDNA encoding novel human secreted protein seq id 208.
XX
KW cytostatic; gene therapy; cancer; human; secreted protein; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003175858-A1.
XX
PD 18-SEP-2003.
XX
PF 18-JUN-2001; 2001US-00882171.
XX
PR 07-MAR-1997; 97US-0038621P.
PR 07-MAR-1997; 97US-0040162P.
PR 07-MAR-1997; 97US-0040163P.
PR 07-MAR-1997; 97US-0040333P.
PR 07-MAR-1997; 97US-0040334P.
PR 07-MAR-1997; 97US-0040336P.
PR 07-MAR-1997; 97US-0040626P.
PR 11-APR-1997; 97US-0043311P.
PR 11-APR-1997; 97US-0043312P.
PR 11-APR-1997; 97US-0043313P.
PR 11-APR-1997; 97US-0043314P.
PR 11-APR-1997; 97US-0043315P.
PR 11-APR-1997; 97US-0043568P.
PR 11-APR-1997; 97US-0043569P.
PR 11-APR-1997; 97US-0043576P.
PR 11-APR-1997; 97US-0043578P.
PR 11-APR-1997; 97US-0043580P.
PR 11-APR-1997; 97US-0043669P.
PR 11-APR-1997; 97US-0043670P.
PR 11-APR-1997; 97US-0043671P.
PR 11-APR-1997; 97US-0043672P.
PR 11-APR-1997; 97US-0043674P.
PR 23-MAY-1997; 97US-0047492P.
PR 23-MAY-1997; 97US-0047500P.
PR 23-MAY-1997; 97US-0047501P.
PR 23-MAY-1997; 97US-0047502P.
PR 23-MAY-1997; 97US-0047503P.
PR 23-MAY-1997; 97US-0047581P.
PR 23-MAY-1997; 97US-0047582P.
PR 23-MAY-1997; 97US-0047583P.
PR 23-MAY-1997; 97US-0047584P.
PR 23-MAY-1997; 97US-0047585P.
PR 23-MAY-1997; 97US-0047586P.
PR 23-MAY-1997; 97US-0047587P.
PR 23-MAY-1997; 97US-0047588P.
PR 23-MAY-1997; 97US-0047589P.
PR 23-MAY-1997; 97US-0047590P.
PR 23-MAY-1997; 97US-0047592P.
```





OS Homo sapiens.  
XX  
PN US2003225248-A1.  
XX  
PD 04-DEC-2003.  
XX  
PF 10-JUN-2002; 2002US-00164861.  
XX  
PR 07-MAR-1997; 97US-0038621P.  
PR 07-MAR-1997; 97US-0040161P.  
PR 07-MAR-1997; 97US-0040162P.  
PR 07-MAR-1997; 97US-0040163P.  
PR 07-MAR-1997; 97US-0040333P.  
PR 07-MAR-1997; 97US-0040334P.  
PR 07-MAR-1997; 97US-0040336P.  
PR 07-MAR-1997; 97US-0040626P.  
PR 11-APR-1997; 97US-0043311P.  
PR 11-APR-1997; 97US-0043312P.  
PR 11-APR-1997; 97US-0043313P.  
PR 11-APR-1997; 97US-0043314P.  
PR 11-APR-1997; 97US-0043315P.  
PR 11-APR-1997; 97US-0043568P.  
PR 11-APR-1997; 97US-0043569P.  
PR 11-APR-1997; 97US-0043576P.  
PR 11-APR-1997; 97US-0043578P.  
PR 11-APR-1997; 97US-0043580P.  
PR 11-APR-1997; 97US-0043669P.  
PR 11-APR-1997; 97US-0043670P.  
PR 11-APR-1997; 97US-0043671P.  
PR 11-APR-1997; 97US-0043672P.  
PR 11-APR-1997; 97US-0043674P.  
PR 23-MAY-1997; 97US-0047492P.  
PR 23-MAY-1997; 97US-0047500P.  
PR 23-MAY-1997; 97US-0047501P.  
PR 23-MAY-1997; 97US-0047502P.  
PR 23-MAY-1997; 97US-0047503P.  
PR 23-MAY-1997; 97US-0047581P.  
PR 23-MAY-1997; 97US-0047582P.  
PR 23-MAY-1997; 97US-0047583P.  
PR 23-MAY-1997; 97US-0047584P.  
PR 23-MAY-1997; 97US-0047585P.  
PR 23-MAY-1997; 97US-0047586P.  
PR 23-MAY-1997; 97US-0047587P.  
PR 23-MAY-1997; 97US-0047588P.  
PR 23-MAY-1997; 97US-0047589P.  
PR 23-MAY-1997; 97US-0047590P.  
PR 23-MAY-1997; 97US-0047592P.  
PR 23-MAY-1997; 97US-0047593P.  
PR 23-MAY-1997; 97US-0047594P.  
PR 23-MAY-1997; 97US-0047595P.  
PR 23-MAY-1997; 97US-0047596P.  
PR 23-MAY-1997; 97US-0047597P.  
PR 23-MAY-1997; 97US-0047598P.  
PR 23-MAY-1997; 97US-0047599P.  
PR 23-MAY-1997; 97US-0047600P.  
PR 23-MAY-1997; 97US-0047601P.  
PR 23-MAY-1997; 97US-0047612P.  
PR 23-MAY-1997; 97US-0047613P.  
PR 23-MAY-1997; 97US-0047614P.  
PR 23-MAY-1997; 97US-0047615P.  
PR 23-MAY-1997; 97US-0047617P.  
PR 23-MAY-1997; 97US-0047618P.  
PR 23-MAY-1997; 97US-0047632P.  
PR 23-MAY-1997; 97US-0047633P.  
PR 06-JUN-1997; 97US-0048964P.  
PR 06-JUN-1997; 97US-0048974P.  
PR 13-JUN-1997; 97US-0049610P.  
PR 08-JUL-1997; 97US-0051926P.  
PR 16-JUL-1997; 97US-0052874P.  
PR 18-AUG-1997; 97US-0055724P.  
PR 22-AUG-1997; 97US-0056630P.  
PR 22-AUG-1997; 97US-0056631P.  
PR 22-AUG-1997; 97US-0056632P.

PR 22-AUG-1997; 97US-0056636P.  
PR 22-AUG-1997; 97US-0056637P.  
PR 22-AUG-1997; 97US-0056662P.  
PR 22-AUG-1997; 97US-0056664P.  
PR 22-AUG-1997; 97US-0056845P.  
PR 22-AUG-1997; 97US-0056862P.  
PR 22-AUG-1997; 97US-0056864P.  
PR 22-AUG-1997; 97US-0056872P.  
PR 22-AUG-1997; 97US-0056874P.  
PR 22-AUG-1997; 97US-0056875P.  
PR 22-AUG-1997; 97US-0056876P.  
PR 22-AUG-1997; 97US-0056877P.  
PR 22-AUG-1997; 97US-0056878P.  
PR 22-AUG-1997; 97US-0056879P.  
PR 22-AUG-1997; 97US-0056880P.  
PR 22-AUG-1997; 97US-0056881P.  
PR 22-AUG-1997; 97US-0056882P.  
PR 22-AUG-1997; 97US-0056884P.  
PR 22-AUG-1997; 97US-0056886P.  
PR 22-AUG-1997; 97US-0056887P.  
PR 22-AUG-1997; 97US-0056888P.  
PR 22-AUG-1997; 97US-0056889P.  
PR 22-AUG-1997; 97US-0056892P.  
PR 22-AUG-1997; 97US-0056893P.  
PR 22-AUG-1997; 97US-0056894P.  
PR 22-AUG-1997; 97US-0056903P.  
PR 22-AUG-1997; 97US-0056908P.  
PR 22-AUG-1997; 97US-0056909P.  
PR 22-AUG-1997; 97US-0056910P.  
PR 22-AUG-1997; 97US-0056911P.  
PR 05-SEP-1997; 97US-0057650P.  
PR 05-SEP-1997; 97US-0057669P.  
PR 05-SEP-1997; 97US-0057761P.  
PR 12-SEP-1997; 97US-0058785P.  
PR 02-OCT-1997; 97US-0061060P.  
PR 06-MAR-1998; 98WO-US004493.  
PR 08-SEP-1998; 98US-00149476.  
XX  
PA (HUMA-) HUMAN GENOME SCI INC.  
XX  
PI Ruben SM, Rosen CA, Soppet DR, Carter KC, Bednarik DP;  
PI Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM, Ferrie AM;  
PI Duan R, Hu J, Florence KA, Olsen HS, Fischer CL, Ebner R;  
PI Brewer LA, Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;  
XX  
DR WPI; 2004-131264/13.  
DR P-PSDB; ADH74234.

Isolated nucleic acid molecules encoding human secreted proteins, useful for preventing, diagnosing and treating disorders associated with aberrant expression and activity.

Claim 3; SEQ ID NO 208; 142pp; English.

The invention relates to isolated nucleic acid molecules and the human secreted proteins (SPs) they encode. The proteins and nucleic acids may be used in the prevention, diagnosis and treatment of diseases associated with inappropriate SP expression e.g. cancer, haematopoietic disorders, endocrine disorders, diseases of the immune system, inflammatory disorders and many others. Full details of disorders that may be prevented, diagnosed and/or treated by the above methods are given in the specification. The nucleic acid molecules may be used to produce their proteins. The nucleic acid and it's complementary sequences may also be used as DNA probes in diagnostic assays to detect and quantitate the presence of similar nucleic acids in samples, and therefore which patients may be in need of restorative therapy. The SPs may also be used as antigens in the production of antibodies against the proteins and in assays to identify modulators of SP expression and activity. The anti-SP antibodies and antagonists may also be used to down regulate expression and activity. The anti-SP antibodies may also be used as diagnostic agents for detecting the presence of the proteins in samples (e.g. by enzyme linked immunosorbant assay (ELISA)). The present sequence represents a human secreted protein cDNA.





```
CC modification and maintenance molecules (PMMM), and the polynucleotide
CC sequences encoding them. A total of 40 PMMM polypeptides (designated PMMM
CC -1 to PMMM-40) are disclosed. The sequences of the invention are useful
CC for diagnosing a condition or disease associated with the expression of
CC PMMM in a subject, preparing a polyclonal or monoclonal antibody, and
CC generating an expression profile of a sample containing the
CC polynucleotides. The diseases or conditions associated with decreased
CC expression or overexpression of PMMM are cell proliferation disorders
CC (e.g. cancer, atherosclerosis), neurological disorders (e.g. epilepsy,
CC Huntington's disease, stroke), immune/inflammatory disorders, (e.g. AIDS,
CC allergies), developmental disorders (e.g. hypothyroidism, Cushing's
CC syndrome), gastrointestinal or epithelial disorders, and infections. The
CC PMMM polypeptides or their fragments are useful in screening compounds
CC for effectiveness as agonists or antagonists of the polypeptides, or in
CC altering the expression of the target polynucleotide and compounds that
CC specifically bind to, or modulate the activity of the polypeptide.
CC ACA92416-ACA92455 encode the human PMMM polypeptides of the invention
XX
SQ Sequence 1867 BP; 536 A; 413 C; 509 G; 409 T; 0 U; 0 Other;

Query Match      3.0%; Score 66.2; DB 10; Length 1867;
Best Local Similarity 71.7%; Pred. No. 0.00025;
Matches 86; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 2123 TTGTCTTTACCACTCTTCTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCCTGNC 2182
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1723 TTGGCCCACTCTCTTCTTACTGGAGGCTATTAAATAAAATGTAGACTTCAAAAAAAA 1782

QY 2183 TCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1783 AAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1842

RESULT 1012
AAV59524
ID AAV59524 standard; DNA; 2323 BP.
XX
AC AAV59524;
XX
DT 06-JAN-1999 (first entry)
DE Human secreted protein gene 14 clone HPMFD84.
XX
KW Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
KW developmental abnormality; foetal deficiency; blood; allergy; renal; ds;
KW immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
KW cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
KW endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
XX
OS Homo sapiens.
XX
PN WO9839448-A2.
XX
PD 11-SEP-1998.
XX
PF 06-MAR-1998; 98WO-US0004493.
XX
PR 07-MAR-1997; 97US-0038621P.
PR 07-MAR-1997; 97US-0040161P.
PR 07-MAR-1997; 97US-0040162P.
PR 07-MAR-1997; 97US-0040163P.
PR 07-MAR-1997; 97US-0040333P.
PR 07-MAR-1997; 97US-0040334P.
PR 07-MAR-1997; 97US-0040336P.
PR 07-MAR-1997; 97US-0040626P.
PR 11-APR-1997; 97US-0043311P.
PR 11-APR-1997; 97US-0043312P.
PR 11-APR-1997; 97US-0043313P.
PR 11-APR-1997; 97US-0043314P.
PR 11-APR-1997; 97US-0043315P.
PR
PR 11-APR-1997; 97US-0043568P.
PR 11-APR-1997; 97US-0043569P.
PR 11-APR-1997; 97US-0043576P.
PR 11-APR-1997; 97US-0043578P.
PR 11-APR-1997; 97US-0043580P.
PR 11-APR-1997; 97US-0043669P.
PR 11-APR-1997; 97US-0043670P.
PR 11-APR-1997; 97US-0043671P.
PR 11-APR-1997; 97US-0043672P.
PR 11-APR-1997; 97US-0043674P.
PR 23-MAY-1997; 97US-0047492P.
PR 23-MAY-1997; 97US-0047500P.
PR 23-MAY-1997; 97US-0047501P.
PR 23-MAY-1997; 97US-0047502P.
PR 23-MAY-1997; 97US-0047503P.
PR 23-MAY-1997; 97US-0047581P.
PR 23-MAY-1997; 97US-0047582P.
PR 23-MAY-1997; 97US-0047583P.
PR 23-MAY-1997; 97US-0047584P.
PR 23-MAY-1997; 97US-0047585P.
PR 23-MAY-1997; 97US-0047586P.
PR 23-MAY-1997; 97US-0047587P.
PR 23-MAY-1997; 97US-0047588P.
PR 23-MAY-1997; 97US-0047589P.
PR 23-MAY-1997; 97US-0047590P.
PR 23-MAY-1997; 97US-0047592P.
PR 23-MAY-1997; 97US-0047593P.
PR 23-MAY-1997; 97US-0047594P.
PR 23-MAY-1997; 97US-0047595P.
PR 23-MAY-1997; 97US-0047596P.
PR 23-MAY-1997; 97US-0047597P.
PR 23-MAY-1997; 97US-0047598P.
PR 23-MAY-1997; 97US-0047599P.
PR 23-MAY-1997; 97US-0047600P.
PR 23-MAY-1997; 97US-0047601P.
PR 23-MAY-1997; 97US-0047612P.
PR 23-MAY-1997; 97US-0047613P.
PR 23-MAY-1997; 97US-0047614P.
PR 23-MAY-1997; 97US-0047615P.
PR 23-MAY-1997; 97US-0047617P.
PR 23-MAY-1997; 97US-0047618P.
PR 23-MAY-1997; 97US-0047632P.
PR 23-MAY-1997; 97US-0047633P.
PR 06-JUN-1997; 97US-0048964P.
PR 06-JUN-1997; 97US-0048974P.
PR 13-JUN-1997; 97US-0049610P.
PR 08-JUL-1997; 97US-0051926P.
PR 16-JUL-1997; 97US-0052874P.
PR 18-AUG-1997; 97US-0055724P.
PR 22-AUG-1997; 97US-0056630P.
PR 22-AUG-1997; 97US-0056631P.
PR 22-AUG-1997; 97US-0056632P.
PR 22-AUG-1997; 97US-0056636P.
PR 22-AUG-1997; 97US-0056637P.
PR 22-AUG-1997; 97US-0056662P.
PR 22-AUG-1997; 97US-0056664P.
PR 22-AUG-1997; 97US-0056845P.
PR 22-AUG-1997; 97US-0056862P.
PR 22-AUG-1997; 97US-0056864P.
PR 22-AUG-1997; 97US-0056872P.
PR 22-AUG-1997; 97US-0056874P.
PR 22-AUG-1997; 97US-0056875P.
PR 22-AUG-1997; 97US-0056876P.
PR 22-AUG-1997; 97US-0056877P.
PR 22-AUG-1997; 97US-0056878P.
PR 22-AUG-1997; 97US-0056879P.
PR 22-AUG-1997; 97US-0056880P.
PR 22-AUG-1997; 97US-0056881P.
PR 22-AUG-1997; 97US-0056882P.
PR 22-AUG-1997; 97US-0056884P.
PR 22-AUG-1997; 97US-0056886P.
PR 22-AUG-1997; 97US-0056887P.
PR 22-AUG-1997; 97US-0056888P.
```

```
PR 22-AUG-1997; 97US-0056889P.
PR 22-AUG-1997; 97US-0056892P.
PR 22-AUG-1997; 97US-0056893P.
PR 22-AUG-1997; 97US-0056894P.
PR 22-AUG-1997; 97US-0056903P.
PR 22-AUG-1997; 97US-0056908P.
PR 22-AUG-1997; 97US-0056909P.
PR 22-AUG-1997; 97US-0056910P.
PR 22-AUG-1997; 97US-0056911P.
PR 05-SEP-1997; 97US-0057650P.
PR 05-SEP-1997; 97US-0057669P.
PR 05-SEP-1997; 97US-0057761P.
PR 12-SEP-1997; 97US-0058785P.
PR 02-OCT-1997; 97US-0061060P.
XX
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
XX
PI Ruben SM, Rosen CA, Fischer CL, Soppet DR, Carter KC;
PI Bednarik DP, Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM;
PI Ferrie AM, Duan R, Hu J, Florence KA, Olsen HS, Ebner R, Brewer LA;
PI Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;
XX
DR WPI; 1998-506364/43.
DR P-PSDB; AAW74744.
XX
XX
PT New isolated human genes and the secreted polypeptide(s) they encode -
PT useful for diagnosis and treatment of e.g. cancers, neurological
PT disorders, immune diseases, inflammation or blood disorders.
XX
XX
PS Claim 1; Page 252-253; 721pp; English.
XX
CC This sequence represents a nucleic acid molecule designated Gene 14 from
CC the human cDNA clone HPMFD84 (deposited as clone ATCC 97897 and ATCC
CC 209043) which encodes a secreted human protein. The gene can be used to
CC generate fusion proteins by linking to the gene to a human immunoglobulin
CC Fc portion (e.g. AAV59502) for increasing the stability of the fused
CC protein as compared to the human protein only. The invention relates to
CC 186 novel genes and their fragments (nucleic acid sequences: AAV59511-
CC V59812; amino acid sequences AAW74731-W75026) which are useful for
CC preventing, treating or ameliorating medical conditions e.g. by protein
CC or gene therapy. Also, pathological conditions can be diagnosed by
CC determining the amount of the new polypeptides in a sample or by
CC determining the presence of mutations in the new polynucleotides.
CC Specific uses are described for each of the 186 polynucleotides, based on
CC which tissues they are most highly expressed in (see AAV59511 for
CC described uses)
XX
SQ Sequence 2323 BP; 760 A; 467 C; 438 G; 658 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.2; DB 2; Length 2323;
Best Local Similarity 71.7%; Pred. No. 0.00027;
Matches 86; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 2123 TTGCTTTACCACCTCTTCCCTTTTATCTTATTATAATAAATGTTGGTCTCCACCCTGNC 2182
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2183 TTCTATGTACAACCTGATGCTTCTTCTTATTTTAAATAATTATCAGAGTGAAAAAAA 2242
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 2183 TCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2243 AAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2302
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 1013
ABS73511
ID ABS73511 standard; cDNA; 2323 BP.
XX
AC ABS73511;
XX
DT 15-JAN-2003 (first entry)
XX
DE Human cDNA #1 for novel secreted protein gene 14.
XX
KW Human; ss; gene; secreted protein; autoimmune disease; chemotaxis;
```

```
KW rheumatoid arthritis; hyperproliferative disorder; breast neoplasm;
KW liver neoplasm cardiovascular disorder; cardiac arrest; skin aging;
KW cerebrovascular disorders; cerebral ischaemia; angiogenesis; sunburn;
KW nervous system disorders; Alzheimer's disease; infection;
KW ocular disorder; corneal infection; wound healing; tissue regeneration;
KW epithelial cell proliferation; organ transplantation; food additive;
preservative; nutritional.
XX
OS Homo sapiens.
XX
PN US6420526-B1.
XX
PD 16-JUL-2002.
XX
PF 08-SEP-1998; 98US-00149476.
XX
PR 07-MAR-1997; 97US-0038621P.
PR 07-MAR-1997; 97US-0040161P.
PR 07-MAR-1997; 97US-0040162P.
PR 07-MAR-1997; 97US-0040163P.
PR 07-MAR-1997; 97US-0040333P.
PR 07-MAR-1997; 97US-0040334P.
PR 07-MAR-1997; 97US-0040336P.
PR 07-MAR-1997; 97US-0040626P.
PR 11-APR-1997; 97US-0043311P.
PR 11-APR-1997; 97US-0043312P.
PR 11-APR-1997; 97US-0043313P.
PR 11-APR-1997; 97US-0043314P.
PR 11-APR-1997; 97US-0043315P.
PR 11-APR-1997; 97US-0043568P.
PR 11-APR-1997; 97US-0043569P.
PR 11-APR-1997; 97US-0043576P.
PR 11-APR-1997; 97US-0043578P.
PR 11-APR-1997; 97US-0043580P.
PR 11-APR-1997; 97US-0043669P.
PR 11-APR-1997; 97US-0043670P.
PR 11-APR-1997; 97US-0043671P.
PR 11-APR-1997; 97US-0043672P.
PR 11-APR-1997; 97US-0043674P.
PR 23-MAY-1997; 97US-0047492P.
PR 23-MAY-1997; 97US-0047500P.
PR 23-MAY-1997; 97US-0047501P.
PR 23-MAY-1997; 97US-0047502P.
PR 23-MAY-1997; 97US-0047503P.
PR 23-MAY-1997; 97US-0047581P.
PR 23-MAY-1997; 97US-0047582P.
PR 23-MAY-1997; 97US-0047583P.
PR 23-MAY-1997; 97US-0047584P.
PR 23-MAY-1997; 97US-0047585P.
PR 23-MAY-1997; 97US-0047586P.
PR 23-MAY-1997; 97US-0047587P.
PR 23-MAY-1997; 97US-0047588P.
PR 23-MAY-1997; 97US-0047589P.
PR 23-MAY-1997; 97US-0047590P.
PR 23-MAY-1997; 97US-0047592P.
PR 23-MAY-1997; 97US-0047593P.
PR 23-MAY-1997; 97US-0047594P.
PR 23-MAY-1997; 97US-0047595P.
PR 23-MAY-1997; 97US-0047596P.
PR 23-MAY-1997; 97US-0047597P.
PR 23-MAY-1997; 97US-0047598P.
PR 23-MAY-1997; 97US-0047599P.
PR 23-MAY-1997; 97US-0047600P.
PR 23-MAY-1997; 97US-0047601P.
PR 23-MAY-1997; 97US-0047612P.
PR 23-MAY-1997; 97US-0047613P.
PR 23-MAY-1997; 97US-0047614P.
PR 23-MAY-1997; 97US-0047615P.
PR 23-MAY-1997; 97US-0047617P.
PR 23-MAY-1997; 97US-0047618P.
PR 23-MAY-1997; 97US-0047632P.
PR 23-MAY-1997; 97US-0047633P.
PR 06-JUN-1997; 97US-0048964P.
```

PR	06-JUN-1997;	97US-0048974P.
PR	13-JUN-1997;	97US-0049610P.
PR	08-JUL-1997;	97US-0051926P.
PR	16-JUL-1997;	97US-0052874P.
PR	18-AUG-1997;	97US-0055724P.
PR	22-AUG-1997;	97US-0056630P.
PR	22-AUG-1997;	97US-0056631P.
PR	22-AUG-1997;	97US-0056632P.
PR	22-AUG-1997;	97US-0056636P.
PR	22-AUG-1997;	97US-0056637P.
PR	22-AUG-1997;	97US-0056662P.
PR	22-AUG-1997;	97US-0056664P.
PR	22-AUG-1997;	97US-0056845P.
PR	22-AUG-1997;	97US-0056862P.
PR	22-AUG-1997;	97US-0056864P.
PR	22-AUG-1997;	97US-0056872P.
PR	22-AUG-1997;	97US-0056874P.
PR	22-AUG-1997;	97US-0056875P.
PR	22-AUG-1997;	97US-0056876P.
PR	22-AUG-1997;	97US-0056877P.
PR	22-AUG-1997;	97US-0056878P.
PR	22-AUG-1997;	97US-0056879P.
PR	22-AUG-1997;	97US-0056880P.
PR	22-AUG-1997;	97US-0056881P.
PR	22-AUG-1997;	97US-0056882P.
PR	22-AUG-1997;	97US-0056884P.
PR	22-AUG-1997;	97US-0056886P.
PR	22-AUG-1997;	97US-0056887P.
PR	22-AUG-1997;	97US-0056888P.
PR	22-AUG-1997;	97US-0056889P.
PR	22-AUG-1997;	97US-0056892P.
PR	22-AUG-1997;	97US-0056893P.
PR	22-AUG-1997;	97US-0056894P.
PR	22-AUG-1997;	97US-0056903P.
PR	22-AUG-1997;	97US-0056908P.
PR	22-AUG-1997;	97US-0056909P.
PR	22-AUG-1997;	97US-0056910P.
PR	22-AUG-1997;	97US-0056911P.
PR	05-SEP-1997;	97US-0057650P.
PR	05-SEP-1997;	97US-0057669P.
PR	05-SEP-1997;	97US-0057761P.
PR	12-SEP-1997;	97US-0058785P.
PR	02-OCT-1997;	97US-0061060P.
PR	06-MAR-1998;	98WO-US004493.
XX		
PA	(HUMA-) HUMAN GENOME SCI INC.	
XX		
PI	Ruben SM, Rosen CA, Fischer CL, Soppet DP, Carter KC;	
PI	Bednarik DR, Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM;	
PI	Ferrie AM, Duan R, Hu J, Florence KA, Olsen HS, Ebner R, Brewer LA;	
PI	Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;	
XX		
DR	WPI; 2002-634796/68.	
DR	P-PSDB; ABG95193.	
XX		
PT	New isolated human secreted protein for diagnosing, preventing, treating	
PT	or ameliorating medical conditions and used as a food additive or	
PT	preservative.	
XX		
PS	Example 1; SEQ ID NO 24; 129pp; English.	
XX		
CC	The invention relates to an isolated protein that is one of 186 human	
CC	secreted proteins, given in the specification, encoded by one of 309 cDNA	
CC	sequences also given in the specification. The protein is used in a	
CC	pharmaceutical composition used to prevent, treat or ameliorate a medical	
CC	condition in e.g. humans, mice, rabbits, goats, horses, cats, dogs,	
CC	chickens or sheep. Disorders which are diagnosed or treated include	
CC	autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative	
CC	disorders e.g. neoplasms of the breast or liver, cardiovascular disorders	
CC	e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,	
CC	angiogenesis, nervous system disorders e.g. Alzheimer's disease,	
CC	infections caused by bacteria, viruses and fungi and ocular disorders	
CC	e.g. corneal infection. The polypeptides can also be used to aid wound	

CC healing and epithelial cell proliferation, to prevent skin aging due to  
CC sunburn, to maintain organs before transplantation, for supporting cell  
CC culture of primary tissues, to regenerate tissues and in chemotaxis. The  
CC polypeptides can also be used as a food additive or preservative to  
CC increase or decrease storage capabilities, fat content, lipid, protein,  
CC carbohydrate, vitamins, minerals, cofactors and other nutritional  
CC components. The present sequence represents a cDNA derived from a gene  
CC encoding one of the novel human secreted proteins of the invention. Note:  
CC This sequence did not form part of the printed specification, but was  
CC obtained in electronic format directly from USPTO at  
CC seqdata.uspto.gov/sequence.html?DocID=6420526B1

XX  
SQ Sequence 2323 BP; 760 A; 467 C; 438 G; 658 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.2; DB 6; Length 2323;  
Best Local Similarity 71.7%; Pred. No. 0.00027;  
Matches 86; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 2123 TTTCGCTTTACCACTCTTTTCCCTTTTATCTTATTATAAATAAGTTGGTCTCCACCACACTGNC 2182  
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||  
Db 2183 TTCTATGTACAACCTGATGCTTGTTCTTATTTTAATAAATTTATCAGAGTGAAAAAAA 2242

QY 2183 TCCCCAA 2242  
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||  
Db 2243 AAA 2302

RESULT 1014  
ACD82654

ID ACD82654 standard; cDNA; 2323 BP.  
XX  
AC ACD82654;  
XX  
DT 22-SEP-2003 (first entry)  
DE  
XX  
KW Human; secreted protein; hyperproliferative disorder; leukaemia;  
KW breast cancer; wound; reproductive disorder; blood-related disorder;  
KW haemophilia; thrombocytopaenia; immunodeficiency; thymic hypoplasia;  
KW Wiskott-Aldrich syndrome; autoimmune disorder; multiple sclerosis;  
KW graft-versus-host disease; Hashimoto's thyroiditis; allergy; asthma;  
KW viral infection; bacterial infection; fungal infection; AIDS; sepsis;  
KW renal disorder; kidney failure; cardiovascular disorder; cytostatic;  
KW angina pectoris; cerebral ischaemia; congenital heart defect;  
KW respiratory disorder; neurological disorder; Alzheimer's disease;  
KW Parkinson's disease; inflammation; Crohn's disease; vulneryary;  
KW immunosuppressive; antibacterial; haemostatic; thrombolytic;  
KW anticoagulant; neuroprotective; thyromimetic; antiallergic;  
KW antiasthmatic; virucide; fungicide; anti-HIV; nephrotropic; antidiabetic;  
KW cerebroprotective; cardiant; nootropic; antiparkinsonian;  
KW antiinflammatory; gene; ss.

XX Homo sapiens.  
OS  
XX US2003049618-A1.  
PN  
XX  
PD 13-MAR-2003.  
XX  
PF 16-MAR-2001; 2001US-00809391.  
XX  
PR 07-MAR-1997; 97US-0038621P.  
PR 07-MAR-1997; 97US-0040162P.  
PR 07-MAR-1997; 97US-0040163P.  
PR 07-MAR-1997; 97US-0040333P.  
PR 07-MAR-1997; 97US-0040334P.  
PR 07-MAR-1997; 97US-0040336P.  
PR 07-MAR-1997; 97US-0040626P.  
PR 11-APR-1997; 97US-0043311P.  
PR 11-APR-1997; 97US-0043312P.  
PR 11-APR-1997; 97US-0043313P.  
PR 11-APR-1997; 97US-0043314P.  
PR 11-APR-1997; 97US-0043315P.



PR 11-APR-1997; 97US-0043568P.  
PR 11-APR-1997; 97US-0043569P.  
PR 11-APR-1997; 97US-0043576P.  
PR 11-APR-1997; 97US-0043578P.  
PR 11-APR-1997; 97US-0043580P.  
PR 11-APR-1997; 97US-0043669P.  
PR 11-APR-1997; 97US-0043670P.  
PR 11-APR-1997; 97US-0043671P.  
PR 11-APR-1997; 97US-0043672P.  
PR 11-APR-1997; 97US-0043674P.  
PR 23-MAY-1997; 97US-0047492P.  
PR 23-MAY-1997; 97US-0047500P.  
PR 23-MAY-1997; 97US-0047501P.  
PR 23-MAY-1997; 97US-0047502P.  
PR 23-MAY-1997; 97US-0047503P.  
PR 23-MAY-1997; 97US-0047581P.  
PR 23-MAY-1997; 97US-0047582P.  
PR 23-MAY-1997; 97US-0047583P.  
PR 23-MAY-1997; 97US-0047584P.  
PR 23-MAY-1997; 97US-0047585P.  
PR 23-MAY-1997; 97US-0047586P.  
PR 23-MAY-1997; 97US-0047587P.  
PR 23-MAY-1997; 97US-0047588P.  
PR 23-MAY-1997; 97US-0047589P.  
PR 23-MAY-1997; 97US-0047590P.  
PR 23-MAY-1997; 97US-0047592P.  
PR 23-MAY-1997; 97US-0047593P.  
PR 23-MAY-1997; 97US-0047594P.  
PR 23-MAY-1997; 97US-0047595P.  
PR 23-MAY-1997; 97US-0047596P.  
PR 23-MAY-1997; 97US-0047597P.  
PR 23-MAY-1997; 97US-0047598P.  
PR 23-MAY-1997; 97US-0047599P.  
PR 23-MAY-1997; 97US-0047600P.  
PR 23-MAY-1997; 97US-0047601P.  
PR 23-MAY-1997; 97US-0047612P.  
PR 23-MAY-1997; 97US-0047613P.  
PR 23-MAY-1997; 97US-0047614P.  
PR 23-MAY-1997; 97US-0047615P.  
PR 23-MAY-1997; 97US-0047617P.  
PR 23-MAY-1997; 97US-0047618P.  
PR 23-MAY-1997; 97US-0047632P.  
PR 23-MAY-1997; 97US-0047633P.  
PR 06-JUN-1997; 97US-0048964P.  
PR 06-JUN-1997; 97US-0048974P.  
PR 13-JUN-1997; 97US-0049610P.  
PR 08-JUL-1997; 97US-0051926P.  
PR 16-JUL-1997; 97US-0052874P.  
PR 18-AUG-1997; 97US-0055724P.  
PR 22-AUG-1997; 97US-0056630P.  
PR 22-AUG-1997; 97US-0056631P.  
PR 22-AUG-1997; 97US-0056632P.  
PR 22-AUG-1997; 97US-0056636P.  
PR 22-AUG-1997; 97US-0056637P.  
PR 22-AUG-1997; 97US-0056662P.  
PR 22-AUG-1997; 97US-0056664P.  
PR 22-AUG-1997; 97US-0056845P.  
PR 22-AUG-1997; 97US-0056862P.  
PR 22-AUG-1997; 97US-0056864P.  
PR 22-AUG-1997; 97US-0056872P.  
PR 22-AUG-1997; 97US-0056874P.  
PR 22-AUG-1997; 97US-0056875P.  
PR 22-AUG-1997; 97US-0056876P.  
PR 22-AUG-1997; 97US-0056877P.  
PR 22-AUG-1997; 97US-0056878P.  
PR 22-AUG-1997; 97US-0056879P.  
PR 22-AUG-1997; 97US-0056880P.  
PR 22-AUG-1997; 97US-0056881P.  
PR 22-AUG-1997; 97US-0056882P.  
PR 22-AUG-1997; 97US-0056884P.  
PR 22-AUG-1997; 97US-0056886P.  
PR 22-AUG-1997; 97US-0056887P.  
PR 22-AUG-1997; 97US-0056888P.

PR 22-AUG-1997; 97US-0056889P.  
PR 22-AUG-1997; 97US-0056892P.  
PR 22-AUG-1997; 97US-0056893P.  
PR 22-AUG-1997; 97US-0056894P.  
PR 22-AUG-1997; 97US-0056903P.  
PR 22-AUG-1997; 97US-0056908P.  
PR 22-AUG-1997; 97US-0056909P.  
PR 22-AUG-1997; 97US-0056910P.  
PR 22-AUG-1997; 97US-0056911P.  
PR 05-SEP-1997; 97US-0057650P.  
PR 05-SEP-1997; 97US-0057669P.  
PR 05-SEP-1997; 97US-0057761P.  
PR 12-SEP-1997; 97US-0058785P.  
PR 09-OCT-1997; 97US-0061660P.  
PR 06-MAR-1998; 98WO-US004493.  
PR 08-SEP-1998; 98US-00149476.  
PR 17-MAR-2000; 2000US-0190068P.  
XX  
PA (RUBE/) RUBEN S M.  
PA (ROSE/) ROSEN C A.  
PA (SOPP/) SOPPET D R.  
PA (CART/) CARTER K C.  
PA (BEDN/) BEDNARIK D P.  
PA (ENDR/) ENDRESS G A.  
PA (YUGG/) YU G.  
PA (NIJU/) NI J.  
PA (FENG/) FENG P.  
PA (YOUN/) YOUNG P E.  
PA (GREE/) GREENE J M.  
PA (FERR/) FERRIE A M.  
PA (DUAN/) DUAN D R.  
PA (HUJU/) HU J.  
PA (FLOR/) FLORENCE K A.  
PA (OLSE/) OLSEN H S.  
PA (FISC/) FISCHER C L.  
PA (EBNE/) EBNER R.  
PA (BREW/) BREWER L A.  
PA (MOOR/) MOORE P A.  
PA (SHIY/) SHI Y.  
PA (LAFI/) LAFLEUR D W.  
PA (LIYI/) LI Y.  
PA (ZENG/) ZENG Z.  
PA (KYAW/) KYAW H.  
XX  
PI Ruben SM, Rosen CA, Soppet DR, Carter KC, Bednarik DP;  
PI Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM, Ferrie AM;  
PI Duan DR, Hu J, Florence KA, Olsen HS, Fischer CL, Ebner R;  
PI Brewer LA, Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;  
XX WPI; 2003-521800/49.  
DR P-PSDB; ABO34387.  
XX  
PT New genes and its encoded prostate cancer antigen proteins, useful for  
PT preventing, treating, ameliorating or diagnosing e.g. prostate cancers,  
PT thymic hypoplasia, multiple sclerosis, AIDS, angina pectoris or cerebral  
PT ischemia.  
XX  
PS Claim 4; SEQ ID NO 24; 260pp; English.  
XX  
CC The present invention relates to the isolation of novel human secreted  
CC proteins and the polynucleotide sequences encoding them. The invention  
CC also discloses vectors, host cells, antibodies, and recombinant methods  
CC for producing human secreted proteins. The polypeptide and polynucleotide  
CC sequences for the secreted proteins are useful for preventing, treating,  
CC ameliorating or diagnosing medical conditions such as hyperproliferative  
CC disorders (e.g. leukaemia or breast cancers), wounds, reproductive  
CC disorders, blood-related disorders (e.g. haemophilia or  
CC thrombocytopaenia), immunodeficiencies (e.g. Wiskott-Aldrich syndrome or  
CC thymic hypoplasia), autoimmune disorders (e.g. graft-versus-host disease,  
CC multiple sclerosis or Hashimoto's thyroiditis), allergies (e.g. asthma),  
CC viral or bacterial or fungal infections (e.g. AIDS or sepsis), renal  
CC disorders (e.g. kidney failure), cardiovascular disorders (e.g. angina  
CC pectoris, cerebral ischaemia or congenital heart defects), respiratory

```
CC disorders, neurological disorders (e.g. Alzheimer's disease or
CC Parkinson's disease), and inflammations (e.g. Crohn's disease). The
CC polynucleotide or polypeptide may also be used as vaccine adjuvants.
CC ACD82641-ACD82950 encode human secreted proteins or their fragments.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from the
CC USPTO web site at seqdata.uspto.gov/psipsDIDentry.html
XX
SQ Sequence 2323 BP; 760 A; 467 C; 438 G; 658 T; 0 U; 0 Other;

Query Match          3.0%; Score 66.2; DB 9; Length 2323;
Best Local Similarity 71.7%; Pred. No. 0.00027;
Matches 86; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 2123 TTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCCTGNC 2182
    ||| ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2183 TTCTATGTACAACTGATGCTTGTTCTTATTTAATAAATTTATCAGAGTGAAAAA 2242

QY 2183 TCCCAAAAAA 2242
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2243 AAAAAA 2302

RESULT 1015
ADI22739
ID ADI22739 standard; cDNA; 2323 BP.
XX
AC ADI22739;
XX
DT 22-APR-2004 (first entry)
XX
DE cDNA encoding novel human secreted protein seq id 24.
XX
KW cytotstatic; gene therapy; cancer; human; secreted protein; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003175858-A1.
XX
PD 18-SEP-2003.
XX
PF 18-JUN-2001; 2001US-00882171.
XX
PR 07-MAR-1997; 97US-0038621P.
PR 07-MAR-1997; 97US-0040162P.
PR 07-MAR-1997; 97US-0040163P.
PR 07-MAR-1997; 97US-0040333P.
PR 07-MAR-1997; 97US-0040334P.
PR 07-MAR-1997; 97US-0040336P.
PR 07-MAR-1997; 97US-0040626P.
PR 11-APR-1997; 97US-0043311P.
PR 11-APR-1997; 97US-0043312P.
PR 11-APR-1997; 97US-0043313P.
PR 11-APR-1997; 97US-0043314P.
PR 11-APR-1997; 97US-0043315P.
PR 11-APR-1997; 97US-0043568P.
PR 11-APR-1997; 97US-0043569P.
PR 11-APR-1997; 97US-0043576P.
PR 11-APR-1997; 97US-0043578P.
PR 11-APR-1997; 97US-0043580P.
PR 11-APR-1997; 97US-0043669P.
PR 11-APR-1997; 97US-0043670P.
PR 11-APR-1997; 97US-0043671P.
PR 11-APR-1997; 97US-0043672P.
PR 11-APR-1997; 97US-0043674P.
PR 23-MAY-1997; 97US-0047492P.
PR 23-MAY-1997; 97US-0047500P.
PR 23-MAY-1997; 97US-0047501P.
PR 23-MAY-1997; 97US-0047502P.
PR 23-MAY-1997; 97US-0047503P.
PR 23-MAY-1997; 97US-0047581P.
PR 23-MAY-1997; 97US-0047582P.
PR 23-MAY-1997; 97US-0047583P.
PR 23-MAY-1997; 97US-0047584P.
PR 23-MAY-1997; 97US-0047585P.
PR 23-MAY-1997; 97US-0047586P.
PR 23-MAY-1997; 97US-0047587P.
PR 23-MAY-1997; 97US-0047588P.
PR 23-MAY-1997; 97US-0047589P.
PR 23-MAY-1997; 97US-0047590P.
PR 23-MAY-1997; 97US-0047592P.
PR 23-MAY-1997; 97US-0047593P.
PR 23-MAY-1997; 97US-0047594P.
PR 23-MAY-1997; 97US-0047595P.
PR 23-MAY-1997; 97US-0047596P.
PR 23-MAY-1997; 97US-0047597P.
PR 23-MAY-1997; 97US-0047598P.
PR 23-MAY-1997; 97US-0047599P.
PR 23-MAY-1997; 97US-0047600P.
PR 23-MAY-1997; 97US-0047601P.
PR 23-MAY-1997; 97US-0047612P.
PR 23-MAY-1997; 97US-0047613P.
PR 23-MAY-1997; 97US-0047614P.
PR 23-MAY-1997; 97US-0047615P.
PR 23-MAY-1997; 97US-0047617P.
PR 23-MAY-1997; 97US-0047618P.
PR 23-MAY-1997; 97US-0047632P.
PR 23-MAY-1997; 97US-0047633P.
PR 06-JUN-1997; 97US-0048964P.
PR 13-JUN-1997; 97US-0049610P.
PR 08-JUL-1997; 97US-0051926P.
PR 16-JUL-1997; 97US-0052874P.
PR 18-AUG-1997; 97US-0055724P.
PR 22-AUG-1997; 97US-0056630P.
PR 22-AUG-1997; 97US-0056631P.
PR 22-AUG-1997; 97US-0056632P.
PR 22-AUG-1997; 97US-0056636P.
PR 22-AUG-1997; 97US-0056637P.
PR 22-AUG-1997; 97US-0056662P.
PR 22-AUG-1997; 97US-0056664P.
PR 22-AUG-1997; 97US-0056845P.
PR 22-AUG-1997; 97US-0056862P.
PR 22-AUG-1997; 97US-0056864P.
PR 22-AUG-1997; 97US-0056872P.
PR 22-AUG-1997; 97US-0056874P.
PR 22-AUG-1997; 97US-0056875P.
PR 22-AUG-1997; 97US-0056876P.
PR 22-AUG-1997; 97US-0056877P.
PR 22-AUG-1997; 97US-0056878P.
PR 22-AUG-1997; 97US-0056879P.
PR 22-AUG-1997; 97US-0056880P.
PR 22-AUG-1997; 97US-0056881P.
PR 22-AUG-1997; 97US-0056882P.
PR 22-AUG-1997; 97US-0056884P.
PR 22-AUG-1997; 97US-0056886P.
PR 22-AUG-1997; 97US-0056887P.
PR 22-AUG-1997; 97US-0056888P.
PR 22-AUG-1997; 97US-0056889P.
PR 22-AUG-1997; 97US-0056892P.
PR 22-AUG-1997; 97US-0056893P.
PR 22-AUG-1997; 97US-0056894P.
PR 22-AUG-1997; 97US-0056903P.
PR 22-AUG-1997; 97US-0056908P.
PR 22-AUG-1997; 97US-0056909P.
PR 22-AUG-1997; 97US-0056910P.
PR 22-AUG-1997; 97US-0056911P.
PR 05-SEP-1997; 97US-0057650P.
PR 05-SEP-1997; 97US-0057669P.
PR 05-SEP-1997; 97US-0057761P.
PR 12-SEP-1997; 97US-0058785P.
PR 09-OCT-1997; 97US-0061660P.
PR 06-MAR-1998; 98WO-US004493.
PR 08-SEP-1998; 98US-00149476.
PR 17-MAR-2000; 2000US-0190068P.
PR 16-MAR-2001; 2001US-00809391.
```

```
XX (RUBE/) RUBEN S M.
PA (ROSE/) ROSEN C A.
PA (SOPP/) SOPPET D R.
PA (CART/) CARTER K C.
PA (BEDN/) BEDNARIK D P.
PA (ENDR/) ENDRESS G A.
PA (YUGG/) YU G.
PA (NIJJ/) NI J.
PA (FENG/) FENG P.
PA (YOUN/) YOUNG P E.
PA (GREE/) GREENE J M.
PA (FERR/) FERRIE A M.
PA (DUAN/) DUAN D R.
PA (HUJJ/) HU J.
PA (FLOR/) FLORENCE K A.
PA (OLSE/) OLSEN H S.
PA (FISC/) FISCHER C L.
PA (EBNE/) EBNER R.
PA (BREW/) BREWER L A.
PA (MOOR/) MOORE P A.
PA (SHIY/) SHI Y.
PA (LAFL/) LAFLEUR D W.
PA (LIYY/) LI Y.
PA (ZENG/) ZENG Z.
PA (KYAW/) KYAW H.
XX
PI Ruben SM, Rosen CA, Soppet DR, Carter KC, Bednarik DP;
PI Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM, Ferrie AM;
PI Duan DR, Hu J, Florence KA, Olsen HS, Fischer CL, Ebner R;
PI Brewer LA, Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;
XX
DR WPI; 2003-898535/82.
DR P-PSDB; ADI23048.
XX
PT New nucleic acid molecule, useful for preparing a medicament for
PT diagnosing, preventing, treating or ameliorating a medical condition
PT e.g., cancer.
XX
PS Claim 1; SEQ ID NO 24; 256pp; English.
XX
CC The invention describes an isolated nucleic acid comprising a sequence
CC having 95 % identity with: a polynucleotide fragment of a sequence not
CC given in the specification, or its allelic variant; a polynucleotide
CC fragment of the cDNA sequence; a polynucleotide sequence encoding a
CC polypeptide, or its fragment, domain, epitope or species homologue; or a
CC polynucleotide that hybridises under stringent conditions to any one of
CC the sequences of (a)-(c). The nucleic acid is useful for preparing a
CC medicament for diagnosing, preventing, treating or ameliorating a medical
CC condition e.g., cancer. The sequence encodes a novel human secreted
CC protein of the invention.
XX
SQ Sequence 2323 BP; 760 A; 467 C; 438 G; 658 T; 0 U; 0 Other;

Query Match          3.0%; Score 66.2; DB 10; Length 2323;
Best Local Similarity 71.7%; Pred. No. 0.00027;
Matches 86; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 2123 TTTGCTTTACCACTCTTTCTTTTATCTTATTAATAAAATGTTGGTCTCCCACTGNC 2182
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2183 TTCTATGTACAACCTGATGCTTGTCTTATTTAATAAATTTATCAGAGTGAAAAA 2242

QY 2183 TCCCAAAAAA 2242
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2243 AAAAAA 2302

RESULT 1016
ADH73741
ID ADH73741 standard; cDNA; 2323 BP.
XX
AC ADH73741;
XX
```

```
DT 25-MAR-2004 (first entry)
XX
DE Human secreted protein cDNA #14.
XX
KW human; secreted protein; cancer; haematopoietic disorder;
KW endocrine disorder; immune system disease; inflammatory disorder; ss;
KW gene.
XX
OS Homo sapiens.
XX
PN US2003225248-A1.
XX
PD 04-DEC-2003.
XX
PF 10-JUN-2002; 2002US-00164861.
XX
PR 07-MAR-1997; 97US-0038621P.
PR 07-MAR-1997; 97US-0040161P.
PR 07-MAR-1997; 97US-0040162P.
PR 07-MAR-1997; 97US-0040163P.
PR 07-MAR-1997; 97US-0040333P.
PR 07-MAR-1997; 97US-0040334P.
PR 07-MAR-1997; 97US-0040336P.
PR 07-MAR-1997; 97US-0040626P.
PR 11-APR-1997; 97US-0043311P.
PR 11-APR-1997; 97US-0043312P.
PR 11-APR-1997; 97US-0043313P.
PR 11-APR-1997; 97US-0043314P.
PR 11-APR-1997; 97US-0043315P.
PR 11-APR-1997; 97US-0043568P.
PR 11-APR-1997; 97US-0043569P.
PR 11-APR-1997; 97US-0043576P.
PR 11-APR-1997; 97US-0043578P.
PR 11-APR-1997; 97US-0043580P.
PR 11-APR-1997; 97US-0043669P.
PR 11-APR-1997; 97US-0043670P.
PR 11-APR-1997; 97US-0043671P.
PR 11-APR-1997; 97US-0043672P.
PR 11-APR-1997; 97US-0043674P.
PR 23-MAY-1997; 97US-0047492P.
PR 23-MAY-1997; 97US-0047500P.
PR 23-MAY-1997; 97US-0047501P.
PR 23-MAY-1997; 97US-0047502P.
PR 23-MAY-1997; 97US-0047503P.
PR 23-MAY-1997; 97US-0047581P.
PR 23-MAY-1997; 97US-0047582P.
PR 23-MAY-1997; 97US-0047583P.
PR 23-MAY-1997; 97US-0047584P.
PR 23-MAY-1997; 97US-0047585P.
PR 23-MAY-1997; 97US-0047586P.
PR 23-MAY-1997; 97US-0047587P.
PR 23-MAY-1997; 97US-0047588P.
PR 23-MAY-1997; 97US-0047589P.
PR 23-MAY-1997; 97US-0047590P.
PR 23-MAY-1997; 97US-0047592P.
PR 23-MAY-1997; 97US-0047593P.
PR 23-MAY-1997; 97US-0047594P.
PR 23-MAY-1997; 97US-0047595P.
PR 23-MAY-1997; 97US-0047596P.
PR 23-MAY-1997; 97US-0047597P.
PR 23-MAY-1997; 97US-0047598P.
PR 23-MAY-1997; 97US-0047599P.
PR 23-MAY-1997; 97US-0047600P.
PR 23-MAY-1997; 97US-0047601P.
PR 23-MAY-1997; 97US-0047612P.
PR 23-MAY-1997; 97US-0047613P.
PR 23-MAY-1997; 97US-0047614P.
PR 23-MAY-1997; 97US-0047615P.
PR 23-MAY-1997; 97US-0047617P.
PR 23-MAY-1997; 97US-0047618P.
PR 23-MAY-1997; 97US-0047632P.
PR 23-MAY-1997; 97US-0047633P.
PR 06-JUN-1997; 97US-0048964P.
```







CC cancerous) ovarian cells. The invention also relates to polypeptides  
CC encoded by the markers, antibodies that selectively bind to the  
CC polypeptides, a method of inhibiting ovarian cancer in a patient at risk  
CC of developing ovarian cancer involving inhibiting expression of a gene  
CC corresponding to a marker of the invention and a method of treating a  
CC patient afflicted with ovarian cancer comprising providing to cells of the  
CC the patient an antisense oligonucleotide complementary to a marker of the  
CC invention. The markers are useful for assessing if a patient is afflicted  
CC with ovarian cancer, which involves comparing the level of expression of  
CC a marker in a patient sample and a normal level of expression of the  
CC marker in a control non-ovarian cancer sample. A difference between the  
CC expression levels indicates ovarian cancer. The level of expression of a  
CC marker corresponds to a secreted protein or to a transcribed  
CC polynucleotide or its portion. The level of expression of the marker is  
CC assessed by detecting the presence in the sample, a protein or protein  
CC fragment corresponding to the marker. The presence of protein or protein  
CC fragment is detected using an antibody that specifically binds with the  
CC protein or protein fragment. Alternatively, the level of expression of  
CC the marker is assessed by detecting the presence of a transcribed  
CC polynucleotide which anneals with the marker or anneals with a portion of  
CC the polynucleotide comprising the marker, under stringent conditions. The  
CC marker is also used for monitoring the progression of ovarian cancer in a  
CC patient which involves detecting expression of the marker in a patient  
CC sample at a first point in time, repeating the method at a subsequent  
CC time and comparing the level of expression. The method is carried out  
CC using an ovarian tissue sample. A composition comprising a marker,  
CC polypeptide or antibody of the invention is used to treat ovarian cancer.  
CC This sequence represents a human ovarian cancer DNA marker of the  
CC invention.

SQ Sequence 384 BP; 93 A; 41 C; 47 G; 150 T; 0 U; 53 Other;

Query Match 2.9%; Score 66; DB 5; Length 384;  
Best Local Similarity 70.4%; Pred. No. 0.00017;  
Matches 81; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 2128 TTTACCACTCTTTCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACTGNTCTCCA 2187  
Db 215 TTTTTTANTTTTTTTTTTTTTTTTTTTNGAANNAANGNTTNTAATTTCCCCCNAA 156

QY 2188 AA 2242  
Db 155 AA 101

RESULT 1020  
AAI82937  
ID AAI82937 standard; cDNA; 403 BP.  
XX  
AC AAI82937;  
XX  
DT 06-NOV-2001 (first entry)  
XX  
DE Human polynucleotide SEQ ID NO 2997.

XX Human; cytokine; cell proliferation; cell differentiation; gene therapy;  
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;  
KW tissue growth factor; immunomodulatory; cancer; leukaemia;  
KW nervous system disorders; arthritis; inflammation; ss.

OS Homo sapiens.  
XX  
PN WO200164835-A2.  
XX  
PD 07-SEP-2001.  
XX  
PF 26-FEB-2001; 2001WO-US004927.  
XX  
PR 28-FEB-2000; 2000US-00515126.  
PR 18-MAY-2000; 2000US-00577409.

PA (HYSE-) HYSEQ INC.

XX

PI Tang YT, Liu C, Drmanac RT;  
XX  
DR WPI; 2001-514838/56.  
DR P-PSDB; AAO03006.  
XX  
PT Isolated nucleic acids and polypeptides, useful for preventing diagnosing  
PT and treating e.g. leukemia, inflammation and immune disorders.  
XX  
PS Claim 1; SEQ ID NO 2997; 1399pp + Sequence Listing; English.  
XX  
CC The invention relates to human polynucleotides (AAI79941-AAI93841) and  
CC the encoded proteins (AAO00010-AAO13910) that exhibit activity elating to  
CC cytokine, cell proliferation or cell differentiation or which may induce  
CC production of other cytokines in other cell populations. The  
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or  
CC peptide therapy. The polypeptides have various cytokine-like activities,  
CC e.g. stem cell growth factor activity, haematopoiesis regulating  
CC activity, tissue growth factor activity, immunomodulatory activity and  
CC activin/inhibin activity and may be useful in the diagnosis and/or  
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and  
CC inflammation. Note: The sequence data for this patent did not form part  
CC of the printed specification, but was obtained in electronic format  
CC directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 403 BP; 186 A; 83 C; 53 G; 60 T; 0 U; 21 Other;

Query Match 2.9%; Score 66; DB 4; Length 403;  
Best Local Similarity 89.6%; Pred. No. 0.00017;  
Matches 69; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2166 TGGTCTCCACCACTGNTCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2225  
Db 250 TGGCCTCCATGACTTTTCNNAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 309  
QY 2226 AAAAAAAAAAAAAAAAAAAAAA 2242  
Db 310 AAAAAAAAAAAAAAAAAAAAAA 326

RESULT 1021  
ABV03810/c  
ID ABV03810 standard; cDNA; 464 BP.  
XX  
AC ABV03810;  
XX  
DT 13-SEP-2002 (first entry)  
XX  
DE Human prostate expression marker cDNA 3801.

XX Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;  
KW pharmacogenomic marker; gene; ss.

OS Homo sapiens.  
XX  
PN WO200160860-A2.  
XX  
PD 23-AUG-2001.  
XX  
PF 20-FEB-2001; 2001WO-US005171.  
XX  
PR 17-FEB-2000; 2000US-0183319P.  
PR 16-MAR-2000; 2000US-0189862P.  
PR 25-MAY-2000; 2000US-0207454P.  
PR 09-JUN-2000; 2000US-0211314P.  
PR 18-JUL-2000; 2000US-0219007P.  
PR 13-DEC-2000; 2000US-0255281P.

XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.  
PA  
XX Schlegel R, Endege WO, Monahan JE;  
PI  
XX WPI; 2001-662795/76.  
DR  
XX



```

PT Novel isolated nucleic acid molecule associated with cancerous state of
PT prostate cells and correlating with presence of prostate cancer, useful
PT for detecting presence of prostate cancer, stage of prostate cancer.
XX
PS Claim 1; Page 677; 11750pp; English.
XX
CC The invention relates to an isolated nucleic acid molecule (I) comprising
CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
CC specification or its complement. (I) is useful for: (a) assessing whether
CC a patient is afflicted with prostate cancer; (b) monitoring the
CC progression of prostate cancer in a patient; (c) assessing the efficacy
CC of a test compound to inhibit prostate cancer in a patient; (d) assessing
CC the efficacy of a therapy for inhibiting prostate cancer in a patient;
CC (e) selecting a composition for inhibiting prostate cancer in a patient;
CC (f) assessing the prostate cell carcinogenic potential of a compound; (g)
CC determining whether prostate cancer has metastasized in a patient; (h)
CC assessing the aggressiveness or indolence of prostate cancer in a patient
CC ; (I) is also useful as a pharmacodynamic or pharmacogenomic marker
XX
SQ Sequence 464 BP; 199 A; 74 C; 16 G; 116 T; 0 U; 59 Other;

Query Match      2.9%; Score 66; DB 5; Length 464;
Best Local Similarity 70.0%; Pred. No. 0.00018;
Matches 84; Conservative 0; Mismatches 36; Indels 0; Gaps 0;

QY 2123 TTTCCTTTACCACCTCTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACCTGNC 2182
Db    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
      146 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
QY 2183 TCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
Db    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
      86 AATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 27

RESULT 1022
ACN61841/c
ID ACN61841 standard; cDNA; 483 BP.
XX
AC ACN61841;
XX
DT 02-DEC-2004 (first entry)
XX
DE Cotton gynoecium tissue EST Clone ID: LIB3829-021-Q6-N6-F8, SEQ:16622.
XX
KW Cotton; plant; EST; expressed sequence tag; transgenic plant; gynoecium;
KW variety Nucotton33B; library LIB3829; molecular tag; molecular marker;
KW genetic mapping; molecular mapping; seed germination; plant growth;
KW plant quality; plant yield; plant breeding; tissue printing; ss.
XX
OS Gossypium hirsutum.
XX
FN US2004123340-A1.
XX
PD 24-JUN-2004.
XX
PF 12-DEC-2001; 2001US-00021323.
XX
PR 14-DEC-2000; 2000US-0255619P.
XX
PA (DEIK/) DEIKMAN J.
PA (FENG/) FENG P C C.
PA (FINC/) FINCHER K L.
PA (ZIEG/) ZIEGLER T E.
XX
PI Deikman J, Feng PCC, Fincher KL, Ziegler TE;
XX
DR WPI; 2004-479808/45.
XX
PT New isolated nucleic acid molecule that encodes a plant protein or its
PT fragment, useful for isolating a variety of agronomically significant
PT genes associated with plant growth, quality or yield, and as molecular
PT tags to map genes.
XX

```



QY 2104 ATTCCATCCAATGATCGCTTGTGCTTTACCACCTCTTTCCTTTATCTTATTATAATAAAT 2163  
Db 756 ATTTCATTGAATGTTTGAGTGCATTCTGTGACCTTTTATATTATGTATATTAAATG 815  
QY 2164 GTTGGTCTCCACCACCTGNCTCCCAAAAAA 2223  
Db 816 TTCCGTTAAAAA 875  
QY 2224 AAAAAA 2242  
Db 876 AAAAAA 894  
RESULT 1025  
AAV59803  
ID AAV59803 standard; DNA; 1181 BP.  
XX  
AC AAV59803;  
XX  
DT 19-JAN-1999 (first entry)  
XX  
DE Human secreted protein gene 176 clone HFTBR48.  
XX  
KW Human; secreted protein; fusion protein; gene therapy; protein therapy;  
KW diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;  
KW developmental abnormality; foetal deficiency; blood; allergy; renal; ds;  
KW immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;  
KW inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;  
KW cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;  
KW osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;  
KW endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.  
XX  
OS Homo sapiens.  
XX  
PN WO98339448-A2.  
XX  
PD 11-SEP-1998.  
XX  
PF 06-MAR-1998; 98WO-US004493.  
XX  
PR 07-MAR-1997; 97US-0038621P.  
PR 07-MAR-1997; 97US-0040161P.  
PR 07-MAR-1997; 97US-0040162P.  
PR 07-MAR-1997; 97US-0040163P.  
PR 07-MAR-1997; 97US-0040333P.  
PR 07-MAR-1997; 97US-0040336P.  
PR 07-MAR-1997; 97US-0040334P.  
PR 07-MAR-1997; 97US-0040626P.  
PR 11-APR-1997; 97US-0043311P.  
PR 11-APR-1997; 97US-0043312P.  
PR 11-APR-1997; 97US-0043313P.  
PR 11-APR-1997; 97US-0043314P.  
PR 11-APR-1997; 97US-0043315P.  
PR 11-APR-1997; 97US-0043356P.  
PR 11-APR-1997; 97US-0043576P.  
PR 11-APR-1997; 97US-0043578P.  
PR 11-APR-1997; 97US-0043580P.  
PR 11-APR-1997; 97US-0043669P.  
PR 11-APR-1997; 97US-0043670P.  
PR 11-APR-1997; 97US-0043671P.  
PR 11-APR-1997; 97US-0043672P.  
PR 11-APR-1997; 97US-0043674P.  
PR 23-MAY-1997; 97US-0047492P.  
PR 23-MAY-1997; 97US-0047500P.  
PR 23-MAY-1997; 97US-0047501P.  
PR 23-MAY-1997; 97US-0047502P.  
PR 23-MAY-1997; 97US-0047503P.  
PR 23-MAY-1997; 97US-0047581P.  
PR 23-MAY-1997; 97US-0047582P.  
PR 23-MAY-1997; 97US-0047583P.  
PR 23-MAY-1997; 97US-0047584P.  
PR 23-MAY-1997; 97US-0047585P.

PR 23-MAY-1997; 97US-0047586P.  
PR 23-MAY-1997; 97US-0047587P.  
PR 23-MAY-1997; 97US-0047588P.  
PR 23-MAY-1997; 97US-0047589P.  
PR 23-MAY-1997; 97US-0047590P.  
PR 23-MAY-1997; 97US-0047592P.  
PR 23-MAY-1997; 97US-0047593P.  
PR 23-MAY-1997; 97US-0047594P.  
PR 23-MAY-1997; 97US-0047595P.  
PR 23-MAY-1997; 97US-0047596P.  
PR 23-MAY-1997; 97US-0047597P.  
PR 23-MAY-1997; 97US-0047598P.  
PR 23-MAY-1997; 97US-0047599P.  
PR 23-MAY-1997; 97US-0047600P.  
PR 23-MAY-1997; 97US-0047601P.  
PR 23-MAY-1997; 97US-0047612P.  
PR 23-MAY-1997; 97US-0047613P.  
PR 23-MAY-1997; 97US-0047614P.  
PR 23-MAY-1997; 97US-0047615P.  
PR 23-MAY-1997; 97US-0047617P.  
PR 23-MAY-1997; 97US-0047618P.  
PR 23-MAY-1997; 97US-0047632P.  
PR 23-MAY-1997; 97US-0047633P.  
PR 06-JUN-1997; 97US-0048964P.  
PR 06-JUN-1997; 97US-0048974P.  
PR 13-JUN-1997; 97US-0049610P.  
PR 08-JUL-1997; 97US-0051926P.  
PR 16-JUL-1997; 97US-0052874P.  
PR 18-AUG-1997; 97US-0055724P.  
PR 22-AUG-1997; 97US-0056630P.  
PR 22-AUG-1997; 97US-0056631P.  
PR 22-AUG-1997; 97US-0056632P.  
PR 22-AUG-1997; 97US-0056636P.  
PR 22-AUG-1997; 97US-0056637P.  
PR 22-AUG-1997; 97US-0056662P.  
PR 22-AUG-1997; 97US-0056664P.  
PR 22-AUG-1997; 97US-0056845P.  
PR 22-AUG-1997; 97US-0056862P.  
PR 22-AUG-1997; 97US-0056864P.  
PR 22-AUG-1997; 97US-0056872P.  
PR 22-AUG-1997; 97US-0056874P.  
PR 22-AUG-1997; 97US-0056875P.  
PR 22-AUG-1997; 97US-0056876P.  
PR 22-AUG-1997; 97US-0056877P.  
PR 22-AUG-1997; 97US-0056878P.  
PR 22-AUG-1997; 97US-0056879P.  
PR 22-AUG-1997; 97US-0056881P.  
PR 22-AUG-1997; 97US-0056882P.  
PR 22-AUG-1997; 97US-0056884P.  
PR 22-AUG-1997; 97US-0056886P.  
PR 22-AUG-1997; 97US-0056887P.  
PR 22-AUG-1997; 97US-0056888P.  
PR 22-AUG-1997; 97US-0056889P.  
PR 22-AUG-1997; 97US-0056892P.  
PR 22-AUG-1997; 97US-0056893P.  
PR 22-AUG-1997; 97US-0056894P.  
PR 22-AUG-1997; 97US-0056903P.  
PR 22-AUG-1997; 97US-0056908P.  
PR 22-AUG-1997; 97US-0056909P.  
PR 22-AUG-1997; 97US-0056910P.  
PR 22-AUG-1997; 97US-0056911P.  
PR 05-SEP-1997; 97US-0057650P.  
PR 05-SEP-1997; 97US-0057669P.  
PR 05-SEP-1997; 97US-0057761P.  
PR 12-SEP-1997; 97US-0058785P.  
PR 02-OCT-1997; 97US-0061060P.  
XX  
PA (HUMA-) HUMAN GENOME SCI INC.  
XX  
PI Ruben SM, Rosen CA, Fischer CL, Soppet DR, Carter KC;  
PI Bednarik DP, Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM;  
PI Ferrie AM, Duan R, Hu J, Florence KA, Olsen HS, Ebner R, Brewer LA;







PR 23-MAY-1997; 97US-0047501P.  
PR 23-MAY-1997; 97US-0047502P.  
PR 23-MAY-1997; 97US-0047503P.  
PR 23-MAY-1997; 97US-0047581P.  
PR 23-MAY-1997; 97US-0047582P.  
PR 23-MAY-1997; 97US-0047583P.  
PR 23-MAY-1997; 97US-0047584P.  
PR 23-MAY-1997; 97US-0047585P.  
PR 23-MAY-1997; 97US-0047586P.  
PR 23-MAY-1997; 97US-0047587P.  
PR 23-MAY-1997; 97US-0047588P.  
PR 23-MAY-1997; 97US-0047589P.  
PR 23-MAY-1997; 97US-0047590P.  
PR 23-MAY-1997; 97US-0047592P.  
PR 23-MAY-1997; 97US-0047593P.  
PR 23-MAY-1997; 97US-0047594P.  
PR 23-MAY-1997; 97US-0047595P.  
PR 23-MAY-1997; 97US-0047596P.  
PR 23-MAY-1997; 97US-0047597P.  
PR 23-MAY-1997; 97US-0047598P.  
PR 23-MAY-1997; 97US-0047599P.  
PR 23-MAY-1997; 97US-0047600P.  
PR 23-MAY-1997; 97US-0047601P.  
PR 23-MAY-1997; 97US-0047612P.  
PR 23-MAY-1997; 97US-0047613P.  
PR 23-MAY-1997; 97US-0047614P.  
PR 23-MAY-1997; 97US-0047615P.  
PR 23-MAY-1997; 97US-0047617P.  
PR 23-MAY-1997; 97US-0047618P.  
PR 23-MAY-1997; 97US-0047632P.  
PR 23-MAY-1997; 97US-0047633P.  
PR 06-JUN-1997; 97US-0048964P.  
PR 06-JUN-1997; 97US-0048974P.  
PR 13-JUN-1997; 97US-0049610P.  
PR 08-JUL-1997; 97US-0051926P.  
PR 16-JUL-1997; 97US-0052874P.  
PR 18-AUG-1997; 97US-0055724P.  
PR 22-AUG-1997; 97US-0056630P.  
PR 22-AUG-1997; 97US-0056631P.  
PR 22-AUG-1997; 97US-0056632P.  
PR 22-AUG-1997; 97US-0056636P.  
PR 22-AUG-1997; 97US-0056637P.  
PR 22-AUG-1997; 97US-0056662P.  
PR 22-AUG-1997; 97US-0056664P.  
PR 22-AUG-1997; 97US-0056845P.  
PR 22-AUG-1997; 97US-0056862P.  
PR 22-AUG-1997; 97US-0056864P.  
PR 22-AUG-1997; 97US-0056872P.  
PR 22-AUG-1997; 97US-0056874P.  
PR 22-AUG-1997; 97US-0056875P.  
PR 22-AUG-1997; 97US-0056876P.  
PR 22-AUG-1997; 97US-0056877P.  
PR 22-AUG-1997; 97US-0056878P.  
PR 22-AUG-1997; 97US-0056879P.  
PR 22-AUG-1997; 97US-0056880P.  
PR 22-AUG-1997; 97US-0056881P.  
PR 22-AUG-1997; 97US-0056882P.  
PR 22-AUG-1997; 97US-0056884P.  
PR 22-AUG-1997; 97US-0056886P.  
PR 22-AUG-1997; 97US-0056887P.  
PR 22-AUG-1997; 97US-0056888P.  
PR 22-AUG-1997; 97US-0056889P.  
PR 22-AUG-1997; 97US-0056892P.  
PR 22-AUG-1997; 97US-0056893P.  
PR 22-AUG-1997; 97US-0056894P.  
PR 22-AUG-1997; 97US-0056903P.  
PR 22-AUG-1997; 97US-0056908P.  
PR 22-AUG-1997; 97US-0056909P.  
PR 22-AUG-1997; 97US-0056910P.  
PR 22-AUG-1997; 97US-0056911P.  
PR 05-SEP-1997; 97US-0057650P.  
PR 05-SEP-1997; 97US-0057669P.  
PR 05-SEP-1997; 97US-0057761P.

PR 12-SEP-1997; 97US-0058785P.  
PR 09-OCT-1997; 97US-0061660P.  
PR 06-MAR-1998; 98WO-US004493.  
PR 08-SEP-1998; 98US-00149476.  
PR 17-MAR-2000; 2000US-0190068P.  
XX  
PA (RUBE/) RUBEN S M.  
PA (ROSE/) ROSEN C A.  
PA (SOPP/) SOPPET D R.  
PA (CART/) CARTER K C.  
PA (BEDN/) BEDNARIK D P.  
PA (ENDR/) ENDRESS G A.  
PA (YUGG/) YU G.  
PA (NIJJ/) NI J.  
PA (FENG/) FENG P.  
PA (YOUN/) YOUNG P E.  
PA (GREE/) GREENE J M.  
PA (FERR/) FERRIE A M.  
PA (DUAN/) DUAN D R.  
PA (HUJJ/) HU J.  
PA (FLOR/) FLORENCE K A.  
PA (OLSE/) OLSEN H S.  
PA (FISC/) FISCHER C L.  
PA (EBNE/) EBNER R.  
PA (BREW/) BREWER L A.  
PA (MOOR/) MOORE P A.  
PA (SHIY/) SHI Y.  
PA (LAFL/) LAFLEUR D W.  
PA (LIYY/) LI Y.  
PA (ZENG/) ZENG Z.  
PA (KYAW/) KYAW H.  
XX  
PI Ruben SM, Rosen CA, Soppet DR, Carter KC, Bednarik DP;  
PI Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM, Ferrie AM;  
PI Duan DR, Hu J, Florence KA, Olsen HS, Fischer CL, Ebner R;  
PI Brewer LA, Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;  
XX  
DR WPI; 2003-521800/49.  
DR P-PSDB; ABO34673.  
XX  
PT New genes and its encoded prostate cancer antigen proteins, useful for  
PT preventing, treating, ameliorating or diagnosing e.g. prostate cancers,  
PT thymic hypoplasia, multiple sclerosis, AIDS, angina pectoris or cerebral  
PT ischemia.  
XX  
PS Claim 4; SEQ ID NO 310; 260pp; English.  
XX  
CC The present invention relates to the isolation of novel human secreted  
CC proteins and the polynucleotide sequences encoding them. The invention  
CC also discloses vectors, host cells, antibodies, and recombinant methods  
CC for producing human secreted proteins. The polypeptide and polynucleotide  
CC sequences for the secreted proteins are useful for preventing, treating,  
CC ameliorating or diagnosing medical conditions such as hyperproliferative  
CC disorders (e.g. leukaemia or breast cancers), wounds, reproductive  
CC disorders, blood-related disorders (e.g. haemophilia or  
CC thrombocytopaenia), immunodeficiencies (e.g. Wiskott-Aldrich syndrome or  
CC thymic hypoplasia), autoimmune disorders (e.g. graft-versus-host disease,  
CC multiple sclerosis or Hashimoto's thyroiditis), allergies (e.g. asthma),  
CC viral or bacterial or fungal infections (e.g. AIDS or sepsis), renal  
CC disorders (e.g. kidney failure), cardiovascular disorders (e.g. angina  
CC pectoris, cerebral ischaemia or congenital heart defects), respiratory  
CC disorders, neurological disorders (e.g. Alzheimer's disease or  
CC Parkinson's disease), and inflammations (e.g. Crohn's disease). The  
CC polynucleotide or polypeptide may also be used as vaccine adjuvants.  
CC ACD82641-ACD82950 encode human secreted proteins or their fragments.  
CC Note: The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from the  
CC USPTO web site at seqdata.uspto.gov/psipsDIDEntry.html  
XX  
SQ Sequence 1181 BP; 357 A; 228 C; 295 G; 298 T; 0 U; 3 Other;

Query Match 2.9%; Score 66; DB 9; Length 1181;  
Best Local Similarity 70.7%; Pred. No. 0.00024;











[illegible]







OS Homo sapiens.  
XX US2003049618-A1.  
XX  
PD 13-MAR-2003.  
XX  
PF 16-MAR-2001; 2001US-00809391.  
XX  
PR 07-MAR-1997; 97US-0038621P.  
PR 07-MAR-1997; 97US-0040162P.  
PR 07-MAR-1997; 97US-0040163P.  
PR 07-MAR-1997; 97US-0040333P.  
PR 07-MAR-1997; 97US-0040334P.  
PR 07-MAR-1997; 97US-0040336P.  
PR 07-MAR-1997; 97US-0040626P.  
PR 11-APR-1997; 97US-0043311P.  
PR 11-APR-1997; 97US-0043312P.  
PR 11-APR-1997; 97US-0043313P.  
PR 11-APR-1997; 97US-0043314P.  
PR 11-APR-1997; 97US-0043315P.  
PR 11-APR-1997; 97US-0043568P.  
PR 11-APR-1997; 97US-0043569P.  
PR 11-APR-1997; 97US-0043576P.  
PR 11-APR-1997; 97US-0043578P.  
PR 11-APR-1997; 97US-0043580P.  
PR 11-APR-1997; 97US-0043669P.  
PR 11-APR-1997; 97US-0043670P.  
PR 11-APR-1997; 97US-0043671P.  
PR 11-APR-1997; 97US-0043672P.  
PR 11-APR-1997; 97US-0043674P.  
PR 23-MAY-1997; 97US-0047492P.  
PR 23-MAY-1997; 97US-0047500P.  
PR 23-MAY-1997; 97US-0047501P.  
PR 23-MAY-1997; 97US-0047502P.  
PR 23-MAY-1997; 97US-0047503P.  
PR 23-MAY-1997; 97US-0047581P.  
PR 23-MAY-1997; 97US-0047582P.  
PR 23-MAY-1997; 97US-0047583P.  
PR 23-MAY-1997; 97US-0047584P.  
PR 23-MAY-1997; 97US-0047585P.  
PR 23-MAY-1997; 97US-0047586P.  
PR 23-MAY-1997; 97US-0047587P.  
PR 23-MAY-1997; 97US-0047588P.  
PR 23-MAY-1997; 97US-0047589P.  
PR 23-MAY-1997; 97US-0047590P.  
PR 23-MAY-1997; 97US-0047592P.  
PR 23-MAY-1997; 97US-0047593P.  
PR 23-MAY-1997; 97US-0047594P.  
PR 23-MAY-1997; 97US-0047595P.  
PR 23-MAY-1997; 97US-0047596P.  
PR 23-MAY-1997; 97US-0047597P.  
PR 23-MAY-1997; 97US-0047598P.  
PR 23-MAY-1997; 97US-0047599P.  
PR 23-MAY-1997; 97US-0047600P.  
PR 23-MAY-1997; 97US-0047601P.  
PR 23-MAY-1997; 97US-0047612P.  
PR 23-MAY-1997; 97US-0047613P.  
PR 23-MAY-1997; 97US-0047614P.  
PR 23-MAY-1997; 97US-0047615P.  
PR 23-MAY-1997; 97US-0047617P.  
PR 23-MAY-1997; 97US-0047618P.  
PR 23-MAY-1997; 97US-0047632P.  
PR 23-MAY-1997; 97US-0047633P.  
PR 06-JUN-1997; 97US-0048964P.  
PR 06-JUN-1997; 97US-0048974P.  
PR 13-JUN-1997; 97US-0049610P.  
PR 08-JUL-1997; 97US-0051926P.  
PR 16-JUL-1997; 97US-0052874P.  
PR 18-AUG-1997; 97US-0055724P.  
PR 22-AUG-1997; 97US-0056630P.  
PR 22-AUG-1997; 97US-0056631P.  
PR 22-AUG-1997; 97US-0056632P.  
PR 22-AUG-1997; 97US-0056636P.

PR 22-AUG-1997; 97US-0056637P.  
PR 22-AUG-1997; 97US-0056662P.  
PR 22-AUG-1997; 97US-0056664P.  
PR 22-AUG-1997; 97US-0056845P.  
PR 22-AUG-1997; 97US-0056862P.  
PR 22-AUG-1997; 97US-0056864P.  
PR 22-AUG-1997; 97US-0056872P.  
PR 22-AUG-1997; 97US-0056874P.  
PR 22-AUG-1997; 97US-0056875P.  
PR 22-AUG-1997; 97US-0056876P.  
PR 22-AUG-1997; 97US-0056877P.  
PR 22-AUG-1997; 97US-0056878P.  
PR 22-AUG-1997; 97US-0056879P.  
PR 22-AUG-1997; 97US-0056880P.  
PR 22-AUG-1997; 97US-0056881P.  
PR 22-AUG-1997; 97US-0056882P.  
PR 22-AUG-1997; 97US-0056884P.  
PR 22-AUG-1997; 97US-0056886P.  
PR 22-AUG-1997; 97US-0056887P.  
PR 22-AUG-1997; 97US-0056888P.  
PR 22-AUG-1997; 97US-0056889P.  
PR 22-AUG-1997; 97US-0056892P.  
PR 22-AUG-1997; 97US-0056893P.  
PR 22-AUG-1997; 97US-0056894P.  
PR 22-AUG-1997; 97US-0056903P.  
PR 22-AUG-1997; 97US-0056908P.  
PR 22-AUG-1997; 97US-0056910P.  
PR 22-AUG-1997; 97US-0056911P.  
PR 05-SEP-1997; 97US-0057650P.  
PR 05-SEP-1997; 97US-0057669P.  
PR 05-SEP-1997; 97US-0057761P.  
PR 12-SEP-1997; 97US-0058785P.  
PR 09-OCT-1997; 97US-0061660P.  
PR 06-MAR-1998; 98WO-US004493.  
PR 08-SEP-1998; 98US-00149476.  
PR 17-MAR-2000; 2000US-0190068P.  
XX  
PA (RUBE/) RUBEN S M.  
PA (ROSE/) ROSEN C A.  
PA (SOPP/) SOPPET D R.  
PA (CART/) CARTER K C.  
PA (BEDN/) BEDNARIK D P.  
PA (ENDR/) ENDRESS G A.  
PA (YUGG/) YU G.  
PA (NIJJ/) NI J.  
PA (FENG/) FENG P.  
PA (YOUN/) YOUNG P E.  
PA (GREE/) GREENE J M.  
PA (FERR/) FERRIE A M.  
PA (DUAN/) DUAN D R.  
PA (HUJJ/) HU J.  
PA (FLOR/) FLORENCE K A.  
PA (OLSE/) OLSEN H S.  
PA (FISC/) FISCHER C L.  
PA (EBNE/) EBNER R.  
PA (BREW/) BREWER L A.  
PA (MOOR/) MOORE P A.  
PA (SHIY/) SHI Y.  
PA (LAF/) LAFLEUR D W.  
PA (LIYV/) LI Y.  
PA (ZENG/) ZENG Z.  
PA (KYAW/) KYAW H.  
XX  
PI Ruben SM, Rosen CA, Soppet DR, Carter KC, Bednarik DP;  
PI Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM, Ferrie AM;  
PI Duan DR, Hu J, Florence KA, Olsen HS, Fischer CL, Ebner R;  
PI Brewer LA, Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;  
XX  
DR WPI; 2003-521800/49.  
DR P-PSDB; ABO34549.  
XX  
PT New genes and its encoded prostate cancer antigen proteins, useful for



PR	22-AUG-1997;	97US-0056881P;
PR	22-AUG-1997;	97US-0056882P;
PR	22-AUG-1997;	97US-0056884P;
PR	22-AUG-1997;	97US-0056886P;
PR	22-AUG-1997;	97US-0056887P;
PR	22-AUG-1997;	97US-0056888P;
PR	22-AUG-1997;	97US-0056889P;
PR	22-AUG-1997;	97US-0056892P;
PR	22-AUG-1997;	97US-0056893P;
PR	22-AUG-1997;	97US-0056894P;
PR	22-AUG-1997;	97US-0056903P;
PR	22-AUG-1997;	97US-0056908P;
PR	22-AUG-1997;	97US-0056909P;
PR	22-AUG-1997;	97US-0056910P;
PR	22-AUG-1997;	97US-0056911P;
PR	05-SEP-1997;	97US-0057650P;
PR	05-SEP-1997;	97US-0057650P;
PR	05-SEP-1997;	97US-0057669P;
PR	05-SEP-1997;	97US-0057761P;
PR	05-SEP-1997;	97US-0058785P;
PR	09-OCT-1997;	97US-0061660P;
PR	06-MAR-1998;	98WO-US004493;
PR	08-SEP-1998;	98US-00149476;
PR	17-MAR-2000;	2000US-0190068P;
PR	16-MAR-2001;	2001US-00809391;

The invention describes an isolated nucleic acid comprising a sequence having 95 % identity with: a polynucleotide fragment of a sequence not given in the specification, or its allelic variant; a polynucleotide fragment of the cDNA sequence; a polynucleotide sequence encoding a polypeptide, or its fragment, domain, epitope or species homologue; or a polynucleotide that hybridises under stringent conditions to any one of the sequences of (a)-(c). The nucleic acid is useful for preparing a medicament for diagnosing, preventing, treating or ameliorating a medical

CC	condition e.g., cancer. The sequence encodes a novel human secreted
CC	protein of the invention.
XX	
SQ	Sequence 1212 BP; 363 A; 241 C; 307 G; 300 T; 0 U; 1 Other;
	Query Match 2.9%; Score 66; DB 10; Length 1212;
	Best Local Similarity 70.7%; Pred. No. 0.00024;
	Matches 87; Conservative 0; Mismatches 36; Indels 0; Gaps 0;
QY	2120 GCCTTTGCTTTACCACTCTTTCTCTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACT 21799
Db	1086 GCATTGCTTTTAAACCATTTCTTTTGTTTTAAATAAAATAAGTAAATAAGCTAGTT 1145
QY	2180 GNTCCCAAAAAA AA 2239
Db	1146 CTATTGAAATGCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1205
QY	2240 AAA 2242
Db	1206 AAA 1208

RESULT	I035
ADH73903	
ID	ADH73903 standard; cDNA; 1212 BP.
XX	
AC	ADH73903;
XX	
DT	25-MAR-2004 (first entry)
XX	
DE	Human secreted protein cDNA #176.
XX	
KW	human; secreted protein; cancer; haematopoietic disorder;
KW	endocrine disorder; immune system disease; inflammatory disorder; ss;
KW	gene.
XX	
OS	Homo sapiens.
XX	
PN	US2003225248-A1.
XX	
PD	04-DEC-2003.
XX	
PF	10-JUN-2002; 2002US-00164861.
XX	
PR	07-MAR-1997; 97US-0038621P.
PR	07-MAR-1997; 97US-0040161P.
PR	07-MAR-1997; 97US-0040162P.
PR	07-MAR-1997; 97US-0040163P.
PR	07-MAR-1997; 97US-0040333P.
PR	07-MAR-1997; 97US-0040334P.
PR	07-MAR-1997; 97US-0040336P.
PR	07-MAR-1997; 97US-0040626P.
PR	11-APR-1997; 97US-0043311P.
PR	11-APR-1997; 97US-0043312P.
PR	11-APR-1997; 97US-0043313P.
PR	11-APR-1997; 97US-0043314P.
PR	11-APR-1997; 97US-0043315P.
PR	11-APR-1997; 97US-0043568P.
PR	11-APR-1997; 97US-0043569P.
PR	11-APR-1997; 97US-0043576P.
PR	11-APR-1997; 97US-0043578P.
PR	11-APR-1997; 97US-0043580P.
PR	11-APR-1997; 97US-0043669P.
PR	11-APR-1997; 97US-0043670P.
PR	11-APR-1997; 97US-0043671P.
PR	11-APR-1997; 97US-0043672P.
PR	11-APR-1997; 97US-0043674P.
PR	23-MAY-1997; 97US-0047492P.
PR	23-MAY-1997; 97US-0047500P.
PR	23-MAY-1997; 97US-0047501P.
PR	23-MAY-1997; 97US-0047502P.
PR	23-MAY-1997; 97US-0047503P.
PR	23-MAY-1997; 97US-0047581P.



PR	23-MAY-1997;	97US-0047582P;
PR	23-MAY-1997;	97US-0047583P;
PR	23-MAY-1997;	97US-0047584P;
PR	23-MAY-1997;	97US-0047585P;
PR	23-MAY-1997;	97US-0047586P;
PR	23-MAY-1997;	97US-0047587P;
PR	23-MAY-1997;	97US-0047588P;
PR	23-MAY-1997;	97US-0047589P;
PR	23-MAY-1997;	97US-0047590P;
PR	23-MAY-1997;	97US-0047592P;
PR	23-MAY-1997;	97US-0047593P;
PR	23-MAY-1997;	97US-0047594P;
PR	23-MAY-1997;	97US-0047595P;
PR	23-MAY-1997;	97US-0047596P;
PR	23-MAY-1997;	97US-0047597P;
PR	23-MAY-1997;	97US-0047598P;
PR	23-MAY-1997;	97US-0047599P;
PR	23-MAY-1997;	97US-0047600P;
PR	23-MAY-1997;	97US-0047601P;
PR	23-MAY-1997;	97US-0047612P;
PR	23-MAY-1997;	97US-0047613P;
PR	23-MAY-1997;	97US-0047614P;
PR	23-MAY-1997;	97US-0047615P;
PR	23-MAY-1997;	97US-0047617P;
PR	23-MAY-1997;	97US-0047618P;
PR	23-MAY-1997;	97US-0047632P;
PR	23-MAY-1997;	97US-0047633P;
PR	06-JUN-1997;	97US-0048964P;
PR	06-JUN-1997;	97US-0048974P;
PR	13-JUN-1997;	97US-0049610P;
PR	08-JUL-1997;	97US-0051926P;
PR	16-JUL-1997;	97US-0052874P;
PR	18-AUG-1997;	97US-0055724P;
PR	22-AUG-1997;	97US-0056630P;
PR	22-AUG-1997;	97US-0056631P;
PR	22-AUG-1997;	97US-0056632P;
PR	22-AUG-1997;	97US-0056636P;
PR	22-AUG-1997;	97US-0056637P;
PR	22-AUG-1997;	97US-0056662P;
PR	22-AUG-1997;	97US-0056664P;
PR	22-AUG-1997;	97US-0056845P;
PR	22-AUG-1997;	97US-0056862P;
PR	22-AUG-1997;	97US-0056864P;
PR	22-AUG-1997;	97US-0056872P;
PR	22-AUG-1997;	97US-0056874P;
PR	22-AUG-1997;	97US-0056875P;
PR	22-AUG-1997;	97US-0056876P;
PR	22-AUG-1997;	97US-0056877P;
PR	22-AUG-1997;	97US-0056878P;
PR	22-AUG-1997;	97US-0056879P;
PR	22-AUG-1997;	97US-0056880P;
PR	22-AUG-1997;	97US-0056881P;
PR	22-AUG-1997;	97US-0056882P;
PR	22-AUG-1997;	97US-0056884P;
PR	22-AUG-1997;	97US-0056886P;
PR	22-AUG-1997;	97US-0056887P;
PR	22-AUG-1997;	97US-0056888P;
PR	22-AUG-1997;	97US-0056889P;
PR	22-AUG-1997;	97US-0056892P;
PR	22-AUG-1997;	97US-0056893P;
PR	22-AUG-1997;	97US-0056894P;
PR	22-AUG-1997;	97US-0056903P;
PR	22-AUG-1997;	97US-0056908P;
PR	22-AUG-1997;	97US-0056909P;
PR	22-AUG-1997;	97US-0056910P;
PR	22-AUG-1997;	97US-0056911P;
PR	05-SEP-1997;	97US-0057650P;
PR	05-SEP-1997;	97US-0057659P;
PR	05-SEP-1997;	97US-0057761P;
PR	12-SEP-1997;	97US-0058785P;
PR	02-OCT-1997;	97US-0061060P;
PR	06-MAR-1998;	98WO-US0004493;
PR	08-SEP-1998;	98US-US00149476;

(HUMA-) HUMAN GENOME SCI INC.

Ruben SM, Rosen CA, Soppet DR, Carter KC, Bednarik DP; Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM, Ferrie AM; Duan R, Hu J, Florence KA, Olsen HS, Fischer CL, Ebner R; Brewer LA, Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;

WPI; 2004-131264/13.  
P-PSDB; ADH74212.

Isolated nucleic acid molecules encoding human secreted proteins, useful for preventing, diagnosing and treating disorders associated with aberrant expression and activity.

Claim 3; SEQ ID NO 186; 142pp; English.

The invention relates to isolated nucleic acid molecules and the human secreted proteins (SPs) they encode. The proteins and nucleic acids may be used in the prevention, diagnosis and treatment of diseases associated with inappropriate SP expression e.g. cancer, haematopoietic disorders, endocrine disorders, diseases of the immune system, inflammatory disorders and many others. Full details of disorders that may be prevented, diagnosed and/or treated by the above methods are given in the specification. The nucleic acid molecules may be used to produce their proteins. The nucleic acid and it's complementary sequences may also be used as DNA probes in diagnostic assays to detect and quantitate the presence of similar nucleic acids in samples, and therefore which patients may be in need of restorative therapy. The SPs may also be used as antigens in the production of antibodies against the proteins and in assays to identify modulators of SP expression and activity. The anti-SP antibodies and antagonists may also be used to down regulate expression and activity. The anti-SP antibodies may also be used as diagnostic agents for detecting the presence of the proteins in samples (e.g. by enzyme linked immunosorbent assay (ELISA)). The present sequence represents a human secreted protein cDNA.

Sequence 1212 BP; 363 A; 241 C; 307 G; 300 T; 0 U; 1 Other;

Query Match            2.9%;   Score 66; DB 12; Length 1212;  
Best Local Similarity 70.7%; Pred. No. 0.00024;  
Matches 87; Conservative 0; Mismatches 36; Indels 0; Gaps 0;

QY     2120 GCCTTTGCTTACCACACTCTTCCTTTTATCTTATTATAAAATGTTGGTCTCCACCCT 2179  
      |||||      |||||      |||||      |||||      |||||      |||||      |||||  
Db     1086 GCATTGCTTTTAACCACTTCTTTTGTTAAATAAATAAGTAATAAGCTAGTT 1145

QY     2180 GNCTCCCRAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2239  
      |      |||||      |||||      |||||      |||||      |||||      |||||  
Db     1146 CTATTGAATGCRAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1205

QY     2240 AAA 2242  
      |||||  
Db     1206 AAA 1208

RESULT 1036  
ABX71274  
ID ABX71274 standard; cDNA; 1447 BP.  
XX  
AC ABX71274;  
DT  
XX 14-APR-2003 (first entry)  
DE Human brain-derived cDNA from clone DKFZphfbr2\_78n23.  
XX Human; gene; gene therapy; vaccine; disease treatment; detection; ss.  
KW Homo sapiens.  
OS  
XX WO200112659-A2.  
PN  
XX 22-FEB-2001.









XX Disclosure; Page 106-109; 114pp; English.

PS The invention relates to a method for identifying a compound capable of

XX treating a haematologic disorder. The method comprising assaying the

CC ability of the compound to modulate the nucleic acid expression or

CC polypeptide activity. The methods are useful for identifying a compound

CC capable of treating a haematologic disorder or modulating haematopoiesis.

CC The invention is useful for modulating haematopoiesis in a cell or

CC treating a subject with a haematologic disorder, e.g. disorders resulting

CC from bone marrow irradiation or chemotherapy treatments for cancer,

CC anaemias such as pernicious, haemorrhagic, haemolytic, aplastic sickle

CC cell, sideroblastic and anaemia associated with chronic infections such

CC as malaria, trypanosomiasis, HIV, hepatitis virus or other viruses,

CC anaemias caused by marrow deficiencies, renal failure resulting from

CC anaemia, polycythaemia, infectious mononucleosis (IM), acute non-

CC lymphocytic leukaemia (ANLL), acute myeloid leukaemia (AML), acute

CC promyelocytic leukaemia (APL), acute myelomonocytic leukaemia (AMML),

CC polycythaemia vera, lymphoma, acute lymphocytic leukaemia (ALL), chronic

CC lymphocytic leukaemia, Wilm's tumour, Ewing's sarcoma, retinoblastoma,

CC haemophilia, disorders associated with an increased risk of thrombosis,

CC herpes, thalassaemia, antibody-mediated disorders such as transfusion

CC reactions and erythroblastosis, mechanical trauma to red blood cells such

CC as micro-angiopathic haemolytic anaemias, thrombotic thrombocytopenic

CC purpura and disseminated intravascular coagulation, infections by

CC parasites such as plasmodium, chemical injuries from lead poisoning or

CC hypersplenism. The invention is useful in gene therapy. The present

CC sequence is human oxidase DNA used to illustrate the method of the

CC invention

XX

SQ Sequence 2291 BP; 530 A; 638 C; 660 G; 463 T; 0 U; 0 Other;

Query Match 2.9%; Score 66; DB 9; Length 2291;

Best Local Similarity 75.7%; Pred. No. 0.00029;

Matches 81; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 2136 TCTTTCCTTTTATCTTATTATAATAAAATGTTGGTCTCCACCACCTGCTCCCAAAAAA 2195

Db 2159 TCAATACTTTGTCATTTTGGGATAATAAAAAAGGCTCCCTCCCTGCAAAAAA 2218

QY 2196 AA 2242

Db 2219 AA 2265

RESULT 1043

ADR25949

ID ADR25949 standard; DNA; 2291 BP.

XX

AC ADR25949;

XX

DT 21-OCT-2004 (first entry)

XX

DE Breast cancer prognosis marker #1810.

XX

KW db; breast cancer; prognosis; gene expression; diagnosis.

XX

OS Homo sapiens.

XX

PN WO2004065545-A2.

XX

PD 05-AUG-2004.

XX

PF 15-JAN-2004; 2004WO-US001100.

XX

PR 15-JAN-2003; 2003US-00342887.

XX

PA (ROSE-) ROSETTA INPHARMATICS LLC.

PA (NECA-) NETHERLANDS CANCER INST.

XX

PI Van't Veer LJ, He Y;

DR WPI; 2004-593473/57.

XX Classifying a breast cancer patient according to prognosis comprises

PT determining the similarity between the level of expression of each of

PT five genes in a cell sample taken from patient, to control levels.

XX

PS Disclosure; SEQ ID NO 1810; 226pp; English.

XX

CC The invention relates to a method of classifying a breast cancer patient

CC according to prognosis by determining the similarity between the level of

CC expression of each of five genes for which markers are listed in the

CC specification, in a cell sample taken from the breast cancer patient, to

CC control levels of expression for each respective five genes to obtain a

CC patient similarity value. The methods are useful for classifying a breast

CC cancer patient according to prognosis. Kits and computer program products

CC are useful for data analysis using the diagnostic, prognostic and

CC statistical methods of the invention. This sequence corresponds to a

CC marker used in the method of the invention.

XX

SQ Sequence 2291 BP; 530 A; 638 C; 660 G; 463 T; 0 U; 0 Other;

Query Match 2.9%; Score 66; DB 13; Length 2291;

Best Local Similarity 75.7%; Pred. No. 0.00029;

Matches 81; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 2136 TCTTTCCTTTTATCTTATTATAATAAAATGTTGGTCTCCACCACCTGCTCCCAAAAAA 2195

Db 2159 TCAATACTTTGTCATTTTGGGATAATAAAAAAGGCTCCCTCCCTGCAAAAAA 2218

QY 2196 AA 2242

Db 2219 AA 2265

RESULT 1044

ADQ23141

ID ADQ23141 standard; DNA; 2988 BP.

XX

AC ADQ23141;

XX

DT 26-AUG-2004 (first entry)

XX

DE Human soft tissue sarcoma-upregulated DNA - SEQ ID 5961.

XX

KW soft tissue sarcoma; cytostatic; gene therapy; vaccine; screening; human;

XX

OS Homo sapiens.

XX

PN WO2004048938-A2.

XX

PD 10-JUN-2004.

XX

PF 26-NOV-2003; 2003WO-US038193.

XX

PR 26-NOV-2002; 2002US-0429739P.

XX

PA (PROT-) PROTEIN DESIGN LABS INC.

XX

PI Aziz N, Ginsburg WM, Zlotnik A;

XX

DR WPI; 2004-441208/41.

XX

PT Early detection of soft tissue sarcoma comprises determining expression

PT of a gene in a first soft tissue sample and a normal soft tissue sample

PT and comparing the gene expression, also useful in treating soft tissue

PT sarcoma.

XX

PS Example 2; SEQ ID NO 5961; 210pp; English.

XX

CC The invention relates to a novel method for detecting soft tissue sarcoma

CC which comprises obtaining a first soft tissue sample from an individual

CC and a normal soft tissue sample from the same or different individual,

CC determining the expression of a gene in both samples and comparing the















XX WPI; 2001-611502/70.

DR Novel isolated nucleic acid molecules (markers) overexpressed in ovarian

XX cancer cells as compared to their normal non-cancerous ovarian cells are

PT used to characterize stage, grade, histological type of ovarian cancer.

PT

XX Disclosure; SEQ ID NO 11478; 106pp; English.

PS

XX The invention relates to nucleic acid markers which are overexpressed in

CC ovarian cancer cells as compared to their expression in normal (i.e. non-

CC cancerous) ovarian cells. The invention also relates to polypeptides

CC encoded by the markers, antibodies that selectively bind to the

CC of developing ovarian cancer involving inhibiting expression of a gene

CC corresponding to a marker of the invention and a method of treating a

CC patient afflicted with ovarian cancer comprising providing to cells of

CC the patient an antisense oligonucleotide complementary to a marker of the

CC invention. The markers are useful for assessing if a patient is afflicted

CC with ovarian cancer, which involves comparing the level of expression of

CC a marker in a patient sample and a normal level of expression of the

CC marker in a control non-ovarian cancer sample. A difference between the

CC expression levels indicates ovarian cancer. The level of expression of a

CC marker corresponds to a secreted protein or to a transcribed

CC polynucleotide or its portion. The level of expression of the marker is

CC assessed by detecting the presence in the sample, a protein or protein

CC fragment corresponding to the marker. The presence of protein or protein

CC fragment is detected using an antibody that specifically binds with the

CC protein or protein fragment. Alternatively, the level of expression of

CC the marker is assessed by detecting the presence of a transcribed

CC polynucleotide which anneals with the marker or anneals with a portion of

CC the polynucleotide comprising the marker, under stringent conditions. The

CC marker is also used for monitoring the progression of ovarian cancer in a

CC patient which involves detecting expression of the marker in a patient

CC sample at a first point in time, repeating the method at a subsequent

CC time and comparing the level of expression. The method is carried out

CC using an ovarian tissue sample. A composition comprising a marker,

CC polypeptide or antibody of the invention is used to treat ovarian cancer.

CC This sequence represents a human ovarian cancer DNA marker of the

CC invention.

XX

SQ Sequence 608 BP; 178 A; 42 C; 55 G; 211 T; 0 U; 122 Other;

Query Match 2.9%; Score 65.8; DB 5; Length 608;

Best Local Similarity 68.3%; Pred. No. 0.00021;

Matches 82; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 2123 TTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCTGNC 2182

Db 214 TTTTCCCCCNAATTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT

QY 2183 TCCCAA 2242

Db 154 AA 95

RESULT 1055

ADI72448/c

ID ADI72448 standard; DNA; 608 BP.

XX ADI72448;

XX

XX 20-MAY-2004 (first entry)

XX

XX Human ovarian cancer DNA marker #5190.

DE

XX Human; ovarian cancer; ds; tumour; cytostatic; DNA marker.

XX

XX Homo sapiens.

OS

XX

PN WO200170979-A2.

XX

PD 27-SEP-2001.

XX 21-MAR-2001; 2001WO-US009126.

PF

XX

PR 21-MAR-2000; 2000US-0191031P.

PR 25-MAY-2000; 2000US-0207124P.

PR 15-JUN-2000; 2000US-0211940P.

PR 07-JUL-2000; 2000US-0216820P.

PR 25-JUL-2000; 2000US-0220661P.

PR 21-DEC-2000; 2000US-0257672P.

XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.

PA

XX Lee J, Lillie J;

PI WPI; 2001-611502/70.

XX

DR Novel isolated nucleic acid molecules (markers) overexpressed in ovarian

XX cancer cells as compared to their normal non-cancerous ovarian cells are

PT used to characterize stage, grade, histological type of ovarian cancer.

PT

XX Disclosure; SEQ ID NO 5190; 106pp; English.

PS

XX The invention relates to nucleic acid markers which are overexpressed in

CC ovarian cancer cells as compared to their expression in normal (i.e. non-

CC cancerous) ovarian cells. The invention also relates to polypeptides

CC encoded by the markers, antibodies that selectively bind to the

CC polypeptides, a method of inhibiting ovarian cancer in a patient at risk

CC of developing ovarian cancer involving inhibiting expression of a gene

CC corresponding to a marker of the invention and a method of treating a

CC patient afflicted with ovarian cancer comprising providing to cells of

CC the patient an antisense oligonucleotide complementary to a marker of the

CC invention. The markers are useful for assessing if a patient is afflicted

CC with ovarian cancer, which involves comparing the level of expression of

CC a marker in a patient sample and a normal level of expression of the

CC marker in a control non-ovarian cancer sample. A difference between the

CC expression levels indicates ovarian cancer. The level of expression of a

CC marker corresponds to a secreted protein or to a transcribed

CC polynucleotide or its portion. The level of expression of the marker is

CC assessed by detecting the presence in the sample, a protein or protein

CC fragment corresponding to the marker. The presence of protein or protein

CC fragment is detected using an antibody that specifically binds with the

CC protein or protein fragment. Alternatively, the level of expression of

CC the marker is assessed by detecting the presence of a transcribed

CC polynucleotide which anneals with the marker or anneals with a portion of

CC the polynucleotide comprising the marker, under stringent conditions. The

CC marker is also used for monitoring the progression of ovarian cancer in a

CC patient which involves detecting expression of the marker in a patient

CC sample at a first point in time, repeating the method at a subsequent

CC time and comparing the level of expression. The method is carried out

CC using an ovarian tissue sample. A composition comprising a marker,

CC polypeptide or antibody of the invention is used to treat ovarian cancer.

CC This sequence represents a human ovarian cancer DNA marker of the

CC invention.

XX

SQ Sequence 608 BP; 178 A; 42 C; 55 G; 211 T; 0 U; 122 Other;

Query Match 2.9%; Score 65.8; DB 5; Length 608;

Best Local Similarity 68.3%; Pred. No. 0.00021;

Matches 82; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 2123 TTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCTGNC 2182

Db 214 TTTTCCCCCNAATTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT

QY 2183 TCCCAA 2242

Db 154 AA 95

RESULT 1056

AAA60768

ID AAA60768 standard; cDNA; 638 BP.

XX





PD 08-APR-2004.  
XX  
PF 25-SEP-2003; 2003WO-US030907.  
XX  
PR 25-SEP-2002; 2002US-0414006P.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Bodary S, Clark H, Jackman J, Schoenfeld J, Williams PM, Wood WI;  
PI Wu TD;  
XX  
DR WPI; 2004-305105/28.  
DR P-PSDB; ADN05332.  
XX  
PT New PRO nucleic acid or polypeptide, useful for preparing a  
PT pharmaceutical composition for diagnosing or treating psoriasis in a  
PT mammal.  
XX  
PS Claim 1; SEQ ID NO 1726; 3069pp; English.  
XX  
CC The invention relates to novel polynucleotide and polypeptides for  
CC treating psoriasis or a sequence having at least 80% identity to the  
CC above sequences. The nucleic acid is useful for preparing a composition  
CC for diagnosing or treating psoriasis in a mammal. This sequence  
CC corresponds to one of the polynucleotides of the invention.  
XX  
SQ Sequence 711 BP; 172 A; 210 C; 215 G; 114 T; 0 U; 0 Other;  
  
Query Match 2.9%; Score 65.8; DB 12; Length 711;  
Best Local Similarity 67.9%; Pred. No. 0.00022;  
Matches 91; Conservative 0; Mismatches 43; Indels 0; Gaps 0;  
  
QY 2109 ATCCAATGATCGCCTTGTGCTTTACCACTCTCTTTTATCTTATTAATAAAATGTTGG 2168  
Db 572 AACCAGCCCTGCTCTCGACTTCTCTTCTTAGCTTCATGTGAATAAAGCTATTCTGG 631  
  
QY 2169 TCTCCACCACTGCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2228  
Db 632 TCTCCTCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 691  
  
QY 2229 AAAAAAAAAAAAAA 2242  
Db 692 AAAAAAAAAAAAAA 705  
  
RESULT 1059  
ADQ23192  
ID ADQ23192 standard; DNA; 1383 BP.  
XX  
AC ADQ23192;  
XX  
DT 26-AUG-2004 (first entry)  
XX  
DE Human soft tissue sarcoma-upregulated DNA - SEQ ID 6012.  
XX  
KW soft tissue sarcoma; cytostatic; gene therapy; vaccine; screening; human;  
KW ds.  
XX  
OS Homo sapiens.  
XX  
PN WO2004048938-A2.  
XX  
PD 10-JUN-2004.  
XX  
PF 26-NOV-2003; 2003WO-US038193.  
XX  
PR 26-NOV-2002; 2002US-0429739P.  
XX  
PA (PROT-) PROTEIN DESIGN LABS INC.  
XX  
PI Aziz N, Ginsburg WM, Zlotnik A;  
XX WPI; 2004-441208/41.  
DR

XX Early detection of soft tissue sarcoma comprises determining expression  
PT of a gene in a first soft tissue sample and a normal soft tissue sample  
PT and comparing the gene expression, also useful in treating soft tissue  
PT sarcoma.  
XX  
PS Example 2; SEQ ID NO 6012; 210pp; English.  
XX  
CC The invention relates to a novel method for detecting soft tissue sarcoma  
CC which comprises obtaining a first soft tissue sample from an individual  
CC and a normal soft tissue sample from the same or different individual,  
CC determining the expression of a gene in both samples and comparing the  
CC expression of the gene in both soft tissue samples, where a higher level  
CC of protein expression in the first soft tissue sample indicates the  
CC presence of soft tissue sarcoma. The method of the invention has  
CC cyostatic applications and may be useful for detecting soft tissue  
CC sarcoma, possibly via gene therapy or vaccine production. The nucleic  
CC acid sequences may be useful in diagnostic and screening applications.  
CC The current sequence is that of a human soft tissue sarcoma-upregulated  
CC DNA of the invention. The current sequence is not shown within the  
CC specification per se but was submitted in CD format by the inventor.  
XX  
SQ Sequence 1383 BP; 357 A; 253 C; 528 G; 223 T; 0 U; 22 Other;  
  
Query Match 2.9%; Score 65.8; DB 12; Length 1383;  
Best Local Similarity 77.5%; Pred. No. 0.00028;  
Matches 79; Conservative 0; Mismatches 23; Indels 0; Gaps 0;  
  
QY 2141 CCTTTATCTTATTAATAAAATGTTGGTCTCCACCACTGCTCCCAAAAAA AAAAAA 2200  
Db 1225 CCTGTGACCTCAATACATAAATGTGATCCCCCAAAAAA AAAAAA AAAAAA 1284  
  
QY 2201 AAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242  
Db 1285 AAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1326  
  
RESULT 1060  
ADC38959  
ID ADC38959 standard; CDNA; 1475 BP.  
XX  
AC ADC38959;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE Human cDNA encoding a secreted protein #104.  
XX  
KW ss; gene; immune disorder; severe combined immunodeficiency; SCID;  
KW autoimmune disorder; multiple sclerosis; systemic lupus erythematosus;  
KW rheumatoid arthritis; allergic reaction; asthma; myeloid cell deficiency;  
KW lymphoid cell deficiency; osteoporosis; osteoarthritis;  
KW peripheral nervous system disease; peripheral neuropathy;  
KW Alzheimer's disease; Parkinson's disease; coagulation disorder;  
KW inflammatory disease; systemic inflammatory response syndrome; SIRS;  
KW ischaemia-reperfusion injury; Crohn's disease; anaphylaxis;  
KW hypersensitivity; regeneration; neural cell proliferation; fertility;  
KW tumour; chemokine; human; secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN US2002193567-A1.  
XX  
PD 19-DEC-2002.  
XX  
PF 02-APR-2002; 2002US-00114893.  
XX  
PR 11-AUG-1995; 95US-00514014.  
PR 05-APR-1996; 96US-00628364.  
PR 19-APR-1996; 96US-00635311.  
PR 07-JUN-1996; 96US-00659224.  
PR 17-JUN-1996; 96US-00664596.  
PR 09-JUL-1996; 96US-00677231.  
PR 26-JUL-1996; 96US-00686878.  
PR



















PR 01-DEC-1998; 98WO-US0251108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.

PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR WPI; 2003-466355/44.  
DR P-PSDB; ABO25091.  
XX  
XX  
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in  
PT generating antisense RNA and DNA, and in gene therapy.  
XX  
PS Claim 2; Fig 501; 659pp; English.  
XX  
CC The invention relates to an isolated nucleic acid comprising at least 80%  
CC sequence identity to a PRO (secreted and transmembrane protein) cDNA  
CC comprising a nucleic acid (a) encoding a PRO polypeptide, or its  
CC extracellular domain (with or without its associated signal peptide),  
CC which comprises any of the 275 120-850 residue amino acid sequences,  
CC given in the specification; (b) comprising any of the 275 300-3500  
CC nucleotide sequences, given in the specification; or (c) comprising the  
CC full-length coding sequence of the nucleotide sequences given in the  
CC specification, or of the DNA deposited under any of the American Type  
CC Culture Collection (ATCC) Accession Numbers listed in the specification.  
CC Also included are a vector comprising the novel nucleic acid, a host cell  
CC comprising the vector, producing a PRO polypeptide, the isolated PRO  
CC polypeptides detailed above, a chimaeric molecule comprising the PRO  
CC polypeptide of fused to a heterologous amino acid sequence, an anti-PRO  
CC antibody, detecting a PRO polypeptide in a sample suspected of containing  
CC the PRO polypeptide, linking a bioactive molecule to a cell expressing a  
CC PRO polypeptide, modulating at least one biological activity of a cell  
CC expressing a PRO polypeptide, stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, (or proteoglycans from  
CC cartilage or cytokine from peripheral blood mononuclear cells (PBMC)),  
CC modulating the uptake of glucose or FFA by skeletal muscle cells or  
CC adipocyte cells, stimulating the proliferation or differentiation of  
CC chondrocyte cells (or proliferation of or gene expression in pericyte  
CC cells), stimulating the proliferation of inner ear utricular supporting  
CC cells (or of T-lymphocyte cells, or of endothelial cells), inhibiting the  
CC binding of A-peptide to factor VIIA, or differentiation of adipocyte  
CC cells, detecting the presence of a tumour in a mammal and an  
CC oligonucleotide probe derived from any of the nucleotide sequences given  
CC in the specification. The polynucleotide is useful in molecular biology,  
CC including uses as hybridisation probes, in chromosome and gene mapping,  
CC in generating antisense RNA and DNA, and in gene therapy. The  
CC polynucleotide may also be used in preparing PRO polypeptides by  
CC recombinant techniques, and in generating either transgenic animals or  
CC knock-out animals which, in turn, are useful in the development and  
CC screening of therapeutically useful reagents. The PRO polypeptide or the  
CC antibody is used in preparing a medicament for treating a condition  
CC responsive to the polypeptide or antibody, such as tumours, and in  
CC various diagnostic assays. The present sequence encodes a PRO polypeptide  
XX  
SQ Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;

Query Match 2.9%; Score 65.8; DB 8; Length 1883;  
Best Local Similarity 62.0%; Pred. No. 0.0003;  
Matches 103; Conservative 0; Mismatches 63; Indels 0; Gaps 0;